

## BOARD OF DIRECTORS

Linda J. Porrino, PhD, President  
Sharon Walsh, PhD, Past-President  
Anna Rose Childress, PhD, President-Elect  
Stephen G. Holtzman, PhD, Treasurer  
Patrick M. Beardsley, PhD  
Lawrence S. Brown, MD, MPH  
Steven R. Childers, PhD  
Theodore J. Cicero, PhD  
Sandra D. Comer, PhD  
Richard De La Garza, II, PhD

David A. Fiellin, MD  
Leonard L. Howell, PhD  
Scott E. Lukas, PhD  
Geoffrey K. Mumford, PhD  
Michael A. Nader, PhD  
Edward V. Nunes, MD  
Richard A. Rawson, PhD  
Maxine L. Stitzer, PhD  
Eric C. Strain, MD  
Dace S. Svikis, PhD

## EXECUTIVE OFFICER

Martin W. Adler, PhD

## SCIENTIFIC PROGRAM COMMITTEE

Sari Izenwasser, PhD, Chair  
Martin W. Adler, PhD, *ex officio*  
Ellen B. Geller, MA, *ex officio*  
Alan J. Budney, PhD  
Howard D. Chilcoat, ScD  
Sandra D. Comer, PhD  
Patrick M. Flynn, PhD  
Cindy Kuhn, PhD  
Michelle R. Lofwall, MD  
Lance R. McMahon, PhD  
Janet L. Neisewander, PhD  
Jennifer W. Tidey, PhD  
Ellen M. Unterwald, PhD  
Elise M. Weerts, PhD

## PRE-MEETING SATELLITES

*NIDA: Application of Genetic Approaches to Understand  
Drug Abuse and Addiction*  
Chaired by Minda R. Lynch and David Shurtleff

**Sonoran**  
June 11

*Third Meeting of the International Women's and Children's  
Health and Gender Group*  
Chaired by Frances E. Ashe-Goins and Wendee Wechsberg

**Salon BC**  
June 11

*The 14<sup>th</sup> Annual NIDA International Forum on  
Drug Abuse Research, Policy and the Public Good*  
Chaired by Steven Gust

**Sonoran**  
June 11 - 12

*Addiction Studies Program for Journalists (ASPJ)*  
(By Invitation Only)

**McDowell**  
June 11 - 12

*The International Study Group Investigating  
Drugs as Reinforcers (ISGIDAR)*  
Chaired by S. Barak Caine

**Salon D**  
June 12

*10<sup>th</sup> Annual Meeting Center for Substance Abuse  
Treatment (CSAT)*  
Chaired by Peter Edwards

**Salon BC**  
June 12

*2010 AAAP Addiction Board Review Course at CPDD:  
A Clinical Review of Substance Use Disorders*

**Salon F**  
June 12

## CPDD REGISTRATION Conference Center – East Foyer

<b>Saturday, June 12</b>	<b>1:30 PM - 5:30 PM</b>
<b>Sunday, June 13</b>	<b>8:00 AM - 12:00 PM 1:30 PM - 5:00 PM</b>
<b>Monday, June 14</b>	<b>9:00 AM - 12:30 PM 1:30 PM - 5:00 PM</b>
<b>Tuesday, June 15</b>	<b>11:00 AM - 5:00 PM</b>
<b>Wednesday, June 16</b>	<b>9:00 AM - 11:00 PM 2:00 PM - 5:00 PM</b>
<b>Thursday, June 17</b>	<b>8:00 AM - 1:00 PM</b>

## OPENING RECEPTION (Cash Bar) Hacienda Plaza

<b>Saturday, June 12</b>	<b>7:00 PM - 9:00 PM</b> <i>(Pre-registrants can pick up badges only)</i>
--------------------------	--

**CSAT Travel Awards Breakfast**  
(By Invitation Only)

**Princesa**  
**7:00 - 8:00 AM**

**Plenary Session**

**Salons DEFG**  
**8:45 - 11:30 AM**

- 8:45 *Welcome, CPDD President*  
Linda Porrino
- 8:55 *Report from the National Institute on Drug Abuse*  
Nora D. Volkow, NIDA, Bethesda, MD
- 9:25 *Drug Strategies and Potential for Research Opportunities*  
A. Thomas McLellan, Deputy Director for Demand Reduction, ONDCP, Bethesda, MD
- 9:55 *Presentation of the Distinguished Service Award to Jack Henningfield*  
Introduction by Sharon Walsh
- 10:00 *Presentation of the Media Award to Allan Brandt*  
Introduction by Marc Kaufman
- 10:05 *Presentation of the J. Michael Morrison Award to Cora Lee Wetherington*  
Introduction by Marilyn Carroll
- 10:10 *Presentation of the Joseph Cochin Young Investigator Award to David Jentsch*  
Introduction by Edythe London
- 10:15 *Presentation of the Mentorship Award to Charles O'Brien*  
Introduction by Anna Rose Childress
- 10:20 *Presentation of the Nathan B. Eddy Award to Theodore Cicero*  
Introduction by Linda Cottler
- 10:30 *Nathan B. Eddy Award Lecture by Theodore Cicero*

**Early Career Investigator Awards Luncheon**  
(By Invitation Only)

**La Hacienda**  
**12:00 - 1:30 PM**

**President's Lecture**

**Salons DEFG**  
**1:30 - 2:30 PM**

**GENE X ENVIRONMENT INTERACTIONS IN PRIMATES**

Stephen J. Suomi, National Institutes of Health, DHHS

**Symposium I**

**Salons HI**  
**3:00 - 5:00 PM**

**TRANSLATING THE GENETICS AND NEUROCHEMISTRY OF  
NICOTINE DEPENDENCE TO DRUG DEVELOPMENT**

Chairs: Linda Porrino and Joni L. Rutter

- 3:00 *Genetic variation in nicotine metabolism and implications for targeted therapy for nicotine addiction*  
Caryn Lerman, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 3:25 *Genetics of nicotine dependence and the convergence with lung cancer and chronic obstructive pulmonary disease*  
Laura Bierut, Washington University at St. Louis, St. Louis, MO

- 3:50 *Alpha-5-containing nicotinic acetylcholine receptors transmit a negative reward signal that controls nicotine intake*  
Paul Kenny, Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL
- 4:15 *The influence of the Alpha-5 subunit on the regulation of brain nicotinic cholinergic receptors by nicotine*  
Ken Kellar, Pharmacology, Georgetown University School of Medicine, Washington, DC
- 4:40 *Discussant*  
Nora Volkow, National Institute on Drug Abuse, Bethesda, MD

## Symposium II

**Salons ABC**  
**3:00 - 5:00 PM**

### **CPDD INTERNATIONAL COMMITTEE SYMPOSIUM: A COMPREHENSIVE APPROACH TO EXAMINE THE USE AND IMPACT OF CANNABIS: FROM BRAIN EFFECTS TO EPIDEMIOLOGICAL IMPACT ACROSS THE WORLD**

Chairs: Flavio Pechansky and Alison Ritter

- 3:00 *Cognitive effects of cannabinoids: Lessons from animal models*  
Marco Bortolato, Neurological Science, University of Cagliari, Monserrato, Italy
- 3:25 *Is cannabis smoking harmful? Epidemiological perspectives and evidence on this question*  
James C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 3:50 *Periadolescent cannabinoid exposure effects on self-administration behavior and several neurotransmitter systems in the adulthood*  
Emilio Ambrosio Flores, Psychobiology, UNED-Ciudad Universitaria Madrid, Madrid, Spain
- 4:15 *Imaging trials of cannabis users in South Africa*  
Paul Carey, Psychiatry, University of Stellenbosch, Stellenbosch, South Africa
- 4:40 *Discussant*  
Jan Copeland, National Cannabis Prevention and Information Centre, University of New South Wales, Sydney, NSW, Australia

## Oral Communications 1

**Salon DE**  
**3:00 - 5:00 PM**

### **WHAT'S NEW WITH MU? HUMAN LABORATORY RESEARCH WITH OPIOIDS**

Chairs: Mark Greenwald and Bethea A. Kleykamp

- 3:00 *Yohimbine increases opioid-seeking behavior in buprenorphine-stabilized, heroin-dependent volunteers*  
M. Greenwald, C. L. Steinmiller, Psychiatry, Wayne State University, Detroit, MI
- 3:15 *Pharmacodynamic and pharmacokinetic profile of crushed intranasal Suboxone® and Subutex® in sporadic opioid abusers*  
L. S. Middleton<sup>1</sup>, P. A. Nuzzo<sup>1</sup>, M. R. Lofwall<sup>1,2</sup>, D. E. Moody<sup>3</sup>, M. J. Wunsch<sup>1,2</sup>, S. L. Walsh<sup>1,2</sup>,  
<sup>1</sup>Behavioral Science/Center on Drug & Alcohol Research, and <sup>2</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>3</sup>Center for Human Toxicology, University of Utah, Salt Lake City, UT

- 3:30 *Oral intact extended-release oxymorphone has fewer subjective and cognitive effects than equianalgesic controlled-release oxycodone*  
S. O. McMorn<sup>1</sup>, K. A. Schoedel<sup>2</sup>, B. Chakraborty<sup>2</sup>, E. M. Sellers<sup>2</sup>, <sup>1</sup>Endo Pharmaceuticals Inc., Chadds Ford, PA, <sup>2</sup>Kendle Early Stage, Toronto, ON, Canada
- 3:45 *The effect of methadone on emotional reactivity*  
S. Savvas, A. A. Somogyi, J. M. White, Adelaide University, Adelaide, SA, Australia
- 4:00 *Effects of methadone alone and in combination with alcohol on cognitive performance in methadone-maintained volunteers*  
B. A. Kleykamp, R. G. Vandrey, G. E. Bigelow, E. C. Strain, M. Z. Mintzer, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD
- 4:15 *The effects of the opiate neutral antagonist 6 $\beta$ -naltrexol in opiate-dependent subjects*  
J. Mendelson<sup>1</sup>, K. Flower<sup>1</sup>, M. Jang<sup>1</sup>, C. W. Harris<sup>1</sup>, W. Sadee<sup>2</sup>, W. Snape<sup>1</sup>, G. P. Galloway<sup>1</sup>, <sup>1</sup>Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, <sup>2</sup>Pharmacology, Ohio State University, Columbus, OH
- 4:30 *Effects of cycloserine and gabapentin in methadone-maintained humans under a naloxone novel-response discrimination procedure*  
A. Oliveto<sup>1</sup>, W. B. Gentry<sup>1</sup>, J. B. Guise<sup>1</sup>, C. Cargile<sup>2</sup>, W. K. Bickel<sup>1</sup>, M. J. Mancino<sup>1</sup>, <sup>1</sup>Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>Psychiatry, Texas A & M Health Science Center, College Station, TX
- 4:45 *Assessing temptations to use heroin and cocaine during drug detoxification using ecological momentary assessment*  
A. J. Waters<sup>1</sup>, I. Franken<sup>2</sup>, R. Marhe<sup>2</sup>, <sup>1</sup>Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, <sup>2</sup>Psychology, Erasmus University, Rotterdam, Netherlands

## Oral Communications 2

Salon FG  
3:00 - 5:00 PM

### UP FRONT WITH DRUG ADDICTION: ROLE OF FRONTAL CORTEX

Chairs: Anna R. Childress and Hedy Kober

- 3:00 *Blockade of 5-HT<sub>2A</sub> receptors in the medial prefrontal cortex attenuates cue-elicited reinstatement of cocaine-seeking behavior in rats*  
L. A. Pockros, N. S. Pentkowski, S. E. Swinford, L. M. Robertson, M. Ostos, J. L. Neisewander, Arizona State University, Tempe, AZ
- 3:15 *BDNF in the prefrontal cortex: Involvement in psychostimulant- and social defeat stress-induced behavioral sensitization*  
E. Nikulina<sup>1,2</sup>, M. Lacagnina<sup>1</sup>, J. Wang<sup>2</sup>, S. Fanous<sup>1</sup>, R. Hammer, Jr<sup>1,2</sup>, <sup>1</sup>Basic Medical Sciences, University of Arizona, College of Medicine -Phoenix, Phoenix, AZ, <sup>2</sup>Neuroscience, Arizona State University, Tempe, AZ
- 3:30 *Psychostimulant drug effects on spike train coding of sensory and decision-related signals in rodent thalamic and cortical circuits during quiet resting and sustained attention*  
B. Waterhouse, K. L. Agster, B. D. Clark, J. S. Shumsky, Neurobiology & Anatomy, Drexel University College of Medicine, Philadelphia, PA

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

- 3:45 *Impaired fronto-amygdalar connectivity: A marker of poor behavioral control in cocaine dependence?*  
J. J. Suh<sup>1,2</sup>, R. Ehrman<sup>1,2</sup>, Y. Li<sup>1</sup>, Z. Wang<sup>1</sup>, D. Willard<sup>1</sup>, R. Fabianski<sup>1</sup>, R. Carson<sup>1</sup>, R. Hazan<sup>1</sup>, A. Fornash<sup>1</sup>, M. Goldman<sup>1</sup>, T. Franklin<sup>1</sup>, A. V. Hole<sup>1,2</sup>, R. Szucs<sup>1,2</sup>, C. P. O'Brien<sup>1,2</sup>, A. R. Childress<sup>1,2</sup>, <sup>1</sup>University of Pennsylvania School of Medicine, and <sup>2</sup>VA VISN4 MIRECC, Philadelphia, PA
- 4:00 *Changes in brain activation pattern during cue reactivity after one month abstinence in heroin dependents*  
H. Ganjgahi<sup>1</sup>, P. Hasani Abharian<sup>1,2</sup>, J. Mc Clernon<sup>4</sup>, Z. Alam Mehrjerdi<sup>1</sup>, H. Tabatabaei<sup>1</sup>, M. Oghabian<sup>3</sup>, H. Ekhtiari<sup>1</sup>, <sup>1</sup>Neurocognitive, Iranian National Center for Addiction Studies, <sup>2</sup>Institute for Cognitive Sciences Studies, and <sup>3</sup>Neuroimaging, Research Center for Science and Technologies, Tehran, Islamic Republic of Iran, <sup>4</sup>Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, Durham, NC
- 4:15 *Relationship of impulsive personality traits and orbitofrontal rCBF in cocaine-addicted and healthy subjects*  
J. Braud<sup>1</sup>, A. Mazzarulli<sup>1</sup>, A. Minhajuddin<sup>1</sup>, T. Harris<sup>1</sup>, M. Devous<sup>1</sup>, B. Adinoff<sup>1,2</sup>, <sup>1</sup>UT Southwestern Medical Center, and <sup>2</sup>VA North Texas Health Care System, Dallas, TX
- 4:30 *Prefrontal-subcortical pathways mediating successful regulation of craving in cigarette smokers*  
H. Kober<sup>1,2</sup>, P. Mende-Siedlecki<sup>3</sup>, E. F. Kross<sup>4</sup>, J. Weber<sup>2</sup>, W. Mischel<sup>2</sup>, C. L. Hart<sup>2,5</sup>, K. N. Ochsner<sup>2</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven, CT, <sup>2</sup>Psychology, Columbia University, New York, NY, <sup>3</sup>Psychology, Princeton University, Princeton, NJ, <sup>4</sup>Psychology, University of Michigan, Ann Arbor, MI, <sup>5</sup>Psychiatry, Columbia University, New York, NY
- 4:45 *Neural correlates of habit learning and reward processing in cocaine users*  
G. Tau<sup>1</sup>, R. Marsh<sup>1</sup>, F. Garcia<sup>1</sup>, X. Hao<sup>1</sup>, D. Xu<sup>1</sup>, S. Xu<sup>1</sup>, M. Packard<sup>2</sup>, Z. Wang<sup>1</sup>, Y. Duan<sup>1</sup>, A. Kangarlou<sup>1</sup>, D. Martinez<sup>1</sup>, B. Peterson<sup>1</sup>, <sup>1</sup>Child and Adolescent Psychiatry, Columbia University / New York State Psychiatric Institute, NY, NY, <sup>2</sup>Psychology, Texas A&M University, College Station, TX

## Primm-Singleton Travel Awardees Meeting

Princesa  
5:00 - 6:00 PM

## Workshop I

Salons HI  
8:00 - 10:00 PM

### EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS

Chairs: James C. Anthony and Silvia S. Martins

*Epidemiology and public health research: A Journal Editor's Perspective*

Deborah Hasin, Columbia University Mailman School of Public Health, New York, NY

*Differential item functioning: Issues in measurement across population sub-groups*

Eric Johnson, Research Triangle Institute, Research Triangle Park, NC

*Methods issues in research on non-medical prescription drug use and dependence*

Silvia Martins, Mental Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD

*International and global health research challenges for scientists interested in methods issues*

James C. Anthony, Epidemiology, Michigan State University, East Lansing, MI

## **Workshop II**

**Salons ABC  
8:00 - 10:00 PM**

### **EFFECTIVELY MENTORING TRAINEES FROM DIVERSE BACKGROUNDS: FUNDING OPPORTUNITIES AND PRACTICAL ADVICE**

Chairs: Danielle C. Ompad and Liliane C. Windsor

*Resources to increase diversity in drug abuse research*

Lula A. Beatty, National Institute on Drug Abuse, Bethesda, MD

*Mentoring students from diverse backgrounds: Interventions at UNC*

Linda Dykstra, Psychology, University of North Carolina, Chapel Hill, NC

*The truth about mentoring minorities*

Carl Hart, New York State Psychiatric Institute, Columbia University, New York, NY

*Practical advice for career development from a grateful former mentee*

Martin Iguchi, Department of Community Health Sciences, UCLA School of Public Health, Los Angeles, CA

*TBA*

Danielle C. Ompad, New York Academy of Medicine, New York, NY

## **Workshop III**

**Salon DE  
8:00 - 10:00 PM**

### **MINIMIZE LIABILITY, MANAGE RISK, ENSURE PATIENT SAFETY: EFFECTIVE STRATEGIES IN OUTPATIENT METHADONE TREATMENT**

Chair: Michael T. Flaherty

*Managing risk, patient safety and best practice – Panel Discussion*

Todd Mandell, Vermont ADAP, Burlington, VT

*Managing Risk: Basic definitions, guiding principles, and relationship between risk and practice in OPMM today*

Lisa Torres, New Jersey Division of Addiction Services, Lawrenceville, NJ

## **Workshop IV**

**Salon FG  
8:00 - 10:00 PM**

### **16TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP**

Chairs: Kelly E. Dunn and Kathryn A. Saulsgiver

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*



## **Animals in Research Forum**

**Salons HI  
8:00 - 9:45 AM**

### **WHAT CAN I DO AND HOW CAN WE WORK WITH OTHERS TO BUILD SUPPORT FOR ANIMAL RESEARCH?**

Chairs: Nancy Ator and Shane Perrine

*Ways individual scientists and clinicians support animal research*

J. David Jentsch, Psychology, Psychiatry and Biobehavioral Sciences, University of California-  
LA, Los Angeles, CA

*Ways universities can support animal research and protect investigators and animals*

Marilyn E. Carroll, University of Minnesota, Minneapolis, MN

*Working with other scientific organizations to build support for animal research*

Nancy A. Ator, Johns Hopkins University, Baltimore, MD

*Working with national advocacy groups to build support for animal research*

Kristen Bocanegra, Americans for Medical Progress, Alexandria, VA

## **Symposium III**

**Salons HI  
10:00 AM - 12:00 PM**

### **ADDRESSING THE INTERSECTION OF ADDICTION AND HIV IN CRIMINAL JUSTICE-INVOLVED POPULATIONS**

Chairs: Timothy P. Condon and Redonna Chandler

10:00 *Phase three clinical study of extended release naltrexone*

Evgeny Krupitsky, St. Petersburg Bekhterev Research, St. Petersburg, Russia

10:25 *Addressing HIV and drug addiction in jail settings*

Frederick Altice, Yale School of Medicine, New Haven, CT

10:50 *Addiction treatment in criminal justice populations*

Robert Schwartz, Friends Research Institute, Baltimore, MD

11:15 *HIV continuum of care model in criminal justice populations*

David Wohl, Center for Infectious Diseases, University of North Carolina School of Medicine,  
Chapel Hill, NC

11:40 *Discussant*

Charles O'Brien, University of Pennsylvania, Philadelphia VA Medical Center,  
Philadelphia, PA

## **Symposium IV**

**Salon DE  
10:00 AM - 12:00 PM**

### **GENDER DIFFERENCES IN RESPONSE TO SOCIAL STRESS: PARALLELS FROM COCAINE AND ALCOHOL RESEARCH IN HUMAN AND NON-HUMAN PRIMATES**

Chairs: Colleen A. Hanlon and Cora Lee Wetherington

10:00 *Gender differences in effects of social variables on dopamine function and cocaine self-  
administration*

Paul W. Czoty, Wake Forest University School of Medicine, Winston-Salem, NC



- 10:25 *The interaction of time, gender, and hormones on alcohol consumption*  
Kathleen A. Grant, Oregon National Primate Research Center, Oregon Health Sciences University, Portland, OR
- 10:50 *Imaging the effects of social ostracism in cocaine users*  
Colleen A. Hanlon, Wake Forest University School of Medicine, Winston-Salem, NC
- 11:15 *Female substance abusers and social drinkers show increased sensitivity to stress and stress-related drug intake*  
Helen Fox, Yale University School of Medicine, South New Haven, CT
- 11:40 *Discussant*  
Mary Jeanne Kreek, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

### Oral Communications 3

Salons ABC  
10:00 AM - 12:00 PM

#### PRECLINICAL OPIOID RESEARCH

Chairs: Katharine M. Seip and Drake Morgan

- 10:00 *Rewarding properties of heroin differ by dose and across individuals of an inbred rat strain*  
K. M. Seip, Y. Zhang, B. Reed, A. Ho, M. J. Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York City, NY
- 10:15 *Loperamide-induced taste aversions in F344 and LEW rats: Assessment of peripheral opioid activation*  
C. M. Davis<sup>1</sup>, J. L. Cobuzzi<sup>2</sup>, A. L. Riley<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Division of Behavioral Biology, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychology, American University, Washington, DC
- 10:30 *Brain metabolism in Lewis and Fischer 344 rats after morphine self-administration and extinction: A PET imaging study*  
E. Ambrosio<sup>1</sup>, G. L. Montoya<sup>1</sup>, M. L. Soto-Montenegro<sup>2,3</sup>, V. García-Vázquez<sup>3</sup>, J. Pascau<sup>3</sup>, M. Miguéns<sup>1</sup>, A. Higuera-Matas<sup>1</sup>, N. Del Olmo<sup>4</sup>, J. J. Vaquero<sup>2</sup>, C. García-Lecumberri<sup>1</sup>, M. Desco<sup>2,3</sup>, <sup>1</sup>Psychobiology, UNED, <sup>2</sup>Unidad de Medicina y Cirugía Experimental, and <sup>3</sup>CIBERSAM, Hospital General Universitario Gregorio Marañón, and <sup>4</sup>Pharmacology, Pharmaceutical Technology and Development, CEU University, Madrid, Spain
- 10:45 *Prolonged reward after oxycodone treatment in females*  
V. Batra, L. M. Schrott, Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA
- 11:00 *Effects of morphine on thermal sensitivity in aged rats*  
D. Morgan<sup>1</sup>, L. Koerper<sup>2</sup>, J. D. Mitzelfelt<sup>1</sup>, C. S. Carter<sup>2</sup>, <sup>1</sup>Psychiatry, University of Florida, and <sup>2</sup>Aging and Geriatric Research, University of Florida, Gainesville, FL
- 11:15 *Morphine in combination with metabotropic glutamate receptor antagonists in a model of inflammatory pain*  
D. E. Daugherty<sup>1</sup>, M. J. Picker<sup>1</sup>, L. A. Dykstra<sup>1,2</sup>, <sup>1</sup>Psychology, and <sup>2</sup>Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 11:30 *Why reinforcing drugs reinforce behavior?*  
F. Leri<sup>1</sup>, E. Nahas<sup>2</sup>, N. M. White<sup>2</sup>, <sup>1</sup>Psychology, University of Guelph, Guelph, ON, and <sup>2</sup>Psychology, McGill University, Montreal, QC, Canada

- 11:45 *Morphine-induced motor stimulation and motor incoordination: Age-related differences in mice*  
W. Koek<sup>1,2</sup>, C. P. France<sup>2,1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX

### Oral Communications 4

Salon FG

10:00 AM - 12:00 PM

#### MISERY LOVES COMPANY: CO-OCCURRING DISORDERS

Chairs: Amy S. Bohnert and Roy Pickens

- 10:00 *Psychiatric comorbidity as predictor of relapse after long-term abstinence from smoking*  
H. Chilcoat<sup>1</sup>, A. C. Andorn<sup>2</sup>, F. Tozzi<sup>4</sup>, D. J. Webb<sup>1</sup>, J. A. Graham<sup>3</sup>, <sup>1</sup>Worldwide Epidemiology, <sup>2</sup>Discovery Medicine, and <sup>3</sup>Medicine Development Center, GlaxoSmithKline, Research Triangle Park, NC, <sup>4</sup>Genetics Operations, GlaxoSmithKline, Verona, Italy
- 10:15 *The impact of psychiatric and substance use disorders on the risk of fatal accidental overdose among veterans*  
A. S. Bohnert<sup>1,2</sup>, M. A. Ilgen<sup>1,2</sup>, R. Ignacio<sup>1,2</sup>, F. C. Blow<sup>1,2</sup>, <sup>1</sup>VA National Serious Mental Illness Treatment Research and Evaluation Center, and <sup>2</sup>Psychiatry, University of Michigan, Ann Arbor, MI
- 10:30 *Adding Axis II personality disorders into the mix: Do they increase treatment-seeking behaviors in males and females with substance use disorders?*  
A. Engels Dibble, D. Svikis, L. Keyser-Marcus, R. Pickens, VCU, Richmond, VA
- 10:45 *Personal social networks of women with substance use and co-occurring mental disorders*  
E. M. Tracy<sup>1</sup>, L. Singer<sup>1</sup>, L. Stevenson<sup>1</sup>, S. Brown<sup>1</sup>, M. Oh Min<sup>1</sup>, A. Laudet<sup>1</sup>, C. McCarty<sup>2</sup>, H. Kim<sup>1</sup>, M. Jun<sup>1</sup>, <sup>1</sup>Case Western Reserve University, Mandel School of Applied Social Sciences, Cleveland, OH, <sup>2</sup>University of Florida, Gainesville, FL
- 11:00 *Psychiatric comorbidity and the persistence of drug use disorders*  
M. Fenton<sup>1,2</sup>, K. Keyes<sup>1,2</sup>, T. Geier<sup>2</sup>, D. Hasin<sup>2,1</sup>, <sup>1</sup>Epidemiology, Columbia University, and <sup>2</sup>Psychiatry, New York State Psychiatric Institute, New York, NY
- 11:15 *Adolescent cannabis use disorders and later depression: Effects of psychosocial mediators*  
N. R. Marmorstein<sup>1</sup>, W. G. Iacono<sup>2</sup>, <sup>1</sup>Psychology, Rutgers University, Camden, NJ, <sup>2</sup>Psychology, University of Minnesota, Minneapolis, MN
- 11:30 *Comorbidity among drug use, anxiety, depression, and conduct disorder from adolescence to young adulthood in a population-based prospective cohort study*  
M. Cerda<sup>1,3</sup>, M. S. Tracy<sup>2</sup>, B. N. Sanchez<sup>4</sup>, S. Galea<sup>2,3</sup>, <sup>1</sup>New York Academy of Medicine, New York, NY, <sup>2</sup>Epidemiology, University of Michigan, Ann Arbor, MI, <sup>3</sup>Epidemiology, Columbia University, New York, NY, <sup>4</sup>Biostatistics, University of Michigan, Ann Arbor, MI
- 11:45 *A comparison of independent and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers*  
E. Dakwar, E. V. Nunes, F. R. Levin, New York State Psychiatric Institute, New York City, NY

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS

## Poster Session I (Lunch)

Pavilion  
12:00 - 2:00 PM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Sunday no earlier than 2:30 PM  
Must be removed by Monday no later than 2:30 PM

### ADOLESCENT DRUG ABUSE I

- 1 *Substance use disorders in siblings*  
M. D. Reynolds, S. Mosovsky, L. Kirisci, S. Knopf, R. Tarter, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
- 2 *A latent class analysis of adolescent substance use and childhood sexual abuse*  
S. H. Shin<sup>1</sup>, H. Hong<sup>2</sup>, A. Hazen<sup>3</sup>, <sup>1</sup>School of Social Work, Boston University, Boston, MA, <sup>2</sup>Zicklin School of Business, Baruch College of the City University of New York, New York, NY, <sup>3</sup>Rady Children's Hospital, San Diego, CA
- 3 *Early substance use and risks associated with father absence*  
K. Stewart, M. Waldron, Counseling and Educational Psychology, Indiana University Bloomington, Bloomington, IN
- 4 *Longitudinal study of levels of adolescent drug use: An SEM analysis of parental monitoring*  
K. M. Bohnert, J. C. Anthony, N. Breslau, Epidemiology, Michigan State University, East Lansing, MI
- 5 *Parental approval and adolescent smoking: Gender and race/ethnicity differences*  
G. Kong, R. Desai, D. Cavallo, M. Potenza, S. Krishnan-Sarin, Psychiatry, Yale University School of Medicine, New Haven, CT
- 6 *Neighborhood risk and protective factor influences on school conduct and performance*  
R. J. Evans, A. E. Goldweber, W. W. Latimer, Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
- 7 *How resilience and its factors contribute to drug use in adolescents*  
T. D. Amato<sup>1</sup>, T. M. Ronzani<sup>2</sup>, A. R. Noto<sup>1</sup>, <sup>1</sup>Psychobiology, Federal University of São Paulo, São Paulo, <sup>2</sup>Psychology, Federal University of Juiz de Fora, Juiz de Fora, Brazil
- 8 *Psychoactive drug use and associated risk behaviors in Brazil*  
D. P. Locatelli, E. S. Opaleye, Z. V. Sanchez, A. R. Noto, Psychobiology, Federal University of Sao Paulo, Sao Paulo, Brazil
- 9 *Substance use among urban adolescents presenting to indigent primary care clinics*  
M. Walton<sup>1</sup>, K. T. Barry<sup>1,2</sup>, S. Resko<sup>3</sup>, S. T. Chermack<sup>1,2</sup>, R. A. Zucker<sup>1</sup>, M. A. Zimmerman<sup>1</sup>, B. M. Booth<sup>4</sup>, F. C. Blow<sup>1,2</sup>, <sup>1</sup>University of Michigan, and <sup>2</sup>VA, Ann Arbor, <sup>3</sup>Wayne State University, Detroit, MI, <sup>4</sup>University of Arkansas for Medical Sciences and VA, Little Rock, AR
- 10 *Psychometric evaluation of the A-SIDE assessment of relapse risk for youth*  
L. Brackenbury, M. Buras, K. G. Anderson, Psychology, Reed College, Portland, OR
- 11 *Illicit drug use and extracurricular involvement during college*  
L. M. Garnier-Dykstra<sup>1</sup>, K. E. O'Grady<sup>2</sup>, K. M. Caldeira<sup>1</sup>, K. B. Vincent<sup>1</sup>, A. Arria<sup>1</sup>, <sup>1</sup>Center on Young Adult Health and Development, and <sup>2</sup>Psychology, University of Maryland, College Park, MD

## SEDATIVE-HYPNOTICS

- 12 *Subtypes of adolescent sedative/anxiolytic misusers: A latent profile analysis*  
M. T. Hall<sup>1</sup>, M. O. Howard<sup>2</sup>, S. E. McCabe<sup>3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>3</sup>Substance Abuse Research Center and Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI
- 13 *Progesterone modulation of the discriminative stimulus effects of triazolam*  
S. Babalonis, J. A. Lile, C. A. Martin, T. H. Kelly, University of Kentucky, Lexington, KY
- 14 *Twelve months of nightly zolpidem does not enhance the likelihood of rebound insomnia: A prospective placebo controlled study*  
S. Randall, T. Roehrs, E. Harris, R. Maan, T. Roth, Sleep Disorders Center, Henry Ford Health System, Detroit, MI
- 15 *Twelve months of nightly zolpidem does not lead to dose escalation: A prospective placebo-controlled study*  
T. Roehrs, S. Randall, E. Harris, R. Maan, T. Roth, T. Roth, Sleep Disorders Center, Henry Ford Health System, Detroit, MI
- 16 *Acute effects of Ambien CR™ on cognitive performance and sleep in healthy male volunteers after chronic nightly use*  
M. Z. Mintzer, B. A. Kleykamp, R. R. Griffiths, U. D. McCann, M. T. Smith, Johns Hopkins University, Baltimore, MD
- 17 *Healthy volunteers feel “high” and “like” the subjective effects of zolpidem but do not choose it over money*  
Y. Mashhoon<sup>1</sup>, S. E. Lukas<sup>1,2</sup>, S. C. Licata<sup>1</sup>, <sup>1</sup>Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA, <sup>2</sup>Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA

## ALCOHOL

- 18 *Kudzu root extract does not affect the sleep/wake cycle in moderate drinkers*  
B. K. Bracken<sup>1,2</sup>, D. M. Penetar<sup>1,2</sup>, R. R. Maclean<sup>3</sup>, D. Y. Lee<sup>1,2</sup>, S. E. Lukas<sup>1,2</sup>, <sup>1</sup>McLean Hospital, and <sup>2</sup>Harvard Medical School, Belmont, MA, <sup>3</sup>Penn State, State College, PA
- 19 *Electronic monitoring of cortisol daytime profiles during alcohol withdrawal in humans*  
M. Warnecke<sup>1</sup>, J. Cordes<sup>1</sup>, W. Gaebel<sup>1</sup>, C. G. Schuetz<sup>2</sup>, H. D. Chilcoat<sup>3</sup>, <sup>1</sup>Psychiatry, Section Addictive Disorders, University of Duesseldorf, Duesseldorf, Germany, <sup>2</sup>Psychiatry, University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Glaxo Smith Kline, Chapel Hill, NC
- 20 *Are the effects of alcohol on cue-induced craving mediated by attentional bias?*  
A. Ataya, M. R. Munafò, University of Bristol, Bristol, United Kingdom
- 21 *Effects of acute alcohol consumption on response inhibition: Evidence of a task- dependent effect*  
S. Adams, M. R. Munafò, Experimental Psychology, University of Bristol, Bristol, United Kingdom
- 22 *The anticonvulsant Levetiracetam can potentiate alcohol consumption in non-treatment-seeking heavy drinkers: Contribution of DRD2 polymorphisms*  
J. Mitchell, L. E. Grossman, A. R. Coker, R. O. Messing, Department of Neurology: Ernest Gallo Clinic and Research Center, UCSF, San Francisco, CA
- 23 *Exercise and fitness levels among treatment-seeking substance-dependent individuals*  
J. G. Plebani, M. Hendrickson, A. Koutroulakis, A. McGlinchy, K. M. Kampman, Psychiatry, University of Pennsylvania, Philadelphia, PA

- 24 *Alcohol and other drugs related violence reported at special police stations for women*  
A. R. Noto, L. P. Augusto, Psicobiologia, UNIFESP, São Paulo, Brazil
- 25 *Changing university students' stigmatizing attitudes toward substance abuse using a research-based neuroscience of addiction curriculum infusion: Results from the NIDA enters college project*  
J. A. Hartje<sup>1</sup>, N. A. Roget<sup>1</sup>, M. S. Berry<sup>1</sup>, W. L. Woods<sup>1</sup>, P. Riggs<sup>2</sup>, <sup>1</sup>Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, NV, <sup>2</sup>Health Sciences Center, University of Colorado, Denver, CO
- 26 *Drunk and drugged driving on Brazilian highways*  
F. Pechansky<sup>1</sup>, R. DeBoni<sup>1</sup>, D. Benzano<sup>1</sup>, C. G. Leukefeld<sup>2</sup>, <sup>1</sup>Psychiatry, Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil, <sup>2</sup>University of Kentucky, Lexington, KY
- 27 *Drinking and driving in a driver probabilistic sample from alcohol outlets of Porto Alegre, Brazil: Preliminary findings*  
R. De Boni<sup>1</sup>, M. T. Vasconcellos<sup>2</sup>, F. I. Bastos<sup>3</sup>, F. Pechansky<sup>1</sup>, <sup>1</sup>Psychiatry, CPAD- Federal University Rio Grande do Sul, Porto Alegre, <sup>2</sup>ENCE/IBGE, and <sup>3</sup>FIOCRUZ, Rio de Janeiro, Brazil
- 28 *Beyond sanctions: Is there a need to treat first-time DUI offenders?*  
J. C. Maxwell<sup>1</sup>, J. Freeman<sup>2</sup>, J. Davey<sup>2</sup>, <sup>1</sup>University of Texas, Austin, TX, <sup>2</sup>Queensland University of Technology, Brisbane, QLD, Australia
- 29 *Abstinence and drinking patterns among women in Africa*  
P. Martinez, J. Røislien, T. Clausen, Norwegian Center for Addiction Research, University of Oslo, Oslo, Norway
- 30 *A cross-national view of socially maladaptive behavior and drug use: Evidence from seven Latin American countries*  
O. McBride, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 31 *Prevalence of hepatitis B in a group of French alcohol abusers*  
M. Marc<sup>1,2</sup>, P. Melin<sup>1,2</sup>, A. Hij<sup>1</sup>, M. Guillaumot<sup>2</sup>, S. Samouri<sup>1</sup>, M. Schoeny<sup>1</sup>, F. Fournier<sup>2</sup>, C. Bremart<sup>2</sup>, <sup>1</sup>CHG St dizier, and <sup>2</sup>CSAPA52, Saint dizier, France
- 32 *Can Fibroscan® predict esophageal varices among cirrhotic alcohol abusers?*  
A. Hij<sup>1</sup>, P. Melin<sup>1,2</sup>, S. Samouri<sup>3</sup>, M. Marc<sup>1,2</sup>, M. Schoeny<sup>1</sup>, M. Guillaumot<sup>2</sup>, J. Fournier<sup>2</sup>, C. Bremard<sup>2</sup>, <sup>1</sup>CHG St dizier, <sup>2</sup>CSAPA 52, and <sup>3</sup>gastro enterology, CHG, Saint dizier, France
- 33 *Preliminary NIATx 200 results: Waiting time reduction from first request to assessment*  
A. Quanbeck<sup>1</sup>, A. Wheelock<sup>1</sup>, J. H. Ford<sup>1</sup>, A. Pulvermacher<sup>1</sup>, J. Robinson<sup>1</sup>, D. McCarty<sup>2</sup>, D. Gustafson<sup>1</sup>, <sup>1</sup>University of Wisconsin - Madison, Madison, WI, <sup>2</sup>Oregon Health Sciences University, Portland, OR
- 34 *Staff perspectives on innovation adoption: Lessons learned from NIATx 200*  
J. H. Ford, A. Pulvermacher, A. Quanbeck, A. Wheelock, D. Gustafson, University of Wisconsin - Madison, Madison, WI
- 34 *Positive reinforcement improves attendance and achievement on self-paced typing training programs in a Therapeutic Workplace for alcohol dependence*  
M. N. Koffarnus, C. J. Wong, K. Diemer, M. Fingerhood, G. E. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD
- 36 *Relational and technical processes of MI, Cognitive, and Client-Centered therapies*  
K. S. Ingersoll<sup>1</sup>, C. C. Wagner<sup>2</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, <sup>2</sup>Rehab Counseling, Virginia Commonwealth University, Richmond, VA



- 37 *Perceptions of alcohol stigma: Consequences for treatment utilization in a general population sample*

K. Keyes<sup>1</sup>, M. Hatzenbuehler<sup>2</sup>, K. McLaughlin<sup>3</sup>, T. Kushnir<sup>1</sup>, D. Hasin<sup>1</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Yale University, New Haven, CT, <sup>3</sup>Harvard University, Cambridge, MA

### EPIDEMIOLOGY

- 38 *Relationships between substance use and neuropsychological functioning among drug users in Novosibirsk, Russia*  
E. Dunne, J. Zur, A. Melnikov, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 39 *Emergence of clinical features of dependence soon after onset of extra-medical use of opioid-analgesic compounds*  
O. A. Adelaja, N. S. Miller, J. C. Anthony, Michigan State University, East Lansing, MI
- 40 *Resolving diagnostic comparability of opiate addiction using two datasets collected 30 years apart*  
R. K. Price, G. Widner, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 41 *Persistent nonmarijuana drug use trajectories and general health status among adults followed over 18 years (the CARDIA study)*  
S. Kertesz<sup>1,2</sup>, Y. Khodneva<sup>1</sup>, M. Safford<sup>1</sup>, J. Richman<sup>1</sup>, M. Pletcher<sup>3</sup>, <sup>1</sup>University of Alabama, and <sup>2</sup>VA Medical Center, Birmingham, AL, <sup>3</sup>University of California, San Francisco, CA
- 42 *Young adult substance use and workplace policies and conditions*  
C. L. Storr<sup>1,2</sup>, K. B. Roth<sup>2</sup>, <sup>1</sup>University of Maryland Baltimore, and <sup>2</sup>Johns Hopkins University, Baltimore, MD
- 43 *Prevalence of substance use and dependence in the workplace. A cross-sectional study in French occupational medicine centers, Aquitaine, France, EU*  
F. Serre<sup>1</sup>, S. Moulonguet-Cordier<sup>2,1</sup>, C. Denis<sup>1</sup>, M. Fatséas<sup>1</sup>, C. Maysonave<sup>3</sup>, M. Auriacombe<sup>1</sup>, <sup>1</sup>Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen Bordeaux 2, <sup>2</sup>Occupational medicine, Occupational medicine center, and <sup>3</sup>Occupational medicine, Regional State Control Agency, Bordeaux, France
- 44 *Cumulative occurrence of illegal drug use clinical features in 16 World Mental Health Surveys countries*  
M. Radovanovic<sup>1,2</sup>, J. C. Anthony<sup>2</sup>, H. Cheng<sup>2</sup>, W. M. H. S. Initiative<sup>3</sup>, <sup>1</sup>University Psychiatric Hospital, Ljubljana, Slovenia, <sup>2</sup>Michigan State University, East Lansing, MI, <sup>3</sup>World Mental Health Surveys Consortium, Boston, MA
- 45 *Traumatic event re-exposure increases treatment-seeking in syringe exchange participants*  
J. Peirce, V. L. King, R. K. Brooner, M. S. Kidorf, Johns Hopkins University School of Medicine, Baltimore, MD
- 46 *Early vs. late onset crack use: A case-control study*  
D. C. Ompad, V. Nandi, D. Vlahov, Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY
- 47 *Individual, study, and neighborhood characteristics associated with successful peer recruitment of drug users via respondent-driven sampling in New York City*  
A. Rudolph<sup>1</sup>, N. D. Crawford<sup>2,3</sup>, C. Latkin<sup>1</sup>, D. C. Ompad<sup>3</sup>, E. O. Benjamin<sup>3</sup>, K. White<sup>4</sup>, C. M. Fuller<sup>2,3</sup>, <sup>1</sup>Johns Hopkins School of Public Health, Baltimore, MD, <sup>2</sup>Columbia University, and <sup>3</sup>New York Academy of Medicine, New York, NY, <sup>4</sup>Harvard University, Boston, MA

- 48 *Higher acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis*  
A. Y. Walley<sup>1</sup>, M. K. Paasche-Orlow<sup>1</sup>, E. C. Lee<sup>2</sup>, S. R. Forsythe<sup>2</sup>, B. W. Jack<sup>2</sup>, <sup>1</sup>General Internal Medicine, and <sup>2</sup>Family Medicine, Boston University School of Medicine, Boston, MA
- 49 *Sex, drugs, and rock and roll: Visualizing behavioral mortality for the US population*  
C. Wright, R. K. Lanier, Rock Creek Pharmaceuticals, Inc., Gloucester, MA
- 50 *Is cannabis an aphrodisiac or sexual suppressant? A view from the past*  
S. Chandra, D. Barondess, J. C. Anthony, Michigan State University, East Lansing, MI
- 51 *Cannabis use among convicted drinking drivers*  
B. Brands<sup>1,2,3</sup>, R. Zalcman<sup>2</sup>, R. Mann<sup>2,3</sup>, G. Stoduto<sup>2</sup>, R. Thomas<sup>2</sup>, <sup>1</sup>Office of Drug and Alcohol Research and Surveillance, Health Canada, Ottawa, <sup>2</sup>Centre for Addiction and Mental Health, and <sup>3</sup>University of Toronto, Toronto, ON, Canada
- 52 *Cross-national research on early-onset cannabis use and failure to complete educational milestones*  
F. A. Fiestas, J. C. Anthony, Epidemiology, Michigan State University, Lima, Peru
- 53 *The growth of neighborhood hazards and youthful drug involvement*  
C. M. Furr-Holden, A. J. Milam, N. Ialongo, P. J. Leaf, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 54 *French modified Addiction Severity Index: Psychometrics properties in tobacco users and validity of the added tobacco section*  
C. Denis<sup>1</sup>, M. Fatséas<sup>1</sup>, S. Vittet<sup>1</sup>, V. Beltrand<sup>2,1</sup>, J. Daulouède<sup>2,1</sup>, M. Auriacombe<sup>1,2</sup>, <sup>1</sup>Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen Bordeaux 2, Bordeaux, France, <sup>2</sup>Addiction Treatment Center, Bizia, Bayonne, France
- 55 *Nicotine dependence among very recent-onset cigarette smokers in the USA*  
M. M. Catacora, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 56 *Smoking cessation in a low-income urban setting: Lessons learned*  
P. Sheikhattari<sup>1,2</sup>, M. Bolden<sup>1</sup>, P. Cassat<sup>3</sup>, L. Chao<sup>3</sup>, D. Wall<sup>3</sup>, F. A. Wagner<sup>1,2</sup>, <sup>1</sup>Center for Health Disparity Solutions, Morgan State University, <sup>2</sup>School of Community Health and Policy, Morgan State University, and <sup>3</sup>Peoples' Community Health Centers, Baltimore, MD
- 57 *A population-based investigation of the co-occurrence of non-medical prescription stimulant use and cigarette smoking among US Youth (Age 12-21)*  
S. P. Novak, E. Johnson, D. Fishbein, A. Kral, Behavioral Epidemiology, RTI International, Research Triangle Park, NC
- 58 *Clustering of tobacco use: Results from the Peruvian mental health survey, 2002-2006*  
V. Cruz<sup>1,2</sup>, C. Cachay<sup>2</sup>, J. Saavedra<sup>2,3</sup>, E. Kraenau<sup>4</sup>, J. Galindo<sup>2</sup>, G. Cruz<sup>2</sup>, J. C. Anthony<sup>1</sup>, <sup>1</sup>Department of Epidemiology, Michigan State University, East Lansing, MI, <sup>2</sup>Office of Epidemiology, Peruvian National Institute of Mental Health, Lima, Peru, <sup>3</sup>Department of Psychiatry, Cayetano Heredia Peruvian University, Lima, Peru, <sup>4</sup>School of Statistics, Main National University of San Marcos, Lima, Peru

### THEORETICAL/COMMENTARY

- 59 *The status of drug use among club drug users in Taiwan*  
J. Hsu<sup>1</sup>, W. I. Tsay<sup>1</sup>, C. H. Lin<sup>1</sup>, C. S. Chien<sup>1</sup>, K. S. Leung<sup>2</sup>, L. B. Cottler<sup>2</sup>, <sup>1</sup>Epidemiology and Education Division, National Bureau of Controlled Drugs, DOH, Taipei, Taiwan, <sup>2</sup>Epidemiology and Prevention Research Group, Psychiatry, Washington University School of Medicine, St. Louis, MO



- 60 *Collegiate recovery communities: Facilitating and investigating recovery in the young adult demographic*  
K. S. Harris, S. A. Smock, A. K. Baker, Center for the Study of Addiction and Recovery, Texas Tech University, Lubbock, TX
- 61 *Latin American psychiatrists develop biological protocols to control craving and prevent relapse in cocaine dependence*  
T. Llosa, COCA MEDICA, Lima, Peru
- 62 *A performance-based pilot project in alcohol and other drug treatment*  
L. L. Ransom<sup>1,2</sup>, D. A. Crevecoeur<sup>1</sup>, A. C. Myers<sup>1</sup>, J. A. Annon<sup>1</sup>, R. A. Rawson<sup>1</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Psychology, California Lutheran University, Thousand Oaks, CA
- 63 *Revision of the Reynolds Horton Theory of Executive Functioning: Implications for addictions treatment*  
A. M. Horton, C. R. Reynolds, Neuropsychology Section, Psych Associates of Maryland, Bethesda, MD
- 64 *The exponential model of demand: A novel, robust, and broadly applicable assay for translational behavioral pharmacology*  
P. Roma<sup>1,2</sup>, B. J. Kaminski<sup>2</sup>, R. Spiga<sup>1</sup>, N. A. Ator<sup>1</sup>, S. R. Hursh<sup>1,2</sup>, <sup>1</sup>Institutes for Behavior Resources, and <sup>2</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 65 *Where the rubber meets the road: An integrated model of technology transfer in the innovation process*  
A. ATTC Network Technology Transfer Workgroup, ATTC Network, Kansas City, MO
- 66 *From concept to practice: A strategic approach in disseminating motivational interviewing in a rural and frontier state*  
C. Peters<sup>1,2</sup>, A. H. Skinstad<sup>1,2</sup>, K. Summers<sup>1,2</sup>, <sup>1</sup>Prairieland's Addiction Technology Transfer Center, and <sup>2</sup>Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA
- 67 *Robust optimal decision policies for adaptive, time-varying interventions using Model Predictive Control*  
D. E. Rivera<sup>1</sup>, N. Nandola<sup>1</sup>, L. M. Collins<sup>2,3</sup>, <sup>1</sup>Mechanical, Aerospace, Chemical and Materials Engineering, Arizona State University, Tempe, AZ, <sup>2</sup>The Methodology Center, and <sup>3</sup>Human Development and Family Studies, Penn State University, State College, PA
- 68 *Prescription opioids: Managing the risks while maintaining appropriate patient access*  
J. Henningfield, R. Fant, S. Schnoll, M. Sembower, Research & Health Policy and Risk Management, Pinney Associates, Bethesda, MD
- 69 *Free vs paid services: A comparative analysis in a harm-reduction-oriented outpatient methadone maintenance center*  
A. O. Abagiu<sup>1,2</sup>, M. Anghelescu<sup>2</sup>, R. Ianos-Rancovici<sup>2</sup>, B. Rusu<sup>2</sup>, I. G. Stoica<sup>2</sup>, L. Stanciut<sup>2</sup>, F. Georgescu<sup>2</sup>, F. Gheorghe<sup>2</sup>, L. Velica<sup>2</sup>, E. Cojocaru<sup>2</sup>, <sup>1</sup>Adults 6, National Institute for Infectious Diseases Prof. Dr. Matei Bals, and <sup>2</sup>Arena - First low threshold MMT Center, Bucharest, Romania
- 70 *The CPDD Special Conference on Risk Management and Post-Marketing Surveillance of CNS Drugs: Implications for opioid REMS*  
C. R. Schuster<sup>1</sup>, J. Henningfield<sup>2</sup>, R. Balster<sup>3</sup>, A. Barthwell<sup>4</sup>, C. E. Johanson<sup>1</sup>, <sup>1</sup>CRS Associates, Chicago, IL, <sup>2</sup>Research and Health Policy, Pinney Associates and Johns Hopkins, Bethesda, MD, <sup>3</sup>Medical College of VA, Richmond, VA, <sup>4</sup>EMGlobal, Arlington, VA

- 71 *Comparison of the European and US approaches to the evaluation of abuse liability and drug scheduling for new chemical entities*  
R. Fant<sup>1</sup>, J. E. Henningfield<sup>1</sup>, D. J. Heal<sup>2</sup>, <sup>1</sup>Pinney Associates, Bethesda, MD, <sup>2</sup>RenaSci Consultancy Ltd, Nottingham, United Kingdom
- 72 *The global infrastructure for addiction science: A public health perspective*  
D. Morisano<sup>1</sup>, T. F. Babor<sup>2</sup>, <sup>1</sup>Psychiatry/Child & Family Institute, St. Luke's-Roosevelt Hospital Center, New York, NY, <sup>2</sup>Community Medicine, University of Connecticut School of Medicine, Farmington, CT
- 73 *The development of a new model for international collaborative research and education*  
C. B. McCoy, M. Comerford, Comprehensive Drug Research Center, University of Miami, Miami, FL

### COCAINE: HUMAN STUDIES

- 74 *Assessing the reliability and validity of cocaine use algorithms in clinical trials*  
W. Y. Cheng, E. Nunes, F. Levin, A. Bisaga, Psychiatry, Columbia University, New York, NY
- 75 *Theories of addiction: Cocaine users' explanation for continuing drug use and relapse*  
C. N. Haile, R. De La Garza, II, J. J. Mahoney, A. D. Kalechstein, T. F. Newton, Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX
- 76 *The reinforcing effects of intranasal cocaine on a progressive ratio schedule*  
W. W. Stoops<sup>1,2</sup>, J. A. Lile<sup>1</sup>, C. R. Rush<sup>1,3,4</sup>, <sup>1</sup>Behavioral Science, <sup>2</sup>Center on Drug and Alcohol Research, <sup>3</sup>Psychiatry, and <sup>4</sup>Psychology, University of Kentucky, Lexington, KY
- 77 *Dopamine  $\beta$  hydroxylase inhibitor SYN117 decreases subjective effects of cocaine*  
K. A. Cunningham<sup>1</sup>, C. L. Carbone<sup>1</sup>, N. C. Anastasio<sup>1</sup>, T. A. Harper<sup>1</sup>, F. G. Moeller<sup>2</sup>, D. L. Ware<sup>1</sup>, M. A. Fuller<sup>1</sup>, G. J. Holstein<sup>1</sup>, K. E. Smith<sup>1</sup>, J. B. Jayroe<sup>1</sup>, S. Bandak<sup>3</sup>, K. Reiman<sup>3</sup>, A. Neale<sup>3</sup>, L. Pickford<sup>3</sup>, <sup>1</sup>Center for Addiction Research, University Texas Medical Branch, Galveston, TX, <sup>2</sup>Psychiatry Behavioral Science, University of Texas Health Science Center, Houston, TX, <sup>3</sup>Synosia Therapeutics, Inc., San Francisco, CA
- 78 *Effect of cocaine on buprenorphine or methadone pharmacokinetics: Clinical implications*  
E. McCance-Katz<sup>1</sup>, P. M. Rainey<sup>2</sup>, D. E. Moody<sup>3</sup>, J. Arenander<sup>1</sup>, P. Jatlow<sup>4</sup>, <sup>1</sup>Psychiatry, UCSF, Berkeley, CA, <sup>2</sup>Laboratory Medicine, University of Washington, Seattle, WA, <sup>3</sup>Toxicology, University of Utah, Salt Lake City, UT, <sup>4</sup>Laboratory Medicine, Yale University, New Haven, CT
- 79 *Impact of D-cycloserine on cocaine cue extinction*  
K. L. Price<sup>1</sup>, S. M. DeSantis<sup>2</sup>, M. E. Saladin<sup>1</sup>, A. L. McRae-Clark<sup>1</sup>, C. B. McWhite<sup>1</sup>, K. T. Brady<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, and <sup>2</sup>Biometry, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC
- 80 *The discriminative-stimulus, subject-rated, performance and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans*  
J. Lile, W. Stoops, L. Hays, C. Rush, University of Kentucky College of Medicine, Lexington, KY
- 81 *Extinction of attentional bias to cocaine-related stimuli: Difference between non-treatment-seeking and treatment-seeking cocaine-dependent subjects*  
S. Liu<sup>1</sup>, S. D. Lane<sup>1</sup>, J. M. Schmitz<sup>1</sup>, A. J. Waters<sup>2</sup>, K. A. Cunningham<sup>3</sup>, F. G. Moeller<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, <sup>2</sup>Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, <sup>3</sup>Center for Addiction Research and Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX

- 82 *Neuropsychological performance of cocaine addicts during treatment*  
G. Garcia-Fernandez<sup>1</sup>, O. Garcia-Rodriguez<sup>2</sup>, R. Secades-Villa<sup>1</sup>, S. Fernandez-Artamendi<sup>1</sup>, J. Fernandez-Hermida<sup>1</sup>, <sup>1</sup>Psychology, University of Oviedo, Oviedo, Spain, <sup>2</sup>Clinical Psychology, University of Barcelona, Barcelona, Spain
- 83 *Adding voucher-based incentives to CRA improves outcomes during treatment for cocaine dependence*  
R. Secades-Villa<sup>1</sup>, G. García Fernández<sup>1</sup>, O. García-Rodríguez<sup>2</sup>, H. Álvarez-Rodríguez<sup>3</sup>, J. A. Álvarez-García<sup>3</sup>, E. Sánchez-Hervás<sup>4</sup>, <sup>1</sup>Psychology, University of Oviedo, Oviedo, <sup>2</sup>Clinical Psychology, University of Barcelona, Barcelona, <sup>3</sup>Proyecto Hombre, Oviedo, and <sup>4</sup>Valencia State Health Agency, Valencia, Spain
- 84 *A money management-based therapy increases valuation of future rewards*  
A. C. Black, M. I. Rosen, Psychiatry, Yale University, West Haven, CT
- 85 *Inter-temporal choice of cocaine addicts: Single and cross commodity discounting of cocaine and money*  
W. K. Bickel, D. R. Christensen, R. D. Landes, L. Jackson, B. A. Jones, University of Arkansas for Medical Sciences, Little Rock, AR
- 86 *The case for cash: Contingency management for cocaine dependence*  
D. S. Festinger<sup>1</sup>, K. L. Dugosh<sup>1</sup>, K. C. Kirby<sup>1</sup>, J. C. Croft<sup>1</sup>, D. B. Marlowe<sup>1,2</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>National Association of Drug Court Professionals, Alexandria, VA
- 87 *Effects of voucher payment through contingency management in topiramate treatment for cocaine dependence*  
A. Umbricht<sup>1</sup>, J. P. Nanda<sup>2</sup>, E. L. Winstanley<sup>1</sup>, D. A. Tompkins<sup>1</sup>, M. Z. Mintzer<sup>1</sup>, E. C. Strain<sup>1</sup>, G. E. Bigelow<sup>1</sup>, <sup>1</sup>Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, and <sup>2</sup>Bloomberg School of Public Health, Baltimore, MD
- 88 *CM treatment outcomes for cocaine-dependent homeless as a function of age*  
J. Milby<sup>1</sup>, J. Schumacher<sup>1</sup>, D. Wallace<sup>2</sup>, L. Hayes<sup>1</sup>, M. Cobb-Burns<sup>3</sup>, J. Reese<sup>1</sup>, S. Mennemeyer<sup>1</sup>, R. Vuchinich<sup>1</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>RTI International, Raleigh, NC, <sup>3</sup>Northwestern University, Chicago, IL
- 89 *Alcohol dependence does not influence drug abstinence outcomes from contingency management treatment among cocaine-dependent homeless persons*  
R. Vuchinich<sup>1</sup>, D. Wallace<sup>2</sup>, J. Milby<sup>1</sup>, J. Schumacher<sup>1</sup>, S. Mennemeyer<sup>1</sup>, S. Kertesz<sup>1</sup>, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>RTI International, Research Triangle Park, NC
- 90 *The ability of initial urine drug screen results to identify good prognosis patients among individuals addicted to both cocaine and alcohol*  
K. M. Kampman, C. Dackis, K. Lynch, L. Sacerio, K. Varillo, T. Wolven, H. Pettinati, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 91 *Feasibility and effectiveness of computer-based therapy in a community-based program*  
A. C. Brooks, D. Ryder, D. Carise, K. Kirby, Treatment Research Institute, Philadelphia, PA
- 92 *Balloon Analogue Risk Task and Affect*  
T. L. White<sup>1</sup>, C. W. Lejuez<sup>2</sup>, H. de Wit<sup>3</sup>, <sup>1</sup>Alcohol & Addiction/Community Health, Brown University, Providence, RI, <sup>2</sup>Psychology, University of Maryland, College Park, MD, <sup>3</sup>Psychiatry, University of Chicago, Chicago, IL
- 93 *Changes in risk-taking behavior as a function of motivational saliency and value*  
C. Kopetz, N. Calvin, A. Lee, C. Lejuez, Center for Addictions, Personality, and Emotion Research, University of Maryland, College Park, MD

- 94 *Excited delirium, tasers and sudden death*  
D. C. Mash<sup>1</sup>, B. A. Hyma<sup>2</sup>, S. B. Karch<sup>3</sup>, H. Druid<sup>4</sup>, C. V. Wetli<sup>5</sup>, L. Duque<sup>1</sup>, N. Adi<sup>1</sup>, J. P. Pablo<sup>1</sup>, X. Xie<sup>1</sup>, <sup>1</sup>Neurology, Molecular and Cellular Pharmacology, Univ. of Miami Miller School of Medicine, and <sup>2</sup>Miami-Dade Medical Examiner, Miami, FL, <sup>3</sup>University of California, Berkeley, CA, <sup>4</sup>Karolinska Institute, Stockholm, Sweden, <sup>5</sup>Medical Legal Investigations and Forensic Sciences, Suffolk, NY
- 95 *Specific predictors of suicide attempts in a high risk community corrections population*  
C. McCullumsmith, J. Hammell, J. Fife, K. Cropsey, Psychiatry, University of Alabama at Birmingham, Birmingham, AL
- 96 *Variations in sexual risk behaviors associated with sexually transmitted diseases among African-American and white female drug users*  
C. E. Cavanaugh<sup>1</sup>, L. J. Floyd<sup>1</sup>, T. V. Penniman<sup>1</sup>, A. Hulbert<sup>1</sup>, C. Gaydos<sup>2</sup>, W. W. Latimer<sup>1</sup>, <sup>1</sup>Public Health, Mental Health, and <sup>2</sup>Div Infectious Disease, Medicine, Johns Hopkins University, Baltimore, MD
- 97 *Strategies developed by crack users to deal with the risks resulting from the consumption*  
L. A. Ribeiro, Z. V. Sanchez, S. A. Nappo, Psychobiology, Federal University of Sao Paulo, Sao Paulo, Brazil

### STIMULANTS: ANIMAL I

- 98 *Repeated administration of a longer-acting mutant cocaine esterase: Interactions with the acute cardiovascular effects of cocaine and immune responses in freely moving rhesus monkeys*  
G. T. Collins, D. Narasimhan, K. A. Carey, A. A. Berlin, N. W. Lukacs, R. K. Sunahara, J. H. Woods, M. C. Ko, University of Michigan Medical School, Ann Arbor, MI
- 99 *Tetrahydroisoquinolines as orexin-1 receptor antagonists: Structure-activity relationships*  
Y. Zhang, D. A. Perrey, B. P. Gilmour, K. Warner, T. Langston, H. A. Navarro, B. F. Thomas, Research Triangle Institute, Research Triangle Park, NC
- 100 *Fat content and amount of chow impact the sensitivity of rats to quinpirole-induced yawning*  
M. Baladi<sup>1</sup>, C. P. France<sup>1,2</sup>, <sup>1</sup>Pharmacology, and <sup>2</sup>Psychiatry, University of Texas Health Science Center, San Antonio, TX
- 101 *Knockdown of presynaptic D2 receptors in dorsal striatum inhibits the behavioral and neurochemical effects of haloperidol*  
C. E. Bass, E. B. Oleson, L. C. Blume, D. C. Roberts, A. C. Howlett, E. A. Budygin, Physiology and Pharmacology, Wake Forest University Health Sciences, Winston Salem, NC
- 102 *Attenuation of cocaine self-administration by novel dopamine D3 receptor ligands*  
B. C. Nolan<sup>1</sup>, L. M. Robertson<sup>1</sup>, J. M. Pang<sup>1</sup>, M. Barajas<sup>1</sup>, S. M. Weber<sup>1</sup>, J. Durbin<sup>2</sup>, N. A. Peartree<sup>1</sup>, R. H. Mach<sup>2</sup>, R. R. Luedtke<sup>3</sup>, J. L. Neisewander<sup>1</sup>, <sup>1</sup>Psychology, Arizona State University, Tempe, AZ, <sup>2</sup>Washington University School of Medicine, St. Louis, MO, <sup>3</sup>University of North Texas Health Science Center, Fort Worth, TX
- 103 *Enhanced dopamine release in the dorsolateral caudate putamen during relapse as a function of previous cocaine self-administration history*  
A. Gabriele, A. M. Pacchioni, R. E. See, Neurosciences, Medical University of South Carolina, Charleston, SC
- 104 *Anxiogenic properties of cocaine-paired cues in rats with a prior history of self-administration*  
D. Buffalari, C. K. Baldwin, R. E. See, Neuroscience, Medical University of South Carolina, Charleston, SC

BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS



- 105 *Effects of the monoamine releasers PAL-353 and (+)phenmetrazine on choice between cocaine and food in rhesus monkeys*  
M. L. Banks<sup>1</sup>, B. E. Blough<sup>2</sup>, S. S. Negus<sup>1</sup>, <sup>1</sup>Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC
- 106 *Reversible and persistent decreases in cocaine self-administration after treatment with the cholinesterase inhibitors rivastigmine and donepezil*  
K. Grasing<sup>1</sup>, Y. Yang<sup>2</sup>, S. He<sup>1</sup>, <sup>1</sup>Substance Abuse Research Laboratory, Kansas City VA Medical Center, Kansas City, MO, <sup>2</sup>Institute of Combined Chinese and Western Medicine, Southern Medical University, Guangzhou, China
- 107 *Acetylcholine esterase inhibitor tacrine reduces extinction responding for amphetamine*  
A. S. Giarola<sup>1</sup>, A. Auber<sup>2</sup>, V. Tedesco<sup>2</sup>, G. Fumagalli<sup>2</sup>, C. Chiamulera<sup>2</sup>, <sup>1</sup>Safety Assessment, GlaxoSmithKline, and <sup>2</sup>Medicine and Public Health, University of Verona, Verona, Italy
- 108 *Effects of the nicotinic receptor partial agonist varenicline on cocaine- and food-maintained behavior in rats*  
M. G. LeSage<sup>1,2</sup>, F. I. Carroll<sup>3</sup>, <sup>1</sup>Medicine, Minneapolis Medical Research Foundation, and <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC
- 109 *Galantamine ameliorates the impairment of recognition memory in mice treated with methamphetamine repeatedly*  
A. Mouri<sup>1,2</sup>, Y. Noda<sup>3,4</sup>, D. Wang<sup>1</sup>, Y. Ando<sup>3</sup>, Y. Waki<sup>3</sup>, S. Yamada<sup>3</sup>, T. Nabeshima<sup>1,4</sup>, <sup>1</sup>Chemical Pharmacology, Graduate School of Pharmaceutical Sciences Meijo University, Nagoya, <sup>2</sup>Division of Scientific Affairs, Japanese Society of Pharmacopoeia, Tokyo, <sup>3</sup>Division of Clinical Sciences and Neuropsychopharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, Nagoya, and <sup>4</sup>The Academic Frontier Project for Private Universities, Comparative Cognitive Science Institutes, Meijo University, Nagoya, Japan
- 110 *Effects of dopamine D1 and NMDA receptors on acute cocaine-induced Fos protein expression and MKP-1 phosphorylation in the striatum of Fischer rats*  
S. Jenab, W. Sun, L. Zhou, R. Hazim, V. Quinones-Jenab, Psychology, Hunter College of CUNY, New York, NY
- 111 *A rapid method to measure limbic and striatal behavior and dopamine neurochemistry in mice*  
S. P. Vickers, D. J. Heal, M. R. Prow, S. G. Dykes, S. C. Cheetham, RenaSci Consultancy Ltd, Nottingham, United Kingdom
- 112 *“Neurochemical fingerprinting” as a rapid technique to discriminate between drugs with different presynaptic dopaminergic mechanisms*  
D. J. Heal, M. R. Prow, S. C. Cheetham, RenaSci Consultancy Ltd, Nottingham, United Kingdom
- 113 *Do dopaminergic drugs induce a place preference in normal rat?*  
Y. Zengin<sup>1</sup>, N. Authier<sup>1</sup>, P. Courty<sup>1</sup>, P. Llorca<sup>1</sup>, F. Durif<sup>2</sup>, <sup>1</sup>CHU Gabriel Montpied - CMP B - Service de Psychiatrie du Pr. PM Llorca, and <sup>2</sup>Service de Neurologie, Clermont Ferrand, France
- 114 *Disruption of prepulse inhibition by apomorphine across modalities*  
L. Moran, R. M. Booze, C. F. Mactutus, Psychology, University of South Carolina, Columbia, SC

### HALLUCINOGENS

- 115 *Behavioral effects of the novel hallucinogen 2C-C*  
M. B. Gatch, C. Taylor, C. Elsen, M. J. Forster, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
- 116 *Discriminative stimulus effects of various classes of psychoactive compounds in ketamine-trained rats*  
K. Yoshizawa, K. Aoki, T. Mori, N. Kuzumaki, M. Narita, T. Suzuki, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan
- 117 *Discriminative stimulus effects of the synthetic hallucinogen N,N-diisopropyltryptamine*  
T. Carbonaro, M. B. Gatch, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
- 118 *Discriminative, locomotor, and place conditioning effects of salvinorin A and its synthetic derivatives*  
L. E. Baker, M. M. Peet, S. L. Walker, J. J. Panos, Psychology, Western Michigan University, Kalamazoo, MI
- 119 *MTEP drug discrimination: Psychoactive effects selectively induced by mGluR5 antagonists*  
M. D. Swedberg<sup>1</sup>, P. Raboisson<sup>2</sup>, C. Velasquez<sup>1</sup>, M. Ståhlberg<sup>1</sup>, <sup>1</sup>Safety Pharmacology, and <sup>2</sup>Disease Biology, AstraZeneca R&D Södertälje, Södertälje, Sweden
- 120 *Psilocybin dose-effects in healthy volunteers: Mystical-type experience, fear, and headache*  
R. R. Griffiths<sup>1</sup>, M. W. Johnson<sup>2</sup>, <sup>1</sup>Psychiatry and Neuroscience, and <sup>2</sup>Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD
- 121 *Psilocybin-occasioned mystical experience predicts increases in the NEO-PI personality trait of openness*  
K. MacLean, M. Johnson, R. Griffiths, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

### PROGRAM DESCRIPTION

- 122 *Current drug scheduling reviews reported by the Drug Enforcement Administration*  
S. R. Tella, C. Prioleau, S. G. Ghosland, S. M. Carr, C. A. Sannerud, Office of Diversion Control, Drug Enforcement Administration, Springfield, VA
- 123 *DEA monitoring of anabolic steroids and emerging drugs*  
T. L. Boos, L. L. Wong, C. M. Carr, C. A. Sannerud, Drug & Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Springfield, VA
- 124 *Manufacture, characterization, and stability of standardized marijuana cigarettes*  
K. Davis<sup>1</sup>, P. G. Pande<sup>1</sup>, B. Thomas<sup>1</sup>, S. Sabharwal<sup>1</sup>, M. McCleary<sup>1</sup>, L. Caddell<sup>1</sup>, P. Leahy<sup>1</sup>, M. ElSohly<sup>2</sup>, <sup>1</sup>Analytical Chemistry & Pharmaceuticals, RTI International, Research Triangle Park, NC, <sup>2</sup>University of Mississippi, University, MS
- 125 *Use of the Michigan Automated Prescription System to monitor and manage diversion in an urban methadone clinic*  
C. Christensen, G. L. Rhodes, M. Berman, J. Bado, S. Entenman, M. Greenwald, Wayne State University, Detroit, MI
- 126 *Identification of Internet discussion aimed at defeating abuse deterrent formulations*  
E. McNaughton, T. A. Cassidy, S. F. Butler, S. H. Budman, E. Whalley, Inflexxion, Inc., Newton, MA
- 127 *Internet survey to explore methods for collecting street price of prescription opioids*  
M. Weiss, T. A. Cassidy, E. McNaughton, S. F. Butler, Inflexxion, Inc., Newton, MA

- 128 *Drug life cycle situation awareness: A novel approach to signal detection and post-marketing surveillance of prescription drugs*  
T. A. Cassidy, S. F. Butler, S. H. Budman, Inflexxion, Inc., Newton, MA
- 129 *Development of a behavioral activation intervention for smokers with elevated depressive symptoms in a residential substance use program*  
A. N. Banducci, L. MacPherson, J. R. Leonard, W. Francis, C. W. Lejuez, University of Maryland College Park, College Park, MD
- 130 *Online self-help for methamphetamines users: Development and evaluation of an Australian Website*  
L. L. Jenner<sup>1</sup>, N. K. Lee<sup>1,2,3</sup>, R. Noble<sup>1</sup>, <sup>1</sup>Clinical Research, Turning Point Alcohol and Drug Centre, Fitzroy, VIC, <sup>2</sup>Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, VIC, and <sup>3</sup>National Drug Research Institute, Curtin University, Perth, WA, Australia
- 131 *In-home-messaging devices for veterans with substance use disorders*  
E. J. Santa Ana<sup>1</sup>, S. Martino<sup>2</sup>, D. L. Stallings<sup>3</sup>, B. J. Rounsaville<sup>2</sup>, <sup>1</sup>Charleston VAMC, Charleston, SC, <sup>2</sup>Yale SOM and VA CT Healthcare System, West Haven, CT, <sup>3</sup>VHA Office of Tele-health Services, Lake City, FL
- 132 *Modified therapeutic community approach in partial-day outpatient substance abuse treatment: Attendance, retention, and completion*  
J. Kimbro<sup>1</sup>, S. Smith<sup>1</sup>, C. Duncan<sup>2</sup>, S. Sacks<sup>3</sup>, J. Sacks<sup>4</sup>, K. McKendrick<sup>3</sup>, <sup>1</sup>Phoenix Programs, Inc., and <sup>2</sup>Tre, LLC, Columbia, MO, <sup>3</sup>Center for the Integration of Research & Practice, <sup>4</sup>National Development & Research Institutes, Inc., New York, NY
- 133 *NIDA's Clinical Trials Network can facilitate comparative effectiveness research on addiction treatments*  
U. E. Ghitza, S. Sparenborg, D. Liu, B. Tai, Center for the Clinical Trials Network, NIH/NIDA, Bethesda, MD
- 134 *Implementing research in traditional community treatment programs: Findings from a CTN Trial*  
A. J. Cohen<sup>1</sup>, D. George<sup>3</sup>, C. Langlois<sup>1</sup>, A. Moreno<sup>1</sup>, D. Yomjinda<sup>3</sup>, C. Boubion<sup>3</sup>, J. Martin<sup>1</sup>, R. Donovan<sup>3</sup>, C. Vimieiro<sup>1</sup>, C. Thomas<sup>2</sup>, A. Hasson<sup>2</sup>, M. Hillhouse<sup>2</sup>, W. Ling<sup>2</sup>, <sup>1</sup>Research/Training, Bay Area Addiction, Research and Treatment, Inc., San Francisco, CA, <sup>2</sup>ISAP, UCLA, and <sup>3</sup>Matrix, Los Angeles, CA
- 135 *Small changes – big results: The effects of a reorganization of intake procedures on access to treatment*  
A. H. Skinstad<sup>1,2</sup>, J. Zwick<sup>3</sup>, G. Lutz<sup>4</sup>, T. Bergthold<sup>1,2</sup>, M. Van der Linden<sup>5</sup>, R. Kierksick<sup>5</sup>, K. Summers<sup>1,2</sup>, <sup>1</sup>Prairilands Addiction Technology Transfer Center, and <sup>2</sup>Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, <sup>3</sup>Zwick Healthcare Consultants, Urbandale, <sup>4</sup>Center for Behavioral Research, University of Northern Iowa, Cedar Falls, and <sup>5</sup>Iowa Gambling Treatment Program, Iowa Department of Public Health, Des Moines, IA
- 136 *Physician mentoring to facilitate buprenorphine treatment: The PCSS-Buprenorphine Project*  
J. E. Egan<sup>1</sup>, L. Weiss<sup>1</sup>, A. J. Saxon<sup>2</sup>, P. P. Casadonte<sup>3</sup>, J. Martin<sup>4</sup>, E. McCance-Katz<sup>5</sup>, J. Renner<sup>6</sup>, D. A. Fiellin<sup>7</sup>, <sup>1</sup>The New York Academy of Medicine, New York, NY, <sup>2</sup>Addictions Care Line VA Puget Sound Health Care System, Seattle, WA, <sup>3</sup>New York University, New York, NY, <sup>4</sup>BAART Turk Street Clinic, and <sup>5</sup>University of California, San Francisco, CA, <sup>6</sup>Boston University, Boston, MA, <sup>7</sup>Yale University, New Haven, CT



- 137 *Back to basics: Utilizing training, performance feedback, and coaching to develop a clinical supervision infrastructure for frontier states*  
W. L. Woods, N. A. Roget, J. A. Hartje, K. L. Cahoon, Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, NV
- 138 *A retrospective study of protégés and mentors of the Prairielands ATTC Leadership Development program: The importance of the mentor-protégés relationship*  
T. Bergthold<sup>1,2</sup>, A. H. Skinstad<sup>1,2</sup>, K. Summers<sup>1,2</sup>, <sup>1</sup>Prairielands Addiction Technology Transfer Center, and <sup>2</sup>Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA
- 139 *Treatnet II: Working towards evidence-based drug dependence treatment and care: Capacity Building Cascade*  
G. Gerra, A. Busse, E. Saenz, B. Gerbautz, J. Tomas-Rossello, K. Niaz, I. Palacios, S. Ibanez de Benito, G. Campello, HHDS, United Nations Office on Drugs and Crime, Vienna, Austria
- 140 *On-site hepatitis C treatment in methadone maintenance: Description of a model of care*  
K. Canfield<sup>1,2</sup>, S. L. Batki<sup>2,1</sup>, <sup>1</sup>SUNY Upstate Medical University, Syracuse, NY, <sup>2</sup>Psychiatry, University of California, San Francisco, San Francisco, CA
- 141 *The influence of neuro-cognitive impairment on intervention outcomes among injection drug users living with HIV/AIDS*  
I. Ezeabogu, M. Copenhaver, J. Potrepka, A. Meier, University of Connecticut, Storrs, CT
- 142 *The impact of age of drug use debut on subsequent HIV risk behavior among injection drug users*  
J. Potrepka, M. Copenhaver, I. Ezeabogu, A. Meier, University of Connecticut, Storrs, CT
- 143 *Adoption of HIV counseling and testing following completion of randomized clinical trial*  
L. Haynes<sup>1</sup>, B. Holmes<sup>3</sup>, A. Amberg<sup>3</sup>, K. Brady<sup>1</sup>, L. Metsch<sup>2</sup>, <sup>1</sup>Psychiatry, Medical University of South Carolina, Columbia, SC, <sup>2</sup>Epidemiology and Public Health, University of Miami, Miami, FL, <sup>3</sup>LRADAC, Columbia, SC
- 144 *Integrating HIV medical and behavioral health care in an urban setting*  
C. L. Arfken<sup>1</sup>, M. Greenwald<sup>1</sup>, L. L. Zeman<sup>1</sup>, D. Johnson<sup>1</sup>, C. Christensen<sup>3</sup>, J. Cohn<sup>2</sup>, <sup>1</sup>Psychiatry, <sup>2</sup>Infectious Diseases, and <sup>3</sup>OB-GYN, Wayne State University, Detroit, MI
- 145 *The evolution of combined economic, social network and geographic research with marginalized populations*  
J. K. Roddy<sup>1</sup>, P. J. Draus<sup>1</sup>, M. K. Greenwald<sup>2</sup>, <sup>1</sup>Social Sciences, University of Michigan Dearborn, Dearborn, MI, <sup>2</sup>Substance Abuse Research Division (Psychiatry), Wayne State University, Detroit, MI
- 146 *A national primary care and prevention system for addictions in Mexico*  
O. Campollo<sup>1</sup>, A. Ramos<sup>2</sup>, F. J. Anguiano<sup>2</sup>, <sup>1</sup>Center of Studies on Alcohol and Addictions, Antiguo Hospital Civil, University of Guadalajara, and <sup>2</sup>State Council Against Addictions of Jalisco (CECAJ), Guadalajara, Mexico

## **Symposium V**

**Salons HI  
2:00 - 4:00 PM**

### **THE ROLE OF THE HYPOCRETIN/OREXIN SYSTEM IN ADDICTION: CURRENT STATUS AND RATIONALE AS A DRUG DISCOVERY TARGET**

Chairs: David Shurtleff and Sari Izenwasser

- 2:00 *Optogenetic control of arousal and brain reward*  
Luis De Lecea, Stanford University School of Medicine, Palo Alto, CA
- 2:25 *Role of the orexin/hypocretin system in seeking natural and drug rewards*  
Gary Aston-Jones, Neuroscience, Medical University of South Carolina, Charleston, NC
- 2:50 *Hypocretin/orexin promotes motivation for highly salient rewards*  
Stephanie L. Borgland, The University of British Columbia, Vancouver, BC, Canada
- 3:15 *Selective OX1 and OX2 receptor antagonists differentially modulate brain circuits relevant for sleep and reward processing*  
Emilio Merlo Pich, Neurosciences, CEDD, GlaxoSmithKline, Verona, Italy
- 3:40 *Hypocretin mechanisms as a drug discovery target in nicotine dependence*  
William Corrigall, Division of Basic Neuroscience and Behavioral Science, National Institute on Drug Abuse, Bethesda, MD

## **Oral Communications 5**

**Salon DE  
2:00 - 4:00 PM**

### **AGE MATTERS: ADOLESCENT ISSUES OF DRUG USE**

Chairs: Brent E. Mancha and Catherine Stanger

- 2:00 *Mental health, school problems, and substance use among urban adolescents: The mediating effect of social network quality*  
M. J. Mason, Education & Human Services, Villanova University, Bryn Mawr, PA
- 2:15 *Adolescent access to substance abuse treatment in the United States*  
R. Ramchand, A. Kofner, A. Morral, B. Griffin, K. Harris, RAND, Arlington, VA
- 2:30 *Contingency Management for adolescent marijuana abuse: CACE models*  
C. Stanger, A. Budney, G. Norton, Center for Addiction Research, University of Arkansas for Medical Sciences, Little Rock, AR
- 2:45 *Brief intervention for drug-abusing adolescents*  
K. Winters<sup>1,2</sup>, T. Fahnhorst<sup>1</sup>, A. Botzet<sup>1</sup>, <sup>1</sup>Psychiatry, University of Minnesota, Minneapolis, MN, <sup>2</sup>Treatment Research Institute, Philadelphia, PA
- 3:00 *A multi-site trial of OROS-MPH with CBT for adolescents with ADHD and substance use disorders*  
P. Riggs<sup>1</sup>, T. Winhusen<sup>2</sup>, J. Leimberger<sup>3</sup>, S. K. Mikulich-Gilbertson<sup>1</sup>, <sup>1</sup>Psychiatry, University of Colorado, Denver, Aurora, CO, <sup>2</sup>Psychiatry, University of Cincinnati, Cincinnati, OH, <sup>3</sup>Duke University Research Institute, Duke University Medical Center, Durham, NC
- 3:15 *Patterns of alcohol abuse and dependence symptoms among male youths in the United States: A latent class analysis*  
B. E. Mancha, S. L. Hedden, S. S. Martins, W. W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

- 3:30 *Prescription stimulant misuse among adolescents and young adults*  
S. Lankenau<sup>1</sup>, J. Jackson Bloom<sup>2</sup>, A. Harocopos<sup>3</sup>, M. Treese<sup>2</sup>, M. Teti<sup>1</sup>, <sup>1</sup>School of Public Health, Drexel University, Philadelphia, PA, <sup>2</sup>Childrens Hospital Los Angeles, Los Angeles, CA, <sup>3</sup>National Development and Research Institutes, Inc., New York, NY
- 3:45 *Self-reported stimulant use, ADHD symptoms and knowledge of ADHD diagnosis among a national sample of youth*  
K. D. Fitterling<sup>1,2</sup>, S. E. Bradford<sup>2</sup>, A. Ben Abdallah<sup>2</sup>, L. B. Cottler<sup>2</sup>, <sup>1</sup>St. Louis College of Pharmacy, and <sup>2</sup>Washington University School of Medicine, St. Louis, MO

### Oral Communications 6

Salon FG  
2:00 - 4:00 PM

#### TREATMENTS FOR NICOTINE ADDICTION: MORE THAN SMOKE AND MIRRORS

Chairs: Jennifer Tidey and Laurie A. Zawertailo

- 2:00 *Up in smoke? Cognitive-behavioral motivational enhancement +/- nicotine replacement therapy for adolescent smokers*  
A. Swanson<sup>1</sup>, S. Shoptaw<sup>1,2</sup>, K. G. Heinzerling<sup>1</sup>, E. D. London<sup>1,2</sup>, E. Cederblom<sup>1</sup>, <sup>1</sup>Family Medicine, and <sup>2</sup>Psychiatry and Biobehavioral Sciences, UCLA David Geffen School of Medicine, Los Angeles, CA
- 2:15 *Sensorimotor replacement reduces cigarette craving, withdrawal symptoms and smoking in smokers with schizophrenia*  
J. Tidey<sup>1</sup>, D. Rohsenow<sup>2,1</sup>, R. Swift<sup>2,1</sup>, G. Kaplan<sup>3</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Providence VA Medical Center, Providence, RI, <sup>3</sup>VA Boston Healthcare System, Brockton, MA
- 2:30 *Methods to efficiently recruit and effectively retain unmotivated smokers in a nationwide randomized clinical trial*  
M. J. Carpenter, A. J. Alberg, K. M. Gray, M. E. Saladin, Medical University of South Carolina, Charleston, SC
- 2:45 *Effect of varenicline on cue-induced cigarette craving: A randomized placebo-controlled study*  
L. A. Zawertailo<sup>1,2</sup>, G. Staio<sup>2,3</sup>, S. Wang<sup>3,4</sup>, P. Selby<sup>1</sup>, U. Busto<sup>2,3,4</sup>, <sup>1</sup>Addictions Program, Centre for Addiction and Mental Health, <sup>2</sup>Pharmacology and Toxicology, University of Toronto, <sup>3</sup>Clinical Neuroscience, Centre for Addiction and Mental Health, and <sup>4</sup>Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada
- 3:00 *The brain substrate underlying varenicline's actions in reducing smoking satisfaction*  
T. Franklin, Z. Wang, J. Suh, R. Hazan, J. Cruz, Y. Li, M. Goldman, J. A. Detre, C. P. O'Brien, A. R. Childress, Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA
- 3:15 *Effects of D-cycloserine on extinction of nicotine cues among cocaine-dependent cigarette smokers*  
J. H. Yoon<sup>1</sup>, C. Culbertson<sup>2</sup>, R. T. Fintzy<sup>1</sup>, C. N. Haile<sup>1</sup>, R. Y. Hawkins<sup>1</sup>, J. J. Mahoney<sup>1</sup>, H. R. Patel<sup>1</sup>, T. F. Newton<sup>1</sup>, R. De La Garza, II<sup>1</sup>, K. R. Labounty<sup>1</sup>, D. E. Croft<sup>1</sup>, <sup>1</sup>Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>2</sup>Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA
- 3:30 *Modafinil effects on smoking cessation: A clinical trial*  
C. A. Martin<sup>1,2</sup>, G. Guenther<sup>1</sup>, K. House<sup>1</sup>, B. Beck<sup>1</sup>, R. Charnigo<sup>3</sup>, J. Lile<sup>2</sup>, T. Kelly<sup>2,1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Behavioral Science, University of Kentucky College of Medicine, <sup>3</sup>College of Public Health, University of Kentucky, Lexington, KY

- 3:45 *Effect of chronic treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers*

Y. Liu<sup>1</sup>, Y. Bao<sup>2</sup>, H. Sun<sup>2</sup>, S. Li<sup>2</sup>, L. Lu<sup>2</sup>, <sup>1</sup>School of Medicine, Ningbo University, Ningbo,  
<sup>2</sup>National Institute on Drug Dependence, Peking University, Beijing, China

### Oral Communications 7

Salons ABC  
2:00 - 3:00 PM

#### IT'S ALL ABOUT CHEMISTRY

Chairs: Richard A. Houghten and Madhaven Nair

- 2:00 *3-Aminothiazole derivatives of cyclorphan and morphinan: Affinity, selectivity and pharmacological opioid properties*  
J. M. Bidlack<sup>1</sup>, B. I. Knapp<sup>1</sup>, T. Zhang<sup>2</sup>, J. L. Neumeyer<sup>2</sup>, <sup>1</sup>Pharmacology and Physiology, University of Rochester, Rochester, NY, <sup>2</sup>Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA
- 2:15 *The direct in vivo screening of mixture-based combinatorial libraries for the identification of novel analgesics*  
R. A. Houghten, C. T. Dooley, J. P. McLaughlin, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL
- 2:30 *Nanotherapy for neuroAIDS and opiate addiction*  
Z. M. Saiyed, N. H. Gandhi, M. N. Nair, Institute of NeuroImmune Pharmacology, College of Medicine, Florida International University, Miami, FL
- 2:45 *Analysis of content and in vitro dissolution of morphine in morphine implant pellets for release and stability*  
P. G. Pande<sup>1</sup>, K. Davis<sup>1</sup>, B. Thomas<sup>1</sup>, S. Sabharwal<sup>1</sup>, L. Caddell<sup>1</sup>, R. Murty<sup>2</sup>, <sup>1</sup>Analytical Chemistry and Pharmaceuticals, RTI International, Research Triangle Park, NC, <sup>2</sup>Murty Pharmaceuticals, Inc, Lexington, KY

### Oral Communications 8

Salons ABC  
3:15 - 4:15 PM

#### IMPACT OF PERINATAL DRUG EXPOSURE

Chairs: Hann E. Marroun and Margaret S. Chisolm

- 3:15 *Parental cannabis use during pregnancy and child behavior problems at 18 months*  
H. El Marroun<sup>1,2</sup>, H. Creemers<sup>1</sup>, H. Tiemeier<sup>1,3</sup>, E. Steegers<sup>4</sup>, V. Jaddoe<sup>2,3</sup>, A. Hofman<sup>3</sup>, F. Verhulst<sup>1</sup>, W. van den Brink<sup>5</sup>, A. Huizink<sup>1,6</sup>, <sup>1</sup>Child and Adolescent Psychiatry, <sup>2</sup>The Generation R Study group, <sup>3</sup>Epidemiology, and <sup>4</sup>Obstetrics, ErasmusMC, Rotterdam, Netherlands, <sup>5</sup>Psychiatry, Amsterdam MC, and <sup>6</sup>Social and Behavioral Sciences, University of Amsterdam, Amsterdam, Netherlands
- 3:30 *Cigarette smoking and neonatal outcomes in depressed and non-depressed opioid-dependent agonist-maintained pregnant patients*  
M. S. Chisolm<sup>1</sup>, K. Kaltenbach<sup>2</sup>, G. Fischer<sup>3</sup>, S. Heil<sup>4</sup>, S. Stine<sup>5</sup>, P. Martin<sup>6</sup>, M. Coyle<sup>7</sup>, H. Jones<sup>1</sup>, <sup>1</sup>Johns Hopkins U, Baltimore, MD, <sup>2</sup>Thomas Jefferson U, Philadelphia, PA, <sup>3</sup>Medical U Vienna, Vienna, Austria, <sup>4</sup>U of Vermont, Burlington, VT, <sup>5</sup>Wayne State U, Detroit, MI, <sup>6</sup>Vanderbilt U, Nashville, TN, <sup>7</sup>Brown U, Providence, RI

- 3:45 *Children of women on opioid maintenance therapy: A follow-up study 4 years later*  
C. Konijnenberg<sup>1,2</sup>, M. Sarfi<sup>1</sup>, A. Melinder<sup>2</sup>, <sup>1</sup>Norwegian Centre for Addiction Research, and  
<sup>2</sup>Cognitive Developmental Research Unit (EKUP), University of Oslo, Oslo, Norway
- 4:00 *Effect of prenatal cocaine exposure on childhood growth*  
S. E. Messiah<sup>1</sup>, K. L. Arheart<sup>2,1</sup>, D. Ludwig<sup>1,2</sup>, V. H. Accornero<sup>1</sup>, L. Xue<sup>1</sup>, S. E. Lipshultz<sup>1,2</sup>,  
T. L. Miller<sup>1,2</sup>, E. S. Bandstra<sup>1</sup>, <sup>1</sup>Pediatrics, and <sup>2</sup>Epidemiology and Public Health, University of  
Miami Miller School of Medicine, Miami, FL

### **Marian W. Fischman Memorial Award Lecture**

**Salons DEFG  
4:30 - 5:30 PM**

*Presentation of the Marian W. Fischman Memorial Award to Linda Cottler*

Introduction by William Dewey

### **Pre- and Post-Doc Networking Event**

**McDowell  
5:30 - 7:00 PM**

### **Workshop V**

**Salons HI  
8:00 - 10:00 PM**

#### **SCHOOL-BASED SYSTEMS OF CARE FOR SUBSTANCE ABUSE: STUDENT ASSISTANCE PROGRAMS AND RECOVERY SCHOOLS**

Chairs: Andrew J. Finch and Michael L. Dennis

*Student assistance: Addressing social and emotional barriers to learning*  
Carl Nixon, Evaluation Design, Brentwood, TN

*School-based recovery support: Continuing care services in high schools*  
Andrew Finch, Vanderbilt University, Nashville, TN

*Study of GAIN and brief intervention in true North Program*  
Rob Vincent, ESD113 True North-Student Assistance & Treatment Services, Turnwater, WA

*Research on recovery high schools: Empirical findings and proposed future studies*  
D. Paul Moberg, Population Health Institute, University of Wisconsin School of Medicine,  
Madison, WI

*SASATE Business Meeting*  
Michael Dennis, Chestnut Health System, Normal, IL

### **Workshop VI**

**Salon DE  
8:00 - 10:00 PM**

#### **TEACH YOUR PARENTS WELL: TEACHING AND TRAINING PARENTS CONCERNED ABOUT THEIR CHILD'S DRUG USE**

Chair: Kimberly C. Kirby

*WebSafe: The development of a parent workshop to help protect children from drug threats on the Internet*

David Festinger, Treatment Research Institute, Philadelphia, PA

*Longitudinal associations between parent-child factors and risk of SUD in college*  
Amelia Arria, Treatment Research Institute, Philadelphia, PA

*Teaching parents to be intervention agents*

Ken C. Winters, University of Minnesota and Treatment Research Institute, Minneapolis, MN

*Training parents as change agents for risky behavior*

MaryLouise E. Kerwin, Rowan University and Treatment Research Institute, Glassboro, NJ

### Workshop VII

**Salon FG**

**8:00 - 10:00 PM**

#### **COMPARISON OF METHADONE AND BUPRENORPHINE: RESULTS OF THE MATERNAL OPIOID TREATMENT: HUMAN EXPERIMENTAL RESEARCH (MOTHER) TRIAL**

Chairs: Ivan D. Montoya and Sarah H. Heil

*Which medication is better for mother and baby, methadone or buprenorphine? Primary outcome results of the MOTHER Trial*

Hendree E. Jones, Johns Hopkins School of Medicine, Center for Addiction and Pregnancy, Baltimore, MD

*How representative are MOTHER Study participants of the larger pool of opioid-dependent pregnant patients?*

Susan M. Stine, Substance Abuse Research Division, Wayne State University School of Medicine, Detroit, MI

*Transcontinental Randomized Control Trials in opioid-dependent pregnant women: Are we investigating the same patients?*

Gabriele Fischer, Psychiatry, Addiction Clinic, Medical University of Vienna, Vienna, Austria

*Addressing and managing co-morbid psychiatric disorders in opioid-dependent pregnant patients: Results from the MOTHER study*

Peter R. Martin, Addiction Psychiatry Training Program and Vanderbilt Addiction Center, Nashville, TN

*Placing the MOTHER study results in context: A historical perspective and implications on future practice*

Karol Kaltenbach, Thomas Jefferson University, Philadelphia, PA

### Workshop VIII

**Salons ABC**

**8:00 - 10:00 PM**

#### **CAREER DEVELOPMENT: A PERSPECTIVE FROM JUNIOR AND SENIOR RESEARCHERS**

Chairs: Gerald McLaughlin and Jose Ruiz

Speakers: David Herin, John Grabowski, Kathleen Brady and Mary Jeanne Kreek

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*



Chair: Steven W. Gust

### BASIC SCIENCE

*Effects of harman and norharman on dopamine, serotonin, and their metabolites in mouse brain regions*

S. Ali<sup>1</sup>, G.F. Marrone<sup>2</sup>, S.J. Heishman<sup>2</sup>, M. Baumann<sup>2</sup>. <sup>1</sup>National Center for Toxicological Research, U.S. Food and Drug Administration, United States; <sup>2</sup>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, United States

*Genetic differences in glutamatergic NMDA receptor-binding levels after extinction of morphine self-administration behavior in Lewis and Fischer 344 rats*

E. Ambrosio, G.L. Montoya, S. Martín, C. Nicanor, A. Higuera-Matas, M. Miguéns, S.M. Coria, N. Del Olmo, A. Assís, C. García-Lecumberri. Dept. of Psychobiology, Universidad Nacional de Educación a Distancia, Spain

*Morphine-induced changes of self-stimulation behavior in rat strains*

E.V. Borisova. Research Institute on Addictions, Russian Federation Ministry of Health, Russia

*Are GABAergic neurons of the retrosplenial cortex targets of the neurotoxic effect of the noncompetitive NMDA antagonist MK801?*

S. de Olmos, J. de Olmos, A. Lorenzo. Instituto de Investigacion Mecica Mercedes y Martina Ferreyra, Consejo Nacional de Investigacion Cientifica y Tecnologica, Argentina

*Producing smoking craving by using immersive virtual environments*

O. García-Rodríguez<sup>1</sup>, I. Pericot-Valverde<sup>1</sup>, J. Gutiérrez-Maldonado<sup>1</sup>, M. Ferrer-García<sup>1</sup>, R. Secades-Villa<sup>2</sup>, F. Alonso-Perez<sup>3</sup>. <sup>1</sup>University of Barcelona, Spain; <sup>2</sup>University of Oviedo, Spain; <sup>3</sup>Public Health Service of Asturias, Spain

*Role of nitric oxide synthase inhibitors in the operant decrement produced by naloxone in morphine-treated rats*

R. Jain. All India Institute of Medical Sciences, India

*Circadian alteration in neurobiology during opiate protracted withdrawal in rats*

S. Li<sup>1</sup>, L. Liu<sup>1</sup>, W. Jiang<sup>1</sup>, L. Sun<sup>1</sup>, S. Zhou<sup>1</sup>, L. Lu<sup>1</sup>, B.L. Foll<sup>2</sup>. <sup>1</sup>National Institute on Drug Dependence, Peking University, China; <sup>2</sup>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Canada

*Selective attention to smoking cues in smokers and nonsmokers: An event-related potential study using the visual oddball paradigm*

M. Littell, I. Franken. Erasmus University Rotterdam, The Netherlands



*Attentional control brain regions involved in attentional bias in smokers*

M. Luijten<sup>1</sup>, D.J. Veltman<sup>2,3</sup>, I. Franken<sup>1</sup>. <sup>1</sup>Institute of Psychology, Erasmus University Rotterdam, The Netherlands; <sup>2</sup>Academic Medical Center, University of Amsterdam, The Netherlands; <sup>3</sup>Department of Psychiatry, Amsterdam Institute for Addiction Research, The Netherlands

*Role of CRF and ACTH4-10 in the neuronal mechanisms of stress and drug addiction*

A. Meshcheryakova. I.M. Sechenov Moscow Medical Academy, Russia

*Influence of cytokines (interleukin-1 $\beta$ , interleukin-4) on craving for drugs*

A.F. Meshcheryakov. P.K. Anokhin Institute of Normal Physiology, Russian Academy of Medical Science, Russia

*Attenuation and enhancement of amphetamine-induced behavioral effects by acute and chronic exposure to cannabis smoke in rats*

H. Obianwu<sup>1,2</sup>, A. Ibeh<sup>2</sup>. <sup>1</sup>Niger Delta University, Nigeria; <sup>2</sup>University of Benin, Nigeria

*Characteristics of contact formations between lymphocytes and fibroblasts during the healing process of surgical wounds in drug addicts*

A. Sapargaliyeva, G. Kapanova. Kazakh National Medical University, Kazakhstan

*Dopaminergic neurotoxicity in recreational users of amphetamine: Preliminary results*

M. Schouw, J. Booij, L. Reneman. Academic Medical Center, University of Amsterdam, The Netherlands

*Reinforcing effects of d-amphetamine: Influence of novel ratios on a progressive-ratio schedule*

R. Sevak<sup>1</sup>, W. Stoops<sup>2</sup>, P.E.A. Glaser<sup>2</sup>, C.R. Rush<sup>2</sup>. <sup>1</sup>David Geffen School of Medicine, University of California, Los Angeles, United States; <sup>2</sup>College of Medicine, University of Kentucky, United States

*Association of ADH2 and ALDH2 gene polymorphisms with alcohol dependence: First study from India*

M. Vaswani. All Indian Institute of Medical Sciences, India

*Role of D1 and D2 dopaminergic receptors in MDMA-induced conditioned place preference*

A. Vidal-Infer, M. Rodríguez-Arias, M.A. Aguilar, J. Miñarro. Unit of Research on Psychobiology of Drug Dependence, Department of Psychobiology, University of Valencia, Spain

*Social interaction prevents cocaine relapse in a rat model: Functional brain mapping*

G. Zernig<sup>1</sup>, M. Fritz<sup>1</sup>, R. El Rawas<sup>1</sup>, A. Salti<sup>1</sup>, S. Klement<sup>1</sup>, M.T. Bardo<sup>2</sup>, G. Dechant<sup>1</sup>, A. Saria<sup>1</sup>. <sup>1</sup>Medical University Innsbruck, Austria; <sup>2</sup>University of Kentucky, United States

## EPIDEMIOLOGY

### *Description of areca nut use in a Cordilleran community*

R. Abat, J.C. Pascual. University of the Philippines-Manila, Philippine General Hospital, Philippines

### *Media examines the drug use and abuse problem*

J. Aguilar, C. Hernandez, S. Tomas, N. Llorens, S. Tortajada. The Foundation for the Study, Prevention and Assistance on Drug Addiction, Spain

### *A study of addictive in-patients at Ibn-Rushd Psychiatric Teaching Hospital in Baghdad*

R. Aqraw<sup>1,2</sup>, A. Hussain<sup>1</sup>. <sup>1</sup>Ministry of Health, Iraq; <sup>2</sup>Virginia Commonwealth University, United States

### *Association between substance use and premature sexual behavior among Thai youth*

S. Assanangkornchai, N. Samangsri, U. Pattanasattayawong. Prince of Songkla University, Thailand

### *Ecstasy use among high school children in private schools in the city of São Paulo, Brazil*

M. Battisti<sup>1,2</sup>, D. Locatelli<sup>2</sup>, A.R. Noto<sup>2</sup>. <sup>1</sup>Virginia Commonwealth University, United States; <sup>2</sup>Federal University of São Paulo, Brazil

### *Family attention and coca paste use in four northern regions of Chile, 1999 and 2005: Secondary data analyses from national epidemiological studies*

L. Caris<sup>1</sup>, D. Huepe<sup>2</sup>, J. Anthony<sup>3</sup>. <sup>1</sup>University of Chile, Chile; <sup>2</sup>Diego Portales University, Chile; <sup>3</sup>Michigan State University, United States

### *Shebeen life in two communities: Alcohol, drugs, and risks*

T. Carney<sup>1</sup>, W.M. Wechsberg<sup>2</sup>, F. Browne<sup>2</sup>, R. Fortuin<sup>3</sup>, B. Myers<sup>1</sup>. <sup>1</sup>Medical Research Council, South Africa; <sup>2</sup>RTI International, United States; <sup>3</sup>EngenderHealth, South Africa

### *Nicotine dependence among very recent-onset cigarette smokers in the United States*

M. Catacora, J.C. Anthony. Department of Epidemiology, Michigan State University, United States

### *Predictors of current alcohol use in a rural community in Sikkim, North East India—secondary analysis from a pilot population survey*

A. Chakrabarti, A. Goel. Sikkim Manipal Institute of Medical Sciences, India

### *DRD2/ANKK1 in relation to regular alcohol and cannabis use among adolescents: Does parenting modify the impact of genetic vulnerability? The TRAILS study*

H. Creemers<sup>1,2</sup>, Z. Harakeh<sup>3</sup>, D. Dick<sup>4</sup>, J. Meyers<sup>4</sup>, W. Vollebergh<sup>3</sup>, J. Ormel<sup>5</sup>, F. Verhulst<sup>1</sup>, A. Huizink<sup>2</sup>. <sup>1</sup>Erasmus Medical Center Rotterdam, The Netherlands; <sup>2</sup>University of Amsterdam, The Netherlands; <sup>3</sup>Utrecht University, The Netherlands; <sup>4</sup>Virginia Commonwealth University, United States; <sup>5</sup>University Medical Center Groningen, The Netherlands

*Inhalant misuse in Mexico: Facts and trends*

S.L. Cruz<sup>1,2</sup>, J.A. Villatoro<sup>2</sup>, A. Ortiz<sup>2</sup>. <sup>1</sup>Department of Pharmacobiology, Center for Research and Advanced Studies of National Polytechnic Institute, Mexico;  
<sup>2</sup>Division of Epidemiologic and Social Research, Mexican Institute of Psychiatry, Mexico

*Illicit drug use in seven Latin American countries: Critical perspectives of families and friends on causes, prevention, treatment availability, access, and barriers*

J. Da Silva<sup>1</sup>, C. Ventura<sup>2</sup>, O. Vargens<sup>3</sup>, C.M. Douat Loyola<sup>1</sup>, D. Albarracin<sup>4</sup>, J. Diaz<sup>5</sup>, G. Funes<sup>6</sup>, M. Hernandez<sup>7</sup>, R. Torres<sup>8</sup>, R. Rodriguez<sup>9</sup>. <sup>1</sup>Federal University of Rio de Janeiro, Brazil; <sup>2</sup>World Health Organization Collaborating Centre for Nursing Research Development, Brazil; <sup>3</sup>Rio de Janeiro State University, Brazil; <sup>4</sup>Pontifical Xavierian University, Colombia; <sup>5</sup>University of San Carlos of Guatemala, Guatemala; <sup>6</sup>National Autonomous University of Honduras, Honduras; <sup>7</sup>University of Costa Rica, Costa Rica; <sup>8</sup>Autonomous University of Querétaro, Mexico; <sup>9</sup>School of Nursing, University of Guayaquil, Ecuador

*Drinking and driving in a driver probabilistic sample from alcohol outlets of Porto Alegre, Brazil: Preliminary findings*

R. De Boni<sup>1</sup>, M. de Vasconcellos<sup>2</sup>, F.I. Bastos<sup>3</sup>, F. Pechansky<sup>1</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Brazil; <sup>2</sup>Brazilian Institute for Geography and Statistics, Brazil; <sup>3</sup>Oswaldo Cruz Foundation, Brazil

*Parental cannabis use during pregnancy and child behavior problems at 18 months*

H. El Marroun<sup>1,2</sup>, H. Creemers<sup>1,2</sup>, H. Tiemeier<sup>1,2</sup>, E. Steegers<sup>1,2</sup>, V. Jaddoe<sup>1,2</sup>, A. Hofman<sup>2</sup>, F. Verhulst<sup>1,2</sup>, W. van den Brink<sup>3,4</sup>. <sup>1</sup>Sophia Children's Hospital, Erasmus Medical Center, The Netherlands; <sup>2</sup>Erasmus Medical Center Rotterdam, The Netherlands; <sup>3</sup>Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands; <sup>4</sup>Amsterdam Institute for Addiction Research, The Netherlands

*Substance misuse among Moroccan inpatients with schizophrenia*

F. El Omari<sup>1</sup>, A. Derveau<sup>2</sup>, M. Sabir<sup>1</sup>, M.C. Bourdel<sup>3</sup>, M.O. Krebs<sup>3</sup>, J. Toufiq<sup>1</sup>. <sup>1</sup>Arrazi University Psychiatric Hospital, Morocco; <sup>2</sup>Addiction Service, Sainte-Anne Hospital, France; <sup>3</sup>Laboratory of Physiopathology of Psychiatric Diseases, Center for Neurosciences and Psychiatry, France

*Assessing methamphetamine use among drug-using Filipino youth*

L. Estacio, Jr. University of Washington, United States; University of the Philippines-Manila, Philippines

*The P300 event-related brain potential as a neurobiological marker for substance use disorders: A meta-analytic investigation*

A. Euser<sup>1</sup>, L. Arends<sup>1</sup>, A. Huizink<sup>2</sup>, I. Franken<sup>1</sup>. <sup>1</sup>Institute of Psychology, Erasmus University Rotterdam, The Netherlands; <sup>2</sup>Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Sophia Children's Hospital, The Netherlands

*The relation between HPA axis reactivity and age of onset of alcohol use*

B.E. Evans<sup>1</sup>, K. Greaves-Lord<sup>1</sup>, A. Euser<sup>2</sup>, I.H.A. Franken<sup>2</sup>, A.C. Huizink<sup>3</sup>. <sup>1</sup>Erasmus Medical Center Rotterdam, The Netherlands; <sup>2</sup>Erasmus University Rotterdam, The Netherlands; <sup>3</sup>University of Amsterdam, The Netherlands

*An exploratory study of substance use biomarkers and psychiatric disorders in Brazilian drivers*

S. Faller<sup>1</sup>, J.M. Webster<sup>2</sup>, C.G. Leukefeld<sup>2</sup>, D.B. Bumaguin<sup>1</sup>. <sup>1</sup>Center for Drug and Alcohol Studies, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky, United States

*Cross-national research on early-onset cannabis use and failure to complete educational milestones*

F. Fiestas<sup>1</sup>, J.C. Anthony<sup>2</sup>. <sup>1</sup>Universidad Peruana Cayetano Heredia, Peru; <sup>2</sup>Department of Epidemiology, Michigan State University, United States

*A call for expansion of comparative urban research as an international epidemiologic and policy research tool*

S. Friedman<sup>1</sup>, B. Tempalski<sup>1</sup>, H. Cooper<sup>2</sup>, C. Cleland<sup>1</sup>, S. Chatterjee<sup>1</sup>, E. Pouget<sup>1</sup>. <sup>1</sup>National Development and Research Institutes, United States; <sup>2</sup>Emory University, United States

*Using the Gelberg-Andersen Behavioral Model for Vulnerable Populations to predict health services' utilization among homeless adults by hepatitis B or C serostatus*

L. Gelberg<sup>1</sup>, M. Robertson<sup>2</sup>, R.M. Andersen<sup>3</sup>, J. Stein<sup>4</sup>, L. Arangua<sup>1</sup>. <sup>1</sup>Department of Family Medicine, University of California, Los Angeles (UCLA), United States; <sup>2</sup>Alcohol Research Group, Public Health Institute, United States; <sup>3</sup>School of Public Health, UCLA, United States; <sup>4</sup>Department of Psychology, UCLA, United States

*The role of mental health issues in HIV acquisition among female drug users*

G. Gilchrist<sup>1</sup>, A. Blazquez<sup>1</sup>, J. Mestre<sup>1</sup>, F. Fonseca<sup>1,2</sup>, L. Díaz<sup>1,3</sup>, M. Torrens<sup>1,2,4</sup>. <sup>1</sup>Institut Municipal d'Investigació Mèdica-Hospital del Mar, Spain; <sup>2</sup>Institut d'Atenció Psiquiàtrica i Addiccions-Hospital del Mar, Spain; <sup>3</sup>Unidad de Patología Dual, Centre Fòrum-Hospital del Mar, Spain; <sup>4</sup>Departamento de Psiquiatría, Universidad Autónoma Barcelona

*National regulations of opioid maintenance treatment programs do not guarantee uniform treatment delivery*

L. Gjersing, H. Waal, T. Clausen. Norwegian Center for Addiction Research, University of Oslo, Norway

*Simultaneous polydrug consumption among undergraduate university students in six Latin American countries and in one Caribbean country: Gender, legal, and social implications*

A. Herrera<sup>1</sup>, F. Bautista<sup>2</sup>, J. Harrison<sup>3</sup>, C. Mitchell<sup>3</sup>, M. Nóbrega<sup>4</sup>, R. Prieto<sup>5</sup>, G. Riquelme<sup>6</sup>, M. Veloza<sup>7</sup>, P. Whitehorne<sup>3</sup>, C.I. Zea<sup>8</sup>, F. Brands<sup>9</sup>, L. Simich<sup>9</sup>, C. Strike<sup>9</sup>, R. Mann<sup>9</sup>, N. Giesbrecht<sup>9</sup>, M. Wright<sup>10</sup>. <sup>1</sup>Universidad Nacional de Nicaragua–León, Nicaragua; <sup>2</sup>Universidad Evangélica, El Salvador; <sup>3</sup>University of the West Indies, Jamaica; <sup>4</sup>Faculdade de Medicina da Fundacao do ABC, Brazil; <sup>5</sup>Universidad Nacional de Colombia, Colombia; <sup>6</sup>Pontificia Universidad Católica de Chile, Chile; <sup>7</sup>Universidad de La Sabana, Colombia; <sup>8</sup>Universidad de San Carlos de Guatemala, Guatemala; <sup>9</sup>The Center for Addiction and Mental Health–CAMH/University of Toronto, Canada; <sup>10</sup>Government of Canada–DFAIT, The Inter-American Drug Abuse Control Commission–CICAD/ Organization of American States–OAS

*Birth order and substance use in Latin America*

P. Horner<sup>1</sup>, F. Andrade<sup>2</sup>, J. Delva<sup>2</sup>. <sup>1</sup>Michigan State University, United States; <sup>2</sup>University of Michigan, United States

*Association between alcohol, tobacco, and other drug use and bullying among secondary school students in Nakuru District, Kenya*

M. Kariuki<sup>1</sup>, P. Ndege<sup>2</sup>, J.S. Oteyo<sup>1</sup>. <sup>1</sup>Egerton University, Kenya; <sup>2</sup>Center for Addiction Studies in Africa, Kenya

*Patterns of amphetamine-type stimulant abuse among opiate-dependent individuals in Kuala Lumpur, Malaysia*

V.B. Kasinather<sup>1</sup>, M. Mazlan<sup>2</sup>, M.C. Chawarski<sup>3</sup>, R.S. Schottenfeld<sup>3</sup>. <sup>1</sup>Centre for Drug Research, Universiti Sains, Malaysia; <sup>2</sup>Substance Abuse Research Centre, Malaysia; <sup>3</sup>Yale University School of Medicine, United States

*Characterization of drug-related death cases with a special emphasis on heroin-related cases in Budapest, Hungary, between 1998–2009*

E. Keller<sup>1</sup>, G. Nagy<sup>2</sup>, M. Horvath<sup>1,3</sup>. <sup>1</sup>Department of Forensic and Insurance Medicine, Semmelweis University, Hungary; <sup>2</sup>Drug Laboratory, Institute for Forensic Sciences, Hungary; <sup>3</sup>National Board of Forensic Medicine, Department of Forensic Medicine, Uppsala University, Sweden

*Brazilian crack users who seek treatment show more antisocial personality and less drinking than other drug users*

F. Kessler, M. Terra, S. Faller, A. Peuker. Center for Alcohol and Drug Research, Federal University of Rio Grande do Sul, Brazil

*Correlation between HIV infection prevalence and drug use experience in correctional settings of Odessa Region, Ukraine*

T. Kiriazova<sup>1,2</sup>, O. Neduzhko<sup>3</sup>. <sup>1</sup>Rollins School of Public Health, Emory University, United States; <sup>2</sup>Odessa Regional Coordination Council on HIV/AIDS, Drug Abuse and TB Prevention, Ukraine; <sup>3</sup>Odessa State Medical University, Ukraine

*Exploring the phenomena of home-made stimulant injection in Tbilisi, Georgia*

I. Kirtadze<sup>1</sup>, D. Otiashvili<sup>1</sup>, G. Piralishvili<sup>2</sup>, R. Booth<sup>3</sup>, T. Zabransky<sup>4</sup>. <sup>1</sup>Addiction Research Center, Union Alternative Georgia, Georgia; <sup>2</sup>Medical Centre Uranti, Georgia; <sup>3</sup>University of Colorado-Denver, United States; <sup>4</sup>Center for Addictology, Charles University, Czech Republic

*Consumption of alcohol among high school students in a government secondary school in Southern Philippines*

A.R. Lanaban<sup>1</sup>, J. Pascual<sup>2</sup>, E. Catillo<sup>2</sup>, L.C. Panganiban<sup>2</sup>. <sup>1</sup>Davao Medical Center, Philippines; <sup>2</sup>University of the Philippines-Manila, Philippine General Hospital, Philippines

*The prevalence of anxiety and depression among adult substance abusers admitted at a government drug treatment and rehabilitation center in the Philippines*

J.B. Leabres<sup>1</sup>, J. Pascual<sup>2</sup>, M.R. deGuzman<sup>2</sup>, C.G. Quinking<sup>2</sup>. <sup>1</sup>Department of Health, Treatment and Rehabilitation Center-Bicutan, Philippines; <sup>2</sup>Philippine General Hospital, Philippines

*Factors associated with current substance use among intravenous drug users under antiretroviral treatment in Jakarta and Bali, Indonesia*

Y. Li<sup>1</sup>, R. Hershow<sup>1</sup>, Irwanto<sup>2</sup>, J. Levy<sup>1</sup>, R. Tambunan<sup>2</sup>, O. Kamil<sup>2</sup>, S. Lenggogeni<sup>2</sup>, M. Setiawan<sup>3</sup>. <sup>1</sup>University of Illinois at Chicago, United States; <sup>2</sup>Atma Jaya Catholic University of Indonesia, Indonesia; <sup>3</sup>Udayana University, Indonesia

*Drug use and leisure time in secondary school students in the autonomous region of Valencia, 2008–2009*

N. Llorens<sup>1</sup>, S. Tomas<sup>2</sup>, S. Tortajada<sup>1</sup>, J. Aguilar<sup>1</sup>. <sup>1</sup>The Foundation for the Study, Prevention and Assistance on Drug Addiction, Spain; <sup>2</sup>Dirección General de Drogodependencias, Conselleria de Sanitat, Spain

*Tobacco, alcohol, and caffeine consumption during pregnancy: survey and biomarkers*

R. Magri<sup>1</sup>, M. Suárez<sup>1</sup>, H. Míguez<sup>2</sup>, J. Jones<sup>3</sup>, R. Rios<sup>3</sup>, H. Suarez<sup>4</sup>, P. Putti<sup>5</sup>. <sup>1</sup>Universidad de la República, Uruguay; <sup>2</sup>CONICET, Argentina; <sup>3</sup>United States Testing Laboratory, United States; <sup>4</sup>Observatorio de Drogas, Uruguay; <sup>5</sup>Unidad de Perinatología Social Security Maternity Hospital Uruguay

*Differential survival benefit of universal HAART access in Brazil: A nationwide comparison of injecting drug users versus men who have sex with men*

M. Malta<sup>1</sup>, F. Bastos<sup>1</sup>, C. da Silva<sup>1</sup>, G. Pereira<sup>2</sup>, F. Lucena<sup>2</sup>, M. Fonseca<sup>1</sup>, S. Strathdee<sup>3</sup>. <sup>1</sup>Oswaldo Cruz Foundation, Brazil; <sup>2</sup>Ministry of Health, Brazil; <sup>3</sup>University of California, San Diego, United States

*Comparison of injection drug users in Shanghai, China, and Miami, Florida*

C. McCoy<sup>1</sup>, M. Zhao<sup>2</sup>, M. Comerford<sup>1</sup>. <sup>1</sup>University of Miami, United States; <sup>2</sup>Shanghai Jiao Tong University School of Medicine, China



*Codependency on drug abusers' mothers*

D. Molina, A. Villalobos. José Felix Ribas Foundation, Venezuela

*Outcomes of residential treatment of substance abuse in a Philippine government substance abuse treatment and rehabilitation center*

R. Mollenido<sup>1</sup>, C.G. Quinking<sup>2</sup>, I. Escartin<sup>3</sup>. <sup>1</sup>Western Visayas Medical Center, Philippines; <sup>2</sup>National Poison Control Center, University of the Philippines, Philippine General Hospital, Philippines; <sup>3</sup>Department of Health, Philippines

*Low rates of HIV seroconversion among injecting and noninjecting drug users in Barcelona, Spain, 1997–2006*

R. Muga<sup>1</sup>, E. Martínez<sup>1</sup>, M. Torrens<sup>2</sup>, F. Bolao<sup>3</sup>, I. Rivas<sup>4</sup>, R. Rall<sup>1</sup>, A. Sanvisens<sup>1</sup>, D. Fuster<sup>1</sup>, J. Tor<sup>1</sup>. <sup>1</sup>Hospital Universitari Germans Trias i Pujol, Spain; <sup>2</sup>Institut Municipal d'Investigació Mèdica-Hospital del Mar, Spain; <sup>3</sup>Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain; <sup>4</sup>Centro Delta de Toxicomanías, Badalona, Spain

*Is there a new population of opioid users in Australia? A Web-based survey on nonprescription codeine use*

S. Nielsen<sup>1</sup>, J. Cameron<sup>1</sup>, N. Lee<sup>1,2</sup>. <sup>1</sup>Turning Point Alcohol and Drug Centre, Australia; <sup>2</sup>Monash University, Australia

*Drawing back the veil: Drug use and mental health problems among female adolescents in Uruguay*

G. Olivera<sup>1,2</sup>, M. Kurgans<sup>3</sup>, H. Suarez<sup>4</sup>. <sup>1</sup>Virginia Commonwealth University, United States; <sup>2</sup>National Drug Assembly at the Presidency of Uruguay, Uruguay; <sup>3</sup>Office of Child and Family Services, Virginia Department of Behavioral Health and Developmental Services, United States; <sup>4</sup>Drugs Observatory of Uruguay, Uruguay

*Prevalence of substance abuse among secondary school students—a comparative study of government and private secondary schools in Jos, Nigeria*

M. Onoja. Pathfinder International, Nigeria

*Drug abuse in Thamel, Nepal*

M. Poudel, M. Poudyal Chhetri. Commission for the Investigation of Abuse of Authority, Nepal

*Kathmandu slum dwellers' health and drug abuse problems*

M. Poudyal Chhetri. Commission for the Investigation of Abuse of Authority, Nepal

*Sexual partnering and condom use among injecting drug users in Indonesia*

I. Praptoraharjo<sup>1</sup>, R.I. Syafitri<sup>2</sup>, N. Hadi<sup>2</sup>, T. Zaenuri<sup>2</sup>, M. Suharni<sup>2</sup>, O. Kamil<sup>2</sup>. <sup>1</sup>School of Public Health, University of Illinois at Chicago, United States; <sup>2</sup>Family Health International, Indonesia



*Perception of coercion in the process of informed consent in research on alcohol and traffic in Brazilian highways*

J. Protas<sup>1</sup>, C.F. Fernandes<sup>2</sup>, M.S. Fernandes<sup>2</sup>, R. De Boni<sup>1,2</sup>, F. Pechansky<sup>1,2</sup>, J.R. Goldim<sup>1,2</sup>. <sup>1</sup>Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Hospital de Clinicas de Porto Alegre, Brazil

*Survival of adults with alcohol-dependence syndrome in Barcelona, Spain*

I. Rivas<sup>1</sup>, F. Bolao<sup>2</sup>, A. Sanvisens<sup>3</sup>, E. Martinez<sup>3</sup>, J. Tor<sup>3</sup>, D. Fuster<sup>3</sup>, R. Muga<sup>3</sup>. <sup>1</sup>Centro Delta de Drogodependencias de Badalona, Spain; <sup>2</sup>Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain; <sup>3</sup>Hospital Universitari Germans Trias i Pujol, Spain

*Factors related to use of rice wine (Tapoy) among families in a municipality in Cordillera Region, Philippines*

J. Sagabaen, Jr., R. Abat, J. Pascual, E. Castillo. Postgraduate Institute of Medicine, University of the Philippines College of Medicine, Department of Health, Manila, Philippines

*Changing trends of inhalant abuse in juveniles in India*

S. Sharma, G. Sharma. Institute of Human Behaviour and Allied Sciences, India

*Substance abuse and health-risk behaviors in Baglung, Nepal*

S. Sharma<sup>1</sup>, M. Poudyal Chhetri<sup>2</sup>. <sup>1</sup>Care Nepal, Nepal; <sup>2</sup>Commission for the Investigation of Abuse of Authority, Nepal

*Toward DSM-V: A comprehensive exploration of the latent structure of problematic cannabis use in a community sample*

T. Slade<sup>1</sup>, R. Grove<sup>1</sup>, O. McBride<sup>2</sup>, M. Teesson<sup>1</sup>, A. Baillie<sup>3</sup>, N. Carragher<sup>1</sup>. <sup>1</sup>University of New South Wales, Australia; <sup>2</sup>Ulster University, Ireland; <sup>3</sup>Macquarie University, Australia

*Female drug users and service' accessibility in Burma (Myanmar)*

Z.N. Soe. United Nations Office on Drugs and Crime, Burma (Myanmar)

*Adult substance abusers with attention deficit and hyperactivity disorder show higher prevalence of marijuana and cocaine use*

A. Stolf, F. Kessler, S. Faller, D.B. Bumaguin. Center for Alcohol and Drug Research, Federal University of Rio Grande do Sul, Brazil

*Gender, pregnancy, and treatment completion by criminal justice referral status*

M. Terplan<sup>1</sup>, M. Palisoul<sup>1</sup>, S. Lui<sup>2</sup>, C. Friedman<sup>3</sup>. <sup>1</sup>University of Maryland School of Medicine, United States; <sup>2</sup>University of Huddersfield, United Kingdom; <sup>3</sup>University of Pittsburgh Medical Center, United States

*Liquor accessibility of Chiang Mai youth in Chiang Mai Municipality, Chiang Mai, Thailand*

K. Thaikla. Institute for Health Sciences, Chiang Mai University, Thailand

*Risk factors for substance-induced disorders among illicit drug users*

M. Torrens<sup>1</sup>, G. Gilchrist<sup>1</sup>, A. Domingo-Salvany<sup>3,4</sup>, F. Fonseca<sup>1,2</sup>, The PsycCo Barcelona Group\*<sup>4,5,6</sup>. \*The PsyCoBarcelona Group Includes: M.C. Rodriguez-Llera<sup>3</sup>, M.J.Herrero<sup>3</sup>, M. Astals<sup>1,2</sup>, L. Diaz<sup>1,2</sup>, R. Martin-Santos<sup>2,5,6</sup>, M.T. Brugal<sup>4,7</sup>.

<sup>1</sup>Substance Use Disorders Research Group, Neuropsychopharmacology Program, Institut Municipal d'Investigació Mèdica (IMIM)-Parc de Salut Mar, Parc de Recerca Biomèdica de Barcelona, Spain; <sup>2</sup>Institut d'Atenció Psiquiàtrica i Addiccions-Parc de Salut Mar, Spain; <sup>3</sup>Drug Abuse Epidemiology Research Group, IMIM-Hospital del Mar, Parc de Recerca Biomèdica de Barcelona, Spain; <sup>4</sup>Biomedical Research Center Network of Epidemiology and Public Health, Spain; <sup>5</sup>Pharmacology Research Unit, Neuropsychopharmacology Program, IMIM-Parc de Salut Mar, Parc de Recerca Biomèdica de Barcelona, Spain; <sup>6</sup>Psychiatry Department, Institut de Neurociències, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Spain; <sup>7</sup>Barcelona Public Health Agency, Spain

*Youthful tobacco smoking for males and females in Brazil*

Z. van der Meer Sanchez<sup>1</sup>, A.R. Noto<sup>1,2</sup>. <sup>1</sup>Federal University of São Paulo, Brazil; <sup>2</sup>Brazilian Center of Information on Psychotropic Drugs, Federal University of São Paulo, Brazil

*Prior sexual abuse among female substance dependents admitted in a government-operated drug treatment center in metropolitan Manila*

A. Villaroman<sup>1</sup>, J. Pascual<sup>2</sup>, E. Castillo<sup>2</sup>, C. Quingking<sup>2</sup>. <sup>1</sup>Department of Health, University of the Philippines-Manilla, Philippine General Hospital, Philippines; <sup>2</sup>Department of Toxicology and Pharmacology, University of the Philippines-Manila, Philippines General Hospital, Philippines

*Risk of pathological gambling and associated disorders in adolescents from Medellin, Colombia, 2009*

M. Zapata, Y. Torres de Galvis, L.P. Montoya. CES University, Colombia

*Use of the alcohol, smoking, and substance involvement screening test among HIV-positive patients on regular antiretroviral therapy in southern Brazil*

C. Zubaran<sup>1</sup>, I. Tres<sup>2</sup>, K. Foresti<sup>3</sup>, University of Caxias do Sul-United Nations Educational, Scientific and Cultural Organization Research Group<sup>2</sup>. <sup>1</sup>University of Western Sydney, Australia; <sup>2</sup>University of Caxias do Sul, Brazil; <sup>3</sup>Sydney West Area Health Service, Australia

*Variations in needles and syringes used by injecting drug users*

W. Zule<sup>1</sup>, D. Otiashvili<sup>2</sup>, S. Friedman<sup>3</sup>, D.D. Jarlais<sup>4</sup>, A. Gyarmathy<sup>5</sup>, G. Bobashev<sup>1</sup>, C. Coomes<sup>1</sup>, Winona Poulton<sup>1</sup>. <sup>1</sup>RTI International, United States; <sup>2</sup>Union Alternative Georgia, Georgia; <sup>3</sup>National Development and Research Institutes, United States; <sup>4</sup>Beth Israel Medical Center, United States; <sup>5</sup>European Monitoring Centre for Drugs and Drug Addiction, Portugal

*Pharmacoepidemiology of the use of strong opioids: Comparison between St. Petersburg, Russia, and U.S. data*

E. Zvartau, M. Pchelintsev. St. Petersburg Pavlov Medical University, Russia

### PREVENTION

*Harm reduction knowledge and beliefs among prison armed personnel in Albania*

A. Boci<sup>1</sup>, E. Sharra<sup>2</sup>. <sup>1</sup>STOP AIDS Association, Albania; <sup>2</sup>Global Fund for HIV—Albania Office, Albania

*Methamphetamine use among young black and colored women in Cape Town, South Africa*

F. Browne<sup>1</sup>, W.M. Wechsberg<sup>1</sup>, H.E. Jones<sup>1</sup>, B.J. Myers<sup>2</sup>, T. Carney<sup>2</sup>, R.M. Ellerson<sup>1</sup>, T.L. Kline<sup>1</sup>. <sup>1</sup>RTI International, United States; <sup>2</sup>Medical Research Council, South Africa

*Beliefs significantly associated with the consumption and nonconsumption of tobacco in school students at Valencia City in Spain*

F.J. Bueno-Cañigral<sup>1</sup>, C.C. Morales-Manrique<sup>2</sup>, R. Aleixandre-Benavent<sup>2</sup>, J.C. Valderrama-Zurián<sup>3</sup>. <sup>1</sup>Plan Municipal Drogodependencias, Ayuntamiento de Valencia, Spain; <sup>2</sup>Unidad de Información e Investigación Social y Sanitaria, Universitat de València-CSIC, Spain; <sup>3</sup>Generalitat Valenciana, Spain

*A national primary care and prevention system for addictions in Mexico*

O. Campollo<sup>1</sup>, A. Ramos<sup>2</sup>, F.J. Anguiano<sup>2</sup>. <sup>1</sup>University of Guadalajara, Mexico; <sup>2</sup>Consejo Estatal Contra las Adicciones en Jalisco, Mexico

*“Cannabis—it’s not our culture”: Engaging with indigenous Australians about cannabis and their community*

J. Copeland, P. Dillon, J. Howard. National Cannabis Prevention and Information Centre, Australia

*Republic Act 6425 as amended by Republic Act 9165—the Comprehensive Dangerous Drugs Act of 2002: Its effect on the volume of drug cases in Dipolog City*

A. Cuivillas. Jose Rizal Memorial State University, Philippines

*Crack cocaine—accelerating use in Brazil*

A. Domanico<sup>1</sup>, M. Malta<sup>2</sup>, C. Latkin<sup>1</sup>. <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, United States; <sup>2</sup>Sergio Arouca Public Health School, FIOCRUZ, Brazil

*Hepatitis C knowledge among methadone maintenance treatment staff and social workers in China*

J. Du. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

*High school students with a substance-abusing family member interested in school-based support groups*

B. Gance-Cleveland<sup>1</sup>, M. Choi<sup>1</sup>, K. Ickes<sup>2</sup>, V. Bush<sup>1</sup>. <sup>1</sup>Arizona State University, United States; <sup>2</sup>LaJoya High School, United States

*Drug abuse increasing HIV transmission in sub-Saharan countries*

J.Y. Gatete. Collectif National pour les Droits de l'Homme, Burundi

*Selective prevention: Addressing vulnerability to problem drug use in Europe*

V.A. Gyarmathy<sup>1,2</sup>, A. Bo<sup>1</sup>. <sup>1</sup>European Monitoring Centre for Drugs and Drug Addiction, Portugal; <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, United States

*Strengthening community-based drug prevention and intervention for youngsters in Kosovo*

R. Ismajli. Kosovo Health Foundation, Kosovo; The Center for Developing of Family Medicine, Kosovo; Drug Abuse Center, Kosovo

*Family factors as predictors of drug and alcohol-related problems among Mexican American youth*

A. Kopak<sup>1</sup>, A.C.C. Chen<sup>2</sup>, S.A. Haas<sup>3</sup>, M.R. Gillmore<sup>4</sup>. <sup>1</sup>Southwest Interdisciplinary Research Center, Arizona State University, United States; <sup>2</sup>College of Nursing and Health Care Innovation, Arizona State University, United States; <sup>3</sup>School of Social and Family Dynamics, Arizona State University, United States; <sup>4</sup>School of Social Work, Arizona State University, United States

*Drug resistance strategies of adolescents in Guanajuato, Mexico*

S. Kulis, F.F. Marsiglia, S.L. Ayers, C.O. Calderón-Tena. Southwest Interdisciplinary Research Center, Arizona State University, United States

*Multisectoral collaboration model for prevention of injecting drug use and HIV/AIDS in Burma (Myanmar)*

T. Khin. United Nations Office on Drugs and Crime, Burma (Myanmar); Virginia Commonwealth University, United States

*Tobacco and other substance behaviors among street children*

S. Lamsal<sup>1</sup>, I. Walia<sup>2</sup>, R. Kumar<sup>3</sup>, B. Kaur<sup>2</sup>. <sup>1</sup>B.P. Koirala Institute of Health Sciences, Nepal; <sup>2</sup>National Institute of Nursing Education, India; <sup>3</sup>Postgraduate Institute of Medical Education and Research, India

*Religion and adolescent substance use in Mexico: Exploring the interaction between internal and external religiosity*

F. Marsiglia<sup>1</sup>, S. Ayers<sup>2</sup>, S. Hoffman<sup>1</sup>. <sup>1</sup>Arizona State University, United States; <sup>2</sup>Southwest Interdisciplinary Research Center, United States

*Opal, the silver bullet—an Australian low-aromatic fuel replacement strategy*

B. McFarland. Tangentyere Council, Australia

*Motives associated with resilience of tobacco use among school students in Spain—differences by gender*

C. Morales-Manrique<sup>1</sup>, F.J. Bueno-Cañigral<sup>2</sup>, J.C. Valderrama-Zurián<sup>3</sup>, R. Aleixandre-Benavent<sup>1</sup>. <sup>1</sup>Unidad de Información e Investigación Social y Sanitaria, Universitat Valencia-CSIC, Spain; <sup>2</sup>Plan Municipal Drogodependencias, Ayuntamiento de Valencia, Spain; <sup>3</sup>Generalitat Valenciana, Spain

*Reducing injection intensity is associated with decreased risk for invasive bacterial infection among high-frequency injection drug users*

A. Moriggia<sup>1,2</sup>, J. Astemborski<sup>3</sup>, D. Thomas<sup>1</sup>, S.H. Mehta<sup>3</sup>. <sup>1</sup>Division of Infectious Diseases, Johns Hopkins University School of Medicine, United States; <sup>2</sup>Division of Infectious and Tropical Diseases, IRCCS San Matteo Foundation, University of Pavia, Italy; <sup>3</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, United States

*Ethnic differences in drug-related risks for HIV and intimate partner violence among vulnerable women in Cape Town, South Africa*

B. Myers<sup>1,2</sup>, W.M. Wechsberg<sup>3</sup>, F. Browne<sup>2</sup>, T. Carney<sup>1</sup>, R.M. Ellerson<sup>3</sup>, T. Kline<sup>3</sup>, C.D.H. Parry<sup>1</sup>, R. Jewkes<sup>1</sup>. <sup>1</sup>Medical Research Council, South Africa; <sup>2</sup>University of Cape Town, South Africa; <sup>3</sup>RTI International, United States

*Substance use among students in a public senior secondary school in Lagos, Nigeria*

C. Okonkwo<sup>1,2</sup>, R. Lawal<sup>2</sup>, M. Ojo<sup>2</sup>, C. Eze<sup>2</sup>, H.T. Ladapo<sup>2</sup>, T. Hary<sup>2</sup>, C. Nwigwe<sup>2</sup>, O. Ogunwale<sup>2</sup>, E. Ladeji<sup>2</sup>, M. Aguwa<sup>2</sup>. <sup>1</sup>Virginia Commonwealth University, United States; <sup>2</sup>Federal Neuro Psychiatric Hospital, Yaba, Nigeria

*How effective is street drug testing?*

D. Otiashvili<sup>1</sup>, I. Kirtadze<sup>1</sup>, T. Zabransky<sup>2</sup>. <sup>1</sup>Addiction Research Center, Union Alternative Georgia, Georgia; <sup>2</sup>Centre for Addictology, Charles University in Prague, Czech Republic

*Medical student attitudes toward substance abuse: A study of the effectiveness of an educational program involving small-group and discussion formats of patient management problems*

S. Pati. SCB Medical College, India



*Effectiveness of implementing the Strengthening Families Program for families of schoolchildren in Songkhla Province, Thailand*

M. Pinyuchon<sup>1</sup>, T. Maneesrikham<sup>2</sup>, S. Santiwaranont<sup>3</sup>. <sup>1</sup>Strengthening Families Program, Thailand; <sup>2</sup>Srinakharinwirot University, Thailand; <sup>3</sup>Thaksin University, Thailand

*A comparative study of risk and protective factors for drug abuse among adolescents in Malaysia*

M.M.S.M. Razali<sup>1,2</sup>, W. Kliever<sup>2</sup>. <sup>1</sup>Sultan Idris Education University, Malaysia; <sup>2</sup>Virginia Commonwealth University, United States

*Research on adaptation/design and implementation of an evidence-based drug abuse, HIV, and crime prevention program for schoolchildren in Ukraine*

V. Ryabukha. Virginia Commonwealth University, United States

*Police involvement with HIV-infected Russian heroin users: Insights from the HERMITAGE study*

J. Samet<sup>1</sup>, A.Y. Walley<sup>1,2</sup>, D.M. Cheng<sup>1,2,3</sup>, C. Bridden<sup>1,2</sup>, A. Raj<sup>1,2,3</sup>, R. Booth<sup>4</sup>, C.E. Chaisson<sup>3</sup>, E. Blokhina<sup>5</sup>, E. Zvartau<sup>5</sup>, E. Krupitsky<sup>5</sup>. <sup>1</sup>Boston University School of Medicine, United States; <sup>2</sup>Boston Medical Center, United States; <sup>3</sup>Boston University School of Public Health, United States; <sup>4</sup>University of Colorado School of Medicine, United States; <sup>5</sup>Pavlov State Medical University, Russia

*Health kiosks 2009: Preventing drug use in recreational areas*

S. Tortajada, S. Tomas, N. Llorens, J. Aguilar. Fundación para el Estudio, Prevención y Asistencia a las Drogodependencias, Spain

*Are adolescents gambling with cannabis use? A longitudinal study of observed and reported impulsivity measures in relation to adolescent substance use: The TRAILS study*

A.P. van Leeuwen<sup>1</sup>, H.E. Creemers<sup>2,3</sup>, F.C. Verhulst<sup>3</sup>, J. Ormel<sup>4,5,6</sup>, A.C. Huizink<sup>2,3</sup>. <sup>1</sup>University of Amsterdam, The Netherlands; <sup>2</sup>Research Institute of Child Development and Education, University of Amsterdam, The Netherlands; <sup>3</sup>Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Sophia Children's Hospital, The Netherlands; <sup>4</sup>University Medical Center Groningen, The Netherlands; <sup>5</sup>University of Groningen, The Netherlands; <sup>6</sup>Graduate School for Experimental Psychopathology, The Netherlands

*Impulsivity and HIV sexual risk behaviors in Bulgarian heroin users*

G. Vasilev<sup>1</sup>, I. Raynov<sup>1</sup>, S. Bliznashki<sup>1</sup>, E. Martin-Thormeyer<sup>2</sup>, J. Vassileva<sup>2</sup>. <sup>1</sup>Bulgarian Addictions Institute, Bulgaria; <sup>2</sup>University of Illinois at Chicago, United States

*Impulsive personality traits as a predictor of psychiatric problems of drug users*

Z. Wang, J. Du, H. Sun, M. Zhao. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

*Gender differences in HIV risk behaviors and other issues among Chinese methadone patients*

R. Zhang<sup>1</sup>, Y. Hser<sup>2</sup>, J. Li<sup>1</sup>, B. Zhang<sup>1</sup>, Z. Congbin<sup>1</sup>. <sup>1</sup>Yunnan Institute on Drug Abuse, China; <sup>2</sup>Center for Advancing Longitudinal Drug Abuse Research, University of California, Los Angeles, United States

*A preliminary study of the reliability and validity of the Chinese version of the Alcohol, Smoking, and Substance Use Involvement Screening Test*

M. Zhao, H. Sun, Q. Zheng, J. Du, H. Chen, C. Fan, J. Haifeng. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

*Assessment and comparison of attitudes toward methadone treatment between patients at a methadone maintenance clinic and compulsory detoxification center in China*

W. Zhou<sup>1,2</sup>, Y. Liu<sup>2</sup>. <sup>1</sup>Ningbo Addiction Research and Treatment Center, China; <sup>2</sup>School of Medicine, Ningbo University, China

### TREATMENT

*First analysis of newborns of opiate-addicted mothers in Bucharest, Romania*

A.O. Abagiu<sup>1,2</sup>, M. Anghelescu<sup>2</sup>, R. Ianos-Iancovici<sup>2</sup>, B. Rusu<sup>2</sup>, I.G. Stoica<sup>2</sup>, F. Georgescu<sup>2</sup>, F. Gheorghe<sup>2</sup>, E. Cojocaru<sup>2</sup>, A.M. Tudor<sup>1</sup>, V. Leoveanu<sup>1</sup>, A.S. Craciun<sup>3</sup>, M. Ceausu<sup>3</sup>, A. Koulosousas<sup>2,3</sup>, A. Sirbu<sup>4</sup>. <sup>1</sup>National Institute for Infectious Diseases, Romania; <sup>2</sup>Arena First Low-Threshold Methadone Maintenance Treatment Center, Romania; <sup>3</sup>I. Cantacuzino Hospital, Romania; <sup>4</sup>Bucharest University Hospital, Romania

*Therapeutic communities: A three-country comparison*

G. Bunt<sup>1</sup>, D. Kressel<sup>2</sup>, V. Stanick<sup>1</sup>, M. Au<sup>1</sup>. <sup>1</sup>Daytop Village, Inc., United States; <sup>2</sup>National Development and Research Institutes, United States

*Effect of naltrexone and buprenorphine on smoking in opioid-dependent subjects*

B. Chatterjee, R. Jain, S. Jhanjee. All India Institute of Medical Sciences, India

*A pilot study of relapse prevention intervention for heroin addicts in prison in China*

H. Chen, M. Zhao, J. Du. Shanghai Mental Health Center, Shanghai Jiao Tong University, China

*Assessment of medication-assisted treatment programs' staff perceptions concerning their jobs*

V. Chtenguelov, S. Dvoriak, G. Prib. Ukrainian Institute on Public Health Policy, Ukraine

*System and services integration for homeless persons with substance use and other mental disorders*

E. Conroy<sup>1</sup>, L. Burns<sup>1</sup>, P. Flatau<sup>2</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, Australia; <sup>2</sup>Murdoch Business School, Australia

*Prenatal cocaine exposure in the south of Brazil: Neurobehavioral effects on the newborn infant*

G. Cunha, N. Rotta, R. Riesgo, A.L. Dieder, A.L. Wolf, R. Margis, A. Silva, F. Silva, M. Socal, P. Silva, C. Moser, F. Pechansky. Federal University of Rio Grande do Sul, Brazil

*From stilettos to moccasins: First Nations' women's healing from drug abuse*

C. Dell, University of Saskatchewan, Canada

*From benzos to berries: Treatment offered at an Aboriginal youth solvent abuse treatment center relays the importance of culture*

D. Dell<sup>1</sup>, C.A. Dell<sup>2</sup>, M. Seguin<sup>2</sup>, C. Hopkins<sup>3</sup>, R. Tempier<sup>2</sup>, L. Mehl-Madrona<sup>4,5</sup>, R. Duncan<sup>2</sup>, K. Mosier<sup>6</sup>. <sup>1</sup>National Youth Solvent Addiction Committee, Canada; <sup>2</sup>University of Saskatchewan, Canada; <sup>3</sup>National Native Addictions Partnership Foundation, Canada; <sup>4</sup>University of Hawaii School of Medicine, United States; <sup>5</sup>Coyote Institute for Studies of Change and Transformation, United States; <sup>6</sup>Western College of Veterinary Medicine, University of Saskatchewan, Canada

*Setting up a drug treatment service for female drug users in Iran*

K. Dolan<sup>1</sup>, S. Mohsenifar<sup>2</sup>, B. Nassirimanesh<sup>3</sup>, S. Salimi<sup>1</sup>, M. Azarakhsh<sup>1</sup>.

<sup>1</sup>University of New South Wales, Australia; <sup>2</sup>Iranian National Centre for Addiction Studies, Iran; <sup>3</sup>Persepolis Centre, Iran

*The attendance of babies exposed to drugs of abuse program: A first experience in Brazil*

F.M. Driemeier<sup>1,2</sup>, G. Cunha<sup>1,2</sup>, M.L.S. Zavaschi<sup>1</sup>, J. Dreyer<sup>1</sup>, S. Décimo<sup>2</sup>, M. Zanatta<sup>2</sup>, R. Riesgo<sup>1</sup>, F. Pechansky<sup>1</sup>. <sup>1</sup>Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; <sup>2</sup>Hospital Materno Infantil Presidente Vargas, Brazil

*Lack of hepatic injury during chronic abuse of combination of acetaminophen and codeine: A case series*

S. Djezzar<sup>1,2</sup>, E. Guillem<sup>3</sup>, F. Vorspan<sup>4</sup>, A. Buisine<sup>4</sup>, J. Guilleraut<sup>1</sup>, E. Burin<sup>1,2</sup>, R. Sicot<sup>1</sup>, S. Dally<sup>1,2</sup>. <sup>1</sup>Hôpital Fernand Widal, Assistance Publique Hôpitaux de Paris, France; <sup>2</sup>Center of Evaluation and Information on Pharmacodependence-Addictovigilance, Groupe Hôpitalier Lariboisiere-Fernand Widal, France; <sup>3</sup>Department of Psychiatry, Groupe Hôpitalier Lariboisiere-Fernand Widal, France; <sup>4</sup>Toxicology Laboratory, Groupe Hôpitalier Lariboisiere-Fernand Widal, France

*Qualitative study on residential abstinence-based detoxification program in heroin dependence: Barriers/incentives and advantageous/disadvantageous characteristics in 3-month follow-up*

H. Ekhtiari<sup>1</sup>, P. Hasani-Abharian<sup>1,3</sup>, Z. Alam-Mehrjerdi<sup>1</sup>, A. Deilamizadeh<sup>4</sup>, I.A. Jillson<sup>5</sup>, A. Mokri<sup>2</sup>. <sup>1</sup>Neurocognitive Laboratory, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; <sup>2</sup>Clinical Dept., Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; <sup>3</sup>Institute for Cognitive Sciences Studies, Iran; <sup>4</sup>Rebirth Society, Non- Governmental Organization in Drug Dependence Treatment, Iran; <sup>5</sup>Dept. of Public Health and Nursing Studies, Georgetown University, United States

*Validating medical knowledge internationally: The international certification of addiction medicine*

N. el-Guebaly<sup>1</sup>, C. Violato<sup>2</sup>. <sup>1</sup>Foothills Medical Centre, Canada; <sup>2</sup> Medical Education and Research Unit, Faculty of Medicine, University of Calgary, Canada

*Cytochrome P450 and ABCB1 genetic polymorphisms and methadone plasma concentrations in opioid dependence disorder*

F. Fonseca<sup>1</sup>, A. Pastor<sup>2</sup>, K. Langohr<sup>2</sup>, R. Martín-Santos<sup>2,3</sup>, M. Farré<sup>2,4</sup>, R. de la Torre<sup>4,5</sup>, M. Torrens<sup>2,4</sup>. <sup>1</sup>Institut d'Atenció Psiquiàtrica i Addiccions-Parc de Salut Mar, Spain; <sup>2</sup>Institut Municipal d'Investigació Mèdica, Parc de Salut Mar, Parc de Recerca Biomèdica de Barcelona, Spain; <sup>3</sup>Institut de Neurociències, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Spain; <sup>4</sup>Universitat Autònoma de Barcelona, Spain; <sup>5</sup>Pompeu Fabra University, Spain

*Neuropsychological performance of cocaine addicts during treatment*

G. Garcia-Fernandez<sup>1</sup>, O. García-Rodríguez<sup>2</sup>, R. Secades-Villa<sup>1</sup>, S. Fernández-Artamendi<sup>1</sup>, J.R. Fernández-Hermida<sup>1</sup>. <sup>1</sup>University of Oviedo, Spain; <sup>2</sup>University of Barcelona, Spain

*Morbidity and mortality among drug users admitted to the complication ward of the Drug Dependence Hospital in Jakarta, Indonesia*

M. Hidayat<sup>1</sup>, A. Nurhidayat<sup>1</sup>, R. Sarasvita<sup>1</sup>, D. Utami<sup>1</sup>, D. Metzger<sup>2</sup>. <sup>1</sup>Drug Dependence Hospital RSKO, Indonesia; <sup>2</sup>University of Pennsylvania, United States

*The effectiveness of cognitive behavior therapy for depression and substance use compared to standard care among young people with co-occurring depression/anxiety and substance use*

L. Hides<sup>1</sup>, D.I. Lubman<sup>2</sup>, K. Elkins<sup>2</sup>, S. Carroll<sup>2</sup>, A. Scaffidi<sup>2</sup>, S.M. Cotton<sup>2</sup>, R. Marks<sup>3</sup>. <sup>1</sup>University of Melbourne, Australia; <sup>2</sup>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Australia; <sup>3</sup>Youth Outreach Team, Drug and Alcohol Services West, Western Health, Australia

*Medication-assisted treatment, scale-up strategy for Ukraine*

Z. Islam<sup>1</sup>, S. Filippovych<sup>1</sup>, A. Lebega<sup>1</sup>, R.D. Bruce<sup>2</sup>. <sup>1</sup>International HIV/AIDS Alliance in Ukraine; <sup>2</sup>Yale AIDS Program, Yale University School of Medicine, United States

*Efficacy and safety of extended-release injectable naltrexone for the treatment of opioid dependence*

E. Krupitsky<sup>1</sup>, A. Illeperuma<sup>2</sup>, D. Gastfriend<sup>2</sup>, B. Silverman<sup>2</sup>. <sup>1</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; <sup>2</sup>Alkermes, Inc., United States

*The prevalence and correlates of aberrant drug behaviors among a sample of Australian opioid substitution treatment clients*

B. Larance, L. Degenhardt. National Drug and Alcohol Research Centre, University of New South Wales, Australia

*Change in organizational dual-diagnosis capacity after a whole of workforce initiative in substance use treatment settings*

N. Lee, J. Cameron, A. Harney, S. Roeg. Turning Point Alcohol and Drug Centre, Australia

*Preliminary outcomes of methadone treatment among heroin users in northern Taiwan*

T.S.H. Lee<sup>1</sup>, D.S. Metzger<sup>2</sup>, M. Charwarski<sup>3</sup>. <sup>1</sup>National Taiwan Normal University, Taiwan; <sup>2</sup>Center for AIDS Research, University of Pennsylvania, United States; <sup>3</sup>School of Medicine, Yale University, United States

*Methadone patients' treatment outcomes: Longitudinal study on the associations between background and process variables and retention rate, illicit drug use, and risk behavior*

S. Levit<sup>1</sup>, M. Schiff<sup>2</sup>, R. Benbenishty<sup>3</sup>. <sup>1</sup>Association for Public Health, Israel; <sup>2</sup>School of Social Work and Social Welfare, Hebrew University, Israel; <sup>3</sup>School of Social Work, Bar Ilan University, Israel

*Contingency management for Chinese methadone patients*

J. Li<sup>1</sup>, Y. Hser<sup>2</sup>, R. Zhang<sup>1</sup>, B. Zhang<sup>1</sup>, C. Zhang<sup>1</sup>, X. Tang<sup>1</sup>. <sup>1</sup>Yunnan Institute for Drug Abuse, China; <sup>2</sup>Center for Advancing Longitudinal Drug Abuse Research, University of California, Los Angeles, United States

*Hypnotherapy in the treatment of alcoholism*

B. Lobodov. Center "Semya," Russia



*Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV prevention trials network 058*

G. Lucas<sup>1</sup>, G. Beauchamp<sup>2</sup>, A. Aramrattana<sup>3</sup>, Y. Shao<sup>4</sup>, W. Liu<sup>5</sup>, L. Fu<sup>6</sup>, B. Jackson<sup>1</sup>, D. Celentano<sup>7</sup>, M. Chawarski<sup>8</sup>, D. Burns<sup>9</sup>, K. Davenport<sup>10</sup>, D. Donnell<sup>2</sup>, S. Rose<sup>11</sup>, D. Metzger for HPTN 058 Study Group<sup>12</sup>. <sup>1</sup>Johns Hopkins School of Medicine, United States; <sup>2</sup>Statistical Center for HIV/AIDS Research and Prevention-Fred Hutchinson Cancer Research Center, United States; <sup>3</sup>Chiang Mai University, Thailand; <sup>4</sup>China Center for Disease Control and Prevention, China; <sup>5</sup>Guangxi China Center for Disease Control and Prevention, China; <sup>6</sup>Xinjiang China Center for Disease Control and Prevention, China; <sup>7</sup>Johns Hopkins Bloomberg School of Public Health, United States; <sup>8</sup>Yale University, United States; <sup>9</sup>National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), United States; <sup>10</sup>National Institute on Drug Abuse, NIH, United States; <sup>11</sup>Family Health International, United States; <sup>12</sup>University of Pennsylvania, United States

*Creating lesbian, gay, bisexual, transgender, and queer treatment-sensitive substance abuse counselors: The importance of cultural competency*

A. Lynch, J.N. Karp. Social Solutions International, Inc., United States

*Associations between implicit and explicit drug-related cognitions and relapse: An ecological momentary assessment study*

R. Marhe<sup>1</sup>, I. Franken<sup>1</sup>, A. Walters<sup>2</sup>. <sup>1</sup>Institute of Psychology, Erasmus University Rotterdam, The Netherlands; <sup>2</sup>Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, United States

*Involving family physicians in methadone treatment maintenance programs in Kosovo*

I. Miftari. Main Family Medicine Center, Kosovo

*Is exposure therapy for post-traumatic stress disorder efficacious among people with substance use disorders? Results from a randomized controlled trial*

K. Mills, M. Teesson, E. Barrett, S. Merz, J. Rosenfeld, P. Farrugia. University of New South Wales, Australia

*Factors associated with heroin use in patients on the pilot methadone maintenance therapy program in Vietnam*

N. Nguyen<sup>1</sup>, N.T. Long<sup>2</sup>, N.T. Huynh<sup>2</sup>, N.Q. Mai<sup>2</sup>, T.V. Hoang<sup>1</sup>, P.H. Minh<sup>1</sup>, S.J. Mills<sup>1</sup>, R. Burdon<sup>1</sup>, K.P. Mulvey<sup>3</sup>, N.T.M. Ngoc<sup>4</sup>, N.T. Hong<sup>5</sup>, D. Jacka<sup>6</sup>, R. Ali<sup>7</sup>. <sup>1</sup>Family Health International, Vietnam; <sup>2</sup>Vietnam Administration of HIV/AIDS Control, Ministry of Health, Vietnam; <sup>3</sup>Substance Abuse and Mental Health Services Administration, United States; <sup>4</sup>United States Agency for International Development, Vietnam; <sup>5</sup>HHS Center for Disease Control, Vietnam; <sup>6</sup>World Health Organization, Vietnam; <sup>7</sup>World Health Organization Collaborating Center on Drug and Alcohol Abuse Treatment, Adelaide University, Australia

*Methadone maintenance treatment in Jakarta, Indonesia: Organizational and programmatic challenges*

A. Nurhidayat<sup>1</sup>, V. Fardhdiani<sup>1</sup>, M. Chawarski<sup>2</sup>, G. Woody<sup>3</sup>, D. Metzger<sup>3</sup>.

<sup>1</sup>Drug Dependence Hospital RSKO, Indonesia; <sup>2</sup>Yale University, United States;

<sup>3</sup>University of Pennsylvania, United States

*Peculiarities of methcathinone ("Jeff") consumption in patients on methadone maintenance treatment*

G. Piralishvili, N. Papuashvili, Z. Zikharulidze. Medical Centre Uranti, Georgia

*Bringing gender-based analysis to substance use treatment and policy in Canada*

N. Poole. British Columbia Centre of Excellence for Women's Health, Canada

*Advertising representation of substance abuse treatment clinics in Iran*

S. Rezaee<sup>1,2</sup>, M. Noori<sup>1</sup>, L. Jahromi<sup>1</sup>, M.R. Jamshidi<sup>1</sup>, H. Ekhtiari<sup>1</sup>. <sup>1</sup>Neuro

Cognitive Laboratory, Iranian National Center for Addiction Studies, Tehran

University of Medical Sciences, Iran; <sup>2</sup>Cultural Studies Department, Social Studies

School, Allame Tabatabai University, Iran

*Long-term residential substance abuse treatment for women: Lessons learned from Israel*

M. Schori<sup>1</sup>, E. Lawental<sup>2,3</sup>, Y. Sapir<sup>4</sup>. <sup>1</sup>School of Social Policy and Practice,

University of Pennsylvania, United States; <sup>2</sup>Haifa Drug Abuse Treatment Center,

Israel; <sup>3</sup>Tel-Hai Academic College, Israel; <sup>4</sup>The Central School for Social Welfare

Workers, Ministry of Social Affairs, Israel

*Adding voucher-based incentives to the community reinforcement approach improves outcomes during treatment for cocaine dependence*

R. Secades-Villa<sup>1</sup>, G. García-Fernández<sup>1</sup>, O. García-Rodríguez<sup>2</sup>, H. Álvarez Rodríguez<sup>3</sup>, J.A. Álvarez García<sup>3</sup>, E. Sánchez-Hervás<sup>4</sup>. <sup>1</sup>University of Oviedo,

Spain; <sup>2</sup>University of Barcelona, Spain; <sup>3</sup>Proyecto Hombre Asturias, Spain;

<sup>4</sup>Valencia State Health Agency, Spain

*Relationship between cognitive behavioral therapy knowledge transfer and skill implementation among South African substance abuse clinicians*

R. Sodano<sup>1</sup>, S. Rataemane<sup>2</sup>, L. Rataemane<sup>3</sup>, N. Ntlhe<sup>3</sup>, R.A. Rawson<sup>1</sup>. <sup>1</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States;

<sup>2</sup>Department of Psychiatry, University of Limpopo, South Africa; <sup>3</sup>Mental Health and Addiction Centre, South Africa

*Effects of acute tyrosine, tryptophan, and phenylalanine depletion treatment on cue-induced alcohol urging in patients with alcohol dependence in China*

H. Sun<sup>1</sup>, Y. Liu<sup>2</sup>, X. Bao<sup>2</sup>, X. Di<sup>1</sup>, F. Yang<sup>1</sup>, L. Lu<sup>2</sup>. <sup>1</sup>Beijing Hui-Long-Guan

Hospital, China; <sup>2</sup>National Institute on Drug Dependence, Peking University, China

*Does co-occurring social phobia interfere with alcoholism treatment adherence and relapse?*

M. Terra<sup>1</sup>, H.M. Tannhauser Barros<sup>2</sup>, A. Tetelbom Stein<sup>2</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Federal University of Health Sciences of Porto Alegre, Brazil

*Detection of alcohol-related problems in primary care health centers in the autonomous region of Valencia (Spain)*

S. Tomas<sup>1</sup>, P. Torrijo<sup>2</sup>, S. Tortajada<sup>2</sup>, J. Aguilar<sup>2</sup>, N. Llorens<sup>2</sup>. <sup>1</sup>Dirección General de Drogodependencias, Spain; <sup>2</sup>Fundación para el Estudio, Prevención y Asistencia a las Drogodependencias, Spain

*Injection drug use and anemia among AIDS patients in Vietnam*

H. Vu<sup>1</sup>, P. Sullivan<sup>1</sup>, C. del Rio<sup>1</sup>, N.T. Do<sup>2</sup>, L.T. Nguyen<sup>2</sup>, Q.H. Tran<sup>3</sup>. <sup>1</sup>Rollins School of Public Health, Emory University, United States; <sup>2</sup>Ministry of Health, Vietnam; <sup>3</sup>Hanoi School of Public Health, Vietnam

#### **INFORMATIONAL**

*Hubert Humphrey Fellowship Program at Virginia Commonwealth University*

J.R. Koch, R. Balster, C. Thomas, E. Turf, C. O'Keefe. Virginia Commonwealth University, United States

*International Program in Addiction Studies*

J.R. Koch, R. Balster, M. Loos, E. Turf, C. O'Keefe. Virginia Commonwealth University, United States

*The Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: Follow-up assessment*

J.R. Koch, L. Leonchuk, R. Balster, E. Turf, C. O'Keefe. Virginia Commonwealth University, United States

**Grant-Writing Workshop  
(Pre-Registration Only)**

**Sonoran  
8:00 AM - 12:00 PM**

**Poster Session II (Lunch)**

**Pavilion  
11:30 AM - 1:30 PM**

**Odd-numbered posters manned first hour;  
Even-numbered, second hour**

**Set-up time begins Monday no earlier than 3:00 PM  
Must be removed by Tuesday no later than 2:00 PM**

**CRIMINAL JUSTICE**

- 1 *Predictors of treatment completion among offenders enrolled in a community-based outpatient program*  
D. M. Coviello<sup>1</sup>, D. A. Zanis<sup>1,2</sup>, S. A. Wesnoski<sup>1</sup>, N. R. Palman<sup>1</sup>, A. Erez<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Temple University, Philadelphia, PA
- 2 *Lifetime and past-year prevalence of drug use and drugged driving among rural Appalachian DUI offenders*  
M. Webster, M. F. Dickson, N. E. Wasarhaley, M. Staton-Tindall, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 3 *Gender effects in the Step'N Out Study of substance-use treatment mandated parolees*  
J. E. Johnson<sup>1</sup>, P. Friedmann<sup>2,1</sup>, F. Taxman<sup>3</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Rhode Island Hospital, Providence, RI, <sup>3</sup>George Mason University, Fairfax, VA
- 4 *A comparison of community correction participants enrolled in methadone maintenance treatment*  
A. C. Perkins, K. E. Conti, G. J. Hale, D. O. Jackson, K. L. Cropsey, Psychiatry, University of Alabama at Birmingham, Birmingham, AL
- 5 *Heroin-dependent offenders' experiences with buprenorphine vs. methadone maintenance*  
S. Magura, E. Awgu, A. Rosenblum<sup>2</sup>, <sup>1</sup>Western Michigan University, Kalamazoo, MI, <sup>2</sup>National Development and Research Institutes, New York, NY
- 6 *A randomized control trial using buprenorphine for opiate addiction: A descriptive analysis of female offenders*  
G. J. Hale, D. O. Jackson, P. S. Lane, S. Jones-Whaley, A. Perkins, K. Cropsey, Psychiatry, University of Alabama at Birmingham, Birmingham, AL
- 7 *Characteristics of incarceration among black South African drug users*  
A. Hulbert, J. Zur, L. Ropelewski, S. Hedden, B. Mancha, W. Latimer, Mental Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD
- 8 *Incarceration and sexually transmitted infection/HIV in Bushwick, Brooklyn, NY: A social network perspective*  
M. Khan, S. Friedman, Epidemiology and Biostatistics, University of Maryland, College Park, MD
- 9 *Polysubstance users in the criminal justice system – a comparison with heroin and amphetamine users*  
A. Hakansson<sup>1</sup>, F. Schlyter<sup>2</sup>, M. Berglund<sup>1</sup>, <sup>1</sup>Clinical Alcohol Research, Lund University, Malmö, Sweden, <sup>2</sup>Swedish Prison and Probation Service, Norrköping, Sweden
- 10 *New factors to consider in assessing accuracy of self-reported drug use in treatment settings*  
F. Taxman, A. Wooditch, George Mason University, Manassas, VA

- 11 *Risk of death and crime among program-quitters*  
T. Clausen<sup>1</sup>, S. Skurtveit<sup>2,1</sup>, <sup>1</sup>Norwegian Centre for Addiction Research, University of Oslo, and  
<sup>2</sup>Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway
- 12 *Comparing outcomes of 'voluntary' and 'quasi-compulsory' treatment of substance dependence in Europe*  
M. P. Schaub<sup>1</sup>, A. Stevens<sup>2</sup>, N. Hunt<sup>2</sup>, D. Berto<sup>3</sup>, T. McSweeney<sup>5</sup>, B. Trinkl<sup>6</sup>, V. Kersch<sup>4</sup>,  
W. Werdenich<sup>6</sup>, A. Uchtenhagen<sup>1</sup>, <sup>1</sup>Research Institute for Public Health and Addiction, Zurich,  
Switzerland, <sup>2</sup>European Institute of Social Services, University of Kent, Canterbury, United  
Kingdom, <sup>3</sup>Servizio Tossicodipendenze, Padova, Italy, <sup>4</sup>SPI Forschung, Berlin, Germany,  
<sup>5</sup>Institute for Criminal Policy Research, King's College London, London, United Kingdom,  
<sup>6</sup>Lehr- und Forschungspraxis der Universität Wien, Vienna, Austria
- 13 *Relationship of criminal thinking to personality and criminal behavior among female offenders*  
B. B. Riley<sup>1</sup>, C. K. Scott<sup>1</sup>, M. L. Dennis<sup>1</sup>, R. Funk<sup>1</sup>, S. Kim<sup>2</sup>, <sup>1</sup>Chestnut Health Systems,  
Bloomington, IL, <sup>2</sup>School of Public Health, University of Illinois at Chicago, Chicago, IL
- 14 *Examining the relationship between social support and crack and cocaine use in an incarcerated population of mothers and non-mothers*  
K. L. Harp<sup>1,2</sup>, C. Leukefeld<sup>2,3</sup>, C. B. Oser<sup>1,2</sup>, <sup>1</sup>Sociology, <sup>2</sup>Center on Drug and Alcohol  
Research, and <sup>3</sup>Behavioral Science, University of Kentucky, Lexington, KY
- 15 *Women's TC—preliminary psychological findings at 12-month follow-up*  
J. Y. Sacks, S. Sacks, K. McKendrick, G. Melnick, National Development & Research  
Institutes, Inc., New York, NY
- 16 *Re-entry programming for offenders with co-occurring disorders: Process and outcome findings from a pilot study*  
A. Pande, P. Mulvey, M. S. Shafer, V. Staples, R. Rivera, Center for Applied Behavioral Health  
Policy, Arizona State University, Phoenix, AZ
- 17 *Co-occurring mental health and substance use disorders among recently booked arrestees*  
D. Choate<sup>2</sup>, M. S. Shafer<sup>1</sup>, C. Katz<sup>2</sup>, <sup>1</sup>College of Public Programs, and <sup>2</sup>Center for Violence  
Prevention and Community Safety, Arizona State University, Phoenix, AZ
- 18 *Preliminary analysis of TASC offenders with co-occurring substance use and mental health disorders*  
D. O. Jackson, G. Hale, A. Perkins, K. Cropsey, University of Alabama, Birmingham, AL
- 19 *Collaborative behavioral management reduces crime, drug use among drug-involved parolees*  
P. D. Friedmann<sup>1,2</sup>, M. Harrington<sup>2</sup>, T. C. Green<sup>2</sup>, F. S. Taxman<sup>3</sup>, <sup>1</sup>Research Enhancement Award  
Program, Providence VA Medical Center, Providence, RI, <sup>2</sup>Medicine, Rhode Island Hospital,  
Providence, RI, <sup>3</sup>George Mason University, Fairfax, VA
- 20 *The social networks of drug-using probationers in a randomized trial in Maryland*  
A. G. Rhodes, F. S. Taxman, Administration of Justice, George Mason University,  
Richmond, VA
- 21 *The relationship between substance abuse halfway houses and crime in Baltimore City, Maryland*  
S. J. Boyd<sup>1</sup>, L. J. Fang<sup>1</sup>, D. R. Medoff<sup>1</sup>, L. B. Dixon<sup>1</sup>, D. A. Gorelick<sup>2</sup>, <sup>1</sup>Psychiatry, University of  
Maryland School of Medicine, <sup>2</sup>Intramural Research Program, NIH/NIDA/DHHS,  
Baltimore, MD
- 22 *Re-entry MTC—preliminary findings on reincarceration at 12-month follow-up*  
S. Sacks, J. Y. Sacks, K. McKendrick, National Development and Research Institutes, Inc,  
New York, NY



- 23 *Towards evidence-based dispositions: A preliminary evaluation of the Risk and Needs Triage in a sample of drug court candidates*  
K. L. Dugosh<sup>1</sup>, D. S. Festinger<sup>1</sup>, D. B. Marlowe<sup>1,2</sup>, A. Caron<sup>3</sup>, M. R. Padkopacz<sup>3</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>National Association of Drug Court Professionals, Alexandria, VA, <sup>3</sup>Fourth Judicial District, Minnesota Judicial Branch, Hennepin County, MN
- 24 *Jail sanctions during drug court participation and substance abuse treatment completion*  
R. T. Brown<sup>1,3</sup>, P. A. Allison<sup>2</sup>, F. J. Nieto<sup>3</sup>, <sup>1</sup>Family Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, <sup>2</sup>Sociology, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Population Health Sciences, University of Wisconsin School of Medicine & Public Health, Madison, WI

#### **POLICY**

- 25 *Coordination between Single State Authorities and Departments of Corrections in the treatment of offenders within the community*  
S. P. Kubiak<sup>2</sup>, C. L. Arfken<sup>1</sup>, E. Tillander<sup>2</sup>, <sup>1</sup>Psychiatry, Wayne State University, Detroit, MI, <sup>2</sup>Social Work, Michigan State University, E. Lansing, MI
- 26 *California's Substance Abuse and Crime Prevention Act, aka Proposition 36: Arrest outcomes, state crime trends, and prison population trends associated with implementation*  
D. Urada, M. D. Anglin, J. Fan, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 27 *Cost savings under Proposition 36 - What groups save the most money?*  
M. D. Anglin<sup>2</sup>, A. Jaffe<sup>2,1</sup>, D. Urada<sup>2</sup>, <sup>1</sup>Psychology, UCLA, and <sup>2</sup>Integrated Substance Abuse Program, Los Angeles, CA
- 28 *Mechanisms of prescription drug diversion among impaired physicians*  
S. M. Cummings, L. J. Merlo, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 29 *Adoption of buprenorphine in two health plans*  
D. McCarty<sup>1</sup>, F. Lynch<sup>2</sup>, J. Mertens<sup>3</sup>, C. Green<sup>2</sup>, S. Parthasarathy<sup>3</sup>, M. Polen<sup>2</sup>, A. Hilde<sup>1</sup>, N. Perrin<sup>2</sup>, <sup>1</sup>Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR, <sup>2</sup>Center for Health Research, Kaiser Permanente Northwest, Portland, OR, <sup>3</sup>Division of Research, Kaiser Permanente Northern California, Oakland, CA
- 30 *Nicotine is the thing: Reducing harm from tobacco through proper labeling*  
R. K. Lanier, C. Wright, Rock Creek Pharmaceuticals, Gloucester, MA
- 31 *Toxin delivery after Black & Mild little cigar smoking*  
W. Pickworth, V. M. Smith, R. Martin, L. Canlas, J. Malson, Battelle CPHRE, Baltimore, MD

#### **NICOTINE: HUMAN STUDIES**

- 32 *Oral nicotine discrimination in nicotine non-users*  
A. N. Duke, R. R. Griffiths, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD
- 33 *The effects of varenicline on smoking in a brief abstinence model*  
E. A. McClure, R. G. Vandrey, M. Stitzer, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD
- 34 *A placebo-controlled trial of varenicline treatment on the acute effects of cigarette smoking followed by a one-week quit attempt*  
M. S. Reid, V. Thakkar, Psychiatry, New York University, New York, NY

- 35 *Pretreatment with nicotine patch facilitates smoking reduction in adult smokers with Attention Deficit Hyperactivity Disorder*  
J. S. English, M. Hallyburton, F. J. McClernon, S. H. Kollins, Duke University Medical Center, Durham, NC
- 36 *Findings from a clinical trial of bupropion for smokers in alcohol recovery*  
D. Kalman<sup>1,2</sup>, U. Sambamoorthi<sup>3</sup>, L. Herz<sup>2</sup>, G. Gonzalez<sup>1</sup>, P. Monti<sup>4</sup>, <sup>1</sup>University of Massachusetts, Worcester, MA, <sup>2</sup>ENRM VAMC, Bedford, MA, <sup>3</sup>West Virginia University, Morgantown, WV, <sup>4</sup>Brown University, Providence, RI
- 37 *Individual differences in Iowa Gambling Task: Possible role of early punishment intensity*  
A. A. Lopez<sup>1</sup>, M. P. Bradstreet<sup>1</sup>, S. T. Higgins<sup>1,2</sup>, <sup>1</sup>Psychology, and <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT
- 38 *Pathological learning in smokers: A conditioning experiment utilizing ERP measurements*  
M. Littel, I. Franken, Institute for Psychology, Erasmus University, Rotterdam, Netherlands
- 39 *Individual and concomitant influences of positive and negative affect on urge to smoke*  
A. M. Leventhal, K. J. Ameringer, S. W. Sharifian, Preventive Medicine, University of Southern California, Alhambra, CA
- 40 *Smoker's delay discounting indifference points are associated with changes in opportunity-cost-informed price*  
E. T. Mueller, R. D. Landes, R. Yi, W. K. Bickel, Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR
- 41 *Body composition and metabolic changes in women smokers during a cessation attempt*  
K. M. Gray, M. E. Saladin, M. J. Carpenter, K. J. Hartwell, Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 42 *Distress tolerance and adolescent smoking cessation*  
A. Collado-Rodriguez, W. Francis, K. Young, J. Gottlieb, C. W. Lejuez, L. MacPherson, University of Maryland, College Park, MD
- 43 *Treatment acceptability of Internet-based contingency management for cigarette smoking*  
B. R. Raiff<sup>1,2</sup>, M. Turturici<sup>2</sup>, C. Faix<sup>2</sup>, J. Dallery<sup>2,1</sup>, <sup>1</sup>National Development and Research Institutes, and <sup>2</sup>University of Florida, Gainesville, FL
- 44 *New York state policy to address tobacco dependence in drug treatment: Preliminary client baseline-follow-up results*  
B. Tajima<sup>1</sup>, J. Gudyish<sup>1</sup>, A. Kulaga<sup>2</sup>, L. Brown<sup>2</sup>, R. Zavala<sup>3</sup>, <sup>1</sup>Institute for Health Policy Studies, University of California, San Francisco, CA, <sup>2</sup>New York University, New York City, NY, <sup>3</sup>Addiction Research & Treatment Corporation, Brooklyn, NY
- 45 *Organizational change to address tobacco dependence: Pre, post and follow-up results*  
J. Gudyish<sup>1</sup>, B. Tajima<sup>1</sup>, D. Ziedonis<sup>2</sup>, E. Passalacqua<sup>1</sup>, M. Chan<sup>1</sup>, M. Levy<sup>3</sup>, G. Brigham<sup>4</sup>, L. Zmarelli<sup>5</sup>, <sup>1</sup>Institute for Health Policy Studies, University of California, San Francisco, CA, <sup>2</sup>University of Massachusetts, Worcester, MA, <sup>3</sup>CAB Recovery Services, Inc, Lynn, MA, <sup>4</sup>Maryhaven, Inc, Columbus, OH, <sup>5</sup>Willamette Family, Inc, Eugene, OR
- 46 *Attitudes and behaviors toward smoking cessation interventions by the dental team*  
G. G. Homish<sup>1</sup>, Y. Gonzalez<sup>2</sup>, E. Lozier<sup>2</sup>, L. Blair<sup>3</sup>, J. Fabiano<sup>2</sup>, <sup>1</sup>Health Behavior, and <sup>2</sup>School of Dental Medicine, University at Buffalo, Buffalo, NY, <sup>3</sup>Roswell Park Cancer Institute, Buffalo, NY
- 47 *DSM-IV and Fagerstrom nicotine dependence: Relationship in an Israeli general population sample*  
D. Shmulewitz, E. Aharonovich, D. Hasin, Columbia University, New York, NY

- 48 *The Brazilian smoker: A cross-sectional survey in Brazil*  
E. S. Opaleye<sup>1</sup>, Z. V. Sanchez<sup>1</sup>, Y. G. Moura<sup>2</sup>, D. P. Locatelli<sup>1</sup>, A. R. Noto<sup>1</sup>, <sup>1</sup>Psychobiology, Federal University of Sao Paulo, and <sup>2</sup>AFIP, Sao Paulo, Brazil
- 49 *Youthful tobacco smoking for males and females in Brazil*  
Z. V. Sanchez<sup>1,2</sup>, A. R. Noto<sup>1,2</sup>, <sup>1</sup>Psychobiology, Federal University of Sao Paulo, and <sup>2</sup>Brazilian Center of Information on Psychotropic Drugs (CEBRID), São Paulo, Brazil
- 50 *Beliefs associated with the consumption and non-consumption of tobacco in school students in Spain*  
F. J. Bueno-Cañigral<sup>2</sup>, C. C. Morales-Manrique<sup>1</sup>, R. Aleixandre-Benavent<sup>1</sup>, J. C. Valderrama-Zurián<sup>3</sup>, <sup>1</sup>Unidad de Información e Investigación Social y Sanitaria, Universitat de València-CSIC., <sup>2</sup>Plan Municipal Drogodependencias (PMD), Ayuntamiento de Valencia, and <sup>3</sup>Generalitat Valenciana, Valencia, Spain
- 51 *Tobacco use and spirituality among freshman students in a historically black university*  
C. Johnson, R. Beharie, J. Hazel, J. Carr, Z. Boone, P. Sheikhattari, F. A. Wagner, School of Community Health and Policy, Morgan State University, Baltimore, MD

#### PERINATAL EXPOSURE TO DRUGS

- 52 *Effects of voucher-based treatment for cigarette smoking cessation on maternal weight gain during pregnancy*  
Y. T. Washio<sup>1</sup>, S. T. Higgins<sup>1,2</sup>, S. H. Heil<sup>1,2</sup>, G. J. Badger<sup>3</sup>, J. Skelly<sup>3</sup>, I. M. Bernstein<sup>4</sup>, L. J. Solomon<sup>5</sup>, M. E. Lynch<sup>1</sup>, <sup>1</sup>Psychiatry, <sup>2</sup>Psychology, <sup>3</sup>Medical Biostatistics, <sup>4</sup>Obstetrics and Gynecology, and <sup>5</sup>Family Practice, University of Vermont, Burlington, VT
- 53 *Social discounting among pregnant cigarette smokers, quitters, and never-smokers*  
M. P. Bradstreet<sup>2</sup>, S. T. Higgins<sup>1,2</sup>, S. H. Heil<sup>1,2</sup>, M. C. Flynn<sup>1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Psychology, University of Vermont, Burlington, VT
- 54 *One Tiny Reason to Quit: A prenatal smoking cessation campaign in Richmond, VA*  
A. Sepulveda, M. Kennedy, S. Garland, D. Svikis, W. Smith, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA
- 55 *Nicotine withdrawal in pregnant cigarette smokers*  
S. H. Heil, S. Higgins, S. Sigmon, Psychiatry, University of Vermont, Burlington, VT
- 56 *Reduced-nicotine content cigarettes: Knowledge, attitudes and practice in drug-dependent pregnant and post-partum smokers*  
A. M. Andersen, F. Yunus, M. Chisolm, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD
- 57 *Preliminary evaluation of two high-reach interventions for smoking during pregnancy: Computer-delivered 5As and low-intensity Contingency Management*  
S. J. Ondersma<sup>1</sup>, D. S. Svikis<sup>2</sup>, P. K. Lam<sup>1</sup>, V. Connors<sup>1</sup>, K. Husar<sup>1</sup>, D. M. Ledgerwood<sup>1</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>Virginia Commonwealth University, Richmond, VA
- 58 *Smoking and depression in post-partum women: Does severity matter?*  
S. B. Varner, L. Keyser-Marcus, S. Masho, D. Svikis, L. Meloy, Virginia Commonwealth University, Richmond, VA
- 59 *Greater prevalence of marijuana use than tobacco use among low-income pregnant women in Detroit*  
J. R. Beatty<sup>1</sup>, D. S. Svikis<sup>2</sup>, V. Connors<sup>1</sup>, P. Lam<sup>1</sup>, S. J. Ondersma<sup>1</sup>, <sup>1</sup>Psychiatry and Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, <sup>2</sup>Virginia Commonwealth University, Richmond, VA

- 60 *Fetal neurobehavioral effects of maternal methadone vs. buprenorphine administration*  
L. M. Jansson<sup>1</sup>, J. A. DiPietro<sup>2</sup>, M. L. Velez<sup>1</sup>, A. Elko<sup>1</sup>, H. E. Jones<sup>1</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, and <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 61 *Methadone during pregnancy: Sleep and neurocognitive performance in the neonate*  
M. J. Hayes<sup>1,2</sup>, J. Paul<sup>1</sup>, B. Matano-Logan<sup>1</sup>, N. Heller<sup>1</sup>, M. Brown<sup>3</sup>, R. Krishnan<sup>5</sup>, P. Tisher<sup>4</sup>, <sup>1</sup>Psychology, University of Maine, Orono, ME, <sup>2</sup>Maine Institute for Human Genetics & Health, <sup>3</sup>Pediatrics, Eastern Maine Medical Center, and <sup>4</sup>Private Practice, Bangor, ME, <sup>5</sup>Pediatrics, University of Tennessee Medical Center, Knoxville, TN
- 62 *Methadone dose and NAS*  
A. Holbrook, K. Kaltenbach, Thomas Jefferson University, Philadelphia, PA
- 63 *Intensity of care is the only predictor of out-patient opiate treatment retention among pregnant women*  
M. Terplan<sup>1</sup>, C. Friedman<sup>2</sup>, <sup>1</sup>OB/Gyn, University of Maryland, Baltimore, MD, <sup>2</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 64 *Correlation of fetal heart rate and opioid withdrawal signs in pregnant opioid-dependent women*  
P. Thakur<sup>1</sup>, C. Christensen<sup>2</sup>, D. Tansil<sup>1</sup>, E. Cepeda<sup>3</sup>, G. Gorden<sup>1</sup>, G. Arora<sup>1</sup>, S. Stine<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, <sup>2</sup>Obstetrics and Gynecology, and <sup>3</sup>Pediatrics and Neonatology, WSU School of Medicine, Detroit, MI
- 65 *Children born from mothers treated with substitution (buprenorphine or methadone): Long-term outcomes ?*  
L. Gourarier<sup>1</sup>, C. Lejeune<sup>2</sup>, C. Deslandes<sup>3</sup>, J. Jungman<sup>1</sup>, <sup>1</sup>CASAT La Terrasse, Groupe Hospitalier Maison Blanche, Paris, <sup>2</sup>Service de Néonatalogie, Hopital Louis Mourier, Colombes, <sup>3</sup>Centre Montecristo, HEGP, Paris 15, France
- 66 *Examining the impact of an FASD curriculum infusion on nursing and social work students' attitudes related to FASDs and alcohol use among women of child-bearing age*  
N. A. Roget<sup>1</sup>, J. A. Hartje<sup>1</sup>, M. S. Berry<sup>1</sup>, M. Saleh<sup>1</sup>, R. Tolleson Knee<sup>2</sup>, S. Williams<sup>3</sup>, <sup>1</sup>Center for the Application of Substance Abuse Technologies, University of Nevada, Reno, Reno, NV, <sup>2</sup>University of Montana, Missoula, MT, <sup>3</sup>Colorado State University, Pueblo, CO
- 67 *Methamphetamine-using pregnant women in California drug treatment: Characteristics, referral source, program completion and prenatal care*  
M. S. Stemmler<sup>1</sup>, D. Huang<sup>2</sup>, Y. Hser<sup>3</sup>, <sup>1</sup>School of Nursing, <sup>2</sup>Integrated Substance Abuse Programs, and <sup>3</sup>Center for Advancing Longitudinal Drug Abuse Research, University of California, Los Angeles, Los Angeles, CA
- 68 *Adverse consequences for children of cocaine-dependent parents*  
J. R. Strickland, S. E. Afful, L. B. Cottler, L. J. Bierut, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 69 *Attention at 12 years in prenatally cocaine-exposed children*  
S. Minnes, L. Singer, M. Min, E. Short, Case Western Reserve University, Cleveland, OH
- 70 *Prenatal cocaine exposure and memory and learning deficits in early adolescence: Male-female differences*  
E. S. Bandstra<sup>1</sup>, V. H. Accornero<sup>1</sup>, E. Mansoor<sup>1</sup>, C. E. Morrow<sup>1</sup>, A. Y. Ofir<sup>1</sup>, J. C. Anthony<sup>2</sup>, L. Xue<sup>1</sup>, <sup>1</sup>Pediatrics, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Epidemiology, Michigan State University, East Lansing, MI
- 71 *Environmental enrichment dampens the effects of prenatal cocaine on cocaine reward and dopaminergic markers in adolescent male and female rats*  
D. Dow-Edwards<sup>1</sup>, A. Jackson<sup>1</sup>, M. Iijima<sup>1</sup>, S. Stephenson<sup>1</sup>, C. Mayer<sup>2</sup>, B. Vignoli<sup>2</sup>, S. Izenwasser<sup>2</sup>, <sup>1</sup>SUNY Downstate Medical Center, Brooklyn, NY, <sup>2</sup>University of Miami Miller School of Medicine, Miami, FL

- 72 *Prenatal stress increases cocaine-seeking in C57BL/6J mice*  
T. E. Kippin, J. C. Campbell, K. K. Szumlinski, Psychology, University of California at Santa Barbara, Santa Barbara, CA
- 73 *IV gestational nicotine exposure increases brain-derived neurotrophic factor in adolescent rats*  
R. T. Lacy<sup>1</sup>, R. Brown<sup>2</sup>, L. Ballina<sup>1</sup>, B. Hughes<sup>2</sup>, S. Harrod<sup>1</sup>, <sup>1</sup>Psychology, University of South Carolina, Columbia, SC, <sup>2</sup>Psychology, East Tennessee State University, Johnson City, TN
- 74 *WITHDRAWN*
- 75 *Gestational and postnatal toluene exposure impairs learning and memory in juvenile rats*  
A. Huerta Rivas, C. López-Rubalcava, S. Cruz, Pharmacobiology, Cinvestav, Mexico City, Mexico
- 76 *Neurobehavioral and developmental effects of prenatal exposure to stress and/or toluene in mice*  
P. Soberanes-Chávez, S. Cruz, C. López-Rubalcava, Pharmacobiology, Cinvestav, Mexico City, Mexico

**IMAGING I**

- 77 *Gray matter decline with depression scores in methamphetamine users and control subjects*  
H. Nakama<sup>1</sup>, L. Chang<sup>2</sup>, G. Fein<sup>3</sup>, T. Ernst<sup>2</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Medicine, University of Hawaii, <sup>3</sup>Neurobehavioral Research, Honolulu, HI
- 78 *Altered resting state fMRI default modes in methamphetamine users*  
A. Stenger<sup>1</sup>, H. Nakama<sup>1</sup>, G. Fein<sup>2</sup>, L. Chang<sup>1</sup>, <sup>1</sup>University of Hawaii, and <sup>2</sup>Neurobehavioral Research Inc., Honolulu, HI
- 79 *The effect of methamphetamine addiction on metabolite levels in the human brain using proton magnetic resonance spectroscopy*  
J. C. Lin<sup>1</sup>, R. K. Jan<sup>1</sup>, R. R. Kydd<sup>2</sup>, B. R. Russell<sup>1</sup>, <sup>1</sup>School of Pharmacy, and <sup>2</sup>Psychological Medicine, The University of Auckland, Auckland, New Zealand
- 80 *The effect of methamphetamine addiction on executive function and cognition in the human brain using functional magnetic resonance imaging and the Stroop task*  
R. K. Jan<sup>1</sup>, J. C. Lin<sup>1</sup>, N. A. McNair<sup>1</sup>, I. J. Kirk<sup>2</sup>, R. R. Kydd<sup>3</sup>, B. R. Russell<sup>1</sup>, <sup>1</sup>School of Pharmacy, <sup>2</sup>Psychology, and <sup>3</sup>Psychological Medicine, University of Auckland, Auckland, New Zealand
- 81 *Human MDMA use is associated with increased activation in anterior cingulate gyrus during flanker task performance: An fMRI study*  
R. Cowan, E. Toaz, E. J. Charboneau, M. S. Dietrich, A. Cao, Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN
- 82 *Effect of d-amphetamine on fMRI during cue-reactivity task in cocaine-dependent subjects compared to controls*  
K. L. Kjome<sup>1</sup>, J. L. Steinberg<sup>1</sup>, T. Kosten<sup>3</sup>, S. D. Lane<sup>1</sup>, A. Waters<sup>4</sup>, L. Ma<sup>1</sup>, L. A. Kramer<sup>2</sup>, P. A. Narayana<sup>2</sup>, F. G. Moeller<sup>1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Diagnostic and Interventional Imaging, University of Texas-Houston, Houston, TX, <sup>3</sup>Psychiatry, Baylor College of Medicine, Houston, TX, <sup>4</sup>Medical and Clinical Psychology, Uniformed Services University, Bethesda, MD
- 83 *Lower diffusion in parietal white matter of adolescent drug users*  
R. Gonzales<sup>1</sup>, C. Cloak<sup>1</sup>, D. Alicata<sup>2</sup>, G. King<sup>1</sup>, T. Ernst<sup>1</sup>, L. Chang<sup>1</sup>, <sup>1</sup>Medicine, and <sup>2</sup>Psychiatry, University of Hawaii, Honolulu, HI

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*



- 84 *Decreased N-acetylaspartate levels in adolescents concurrently using both methamphetamine and cannabis*  
Y. H. Sung<sup>1</sup>, P. D. Carey<sup>2</sup>, P. F. Renshaw<sup>1</sup>, D. A. Yurgelun-Todd<sup>1</sup>, <sup>1</sup>University of Utah, Salt Lake City, UT, <sup>2</sup>University of Stellenbosch, Cape Town, South Africa
- 85 *Less efficient psychomotor function in chronic cannabis users*  
G. R. King, T. Ernst, J. Sabugo, R. Gonzales, A. Stenger, L. Chang, Medicine, University of Hawaii, Honolulu, HI
- 86 *Resting state intra-limbic connectivity predicts affective symptoms in marijuana-dependent subjects*  
R. P. Szucs<sup>1,2</sup>, M. Goldman<sup>2</sup>, Z. Wang<sup>2</sup>, Y. Li<sup>2</sup>, R. Ehrman<sup>1,2</sup>, W. Jens<sup>2</sup>, J. Hakun<sup>2</sup>, J. Suh<sup>2,1</sup>, A. Hole<sup>1,2</sup>, K. Kampman<sup>2,1</sup>, C. P. O'Brien<sup>2,1</sup>, A. R. Childress<sup>2,1</sup>, <sup>1</sup>VA Medical Center and, and <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 87 *Impaired anterior cingulate cortex glutamatergic neurotransmission in adolescent marijuana users*  
A. P. Prescott, A. E. Locatelli, P. F. Renshaw, D. A. Yurgelun-Todd, Brain Institute, University of Utah, Salt Lake City, UT
- 88 *Association between cingulate volume and impulsivity in adolescent cannabis smokers*  
J. C. Churchwell, E. Bueler, D. A. Yurgelun-Todd, School of Medicine, University of Utah, The Brain Institute, Salt Lake City, UT

#### MARIJUANA, CANNABINOIDS

- 89 *Amygdalar volume and mood ratings in adolescent marijuana users*  
E. C. McGlade, J. Terry, J. King, D. Yurgelun-Todd, University of Utah Brain Institute, Salt Lake City, UT
- 90 *Estimated cannabis-associated risk of developing a newly incident depression spell: Focus on early-onset cannabis use*  
B. Fairman, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 91 *"Youthful epidemic" or diagnostic bias? Differential item functioning of DSM-IV cannabis use criteria in an Australian general population survey*  
L. R. Mewton, M. Teesson, T. Slade, University of New South Wales, Randwick, NSW, Australia
- 92 *Characteristics of urban adolescents who screen positive for marijuana dependence in indigent primary care clinics*  
K. Barry<sup>1,2</sup>, M. A. Walton<sup>1</sup>, S. Resko<sup>3</sup>, S. T. Chermack<sup>1,2</sup>, R. A. Zucker<sup>1</sup>, M. Zimmerman<sup>4</sup>, B. M. Booth<sup>5</sup>, F. C. Blow<sup>1,2</sup>, <sup>1</sup>Psychiatry, University of Michigan, and <sup>2</sup>VA, Ann Arbor, MI, <sup>3</sup>Social Work, Wayne State University, Detroit, MI, <sup>4</sup>Public Health, University of Michigan, Ann Arbor, MI, <sup>5</sup>Psychiatry, University of Arkansas for Medical Sciences and VA, Little Rock, AR
- 93 *Computerized MET/CBT for the treatment of cannabis abuse and dependence*  
A. J. Budney<sup>1</sup>, S. Fearer<sup>1</sup>, C. Stanger<sup>1</sup>, P. Costello<sup>1</sup>, M. Grabinski<sup>2</sup>, W. K. Bickel<sup>1</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>HealthSim, Inc., New York, NY
- 94 *Quantification of risk for substance use disorder using Computerized Adaptive Test Format: A simulation study*  
L. Kirisci, M. Vanyukov, R. Tarter, T. Ridenour, M. Reynolds, A. Mezzich, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA



- 95 *Marijuana use patterns, but not depressive symptoms, are associated with verbal learning and memory function in marijuana-dependent individuals in treatment*  
P. Roebke<sup>1,2</sup>, N. P. Vadhan<sup>1,2</sup>, D. J. Brooks<sup>1,2</sup>, F. R. Levin<sup>1,2</sup>, <sup>1</sup>Substance Abuse, Columbia University, New York, NY, <sup>2</sup>Substance Abuse, NY State Psychiatric Institute, New York, NY
- 96 *Vividness of mental imagery (Trait Absorption) and impulsivity (Trait Constraint) predict self-reported consumption of cannabis in healthy volunteers*  
J. M. Kang, R. Youssef, T. L. White, Alcohol & Addiction/Community Health, Brown University, Providence, RI
- 97 *Marijuana self-administration under a modified progressive-ratio procedure: Effects of marijuana use history*  
D. C. Lee, J. A. Lile, G. Robbins, C. A. Martin, T. H. Kelly, University of Kentucky, Lexington, KY
- 98 *Influence of marijuana use on the effects of d-amphetamine*  
F. P. Wagner<sup>1</sup>, S. J. Durkin<sup>2</sup>, M. M. Poole<sup>3</sup>, C. R. Rush<sup>1,3,4</sup>, <sup>1</sup>Behavioral Science, <sup>2</sup>Biology, <sup>3</sup>Psychology, and <sup>4</sup>Psychiatry, University of Kentucky, Lexington, KY
- 99 *Quetiapine increases marijuana craving and relapse in the human laboratory*  
M. Haney, Z. D. Cooper, C. L. Hart, S. D. Comer, S. K. Vosburg, R. W. Foltin, Psychiatry, Columbia University and NY State Psychiatric Institute, New York, NY
- 100 *Sleep dysfunction and the effects of extended-release zolpidem during cannabis withdrawal*  
R. Vandrey<sup>1</sup>, U. McCann<sup>1</sup>, M. Smith<sup>1</sup>, A. Budney<sup>2</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR
- 101 *Methadone enhances antinociceptive but not discriminative effects of THC*  
A. A. Wakley, R. M. Craft, Psychology, Washington State University, Pullman, WA
- 102 *The fatty acid amide hydrolase inhibitor, URB597, morphine, and the CB1 agonist, CP55940 in assays of pain-elicited, pain-suppressed, and schedule-controlled behavior*  
L. L. Miller, K. T. Schmidt, M. D. Umberger, M. J. Picker, L. A. Dykstra, Psychology, University of North Carolina, Chapel Hill, NC
- 103 *Cannabinoids inhibit the Mixed Lymphocyte Reaction in vitro*  
R. Hartzell<sup>1,2</sup>, J. J. Meissler<sup>1,2</sup>, M. W. Adler<sup>1</sup>, T. K. Eisenstein<sup>1,2</sup>, <sup>1</sup>Center for Substance Abuse Research, and <sup>2</sup>Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA

**HIV/HCV**

- 104 *Correlates of Mexico-US drug injection relationships among IDUs in Tijuana, Mexico*  
K. D. Wagner<sup>1</sup>, R. Lozada<sup>2</sup>, R. A. Pollini<sup>1</sup>, V. D. Ojeda<sup>1</sup>, K. C. Brouwer<sup>1</sup>, A. Vera<sup>1</sup>, T. A. Volkmann<sup>1</sup>, S. A. Strathdee<sup>1</sup>, <sup>1</sup>Division of Global Public Health, University of California San Diego, La Jolla, CA, <sup>2</sup>Patronado Pro-COMUSIDA A.C., Tijuana, Mexico
- 105 *Development of a risk reduction intervention for injection drug users to reduce bacterial and viral infections*  
K. T. Phillips<sup>1</sup>, K. F. Corsi<sup>2</sup>, J. K. Altman<sup>1</sup>, M. D. Stein<sup>3</sup>, <sup>1</sup>Psychological Sciences, University of Northern Colorado, Greeley, CO, <sup>2</sup>University of Colorado-Denver School of Medicine, Denver, CO, <sup>3</sup>Brown University and Butler Hospital, Providence, RI
- 106 *Hepatitis C viral load: A comparative study between capillary micro sample and venous blood*  
P. Melin<sup>1,2</sup>, A. Hij<sup>1</sup>, M. Marc<sup>1,2</sup>, M. Guillaumot<sup>2</sup>, M. Schoeny<sup>1</sup>, C. Bremard<sup>2</sup>, J. Fournier<sup>2</sup>, S. Samouri<sup>1</sup>, E. Ragot<sup>1</sup>, <sup>1</sup>CHG St dizier, and <sup>2</sup>CSAPA 52, Saint dizier, France

- 107 *Impact of a non-invasive method of liver stiffness measurement (Fibroscan®) in the care of patients suffering from HCV in an addiction center*  
E. Herran<sup>2,1</sup>, P. Lavignasse<sup>1</sup>, C. Kerloc'h<sup>1</sup>, V. Beltran<sup>1</sup>, A. Aguerretxe Colina<sup>1</sup>, J. Daulouede<sup>1,2</sup>,  
<sup>1</sup>Addiction Clinic, BIZIA, and <sup>2</sup>Resapsad Health Network, Bayonne, France
- 108 *Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy*  
L. Michel<sup>1,2</sup>, R. Giorgi<sup>3</sup>, V. Villes<sup>4</sup>, I. Poizot-Martin<sup>5</sup>, P. Dellamonica<sup>6</sup>, B. Spire<sup>4</sup>,  
C. Protopopescu<sup>4</sup>, M. P. Carrieri<sup>4</sup>, <sup>1</sup>Assistance Publique Hôpitaux de Paris, Limeil-Brévannes,  
<sup>2</sup>Inserm U669, Paris, France, <sup>3</sup>Lertim, Marseille, <sup>4</sup>Inserm U912, Marseille, <sup>5</sup>Sainte Marguerite  
Hospital, Marseille, and <sup>6</sup>Archet Hospital, Nice, France
- 109 *Effects of infectious diseases, HCV & HIV, and their treatments on therapeutic management in opiate-dependent patients undergoing a replacement therapy program in Spain: The PROTEUS study*  
C. Roncero<sup>1,2</sup>, B. Box<sup>3</sup>, G. Fuste<sup>1</sup>, N. Martinez-Luna<sup>1</sup>, J. Llaudó<sup>3</sup>, C. Barral<sup>1</sup>, F. Eiroa<sup>1</sup>,  
M. Casas<sup>1,2</sup>, <sup>1</sup>Psychiatry, Out-patient Drug Clinic, Servicio de Psiquiatria, Hospital  
Universitario Vall Hebron, Barcelona, <sup>2</sup>Psychiatry, Universidad Autónoma de Barcelona,  
Barcelona, and <sup>3</sup>Medical Department, Schering-Plough, S.A., Madrid, Spain
- 110 *A controlled trial of on-site hepatitis C treatment in methadone maintenance*  
S. L. Batki<sup>1,2</sup>, K. Canfield<sup>2</sup>, R. Levine<sup>2</sup>, E. Smyth<sup>2</sup>, K. Amodio<sup>2</sup>, K. Manser<sup>2</sup>, R. Ploutz-  
Snyder<sup>3,2</sup>, <sup>1</sup>Psychiatry, University of California, San Francisco, San Francisco, CA, <sup>2</sup>SUNY  
Upstate Medical University, Syracuse, NY, <sup>3</sup>NASA, Houston, TX
- 111 *An electronic health system in opioid agonist treatment clinics: Study design and baseline characteristics*  
M. Chu, S. A. Kritz, R. Zavala, L. S. Brown, Medical Services, Research and Information  
Technology, ARTC, Brooklyn, NY
- 112 *Hepatitis C knowledge among MMT staff and social workers in China*  
J. Du, Z. Wang, M. Zhao, Shanghai Mental Health Center, Shanghai, China
- 113 *Efficacy of an HIV/hepatitis educational intervention during buprenorphine detoxification in prescription opioid abusers*  
M. E. Patrick, K. Saulsgiver, K. Dunn, S. Sigmon, S. Higgins, University of Vermont,  
Burlington, VT
- 114 *Drug users in HCV limbo: Got what? Now what? Perceptions of drug users in and out-of-drug treatment regarding HCV screening and care*  
A. E. Jordan<sup>1</sup>, C. L. Masson<sup>2</sup>, P. Mateu-Gelabert<sup>3,4</sup>, C. McKnight<sup>1</sup>, N. Pepper<sup>2</sup>, R. Seewald<sup>1</sup>,  
C. Young<sup>1</sup>, D. J. Perlman<sup>1</sup>, A. Talal<sup>5</sup>, D. C. Des Jarlais<sup>1,4</sup>, J. L. Sorensen<sup>2</sup>, D. C. Perlman<sup>1,4</sup>,  
<sup>1</sup>Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, <sup>2</sup>University of  
California, San Francisco, CA, <sup>3</sup>Center for Drug Use and HIV Research, <sup>4</sup>NDRI, and <sup>5</sup>Weill  
Cornell Medical College, New York, NY
- 115 *Using the Gelberg-Andersen Behavioral Model for vulnerable populations to predict health services utilization among homeless adults, by hepatitis B or C serostatus*  
L. Gelberg<sup>1,4</sup>, J. Stein<sup>3</sup>, M. Robertson<sup>2</sup>, R. M. Andersen<sup>4</sup>, L. E. Arangua<sup>1</sup>, <sup>1</sup>Family Medicine,  
<sup>2</sup>ARG, PHI, Emoryville, CA, <sup>3</sup>Psychology, and <sup>4</sup>Public Health, UCLA, Los Angeles, CA
- 116 *Hepatitis B and C prevalence in opioid-dependent treatment participants: Comparisons between heroin users and prescription opioid users*  
C. M. Thomas<sup>2,1</sup>, M. Hillhouse<sup>1</sup>, A. L. Hasson<sup>1</sup>, W. Ling<sup>1</sup>, <sup>1</sup>Integrated Substance Abuse  
Programs, UCLA, and <sup>2</sup>Clinical Research, Friends Research Institute, Inc., Los Angeles, CA

- 117 *Prevalence of hepatitis C among a cohort of Hispanic injection drug users*  
J. Sanchez, Health Promotion and Disease Prevention, Florida International University, Doral, FL
- 118 *Prevalence of HIV and hepatitis serology among black drug users in South Africa*  
L. Ropelewski, A. Hulbert, J. Zur, W. W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 119 *The integration of drug and HIV services at a drug treatment center in Durban, South Africa*  
T. Carney, C. D. Parry, P. M. Petersen, A. Pluddemann, Alcohol and Drug Abuse Research Unit, Medical Research Council, Cape Town, South Africa
- 120 *Structural barriers: Qualitative research with social workers in Odessa, Ukraine*  
M. S. Royer, J. T. Brewster, S. Dvoryak, R. Booth, Psychiatry, University of Colorado School of Medicine, Denver, CO
- 121 *Differences in drug use among white and African-American women who use methamphetamine*  
J. Lorvick<sup>1</sup>, A. Lutnick<sup>1</sup>, L. D. Wenger<sup>1</sup>, W. M. Wechsberg<sup>2</sup>, A. H. Kral<sup>1</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>RTI International, Raleigh-Durham, NC
- 122 *HIV/AIDS "conspiracy beliefs" among racial/ethnic minority drug users*  
C. L. Masson<sup>1</sup>, K. L. Delucchi<sup>1</sup>, P. Mateu-Gelabert<sup>4</sup>, N. Pepper<sup>1</sup>, C. Ramin<sup>1</sup>, C. McKnight<sup>3</sup>, A. Jordan<sup>3</sup>, C. Young<sup>3</sup>, R. Seewald<sup>3</sup>, L. Guzman<sup>2</sup>, J. L. Sorensen<sup>1</sup>, D. Des Jarlais<sup>3,5</sup>, D. C. Perlman<sup>3,5</sup>, <sup>1</sup>University of California, and <sup>2</sup>Mission Neighborhood Resource Center, San Francisco, CA, <sup>3</sup>Beth Israel Medical Center, <sup>4</sup>National Development Research Institutes Inc., and <sup>5</sup>Center for Drug Use and HIV Research, New York, NY

**OPIOIDS: HUMAN I**

- 123 *Drug use attitudes and beliefs and treatment outcome*  
M. P. Hillhouse, J. Fahey, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 124 *Counselor attitudes toward buprenorphine in the Clinical Trials Network*  
H. K. Knudsen<sup>1</sup>, P. M. Roman<sup>2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>University of Georgia, Athens, GA
- 125 *Predictors of opiate use following opioid detoxification*  
E. C. Katz<sup>1,2</sup>, B. Brown<sup>3</sup>, R. Schwartz<sup>1</sup>, K. O'Grady<sup>4</sup>, <sup>1</sup>Friends Research Institute, Baltimore, and <sup>2</sup>Psychology, Towson University, Towson, MD, <sup>3</sup>University of North Carolina, Wilmington, NC, <sup>4</sup>University of Maryland, College Park, MD
- 126 *Multicenter study of the switch from buprenorphine to buprenorphine/naloxone in stable patients*  
D. Touzeau<sup>1</sup>, C. Gerbaud<sup>2</sup>, L. Nacache<sup>3</sup>, P. Villeger<sup>4</sup>, S. Sakoman<sup>5</sup>, A. Bagaric<sup>6</sup>, D. Vitezic<sup>8</sup>, G. Plaehn<sup>9</sup>, Y. Wei<sup>7</sup>, L. Amass<sup>7</sup>, <sup>1</sup>Clinique de la Liberte, Bagneux, <sup>2</sup>Hopital Saint-Roch, Nice, <sup>3</sup>Hopital Edouard Herriot, Lyon, <sup>4</sup>CH Esquirol, Limoges, France, <sup>5</sup>Clinical Hospital Sestre milosrdnice, and <sup>6</sup>Psychiatric Hospital Vrapce, Zagreb, Croatia, <sup>7</sup>Schering Corporation, a division of Merck and Company, Kenilworth, NJ, <sup>8</sup>Clinical Hospital Center, Rijeka, Croatia, <sup>9</sup>KABS, Rodovre, Denmark
- 127 *Evaluating multiple buprenorphine treatment approaches*  
L. Madden<sup>1</sup>, A. R. Quanbeck<sup>2</sup>, S. O. Farnum<sup>3</sup>, R. Freeman<sup>3</sup>, S. Ball<sup>1</sup>, <sup>1</sup>APT Foundation and Yale University, New Haven, CT, <sup>2</sup>Industrial and Systems Engineering, University of Wisconsin, Madison, WI, <sup>3</sup>APT Foundation, New Haven, CT
- 128 *Craving intensity and withdrawal severity across phases of opioid detoxification with buprenorphine*  
H. Chen<sup>2</sup>, M. P. Hillhouse<sup>1</sup>, A. Hasson<sup>1</sup>, W. Ling<sup>1</sup>, <sup>1</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, CA, <sup>2</sup>Shanghai Mental Health Center, Shanghai, China

- 129 *Cognitive behavioral therapy session attendance, retention and opioid use in primary-care-based buprenorphine/naloxone treatment*  
C. J. Cutter, D. T. Barry, B. A. Moore, L. E. Sullivan, R. S. Schottenfeld, P. G. O'Connor, D. A. Fiellin, Yale University, School of Medicine, New Haven, CT
- 130 *Physician management with and without cognitive behavioral therapy in primary-care-based buprenorphine/naloxone*  
D. A. Fiellin<sup>1</sup>, L. Sullivan<sup>1</sup>, D. Barry<sup>2</sup>, C. Cutter<sup>2</sup>, B. Moore<sup>2</sup>, P. O'Connor<sup>1</sup>, R. Schottenfeld<sup>2</sup>, <sup>1</sup>Internal Medicine, and <sup>2</sup>Psychiatry, Yale University, New Haven, CT
- 131 *Internet use among opioid-dependent individuals seeking primary-care-based buprenorphine/naloxone treatment*  
B. A. Moore<sup>1,3</sup>, T. Fazzino<sup>3</sup>, L. E. Sullivan<sup>2</sup>, D. A. Fiellin<sup>2</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Internal Medicine, Yale University School of Medicine, <sup>3</sup>APT Foundation, New Haven, CT
- 132 *Retaining participants in Starting Treatment with Agonist Replacement Therapies: Perspectives of early Suboxone dropouts*  
C. Teruya, C. Thomas, A. Hasson, M. Hillhouse, Y. Hser, W. Ling, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 133 *Efficacy of continuing medical education for promoting physician practices aimed at decreasing buprenorphine misuse and diversion*  
M. Lofwall<sup>1,2</sup>, M. Wunsch<sup>2,1</sup>, S. L. Walsh<sup>2,1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Behavioral Science, Center for Drug and Alcohol Research, UK, Lexington, KY
- 134 *Unobserved versus office buprenorphine/naloxone induction: A pilot randomized clinical trial*  
E. W. Gunderson<sup>1,2</sup>, X. Q. Wang<sup>1</sup>, D. A. Fiellin<sup>4</sup>, B. Bryan<sup>2</sup>, F. R. Levin<sup>2,3</sup>, <sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>NYS Psychiatric Institute, New York, NY, <sup>4</sup>Yale University, New Haven, CT
- 135 *Dispensing of methadone and buprenorphine by pharmacists. Cross-sectional survey, Bayonne, France*  
C. Maitre<sup>2,1</sup>, E. Herran<sup>1,2</sup>, J. Renaudin<sup>1</sup>, V. Beltran<sup>3,2</sup>, J. Daulouede<sup>2,1</sup>, M. Auriacombe<sup>3</sup>, <sup>1</sup>Resapsad Health Network, and <sup>2</sup>Addiction Clinic, BIZIA, Bayonne, <sup>3</sup>Addiction Psychiatry, JE2358, INSERM IFR 99, University Victor Segalen Bordeaux 2, Bordeaux, France
- 136 *Duration to achieve "take home" privilege in methadone maintenance treatment as outcome predictor: Retention and survival*  
E. Peles<sup>1,2</sup>, S. Schreiber<sup>1,2</sup>, A. Sason<sup>1</sup>, M. Adelson<sup>1</sup>, <sup>1</sup>Adelson Clinic for Drug Abuse Treatment & Research, Tel Aviv Medical Center, and <sup>2</sup>Tel Aviv University, Tel Aviv, Israel
- 137 *Reducing drug use and other risk behaviors in syringe exchange participants*  
M. S. Kidorf, V. L. King, J. Peirce, R. K. Brooner, Psychiatry, Johns Hopkins, Baltimore, MD
- 138 *Does somatic morbidity increase after termination of opioid maintenance treatment?*  
I. Skeie<sup>3,1,2</sup>, M. Brekke<sup>2</sup>, M. Lindbæk<sup>2</sup>, H. Waal<sup>1,3</sup>, <sup>1</sup>Norwegian Centre for Addiction Research, and <sup>2</sup>Institute of General Practice and Community Medicine, University of Oslo, <sup>3</sup>Oslo University Hospital Aker, Oslo, Norway
- 139 *Methadone-associated deaths by formulation as reported by the Researched Abuse, Diversion and Addiction-Related Surveillance System*  
A. Zosel<sup>1,2</sup>, E. Bailey<sup>1</sup>, C. Buchholtz<sup>1</sup>, E. Ross<sup>3</sup>, R. Dart<sup>1,2</sup>, <sup>1</sup>Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, <sup>2</sup>University of Colorado Denver School of Medicine, Aurora, CO, <sup>3</sup>Rocky Vista University College of Medicine, Parker, CO
- 140 *Methadone maintenance treatment in China: Perspectives of clients and service providers*  
F. Wu<sup>1</sup>, C. Peng<sup>1</sup>, H. Jiang<sup>2</sup>, R. Zhang<sup>3</sup>, M. Zhao<sup>2</sup>, J. Li<sup>3</sup>, Y. Hser<sup>1</sup>, <sup>1</sup>Social Welfare, UCLA, Los Angeles, CA, <sup>2</sup>Center of Drug Abuse, Shanghai Mental Health Center, Shanghai, China, <sup>3</sup>Yun Nan Institute on Drug Abuse, Kunming, China



- 141 *Predictors of treatment entry in a sample of methadone maintenance patients*  
S. M. Kelly<sup>1</sup>, K. E. O'Grady<sup>2</sup>, S. G. Mitchell<sup>1</sup>, B. S. Brown<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Social Research Center, Baltimore, MD, <sup>2</sup>University of Maryland, College Park, College Park, MD, <sup>3</sup>University of North Carolina, Wilmington, NC
- 142 *Methadone patients' treatment outcomes: Longitudinal study on the associations between background and process variables and retention rate, illicit drug use and risk behavior*  
S. Levit<sup>1,2</sup>, M. Schiff<sup>2</sup>, R. Benbenishty<sup>3</sup>, <sup>1</sup>Association for Public Health Services, Methadone Clinic in Jerusalem and Ashdod, and <sup>2</sup>School of Social Work and Social Welfare, Hebrew University, Jerusalem, Israel, <sup>3</sup>School of Social Work, Bar Ilan University, Ramat Gan, Israel
- 143 *Acceptance and commitment therapy as an adjunct to methadone detoxification*  
A. L. Stotts<sup>1</sup>, J. M. Schmitz<sup>1</sup>, C. Green<sup>1</sup>, J. Lindsay<sup>1</sup>, J. Grabowski<sup>2</sup>, <sup>1</sup>University of Texas Medical School at Houston, Houston, TX, <sup>2</sup>University of Minnesota, Minneapolis, MN
- 144 *Acceptance and commitment therapy for methadone detoxification: Identifying mechanisms of change*  
J. A. Lindsay<sup>1</sup>, A. Stotts<sup>2</sup>, C. Dodrill<sup>1</sup>, J. Schmitz<sup>2</sup>, C. Green<sup>2</sup>, <sup>1</sup>Baylor College of Medicine and <sup>2</sup>Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX
- 145 *A randomized trial of entry into methadone treatment via interim maintenance: Preliminary findings*  
R. P. Schwartz<sup>1</sup>, S. M. Kelly<sup>1</sup>, K. E. O'Grady<sup>2</sup>, J. H. Jaffe<sup>3</sup>, <sup>1</sup>Friends Research Institute, Baltimore, <sup>2</sup>University of Maryland, College Park, and <sup>3</sup>University of Maryland School of Medicine, Baltimore, MD

#### LITERATURE REVIEW

- 146 *The safety of prazosin in drug-abusing populations*  
L. Hu<sup>1</sup>, A. J. Saxon<sup>2,3</sup>, C. A. Malte<sup>3</sup>, M. Leff<sup>1</sup>, B. Tai<sup>1</sup>, S. Sparenborg<sup>1</sup>, <sup>1</sup>NIDA, Rockville, MD, <sup>2</sup>University of Washington, Seattle, WA, <sup>3</sup>VA Puget Sound Healthcare System, Seattle, WA
- 147 *Smoking prevalence in addiction treatment: A literature review*  
E. Passalacqua, J. Guydish, B. Tajima, S. Manser, J. Chun, M. Chan, Institute for Health Policy Studies, University of California, San Francisco, CA
- 148 *Agonist replacement therapy for marijuana dependence*  
S. Sparenborg, L. Hu, B. Tai, Center for the Clinical Trials Network, National Institute on Drug Abuse, Bethesda, MD

## Late-Breaking Research News

**Salons HI**  
**1:30 - 2:35 PM**

Chair: Sari Izenwasser

## Symposium VI

**Salons HI**  
**2:45 - 4:45 PM**

### HAIR OF THE DOG: AGONISTS FOR STIMULANT DEPENDENCE

Chairs: John Grabowski and David Herin

- 2:45 *Agonizing over pharmacotherapy: Stimulants for stimulant dependence*  
David Herin, Psychiatry, University of Minnesota, Minneapolis, MN

- 3:10 *Human laboratory research: Closer to treatment but foibles exist*  
Craig R. Rush, College of Medicine, University of Kentucky, Lexington, KY
- 3:35 *Effects of candidate agonists medication on abuse-related effects of stimulants: Preclinical investigations*  
Steve Negus, Pharmacology, Virginia Commonwealth University, Richmond, VA
- 4:00 *Neurochemical underpinnings of agonist therapy for stimulant dependence*  
Michael Baumann, Intramural Research Program, NIDA/NIH/DHHS, Baltimore, MD
- 4:25 *Threading the needle: translation from science through regulation to marketing*  
Jack Henningfield, Pinney Associates, Bethesda, MD

## **Symposium VII**

**Salon DE**  
**2:45 - 4:45 PM**

### **THE ROLE OF GABA IN DRUG ABUSE**

Chairs: Diana Dow-Edwards and Nora Siegal

- 2:45 *GABA B alters cocaine self-administration*  
David Roberts, Physiology and Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC
- 3:10 *Chronic methamphetamine alters tonic inhibition and responses to a stress steroid via increases in Alpha 4-beta-delta GABA-A receptors*  
Sheryl Smith, Psysio/Pharm, State University of New York-Downstate, Brooklyn, NY
- 3:35 *GABA A modulation alters the responses to acute and chronic cocaine administration*  
Diana Dow-Edwards, Physiology and Pharmacology, State University of New York-Downstate, Brooklyn, NY
- 4:00 *Clinical experience with flumazenil*  
J. Greg Sullivan, Parkway Medical Center, Birmingham, AL
- 4:25 *Discussant*  
Thomas Kosten, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX

## **Oral Communications 9**

**Salon FG**  
**2:45 - 4:45 PM**

### **GETTING UP TO SPEED ON AMPHETAMINES**

Chairs: Ellen Unterwald and Michael A. Taffe

- 2:45 *Methamphetamine modulates axonal guidance molecules in mouse hippocampus*  
B. K. Madras<sup>1,2</sup>, G. M. Miller<sup>1</sup>, E. Vallender<sup>1</sup>, <sup>1</sup>NEPRC, Harvard Medical School, Southborough, MA, <sup>2</sup>Psychiatry, Massachusetts General Hospital, Boston, MA
- 3:00 *The clinically validated mGluR5 receptor antagonist fenobam decreases methamphetamine self-administration following escalation of intake*  
M. F. Olive, E. Plasters, R. M. Clewa, Psychiatry, Medical University of South Carolina, Charleston, SC
- 3:15 *Valproic acid attenuates amphetamine-induced behavior in mice*  
N. Enman, E. M. Unterwald, Pharmacology & Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA



- 3:30 *The 5-HT<sub>2C</sub> receptor inverse agonist SB 206553 decreases methamphetamine-seeking in rats*  
S. M. Graves<sup>1,2</sup>, T. C. Napier<sup>1,2</sup>, <sup>1</sup>Pharmacology, and <sup>2</sup>Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL
- 3:45 *L-5-hydroxytryptophan combined with D-amphetamine as potential treatment agents for stimulant addiction: Initial evidence*  
R. B. Rothman, Z. Williams, M. H. Baumann, Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD
- 4:00 *Dopamine receptor involvement in enrichment-induced differences in methamphetamine drug discrimination in rats*  
D. J. Stairs, E. Adams, T. Hickie, B. Hovenga, B. BaDour, Psychology, Creighton University, Omaha, NE
- 4:15 *Dopamine receptor agonists modify the discriminative stimulus effects of rimonabant in  $\Delta^9$ -THC-treated rhesus monkeys*  
J. L. Stewart, L. R. McMahon, Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX
- 4:30 *Sustained locomotor activity increases MDMA-induced hyperthermia and death*  
M. A. Taffe, M. J. Wright, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA

## Oral Communications 10

Salons ABC  
2:45 - 4:45 PM

### HASHING OUT THE STORY ON CANNABINOIDS

Chairs: Leslie H. Lundahl and Jane Metrik

- 2:45 *Would CB<sub>1</sub> neutral antagonists be non-dysphoric?*  
H. H. Seltzman<sup>1</sup>, P. H. Reggio<sup>2</sup>, L. Chun<sup>3</sup>, Z. X. Xi<sup>3</sup>, E. L. Gardner<sup>3</sup>, <sup>1</sup>Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC, <sup>2</sup>Chemistry and Biochemistry, University of North Carolina, Greensboro, NC, <sup>3</sup>Neuropsychopharmacology Section, National Institute on Drug Abuse, NIH, Baltimore, MD
- 3:00 *URB597, a fatty acid amide hydrolase metabolism inhibitor, effects locomotor activity immediately after the forced swim test*  
T. Culmer<sup>1</sup>, L. A. Dykstra<sup>1,2</sup>, <sup>1</sup>Pharmacology, and <sup>2</sup>Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 3:15 *Effect of long-term  $\Delta^9$ -THC exposure on rat cognitive performance*  
L. H. Parsons, I. Polis, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA
- 3:30 *The effects of sleep deprivation on marijuana cue-reactivity and craving*  
G. H. Trksak<sup>1,2</sup>, N. A. Conn<sup>1</sup>, W. L. Tartarini<sup>1</sup>, L. D. Nickerson<sup>1,2</sup>, D. M. Penetar<sup>1,2</sup>, S. E. Lukas<sup>1,2</sup>, <sup>1</sup>Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Belmont, MA, <sup>2</sup>Psychiatry, Harvard Medical School, Boston, MA
- 3:45 *Stress and cue-elicited craving in marijuana-dependent individuals*  
A. McRae-Clark<sup>1</sup>, R. E. Carter<sup>2</sup>, K. L. Price<sup>1</sup>, N. Baker<sup>1</sup>, M. E. Saladin<sup>1</sup>, K. T. Brady<sup>1</sup>, <sup>1</sup>Psychiatry, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Mayo Clinic, Rochester, MN
- 4:00 *Acute effects of marijuana smoking on negative and positive affect*  
J. Metrik<sup>1</sup>, C. W. Kahler<sup>1</sup>, J. McGeary<sup>2,1</sup>, P. M. Monti<sup>2,1</sup>, D. J. Rohsenow<sup>2,1</sup>, <sup>1</sup>Center for Alcohol and Addiction Studies, Brown University, Providence, RI, <sup>2</sup>VA Medical Center, Providence, RI

- 4:15 *Testing the ability of oral THC to block the discriminative stimulus effects of marijuana in cannabis-dependent individuals*  
L. H. Lundahl, C. L. Steinmiller, M. K. Greenwald, C. E. Johanson, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI
- 4:30 *Construct validity of computerized cognitive performance: Implications for measurement of acute drug effects*  
N. P. Vadhan, S. C. Reed, M. Haney, J. G. Keilp, R. W. Foltin, Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY

## **Symposium VIII**

**Salons HI  
5:00 - 6:00 PM**

### **MEDICATIONS DEVELOPMENT FOR THE TREATMENT OF SUBSTANCE DEPENDENCE: STATUS OF ADVANCED PROJECTS**

Chair: David McCann

- 5:00 *Dronabinol for the treatment of cannabis dependence*  
Frances Levin, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY
- 5:20 *Vigabatrin for the treatment of stimulant dependence*  
Charles Gorodetzky, Catalyst Pharmaceutical Partners, Kansas City, MO
- 5:40 *Bupropion for the treatment of methamphetamine dependence*  
David McCann, National Institute on Drug Abuse, Rockville, MD

## **Symposium IX**

**Salon DE  
5:00 - 6:00 PM**

### **NEW PATHWAYS TO FUTURE ADDICTION THERAPY**

Chair: John Satterlee

- 5:00 *From drosophila to drugs: Novel pathways in cocaine responses*  
Ulrike Heberlein, Anatomy, School of Medicine, University of California, San Francisco, San Francisco, CA
- 5:20 *Histone deacetylase inhibitors improve extinction of drug cue learning in rodents*  
Matthew Lattal, Behavioral Neuroscience, Oregon Health Science University, Portland, OR
- 5:40 *Identification of unanticipated nicotine response genes using zebra fish*  
Stephen Ekker, Mayo Clinic, Rochester, MN

## **Symposium X**

**Salon FG  
5:00 - 6:00 PM**

### **NICO-TEEN: ADOLESCENCE IS A PERIOD OF ENHANCED VULNERABILITY TO TOBACCO ABUSE**

Chairs: Laura O'Dell and Janet Neisewander

- 5:00 *Psychobiological factors that contribute to tobacco abuse during adolescence*  
Laura O'Dell, Psychology, The University of Texas at El Paso, El Paso, TX
- 5:20 *Social context is a contributing factor to adolescent vulnerability to nicotine*  
Janet Neisewander, Psychology, Arizona State University, Tempe, AZ

5:40 *Tobacco abuse across the formative years: A road map to developmental vulnerabilities in adolescent smokers*

Suchitra Krishnan-Sarin, Psychiatry, Yale University School of Medicine, New Haven, CT

### Oral Communications 11

Salons ABC

5:00 - 6:00 PM

#### NALTREXONE/ALCOHOL INTERACTIONS

Chairs: Scott E. Lukas and David A. Fiellin

5:00 *Ethanol/Naltrexone interactions at the opioid receptor: CLSM/FCS study in live cells*

L. Terenius<sup>1</sup>, V. Vukojevic<sup>1</sup>, Y. Ming<sup>1</sup>, B. Johansson<sup>1</sup>, C. D'Addario<sup>1</sup>, R. Rigler<sup>2,3</sup>, <sup>1</sup>Clinical Neuroscience, and <sup>2</sup>Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, <sup>3</sup>Laboratory of Biomedical Optics, Swiss Federal Institute of Technology, Lausanne, Switzerland

5:15 *Extended-release injectable naltrexone attenuates BOLD signal activation to olfactory and visual cues in detoxified alcohol-dependent volunteers*

D. M. Penetar<sup>1</sup>, S. Lowen<sup>1</sup>, S. E. Lukas<sup>1</sup>, N. Conn<sup>1</sup>, W. Tartarini<sup>1</sup>, J. Rodolico<sup>1</sup>, G. Mallya<sup>1</sup>, C. Palmer<sup>1</sup>, B. L. Silverman<sup>2</sup>, D. R. Gastfriend<sup>2</sup>, K. Lindsey<sup>1</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Alkermes, Inc, Cambridge, MA

5:30 *Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone*

J. M. Tetrault<sup>1</sup>, K. McGinnis<sup>2</sup>, L. Sullivan<sup>1</sup>, A. Justice<sup>1</sup>, D. Fiellin<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>VA Pittsburgh, Pittsburgh, PA

5:45 *Cost outcomes with extended-release naltrexone in insured alcoholics*

T. Mark<sup>1</sup>, L. Montejano<sup>1</sup>, H. R. Kranzler<sup>2</sup>, M. Chalk<sup>3</sup>, D. R. Gastfriend<sup>4</sup>, <sup>1</sup>Thomson Reuters, Inc, Washington, DC, <sup>2</sup>Psychiatry, University of Connecticut School of Medicine, Farmington, CT, <sup>3</sup>Treatment Research Institute, Philadelphia, PA, <sup>4</sup>Alkermes, Inc., Cambridge, MA

### FILM NIGHT

Sonoran

7:00 - 10:00 PM

#### THE NARCOTIC FARM

*A documentary on the history of drugs, addiction, drug policy, research and treatment*

#### LOST WEEKEND

*1945 Best Picture with Ray Milland*

### Workshop IX

Salons HI

8:00 - 10:00 PM

#### NEW APPROACHES TO DIAGNOSIS IN THE DSM-V

Chairs: Wilson M. Compton and Charles O'Brien

*Neuroscience perspectives on the diagnosis of substance use disorders*

Charles O'Brien, Treatment Research Center, University of Pennsylvania, Philadelphia, PA

*Item response analysis approaches to changes in diagnostic criteria*

Deborah Hasin, Columbia University, New York, NY

*Terminology of substance use disorders for DSM-V*

Wilson M. Compton, National Institute on Drug Abuse, Bethesda, MD

## **Workshop X**

**Salon DE  
8:00 - 10:00 PM**

### **ESTABLISHED AND EMERGING APPROACHES TO HUMAN ABUSE LIABILITY TESTING: IS THERE ROOM FOR IMPROVEMENT?**

Chair: Edward M. Sellers

*Sensitivity and selectivity analysis of subjective abuse liability measures*

Kerri A. Schoedel, Clinical Pharmacology, Kendle Early Stage-Toronto, Toronto, ON, Canada

*Utility of behavioral economic analysis for improving drug abuse liability assessment*

Mark Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI

*Comparison of drug self-administration procedures in human abuse liability testing*

Sandra D. Comer, Division on Substance Abuse, Columbia University and New York State Psychiatric Institute, New York, NY

*Regulatory challenges in evaluating clinical abuse liability studies*

Silvia N. Calderon, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD

*Industry perspective: Assessing abuse liability during drug development*

Doug Feltner, Pfizer Global Research and Development, Groton, CT

## **Workshop XI**

**Salon FG  
8:00 - 10:00 PM**

### **ACADEMICS AND REGULATED INDUSTRIES: PERSPECTIVES ON 21ST CENTURY INTERACTIONS WITH PHARMACEUTICAL AND TOBACCO COMPANIES**

Chairs: Jed Rose and George Uhl

*Ethical principals, academics and for profits*

Barbara Koenig, Program in Professionalism and Bioethics, Mayo College of Medicine, Rochester, NY

*Managing conflicts of interest in academic/tobacco company interactions: Risks and benefits of interactions with a newly regulated industry*

Jed Rose, Psychiatry and Behavioral Sciences and Center for Nicotine and Smoking Cessation Research, Duke University Medical Center, Durham, NC

*Managing conflicts of interest in government/pharma interactions: Special case of pharmaceuticals with abuse liabilities*

Charles Gorodetzky, Consultant, Kansas City, MO

*Managing conflicts of interest in academic/tobacco company interactions: Likely changes in a regulated environment*

Tony Albino, Vector Group Ltd, New York, NY

*Discussant*

George Uhl, NIH, National Institute on Drug Abuse, Baltimore, MD

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

## **Workshop XII**

**Salon AB**  
**8:00 - 10:00 PM**

### **EMPIRICALLY SUPPORTED TREATMENTS AND DIVERSE POPULATIONS: SOME EXAMPLES OF CHALLENGES TO ADAPTATION**

Chairs: Anne H. Skinstad and Lonnetta Albright

*Women: Are they men with special needs?*

Anne Helene Skinstad, Prairielands ATTC, University of Iowa, Iowa City, IA

*Specific needs for research and data for conducting cultural competencies for sexual minorities*

Joseph Amico, Brattleboro Retreat, Fitzwilliam, NH

*Challenges of implementing empirically supported approaches in Native American communities*

E. Somoza, Prairielands ATTC, Vermillion, SD

*It is not just about language and translation*

Marco Jacome, Healthcare Alternative System, Inc., Chicago, IL

*Bridging the gap between empirically supported treatments and African-American communities*

Ijeoma Achara<sup>1</sup>, Lonnetta Albright<sup>2</sup>, <sup>1</sup>Achara Consulting, LLC, Chicago, IL, <sup>2</sup>Great Lakes ATTC, Chicago, IL

## **Workshop XIII**

**Salon C**  
**8:00 - 10:00 PM**

### **WHAT'S NEW AT NIDA AND NIH: ENHANCING PEER REVIEW IMPLEMENTATION AND MORE**

Chairs: Mark R. Green and Mark Swieter

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

## **Public Policy Forum**

**Salons HI  
8:00 - 9:45 AM**

Chairs: Martin Iguchi and William L. Dewey

*Introduction*

Martin Iguchi, RAND, Santa Monica, CA

*DC issues*

Ed Long, Cap Hill, Washington, DC

*Demand control strategies*

John Strang, King's College, London, United Kingdom

*Supply control strategies*

Peter Reuter, University of Maryland, College Park, MD

*Cannabis policy: Moving beyond stalemate*

Robin Room, Turning Point Alcohol and Drug Centre, University of Melbourne, Melbourne, NSW, Australia

*Evidence-informed drug policy: What do we know? What do we need to know?*

Thomas Babor, University of Connecticut, Farmington, CT

*Discussion*

## **Symposium XI**

**Salons HI  
10:00 AM - 12:00 PM**

### **PRECLINICAL TO CLINICAL ABUSE LIABILITY ASSESSMENT: CURRENT CHALLENGES IN INDUSTRY PRACTICES**

Chairs: Mary Jeanne Kallman and David Compton

10:00 *Current Issues in Clinical Trial Design for Assessment of Novel Pharmaceuticals for Abuse and Dependence Liability*

Marta Sokolowska, Center of Excellence for Abuse Liability, Grunenthal, Bedminster, NJ

10:25 *Overview of current challenges facing the pharmaceutical industry in assessment of abuse potential of new drugs*

Carrie G. Markgraf, Merck Research Laboratories, Lafayette, NJ

10:50 *Abuse Potential Assessment for Drug Combinations*

Andy Mead, Pfizer, Sandwich, Kent, UK

11:15 *Regulatory review and scheduling: Roles of nonclinical and clinical studies in recent studies*

Michael Klein, Controlled Substance Staff, FDA, Silver Spring, MD

## **Symposium XII**

**Salon FG  
10:00 - 11:00 AM**

### **METHAMPHETAMINE ADDICTION: FROM MOLECULAR MECHANISMS TO TREATMENT**

Chairs: John Mendelson and Jean Lud Cadet

10:00 *Neurobiological aspects of methamphetamine addiction and toxicity*

Jean Lud Cadet, NIH/NIDA Intramural Research Program, Baltimore, MD

10:20 *The effects of methamphetamine exposure: Evidence from brain imaging studies*

Panayotis Thanos, State University of New York at Stony Brook, New York, NY



- 10:40 *Challenges in developing pharmacotherapies for methamphetamine addiction*  
John Mendelson, California Pacific Medical Center Research Institute, St. Luke's Hospital,  
San Francisco, CA

### Symposium XIII

**Salon FG**  
**11:15 AM - 12:15 PM**

#### **CURRENT ISSUES SURROUNDING CHRONIC PAIN AMONG INDIVIDUALS WITH A SUBSTANCE USE DISORDER**

Chair: Benjamin J. Morasco

- 11:15 *A systematic review of the prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder*  
Benjamin J. Morasco, Behavioral Health and Clinical Neurosciences Division, Oregon Health and Science University, Portland, OR
- 11:35 *Developing and evaluating treatments for co-occurring opioid dependence and chronic pain among methadone-maintained patients*  
Declan T. Barry, Psychiatry, Yale University School of Medicine, New Haven, CT
- 11:55 *Cognitive-behavioral therapy for pain management during addictions treatment*  
Mark Ilgen, VA Serious Mental Illness Treatment Research and Evaluation Center, Ann Arbor  
VA Medical Center, University of Michigan, Ann Arbor, MI

### Oral Communications 12

**Salon DE**  
**10:00 AM - 12:00 PM**

#### **WHAT'S UP WITH COCAINE? REINSTATEMENT RESEARCH**

Chairs: Xiaohu Xie and Kathleen Kantak

- 10:00 *The dorsal hippocampus: A neural substrate for cocaine cue extinction consolidation*  
J. J. Szalay, K. M. Kantak, Psychology and Program in Neuroscience, Boston University,  
Boston, MA
- 10:15 *Preclinical examination of environmental enrichment as an anti-relapse strategy*  
K. J. Thiel, B. Engelhardt, L. E. Hood, N. S. Pentkowski, N. A. Peartree, M. R. Painter,  
J. L. Neisewander, Psychology, Arizona State University, Tempe, AZ
- 10:30 *Subregion-specific effects of mGluR1 antagonism in the nucleus accumbens on drug context-induced reinstatement of cocaine-seeking behavior in rats*  
X. Xie, D. R. Ramirez, H. C. Lasseter, K. L. Ponds, S. J. Kaszycki, R. A. Fuchs, Psychology,  
University of North Carolina at Chapel Hill, Chapel Hill, NC
- 10:45 *D-cycloserine in the nucleus accumbens produces a context-independent enhancement of extinction learning to attenuate cue-induced reinstatement in rats*  
M. M. Torregrossa, H. Sanchez, J. R. Taylor, Psychiatry, Yale University, New Haven, CT
- 11:00 *Individual differences in incentive salience attribution to a food-associated cue modulate both novelty seeking and acquisition of cocaine self-administration in rats*  
J. Beckmann, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY
- 11:15 *Differential recruitment of the Orx/Hcrt system by cocaine vs. palatable natural reward*  
R. Martin-Fardon, F. Weiss, Molecular and Integrative Neuroscience, The Scripps Research  
Institute, La Jolla, CA

- 11:30 *How do prediction errors in conditioned drug-reward influence cocaine place preference?*  
Y. Itzhak, K. L. Anderson, Psychiatry, University of Miami, Miami, FL
- 11:45 *Blockade of dopamine D3 receptors by SB-277011A inhibits incubation of craving for cocaine in rats*  
E. Gardner, X. Li, J. Li, Z. X. Xi, Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD

### Oral Communications 13

Salons ABC  
10:00 AM - 12:00 PM

#### TRAJECTORIES OF DRUG USE: TAKING IT ONE DAY AT A TIME

Chairs: Arpana Agrawal and Eric O. Johnson

- 10:00 *Daily life hour-by-hour, with and without cocaine: An ecological momentary assessment study*  
K. A. Phillips, D. H. Epstein, K. L. Preston, NIH/NIDA-Intramural Research Program, Baltimore, MD
- 10:15 *First 5 years of methamphetamine use: Trajectories, characteristics of trajectory groups, and prediction of later treatment outcomes*  
M. Brecht, D. Herbeck, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 10:30 *Alcohol consumption over 11 years in a problem drinking and dependent general population sample*  
K. L. Delucchi<sup>1</sup>, L. Kaskutas<sup>2</sup>, <sup>1</sup>Psychiatry, University of California, San Francisco, San Francisco, CA, <sup>2</sup>Alcohol Research Group, Public Health Institute, Emeryville, CA
- 10:45 *Examining the differences in the progression to nicotine dependence by gender and ethnicity in the US population*  
R. Behar<sup>1</sup>, F. A. Wagner<sup>1</sup>, D. C. Browne<sup>2</sup>, C. L. Storr<sup>3</sup>, <sup>1</sup>Morgan State University, Baltimore, MD, <sup>2</sup>Norfolk State University, Norfolk, VA, <sup>3</sup>University of Maryland, College Park, MD
- 11:00 *Natural history of changes in cigarette smoking upon learning of pregnancy*  
E. Herrmann, S. H. Heil, S. T. Higgins, L. J. Solomon, I. M. Bernstein, University of Vermont, Burlington, VT
- 11:15 *Executive function clusters predict patterns of drug dependence and use*  
S. A. Golub<sup>1,2,3</sup>, T. Starks<sup>3</sup>, W. Kowalczyk<sup>1,3</sup>, J. T. Parsons<sup>2,3</sup>, <sup>1</sup>Neuropsychology, CUNY Graduate Center, New York, NY, <sup>2</sup>Psychology, Hunter College of the City University of New York, New York, NY, <sup>3</sup>Center for HIV Educational Studies and Training, New York, NY
- 11:30 *Projected lifetime risk of co-occurring substance use and mental disorders among adults in the US*  
E. O. Johnson, S. P. Novak, Behavioral Health Epidemiology, RTI International, Research Triangle Park, NC
- 11:45 *Cannabis involvement and the course and measurement of bipolar disorder*  
A. Agrawal<sup>1</sup>, J. I. Nurnberger<sup>2</sup>, M. T. Lynskey<sup>1</sup>, <sup>1</sup>Psychiatry, Washington University School of Medicine, Saint Louis, MO, <sup>2</sup>Psychiatry, Indiana University School of Medicine, Indianapolis, IN

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

## Poster Session III (Lunch)

Pavilion  
12:00 - 2:00 PM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Tuesday no earlier than 2:30 PM  
Must be removed by Wednesday no later than 2:30 PM

### CO-OCCURRING DISORDERS

- 1 *Effect of varenicline on cue-induced alcohol craving: A randomized placebo-controlled study*  
U. E. Busto, S. Wang, P. Selby, G. Staios, L. Zawertailo, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 2 *Drinking outcomes by order of onset in a placebo controlled trial of acamprosate in anxious or depressed alcoholics*  
S. C. Sonne<sup>1</sup>, J. S. Potter<sup>2</sup>, R. Rosenthal<sup>3,4</sup>, D. Bandyopadhyay<sup>1</sup>, <sup>1</sup>Medical University of SC, Charleston, SC, <sup>2</sup>University of Texas Health Science Center at San Antonio, San Antonio, TX, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>St. Luke's Roosevelt Hospital Center, New York, NY
- 3 *Gender differences in the relationship between neighborhood environment and childhood depression: Results from a community epidemiologic study of predominantly African-American urban children*  
A. J. Milam<sup>1</sup>, D. Whitaker<sup>1</sup>, C. Furr-Holden<sup>1</sup>, S. C. Jones<sup>1</sup>, M. Cooley<sup>1,2</sup>, P. J. Leaf<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Semel Institute, Center for Culture and Health, University of California, Los Angeles, Los Angeles, CA
- 4 *Association between psychiatric disorders, alcohol and other substances use in Brazilian drivers*  
S. Faller, T. Moreira, B. Diniz, M. Ferigolo, H. T. Barros, D. Benzano, R. DeBoni, F. Pechansky, Center for Drug and Alcohol Research - Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 5 *Brazilian crack users who seek treatment show more antisocial personality and less drinking than other drug users*  
F. H. Kessler, A. Peuker, S. Faller, M. Terra, A. Stolf, D. Bumaguin, F. Pechansky, Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 6 *Risk factors for substance-induced disorders among illicit drug users*  
M. Torrens<sup>1,2</sup>, G. Gilchrist<sup>2</sup>, A. Domingo-Salvany<sup>3</sup>, F. Fonseca<sup>1,2</sup>, R. Martin-Santos<sup>4,5</sup>, G. PsyCoBarcelona<sup>2,3,6</sup>, <sup>1</sup>Institut d'Atenció Psiquiàtrica i Addiccions, IAPs, Hospital del Mar, Barcelona, Spain, <sup>2</sup>Substance Use Disorders Research Group. Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain, <sup>3</sup>Drug Abuse Epidemiology Research Group, IMIM-Hospital del Mar, Barcelona, Spain, <sup>4</sup>Pharmacology Research Unit. Neuropsychopharmacology Program., IMIM- Hospital del Mar, Barcelona, Spain, <sup>5</sup>Psychiatry Department, Hospital Clínic i Provincial, Barcelona, Spain, <sup>6</sup>Public Health Agency, ASP, Barcelona, Spain
- 7 *What's with that kid? The relationship between familial substance use and child behavior problems in a general pediatric setting*  
L. A. Keyser-Marcus, L. Meloy, R. Pickens, D. Svikis, Virginia Commonwealth University, Richmond, VA
- 8 *Adult substance abusers with ADHD show higher prevalence of marijuana and cocaine use*  
A. R. Stolf, F. Kessler, S. Faller, D. Bumaguin, H. Moura, C. Szobot, L. von Diemen, F. Pechansky, Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

- 9 *Gender differences in the prevalence of co-occurring mental health disorders in a substance abuse treatment population*  
R. C. Desmond<sup>1</sup>, B. R. Rush<sup>1,2</sup>, S. Castel<sup>2,3</sup>, B. Brands<sup>1,2,4</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Sunnybrook Health Sciences Centre, Toronto, ON, Canada, <sup>4</sup>Health Canada, Ottawa, ON, Canada
- 10 *Neighborhood environment, distance, and individual factors predicting initial outpatient treatment attendance following acute inpatient care*  
G. Stahler, J. Mennis, D. Baron, Temple University, Philadelphia, PA
- 11 *A randomized controlled trial of a brief care coordination intervention for individuals with a mental health and substance abuse problem*  
D. A. Smelson<sup>1</sup>, D. Kalman<sup>1</sup>, M. Losonczy<sup>2,1</sup>, A. Kline<sup>2,1</sup>, G. Gonzalez<sup>1</sup>, B. Sussner<sup>2,1</sup>, D. Ziedonis<sup>1</sup>, <sup>1</sup>Psychiatry, University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>Mental Health and Behavioral Science, VA Jersey Health Care System, Lyons, NJ
- 12 *Psychiatric distress predicts treatment enrollment in syringe exchange participants*  
V. L. King, R. K. Brooner, J. Peirce, M. Kidorf, Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD
- 13 *Opiate dependence, alcohol dependence and ASPD among age cohorts: A triple threat to the service system*  
C. L. Striley, K. S. Leung, A. Ben Abdallah, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 14 *Medical and psychiatric severity of opioid-addicted individuals in- vs. out-of-treatment*  
D. Tzall<sup>1</sup>, S. Mitchell<sup>2</sup>, S. Kelly<sup>2</sup>, K. O'Grady<sup>3</sup>, B. Brown<sup>4</sup>, R. Schwartz<sup>2</sup>, <sup>1</sup>Towson University, Towson, MD, <sup>2</sup>Friends Research Institute, Baltimore, MD, <sup>3</sup>University of Maryland, College Park, MD, <sup>4</sup>University of North Carolina, Wilmington, NC
- 15 *Advisor-Teller Money Manager therapy for substance abuse*  
M. I. Rosen<sup>1,2</sup>, B. J. Rounsaville<sup>1,2</sup>, K. Ablondi<sup>1</sup>, A. C. Black<sup>1</sup>, R. A. Rosenheck<sup>2,1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>VA Connecticut, West Haven, CT
- 16 *Treatment outcomes of methamphetamine-dependent adults with anxiety disorders*  
S. Glasner-Edwards<sup>1</sup>, L. J. Mooney<sup>1</sup>, P. Marinelli-Casey<sup>1</sup>, M. Hillhouse<sup>1</sup>, A. Ang<sup>2</sup>, R. A. Rawson<sup>1</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Family Medicine, UCLA, Los Angeles, CA
- 17 *Do race and sex alter the association between non-marijuana drug use trajectories and depressive symptoms in a community-based adult cohort? (the CARDIA study)*  
Y. Khodneva<sup>1</sup>, M. Pletcher<sup>2</sup>, M. Safford<sup>1</sup>, J. Schumacher<sup>1</sup>, J. Tucker<sup>1</sup>, S. Kertesz<sup>1,3</sup>, <sup>1</sup>University of Alabama, Birmingham, AL, <sup>2</sup>University of California San Francisco, San Francisco, CA, <sup>3</sup>Birmingham VA Medical Center, Birmingham, AL
- 18 *Effects of a brief behavioral activation treatment on substance abuse treatment dropout, depression, and activation among low-income substance users*  
J. Magidson, A. Lavelle, C. W. Lejuez, S. B. Daughters, University of Maryland, College Park, MD

### ADOLESCENT DRUG ABUSE II

- 19 *Retrospective evaluation of ASAM criteria in adolescents receiving weekly outpatient treatment for co-occurring psychiatric and substance use disorders*  
B. W. Holmes<sup>1</sup>, L. Haynes<sup>2</sup>, J. Leimberger<sup>3</sup>, P. Riggs<sup>4</sup>, <sup>1</sup>NIDA CTN, LRADAC, Columbia, SC, <sup>2</sup>Psychiatry and Behavioral Sciences, Medical University of SC, Charleston, SC, <sup>3</sup>Duke Clinical Research Institute, Durham, NC, <sup>4</sup>University of Colorado at Denver, Aurora, CO

- 20 *National Monitoring of Adolescent Prescription Stimulants Study: Stimulant medication use among 10 to 18 year olds*  
L. B. Cottler, A. Ben Abdallah, S. E. Bradford, C. L. Striley, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 21 *Nonmedical use of prescription stimulants among adolescents: Rural vs. urban*  
E. W. Ndichu, C. W. Striley, A. Ben Abdallah, S. E. Bradford, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 22 *Youth perspectives on prescription drug non-medical use among their peers*  
S. E. Bradford, L. J. Wright, S. Cummings, L. B. Cottler, Washington University School of Medicine, St. Louis, MO
- 23 *Trends in prescription drug use disorders secondary to non-medical use in adolescence*  
S. S. Martins<sup>1</sup>, L. N. LaFlair<sup>1</sup>, M. Fenton<sup>2</sup>, K. M. Keyes<sup>2</sup>, C. L. Storr<sup>3,1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Epidemiology, Columbia University, New York City, NY, <sup>3</sup>Family and Community Health, University of Maryland School of Nursing, Baltimore, MD
- 24 *Non-prescribed use of Vicodin® and OxyContin® among US youth*  
L. K. Lee<sup>1</sup>, D. McCarty<sup>2</sup>, J. D. Haddox<sup>3</sup>, J. Fitzgerald<sup>3</sup>, W. Wakeland<sup>4</sup>, L. Webster<sup>5</sup>, <sup>1</sup>University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Oregon Health and Science University, Portland, OR, <sup>3</sup>Purdue Pharma L.P., Stamford, CT, <sup>4</sup>Portland State University, Portland, OR, <sup>5</sup>LifeTree Medical, Salt Lake City, UT
- 25 *Correlates of prescription opioid diversion among middle- and high-school students*  
C. J. Boyd<sup>1,2</sup>, S. E. McCabe<sup>1,2</sup>, C. E. Teter<sup>2</sup>, A. M. Young<sup>1</sup>, P. Ross-Durow<sup>1</sup>, T. H. Ackerson<sup>1</sup>, M. Epstein<sup>2</sup>, J. A. Cranford<sup>3,2</sup>, <sup>1</sup>Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI, <sup>2</sup>Substance Abuse Research Center, University of Michigan, Ann Arbor, MI, <sup>3</sup>Psychiatry, University of Michigan, Ann Arbor, MI
- 26 *Prescription opioid abuse in adult and adolescent substance abuse treatment center populations: Early findings from CHAT™*  
T. Dailey, T. A. Cassidy, S. F. Butler, S. H. Budman, Inflexxion, Inc., Newton, MA
- 27 *Improvement in psychopathology among opioid-dependent youth during behavioral-pharmacological treatment*  
S. K. Moore<sup>1</sup>, L. A. Marsch<sup>1</sup>, R. Solhkhah<sup>2</sup>, Y. Hofstein<sup>1</sup>, <sup>1</sup>Center for Technology and Health, National Development and Research Institutes, New York, NY, <sup>2</sup>Psychiatry, Maimonides Medical Center, Brooklyn, NY
- 28 *Dimensional modeling of substance use and conduct disorder and their association with neurocognition in adolescence*  
M. Worley, K. L. Hanson, J. Winward, S. F. Tapert, S. A. Brown, Psychiatry, University of California, San Diego, La Jolla, CA
- 29 *Double-blind fluoxetine in comorbid MDD-CUD youth*  
J. R. Cornelius<sup>1</sup>, O. Bukstein<sup>1</sup>, A. Douaihy<sup>1</sup>, J. Pettegrew<sup>1</sup>, D. Clark<sup>1</sup>, D. Daley<sup>1</sup>, S. Brown<sup>2</sup>, <sup>1</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychology, University of California, San Diego, CA
- 30 *The added risk of opioid problem use among treatment-seeking youth with marijuana/alcohol problem use*  
G. subramaniam<sup>1,3</sup>, M. L. Ives<sup>2</sup>, M. L. Stitzer<sup>3</sup>, M. L. Dennis<sup>2</sup>, <sup>1</sup>DCNBR, NIDA, Bethesda, MD, <sup>2</sup>Chestnut Health Systems, Bloomington, IL, <sup>3</sup>Psychiatry, Johns Hopkins University, Baltimore, MD



- 31 *Verbal memory, learning and executive functioning among young inhalant and cannabis users*  
M. Takagi<sup>1</sup>, M. Yücel<sup>1</sup>, S. Cotton<sup>1</sup>, Y. Baliz<sup>2</sup>, A. Tucker<sup>2</sup>, K. Elkins<sup>1</sup>, D. Lubman<sup>1</sup>, <sup>1</sup>Psychiatry, University of Melbourne, Parkville, VIC, Australia, <sup>2</sup>Psychology, Victoria University, Footscray, VIC, Australia
- 32 *Developmental momentum and risk for substance use disorder: Natural histories of risk factors in youth experiencing chronic stress*  
T. Ridenour, University of Pittsburgh, Pittsburgh, PA
- 33 *Drugged driving: Prevalence and trends in a college student sample*  
A. Arria<sup>1</sup>, K. M. Caldeira<sup>1</sup>, K. B. Vincent<sup>1</sup>, K. E. O'Grady<sup>2</sup>, <sup>1</sup>Center on Young Adult Health and Development, University of Maryland, College Park, MD, <sup>2</sup>Psychology, University of Maryland, College Park, MD
- 34 *Type of contraception method used at last intercourse and health risk behaviors among US adolescents*  
P. Cavazos<sup>1</sup>, M. Krauss<sup>3</sup>, E. Spitznagel<sup>5</sup>, M. Schootman<sup>4</sup>, J. F. Peipert<sup>2</sup>, L. Cottler<sup>1</sup>, L. Bierut<sup>1</sup>, <sup>1</sup>Psychiatry, <sup>2</sup>Obstetrics and Gynecology, <sup>3</sup>Biostatistics, <sup>4</sup>Health Behavior Research, and <sup>5</sup>Mathematics, Washington University, St. Louis, MO
- 35 *Clinical features associated with alcohol dependence emerging soon after drinking onset*  
L. A. Comment, J. C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 36 *Motivations not to drink alcohol in adolescence*  
K. G. Anderson, I. Grunwald, A. Grant, Psychology, Reed College, Portland, OR
- 37 *Motives associated with resilience of tobacco use among school students in Spain. Differences by gender*  
C. C. Morales-Manrique<sup>1</sup>, F. J. Bueno-Cañigral<sup>2</sup>, J. C. Valderrama-Zurián<sup>3</sup>, R. Aleixandre-Benavent<sup>1</sup>, <sup>1</sup>Unidad de Información e Investigación Social y Sanitaria., Universitat de València-CSIC, Valencia, Spain, <sup>2</sup>Plan Municipal Drogodependencias., Ayuntamiento de Valencia, Valencia, Spain, <sup>3</sup>Generalitat Valenciana., Valencia, Spain

**GENES**

- 38 *DRD2/ANKK1 in relation to regular alcohol and cannabis use among adolescents: Does parenting modify the impact of genetic vulnerability? The TRAILS study*  
H. E. Creemers<sup>1</sup>, Z. Harakeh<sup>2</sup>, D. Dick<sup>3</sup>, J. Meyers<sup>3</sup>, W. Vollebergh<sup>2</sup>, J. Ormel<sup>4</sup>, F. Verhulst<sup>1</sup>, A. Huizink<sup>1,5</sup>, <sup>1</sup>Child and Adolescent Psychiatry, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands, <sup>2</sup>Utrecht University, Utrecht, Netherlands, <sup>3</sup>Virginia Commonwealth University, Richmond, VA, <sup>4</sup>University of Groningen, Groningen, Netherlands, <sup>5</sup>University of Amsterdam, Amsterdam, Netherlands
- 39 *Examination of the effects of the 830 bp indel OPRK1 promoter polymorphism and PDYN mRNA levels on OPRK1 expression in the caudate from postmortem human brain*  
V. Yuferov<sup>1</sup>, N. Fang<sup>1</sup>, A. Ho<sup>1</sup>, S. Morgello<sup>2</sup>, M. J. Kreek<sup>1</sup>, <sup>1</sup>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, <sup>2</sup>Mount Sinai Medical Center, New York, NY
- 40 *Associations between heroin-dependent patient satisfaction with methadone maintenance treatment centers and CYP3A4, CYP2B6, CYP2D6, OPRM1, and DRD2 genetic polymorphisms*  
J. C. Pérez de los Cobos<sup>1</sup>, N. Siñol<sup>1</sup>, F. Calafell<sup>2</sup>, M. Baiget<sup>1</sup>, J. Trujols<sup>1</sup>, J. Salazar<sup>1</sup>, M. Cardus<sup>1</sup>, E. Alvarez<sup>1</sup>, B. Barcelona Group for Addiction Genetics<sup>1,2</sup>, <sup>1</sup>Addictive Behavior Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>2</sup>Unitat de Biologia Evolutiva, Universitat Pompeu Fabra, Barcelona, Spain



- 41 *Genetic studies of the proopiomelanocortin gene with heroin addiction in ethnically diverse population*  
D. Proudnikov<sup>1</sup>, D. Londono<sup>2</sup>, J. Ott<sup>3</sup>, M. J. Kreek<sup>1</sup>, <sup>1</sup>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, <sup>2</sup>Genetics, Rutgers University, Piscataway, NJ, <sup>3</sup>Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
- 42 *Identification of differentially expressed genes and enriched molecular pathways by topiramate for treatment of methamphetamine dependence using genome-wide expression microarrays*  
T. Niu<sup>1</sup>, J. Wang<sup>1</sup>, J. Z. Ma<sup>1</sup>, R. Morris<sup>2</sup>, H. Liu<sup>2</sup>, D. Weis<sup>2</sup>, M. McCann<sup>2</sup>, C. Stock<sup>2</sup>, E. Iturriaga<sup>2</sup>, S. H. Li<sup>2</sup>, N. Chiang<sup>2</sup>, E. Yu<sup>2</sup>, A. Elkashef<sup>2</sup>, B. A. Johnson<sup>1</sup>, M. D. Li<sup>1</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, <sup>2</sup>NIDA, NIH, Bethesda, MD
- 43 *Transcriptome profiling and pathway analysis of genes differentially expressed in response to topiramate for treatment of methamphetamine dependence*  
M. D. Li<sup>1</sup>, J. Wang<sup>1</sup>, T. Niu<sup>1</sup>, J. Saadvandi<sup>2</sup>, R. Morris<sup>2</sup>, N. Ait-Daoud<sup>1</sup>, J. Campbell<sup>2</sup>, W. Haning<sup>2</sup>, J. Mawhinney<sup>2</sup>, R. Kahn<sup>2</sup>, A. Anderson<sup>2</sup>, E. Iturriaga<sup>2</sup>, X. Lou<sup>1</sup>, A. Elkashef<sup>2</sup>, B. A. Johnson<sup>1</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, <sup>2</sup>NIDA, NIH, Bethesda, MD
- 44 *Long-term memory of cue-induced incentive learning is dependent on the nNOS gene and CREB*  
J. B. Kelley<sup>1</sup>, K. L. Anderson<sup>2</sup>, Y. Itzhak<sup>1,2</sup>, <sup>1</sup>Neuroscience, University of Miami, Miami, FL, <sup>2</sup>Psychiatry, University of Miami, Miami, FL
- 45 *Serotonin transporter polymorphisms and attentional bias in cocaine dependence*  
L. Maili<sup>1</sup>, D. N. Nielsen<sup>2</sup>, S. Liu<sup>1</sup>, S. Hamon<sup>3</sup>, K. A. Cunningham<sup>4</sup>, F. G. Moeller<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, <sup>2</sup>Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>3</sup>Statistical Genetics, The Rockefeller University, New York, NY, <sup>4</sup>Pharmacology and Toxicology, Center for Addiction Research, Galveston, TX
- 46 *Epigenetic effects of cocaine on white matter*  
D. A. Nielsen<sup>1,2</sup>, W. Huang<sup>1,2</sup>, S. C. Hamon<sup>3</sup>, L. Maili<sup>4</sup>, K. A. Cunningham<sup>5</sup>, F. G. Moeller<sup>4</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Michael E. DeBakey V.A. Medical Center, Houston, TX, <sup>3</sup>The Rockefeller University, New York, NY, <sup>4</sup>University of Texas Health Science Center at Houston, Houston, TX, <sup>5</sup>University of Texas Medical Branch, Galveston, TX
- 47 *Implication of epigenetic modulation in reduced mesolimbic dopaminergic activity under a neuropathic pain-like state*  
M. Saeki, M. Narita, S. Imai, M. Narita, K. Niikura, N. Kuzumaki, T. Suzuki, Toxicology, Hoshi University School of Pharmacology and Pharmaceutical Sciences, Tokyo, Japan
- 48 *Neuropathogenic mechanisms of HIV-1 clade B and C: Role of dopamine receptor-2*  
S. Thangavel, Z. M. Saiyed, M. Agudelo, N. Gandhi, P. V. Reddy, M. P. Nair, Immunology, Florida International University, Miami, FL

### HIV/AIDS I

- 49 *The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone*  
L. E. Sullivan<sup>1</sup>, M. Botsko<sup>2</sup>, C. Cunningham<sup>3</sup>, J. A. Mitty<sup>5</sup>, D. Hersh<sup>4</sup>, P. J. Lum<sup>4</sup>, R. S. Schottenfeld<sup>1</sup>, P. G. O'Connor<sup>1</sup>, D. A. Fiellin<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>New York Academy of Medicine, New York, NY, <sup>3</sup>Albert Einstein College of Medicine, New York, NY, <sup>4</sup>University of California, San Francisco, CA, <sup>5</sup>Harvard Medical School, Boston, MA

- 50 *Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone*  
L. Weiss<sup>2</sup>, M. Botsko<sup>2</sup>, J. Egan<sup>2</sup>, R. Finkelstein<sup>2</sup>, F. Altice<sup>1</sup>, L. Bazerman<sup>3</sup>, A. Chaudhry<sup>4</sup>, C. Cunningham<sup>5</sup>, M. Gourevitch<sup>6</sup>, P. Lum<sup>7</sup>, L. Sullivan<sup>1</sup>, R. Schottenfeld<sup>1</sup>, P. O'Connor<sup>1</sup>, D. Fiellin<sup>1</sup>, <sup>1</sup>Internal Medicine, Yale University, New Haven, CT, <sup>2</sup>New York Academy of Medicine, New York, NY, <sup>3</sup>Brown University, Providence, RI, <sup>4</sup>CSAT, Rockville, MD, <sup>5</sup>Albert Einstein College of Medicine, Bronx, NY, <sup>6</sup>New York University, New York, NY, <sup>7</sup>University of California, San Francisco, CA
- 51 *Cognitive impairment during alcohol intoxication in HIV positive drinkers*  
V. A. Gruber, R. Sutton, E. F. McCance-Katz, University of California, San Francisco, CA
- 52 *Sexual discounting: HIV/AIDS risk behavior and the delay discounting of sexual rewards in cocaine dependence*  
M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 53 *Neuropsychological predictors of substance use and adherence in HIV+, methamphetamine-using men who have sex with men*  
W. J. Kowalczyk<sup>1,2</sup>, M. P. Pawson<sup>1</sup>, J. T. Parsons<sup>1,2,3</sup>, S. A. Golub<sup>1,2,3</sup>, <sup>1</sup>Center for HIV/AIDS Educational Studies and Training, <sup>2</sup>City University of New York Graduate School and University Center, and <sup>3</sup>Hunter College, New York, NY
- 54 *Integrating theory to address the association between substance use and sexual risk behavior among MSM*  
B. Wells<sup>1</sup>, S. Golub<sup>1,2</sup>, J. Parsons<sup>1,2</sup>, <sup>1</sup>The Center for HIV Educational Studies and Training, and <sup>2</sup>Psychology, Hunter College, New York, NY
- 55 *Gay-related stigma is predictive of problematic drinking and substance use in a sample of high-risk HIV negative YMSM*  
C. Lelutiu-Weinberger<sup>1</sup>, S. A. Golub<sup>1,2,3</sup>, A. Bamonte<sup>1</sup>, J. T. Parsons<sup>1,2,3</sup>, J. Tomassilli<sup>1</sup>, <sup>1</sup>Center for HIV Educational Studies and Training, and <sup>2</sup>Psychology, Hunter College, New York, NY, <sup>3</sup>Social-Personality Psychology, CUNY Graduate Center, New York, NY
- 56 *Sexual risk predicted by motivation to change risk behavior, temptations for and decisions around unsafe sex in YMSM*  
J. T. Parsons<sup>1,2,3</sup>, C. Lelutiu-Weinberger<sup>3</sup>, S. A. Golub<sup>1,2,3</sup>, A. Bamonte<sup>3</sup>, <sup>1</sup>Psychology, Hunter College, CUNY, New York, NY, <sup>2</sup>Social-Personality Psychology, CUNY Graduate Center, New York, NY, <sup>3</sup>Center for HIV Educational Studies and Training, Hunter College, New York, NY
- 57 *Substance use and heterosexual anal sex at the most recent sexual encounter*  
L. J. Ouellet, M. E. Mackesy-Amiti, Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL
- 58 *Internalization of complimentary sexual stereotypes as a correlate of risky sexual attitudes among African-American females*  
J. L. Duvall, C. Oser, J. Mooney, J. Havens, M. Staton-Tindall, C. Leukefeld, Behavioral Science, University of Kentucky, Lexington, KY
- 59 *Intimate partner characteristics and sexual behaviors as correlates of sexually transmitted infections among African-American female drug users*  
C. B. Oser, K. Harp, J. Havens, M. Staton-Tindall, B. Perry, J. Mooney, J. Duvall, C. Leukefeld, University of Kentucky, Lexington, KY

- 60 *The relative role of perceived partner risks in condom use in a three-city sample of low-income women*  
A. J. Ober<sup>1</sup>, M. Y. Iguchi<sup>2,3</sup>, R. E. Weiss<sup>4</sup>, P. M. Gorbach<sup>5</sup>, R. Heimer<sup>6</sup>, L. J. Ouellet<sup>7</sup>, S. Shoptaw<sup>8</sup>, W. A. Zule<sup>9</sup>, <sup>1</sup>Semel Institute of Neuroscience and Behavior, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>Community Health Sciences, UCLA School of Public Health, Los Angeles, CA, <sup>3</sup>RAND Corporation, Santa Monica, CA, <sup>4</sup>Biostatistics, UCLA School of Public Health, Los Angeles, CA, <sup>5</sup>Epidemiology, UCLA School of Public Health, Los Angeles, CA, <sup>6</sup>Yale University School of Public Health, New Haven, CT, <sup>7</sup>UIC School of Public Health, Chicago, IL, <sup>8</sup>Family Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, <sup>9</sup>Research Triangle Institute International, Raleigh Durham, NC
- 61 *Drug use and sexually transmitted infections in rural North Carolina*  
W. A. Zule, W. M. Wechsberg, C. M. Coomes, G. V. Bobashev, RTI International, Research Triangle Park, NC
- 62 *Changes In injection- and sex-related HIV risk behaviors for in- and out-of-treatment opiate-dependent individuals*  
S. G. Mitchell<sup>1</sup>, K. E. O'Grady<sup>2</sup>, S. M. Kelly<sup>1</sup>, B. S. Brown<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>University of Maryland, College Park, MD, <sup>3</sup>University of North Carolina, Wilmington, NC
- 63 *Factors associated with backloading among injection drug users in Baltimore, Maryland: The role of executive functioning*  
C. Graham, D. Whitaker, W. Latimer, Johns Hopkins University, Baltimore, MD
- 64 *Impulsivity and HIV sexual risk behaviors in Bulgarian heroin users*  
G. N. Vasilev<sup>1</sup>, I. T. Raynov<sup>1</sup>, S. E. Bliznashki<sup>1</sup>, E. M. Martin-Thormeyer<sup>2</sup>, J. Vassileva<sup>2</sup>, <sup>1</sup>Bulgarian Addictions Institute, Sofia, Bulgaria, <sup>2</sup>Psychiatry, University of Illinois - Chicago, Chicago, IL
- 65 *Sex-related HIV risk behaviors among injection drug users*  
H. L. Guentzel<sup>1</sup>, M. Iguchi<sup>1,2</sup>, R. Bluthenthal<sup>2,3</sup>, A. Kral<sup>4,5</sup>, <sup>1</sup>CHS, UCLA, Los Angeles, CA, <sup>2</sup>RAND Corporation, Santa Monica, CA, <sup>3</sup>Urban Community Research Center, California State University, Dominguez Hills, Carson, CA, <sup>4</sup>RTI International, San Francisco, CA, <sup>5</sup>UCSF, San Francisco, CA
- 66 *HIV transmission risk behaviors and genotypic drug resistance among HIV+ patients on opioid agonist treatment*  
A. Dinh, J. M. Tetrault, M. Kozal, L. E. Sullivan, D. Fiellin, Internal Medicine, Yale University School of Medicine, New Haven, CT
- 67 *Personality disturbances and HIV risk behaviors in HIV+ individuals*  
H. Newville<sup>1,2</sup>, D. L. Haller<sup>2,3</sup>, <sup>1</sup>Yeshiva University, Bronx, NY, <sup>2</sup>St. Luke's-Roosevelt Hospital, New York, NY, <sup>3</sup>Columbia University, New York, NY

#### PHARMACOKINETICS

- 68 *Interactive role of HIV-1 clade specific tat protein and cocaine in blood-brain barrier dysfunction: Implications for neuroAIDS*  
N. Gandhi, Z. Saiyed, T. Samikkannu, M. Agudelo, P. Khatavkar, J. Napuri, M. Nair, Institute of Neuroimmune Pharmacology, College of Medicine, Florida International University, Miami, FL

- 69 *Estimation of a human satiety threshold for cocaine self-administration*  
G. A. Angarita<sup>1</sup>, R. Gueorguieva<sup>1,2</sup>, B. Pittman<sup>1</sup>, R. Kalayasiri<sup>3</sup>, W. L. Lynch<sup>4</sup>,  
A. Sughondhabirom<sup>3</sup>, P. T. Morgan<sup>1</sup>, R. T. Malison<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University,  
New Haven, CT, <sup>2</sup>Division of Biostatistics, Yale University, New Haven, CT, <sup>3</sup>Psychiatry,  
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, <sup>4</sup>Psychiatry and  
Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA
- 70 *Estimating the intake of abused methamphetamine using experimenter-administered deuterium  
labeled R-methamphetamine: Selection of the R-methamphetamine dose*  
L. Li, J. Lopez, G. Galloway, M. Baggott, T. Everhart, J. Mendelson, Research Institute,  
California Pacific Medical Center, San Francisco, CA
- 71 *Gender differences in the pharmacokinetics and effects of 3,4-methylenedioxymethamphetamine  
in humans*  
M. Farre<sup>1,2</sup>, R. Pardo<sup>1,2</sup>, S. Yubero<sup>1,3</sup>, E. Cuyas<sup>1,2</sup>, M. Torrens<sup>4,5</sup>, C. Mustata<sup>1,2</sup>, C. Perez<sup>1,2</sup>,  
E. Menoyo<sup>1</sup>, M. Perez<sup>1</sup>, S. Martin<sup>1</sup>, B. O'Mahony<sup>1,3</sup>, R. De la Torre<sup>1,3</sup>, <sup>1</sup>Human Pharmacology  
and Neurosciences, IMIM-Hospital del Mar, Barcelona, Spain, <sup>2</sup>Pharmacology, UAB,  
Barcelona, Spain, <sup>3</sup>CEXS, UPF, Barcelona, Spain, <sup>4</sup>Drug Addiction, IAPS-IMAS, Barcelona,  
Spain, <sup>5</sup>Psychiatry, UAB, Barcelona, Spain
- 72 *Pharmacokinetic properties of a bacterial cocaine esterase to be used as a treatment against  
cocaine-induced toxicities*  
R. L. Brim, R. K. Sunahara, J. H. Woods, Pharmacology, University of Michigan,  
Ann Arbor, MI
- 73 *A slow-onset, long-duration methylphenidate analog is not self-administered in cocaine-naïve  
rats*  
M. Froimowitz<sup>1</sup>, X. Peng<sup>2</sup>, X. Li<sup>2</sup>, J. Li<sup>2</sup>, Z. Xi<sup>2</sup>, C. J. Kelley<sup>3</sup>, E. L. Gardner<sup>2</sup>, <sup>1</sup>none,  
Newton, MA, <sup>2</sup>Neuropsychopharmacology Section, Intramural Research Program, National  
Institutes of Health, Baltimore, MD, <sup>3</sup>Massachusetts College of Pharmacy and Health  
Sciences, Boston, MA
- 74 *Blood levels of fluoxetine in rhesus monkeys at doses that attenuate the abuse-related effects of  
cocaine*  
E. Kessler, L. L. Howell, Neuroscience, Yerkes National Primate Research Center, Emory  
University, Atlanta, GA
- 75 *Bupropion transport by placental P-glycoprotein and Breast Cancer Resistance Protein*  
S. J. Hemauer, S. L. Patrikeeva, G. D. Hankins, M. S. Ahmed, T. N. Nanovskaya, Obstetrics  
and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX
- 76 *Bupropion metabolism by human placenta*  
X. Wang, D. Abdelrahman, O. Zharikova, S. Patrikeeva, G. Hankins, M. Ahmed,  
T. Nanovskaya, Obstetrics and Gynecology, University of Texas Medical Branch at Galveston,  
Galveston, TX

COMPLIANCE

- 77 *A study of initial riboflavin levels in 2,738 treatment-seeking substance users*  
M. E. Mooney<sup>1</sup>, D. V. Herin<sup>1</sup>, J. M. Schmitz<sup>2</sup>, J. Grabowski<sup>1</sup>, <sup>1</sup>Psychiatry, University of  
Minnesota, Minneapolis, MN, <sup>2</sup>Psychiatry and Behavioral Sciences, University of Texas  
Health Science Center, Houston, TX

- 78 *Hair analysis vs. conventional methods of drug testing in pre-transplant patients*  
D. L. Haller<sup>1,2</sup>, M. Acosta<sup>3,2</sup>, D. Lewis<sup>4</sup>, D. Miles<sup>5</sup>, T. Schiano<sup>6</sup>, P. Shapiro<sup>2</sup>, J. Gomez<sup>1</sup>,  
S. Sabag-Cohen<sup>1</sup>, H. Newville<sup>7,1</sup>, <sup>1</sup>St. Luke's-Roosevelt Hospital, New York, NY, <sup>2</sup>Columbia  
University, New York, NY, <sup>3</sup>NDRI, Inc., New York, NY, <sup>4</sup>US Drug Testing Laboratories,  
Chicago, IL, <sup>5</sup>North Carolina State Center for Health Statistics, Chapel Hill, NC, <sup>6</sup>Mt. Sinai  
School of Medicine, New York, NY, <sup>7</sup>Yeshiva University, New York, NY
- 79 *Concordance between self-report and urine drug screen data in adolescent opioid-dependent  
clinical trial participants*  
M. Nakazawa<sup>1</sup>, M. P. Bogenschutz<sup>1</sup>, C. Wilcox<sup>1</sup>, G. Woody<sup>2</sup>, <sup>1</sup>CASAA, University of New  
Mexico, Albuquerque, NM, <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 80 *Effects of reimbursement on rates of missing, positive, and negative urine drug among opioid-  
dependent clinical trial participants*  
C. Wilcox<sup>1</sup>, M. P. Bogenschutz<sup>1</sup>, M. Nakazawa<sup>1</sup>, G. Woody<sup>2</sup>, <sup>1</sup>CASAA, University of New  
Mexico, Albuquerque, NM, <sup>2</sup>University of Pennsylvania, Philadelphia, PA

#### **POLYDRUGS I**

- 81 *Factors associated with high vs. low use of evidence-based practices in addiction treatment*  
A. Breland<sup>2</sup>, A. Fitzgerald<sup>1</sup>, J. May<sup>1</sup>, F. Taxman<sup>3</sup>, D. Farrell-Moore<sup>1</sup>, J. R. Koch<sup>2</sup>, D. Svikis<sup>2</sup>,  
<sup>1</sup>Richmond Behavioral Health Authority, Richmond, VA, <sup>2</sup>Virginia Commonwealth University,  
Richmond, VA, <sup>3</sup>George Mason University, Fairfax, VA
- 82 *A randomized controlled trial evaluating the efficacy of a performance improvement system in  
outpatient substance abuse treatment programs*  
B. McClure<sup>1</sup>, A. Kulaga<sup>1</sup>, S. Ring-Kurtz<sup>2</sup>, C. Temes<sup>2</sup>, R. Gallop<sup>2</sup>, R. Forman<sup>3</sup>,  
P. Crits-Christoph<sup>2</sup>, J. Rotrosen<sup>1</sup>, <sup>1</sup>Psychiatry, NYU School of Medicine, New York, NY,  
<sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Alkermes, Inc., Boston, MA
- 83 *Is the association of therapeutic alliance with days of use always negative?*  
A. A. Forcehimes<sup>1</sup>, A. S. Kosinski<sup>2</sup>, O. Silva<sup>1</sup>, K. Burlew<sup>3</sup>, L. Montgomery<sup>3</sup>, <sup>1</sup>CASAA,  
University of New Mexico, Albuquerque, NM, <sup>2</sup>Duke, Durham, NC, <sup>3</sup>University of Cincinnati,  
Cincinnati, OH
- 84 *Six-month outcomes for the Targeted Assessment Welfare to Work Program*  
C. G. Leukefeld<sup>1</sup>, E. Carlton<sup>1</sup>, M. Staton-Tindall<sup>2</sup>, M. Delaney<sup>1</sup>, <sup>1</sup>Behavioral Science, and  
<sup>2</sup>Social Work, University of Kentucky, Lexington, KY
- 85 *The efficacy of Motivational Enhancement Therapy for African-American substance users*  
L. Montgomery<sup>1</sup>, K. Burlew<sup>1</sup>, A. Kosinski<sup>2</sup>, A. Forcehimes<sup>3</sup>, <sup>1</sup>Psychology, University of  
Cincinnati, Cincinnati, OH, <sup>2</sup>Duke University, Durham, NC, <sup>3</sup>University of New Mexico,  
Albuquerque, NM
- 86 *Four-year outcomes from the Early Re-Intervention Experiment with Recovery Management  
Checkups*  
M. L. Dennis<sup>1</sup>, C. K. Scott<sup>2</sup>, <sup>1</sup>Chestnut Health Systems, Normal, IL, <sup>2</sup>Chestnut Health Systems,  
Chicago, IL
- 87 *A 2-year follow-up study to assess experimental Therapeutic Communities in France. An ongoing  
study*  
M. Auriacombe<sup>1</sup>, C. Denis<sup>1</sup>, E. Langlois<sup>2</sup>, M. Fatséas<sup>1</sup>, A. Vêretout<sup>2</sup>, C. Diaz-Gomez<sup>3</sup>,  
<sup>1</sup>Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen Bordeaux 2,  
Bordeaux, France, <sup>2</sup>Sociology LAPSAC, Université Victor Segalen Bordeaux 2, Bordeaux,  
France, <sup>3</sup>OFDT, OFDT, Paris, France



- 88 *Normative data on clients seeking treatment assessed with the French modified Addiction Severity Index. Multidimensional comparison of substance and non-substance dependent patients*  
M. Fatséas<sup>1</sup>, C. Denis<sup>1</sup>, V. Beltrand<sup>2,1</sup>, J. Daulouède<sup>2,1</sup>, M. Auriacombe<sup>1,2</sup>, <sup>1</sup>Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen Bordeaux 2, Bordeaux, France, <sup>2</sup>Bizia, Bayonne, France
- 89 *Predictors and outcomes of treatment readmission: The case for Concurrent Recovery Monitoring*  
A. B. Laudet<sup>1</sup>, V. Stanick<sup>2</sup>, <sup>1</sup>National Development and Research Institute, NYC, NY, <sup>2</sup>Daytop Village, New York, NY
- 90 *Predictors of study retention in drug abuse treatment trials*  
J. E. Korte<sup>1</sup>, K. Magruder<sup>2,1</sup>, S. Sonne<sup>1</sup>, R. Sampson<sup>1</sup>, K. Brady<sup>1,2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H. Johnson VA Medical Center, Charleston, SC
- 91 *Treatment processes within seven brief therapies for addiction*  
C. C. Wagner<sup>2</sup>, K. S. Ingersoll<sup>1</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, CA, <sup>2</sup>Rehabilitation Counseling, Virginia Commonwealth University, Richmond, CA
- 92 *Trying times: Real-time reports of cocaine-use occasions when efforts at abstinence were low or high*  
A. R. Pulaski, D. H. Epstein, K. L. Preston, Treatment Section, National Institute on Drug Abuse - Intramural Research Program, Baltimore, MD
- 93 *Drinking and drug use from a prospective perspective*  
M. L. Jobes, D. H. Epstein, K. L. Preston, Treatment Section, National Institute on Drug Abuse - Intramural Research Program, Baltimore, MD
- 94 *Mixed emotions: Evidence supporting the simultaneous occurrence of conflicting mood states via EMA*  
D. E. Whitaker, D. H. Epstein, K. E. Preston, CPTR Branch, NIH/NIDA Intramural Research Program, Baltimore, MD
- 95 *The P300 event-related brain potential as a neurobiological marker for substance use disorders: A meta-analytic investigation*  
A. S. Euser<sup>1,2</sup>, L. Arends<sup>1</sup>, A. Huizink<sup>2</sup>, I. Franken<sup>1</sup>, <sup>1</sup>Erasmus University Rotterdam, Institute of Psychology, Rotterdam, Netherlands, <sup>2</sup>Erasmus Medical Center/Sophia Children's Hospital, Child and Adolescent Psychiatry, Rotterdam, Netherlands
- 96 *Treatment with flumazenil: Comparisons of treatment outcomes among patients according to primary drug of abuse*  
M. Torrington, M. P. Hillhouse, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 97 *A novel opioid receptor antagonist, ALKS 33, demonstrates full and durable blockade of remifentanyl*  
R. Turncliff<sup>1</sup>, A. Illeperuma<sup>1</sup>, M. Shram<sup>2</sup>, R. Forman<sup>1</sup>, B. Silverman<sup>1</sup>, E. Ehrich<sup>1</sup>, E. Sellers<sup>2</sup>, <sup>1</sup>Alkermes, Inc, Cambridge, MA, <sup>2</sup>Kendle Early Stage, Toronto, ON, Canada
- 98 *Relative performance of subjective measures used in human abuse potential studies*  
K. A. Schoedel<sup>1</sup>, N. Chen<sup>1</sup>, N. Levy-Cooperman<sup>1</sup>, D. Feltner<sup>2</sup>, C. B. Billing, Jr.<sup>1</sup>, E. M. Sellers<sup>1</sup>, <sup>1</sup>Clinical Pharmacology, Kendle Early Stage - Toronto, Toronto, ON, Canada, <sup>2</sup>Pfizer Global Research and Development, Groton, CT



- 99 *Validation of a rat self-administration design for preclinical abuse liability assessment of new compounds*  
M. Ellgren, M. D. Swedberg, Safety Pharmacology, Safety Assessment, AstraZeneca R&D, Södertälje, Sweden

- 100 *Acute administration of drugs of abuse modulates risky decision making*  
M. R. Mitchell, C. M. Vokes, A. L. Blankenship, N. W. Simon, B. Setlow, Psychology, Texas A&M University, College Station, TX

### STIMULANTS: HUMAN I

- 101 *Brief intervention to reduce caffeine consumption in caffeine-dependent treatment seekers*  
D. P. Evatt<sup>1</sup>, L. M. Juliano<sup>2</sup>, J. Cohen<sup>1</sup>, R. R. Griffiths<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychology, American University, Washington, DC
- 102 *Effects of intranasal d-amphetamine and methamphetamine administration in humans*  
M. G. Kirkpatrick<sup>1,2</sup>, E. W. Gunderson<sup>2</sup>, C. E. Johanson<sup>3</sup>, F. R. Levin<sup>2</sup>, R. W. Foltin<sup>2</sup>, C. L. Hart<sup>1,2</sup>, <sup>1</sup>Psychology, Columbia University, New York, NY, <sup>2</sup>Division on Substance Abuse, New York State Psychiatric Institute and Psychiatry, Columbia University, New York, NY, <sup>3</sup>Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 103 *Neurobehavioral effects of intranasal d-amphetamine*  
T. H. Kelly, S. Babalonis, C. E. Emurian, C. R. Corbley, C. A. Martin, D. P. Wermeling, J. E. Joseph, J. A. Lile, University of Kentucky, Lexington, KY
- 104 *Reinforcing effects of d-amphetamine in light and moderate drinkers*  
M. D. Stanley<sup>1</sup>, M. M. Poole<sup>2</sup>, W. W. Stoops<sup>1</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, <sup>2</sup>Psychology, and <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 105 *Reinforcing effects of d-amphetamine: Influence of novel ratios on a progressive-ratio schedule*  
R. Sevak<sup>1</sup>, W. W. Stoops<sup>1</sup>, P. E. Glaser<sup>2,4,5</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, <sup>2</sup>Psychiatry, <sup>3</sup>Psychology, <sup>4</sup>Anatomy and Neurobiology, and <sup>5</sup>Pediatrics, University of Kentucky, Lexington, KY
- 106 *Impact of rivastigmine treatment on methamphetamine-induced subjective and reinforcing effects*  
R. De La Garza, II, T. F. Newton, M. Lokireddy, C. N. Haile, R. Y. Hawkins, S. Mehtani, G. Brown, Y. Omar, J. J. Mahoney, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX
- 107 *Double-blind placebo-controlled pilot trial of modafinil for methamphetamine withdrawal: Results of an Australian pilot study*  
N. K. Lee<sup>1,2,3</sup>, A. Pennay<sup>1,3</sup>, R. Hester<sup>4</sup>, S. Nielsen<sup>1,2</sup>, J. Ferris<sup>1</sup>, <sup>1</sup>Clinical Research, Turning Point Alcohol and Drug Centre, Fitzroy, VIC, Australia, <sup>2</sup>Psychology, Psychiatry & Psychological Medicine, Monash University, Melbourne, VIC, Australia, <sup>3</sup>National Drug Research Institute, Curtin University, Perth, WA, Australia, <sup>4</sup>Psychology, Melbourne University, Melbourne, VIC, Australia
- 108 *Identification of clinical responders to topiramate in a randomized clinical trial for treatment of methamphetamine dependence*  
J. Z. Ma<sup>1</sup>, B. A. Johnson<sup>1</sup>, E. Yu<sup>2</sup>, R. Rawson<sup>2</sup>, D. Weiss<sup>2</sup>, F. McSherry<sup>2</sup>, J. Saadvandi<sup>2</sup>, A. Romano<sup>2</sup>, R. Kahn<sup>2</sup>, A. Anderson<sup>2</sup>, E. Iturriaga<sup>2</sup>, S. H. Li<sup>2</sup>, N. Chiang<sup>2</sup>, M. D. Li<sup>1</sup>, A. Elkashef<sup>2</sup>, <sup>1</sup>Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, <sup>2</sup>NIDA, NIH, Bethesda, MD

- 109 *Disulfiram for methamphetamine dependence: An open-label pilot study*  
M. J. Mancino<sup>1</sup>, J. McGaugh<sup>1</sup>, C. Cargile<sup>2</sup>, A. Oliveto<sup>1</sup>, <sup>1</sup>Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>Psychiatry, Texas A&M Health Science Center, College Station, TX
- 110 *GABAA receptor modulators as medications for methamphetamine abuse*  
C. R. Rush<sup>1,2,3</sup>, J. A. Lile<sup>1</sup>, W. W. Stoops<sup>1</sup>, P. E. Glaser<sup>2</sup>, L. R. Hays<sup>2</sup>, <sup>1</sup>Behavioral Science, <sup>2</sup>Psychiatry, and <sup>3</sup>Psychology, University of Kentucky, Lexington, KY
- 111 *Vigabatrin as a treatment for methamphetamine dependence*  
G. P. Galloway<sup>1</sup>, K. Flower<sup>1</sup>, D. Winship<sup>2</sup>, C. Gorodetzky<sup>2</sup>, J. Mendelson<sup>1</sup>, <sup>1</sup>Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA, <sup>2</sup>Catalyst Pharmaceutical Partners, Inc, Coral Gables, FL

### CLUB DRUGS

- 112 *Patterns of use situations among active club drug users*  
T. J. Starks<sup>1</sup>, S. A. Golub<sup>1,3</sup>, B. C. Kelly<sup>1,2</sup>, J. T. Parsons<sup>1,3</sup>, <sup>1</sup>Center for HIV/AIDS Educational Studies and Training, New York, NY, <sup>2</sup>Sociology, Purdue University, West Lafayette, IN, <sup>3</sup>Psychology, Hunter College CUNY, New York City, NY
- 113 *Gender differences in MDMA-induced CYP2D6 autoinhibition in humans*  
S. Yubero<sup>1,2</sup>, R. Pardo<sup>1,3</sup>, M. Farre<sup>1,3</sup>, B. O'Mahony<sup>1,2</sup>, M. Torrens<sup>4,3</sup>, C. Mustata<sup>1,3</sup>, C. Perez<sup>1,3</sup>, R. De la Torre<sup>1,2</sup>, <sup>1</sup>IMIM, <sup>2</sup>Universitat Pompeu Fabra, <sup>3</sup>Universitat Autònoma de Barcelona, and <sup>4</sup>IAPS-Hospital del Mar, Barcelona, Spain
- 114 *Pharmacodynamic effects of 3,4-methylenedioxymphetamine*  
M. J. Baggott, J. Siegrist, J. R. Coyle, E. K. Flower, G. P. Galloway, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
- 115 *Evaluation of the reinforcing effects of 1,4-butanediol in baboons*  
E. M. Weerts, A. K. Goodwin, B. J. Kaminski, Psychiatry, Johns Hopkins University, Baltimore, MD
- 116 *Drug-seeking in response to a priming injection of MDMA in rats: Relationship to initial sensitivity to self-administered MDMA and dorsal striatal dopamine*  
J. Colussi-Mas, R. J. Wise, S. Schenk, School of Psychology, Victoria University of Wellington, Wellington, New Zealand

### STIMULANTS: ANIMAL II

- 117 *The effects of metyrapone and oxazepam on cocaine self-administration following adrenalectomy in rats*  
G. F. Guerin, N. E. Goeders, Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA
- 118 *The effects of ketamine, pentobarbital and isoflurane on cocaine sensitization in female rats*  
N. Siegal, N. Zhao, D. Dow-Edwards, Physiology/Pharmacology, SUNY Downstate College of Medicine, Brooklyn, NY
- 119 *Cue- and cocaine-induced reinstatement of extinguished cocaine-seeking in methylphenidate pretreated rats*  
M. S. Herbert<sup>1</sup>, L. A. Horn<sup>1</sup>, A. Mohd-Yusof<sup>1</sup>, A. J. Palmer<sup>1</sup>, C. M. Farley<sup>1</sup>, A. R. Zavala<sup>2</sup>, C. A. Crawford<sup>1</sup>, <sup>1</sup>California State University, San Bernardino, San Bernardino, CA, <sup>2</sup>Long Beach State, Long Beach, CA
- 120 *Extended access to intravenous methylphenidate leads to escalation of self-administration in rats*  
J. A. Marusich, M. Bardo, University of Kentucky, Lexington, KY

- 121 *Chronic methylphenidate treatment does not affect the course of dopaminergic development in juvenile rhesus monkeys*  
K. E. Gill, A. J. Bennett, P. J. Pierre, J. B. Daunais, M. A. Nader, L. J. Porrino, Physiology and Pharmacology, Wake Forest University, Winston Salem, NC
- 122 *Long access to self-administered cocaine causes lasting increases in impulsive choice in a delay discounting task*  
C. M. Vokes<sup>1</sup>, M. R. Mitchell<sup>1</sup>, I. A. Mendez<sup>1</sup>, R. A. Fuchs<sup>2</sup>, P. J. Wellman<sup>1</sup>, B. Setlow<sup>1</sup>,  
<sup>1</sup>Psychology, Texas A&M University, College Station, TX, <sup>2</sup>Psychology, University of North Carolina, Chapel Hill, NC
- 123 *Identifying impulsive action in rats using the one-choice serial reaction time task*  
N. C. Anastasio<sup>1,2</sup>, F. G. Moeller<sup>3</sup>, R. G. Fox<sup>1,2</sup>, S. Liu<sup>3</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Center for Addiction Research, Univ Texas Med Branch, Galveston, TX, <sup>2</sup>Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Psychology and Behavioral Science, University of Texas Health Science Center Houston, Galveston, TX
- 124 *Cue-induced response-potential in a runway model of IV heroin and cocaine self-administration*  
Z. Su, A. Ettenberg, University of California, Santa Barbara, CA
- 125 *Social interaction prevents cocaine relapse in a rat model: Functional brain mapping*  
M. Fritz<sup>1</sup>, R. El Rawas<sup>1</sup>, A. Salti<sup>2</sup>, S. Klement<sup>1</sup>, M. Bardo<sup>3</sup>, G. Dechant<sup>2</sup>, A. Saria<sup>1</sup>, G. Zernig<sup>1</sup>,  
<sup>1</sup>Institute for Experimental Psychiatry, Medical University Innsbruck, Innsbruck, Austria, <sup>2</sup>Institute for Neuroscience, Medical University Innsbruck, Innsbruck, Austria, <sup>3</sup>Center for Drug Abuse Research, University of Kentucky, Lexington, KY
- 126 *Effects of basolateral amygdala - dorsal hippocampus disconnection following cocaine memory reactivation on subsequent cocaine-seeking behavior in rats*  
A. M. Wells, K. E. Cowhey, X. Xie, D. R. Ramirez, H. C. Lasseter, P. A. West, R. A. Fuchs, Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 127 *Sub-region specific contribution of the ventral hippocampus to drug context-induced reinstatement of cocaine-seeking behavior*  
H. C. Lasseter, X. Xie, A. M. Wells, R. A. Fuchs, Behavioral Neuroscience, University of North Carolina - Chapel Hill, Chapel Hill, NC
- 128 *Behavioral and functional evidence of mGlu2/3 and mGlu5 metabotropic glutamate receptor dysregulation in cocaine-escalated rats: Factor in the transition to dependence*  
Y. Hao, R. Martin-Fardon, F. Weiss, The Scripps Research Institute, La Jolla, CA
- 129 *Escalated cocaine self-administration is paralleled by significant reduction in basal extracellular glutamate levels within the medial prefrontal cortex*  
O. M. Ben-Shahar, K. K. Szumlinski, K. D. Lominac, E. Gordon, K. L. Ploense, K. Pagano, A. N. Nabhan, N. M. Rudy, A. Sacramento, Psychology, University California Santa Barbara, Santa Barbara, CA
- 130 *Manipulation of GLT1 alters cue-induced cocaine reinstatement*  
K. D. Smith, M. Hatzigeorgiou, J. Teplinsky, G. V. Rebec, Psychological and Brain Sciences, Indiana University, Bloomington, IN
- 131 *Proton magnetic resonance spectroscopy detects putamen glutamate changes during chronic cocaine exposure in squirrel monkeys*  
X. Liu, C. S. Zuo, E. Jensen, A. Prescott, N. Bolo, T. Gillis, M. Brimson, K. Cayetano, B. Adams, P. F. Renshaw, M. J. Kaufman, Brain Imaging Center, Mclean Hospital, Belmont, MA

- 132 *Inhibiting glycine transporter-1: Effects on extinction and reacquisition of cocaine self-administration*  
B. Á. Nic Dhonnchadha<sup>1</sup>, C. Achat-Mendes<sup>2</sup>, D. M. Platt<sup>2</sup>, E. Pinard<sup>3</sup>, D. Alberati<sup>3</sup>, J. G. Wettstein<sup>3</sup>, R. D. Spealman<sup>2</sup>, K. M. Kantak<sup>1</sup>, <sup>1</sup>Psychology, Boston University, Boston, MA, <sup>2</sup>New England Primate Research Center, Harvard Medical School, Southborough, MA, <sup>3</sup>CNS Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland
- 133 *Abrupt discontinuation after chronic treatment with SSRI and SNRI induces withdrawal syndrome-like signs in mice and rats*  
T. Suzuki, M. Rahmadi, S. Imai, N. Kuzumaki, M. Narita, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan
- 134 *Effects of serotonin transporter inhibitors on cocaine-primed reinstatement in rhesus monkeys*  
J. C. McClung<sup>1</sup>, L. L. Howell<sup>1,2</sup>, <sup>1</sup>Yerkes National Primate Research Center, Emory University, Atlanta, GA, <sup>2</sup>Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA
- 135 *Mice that solely express non-edited 5-HT<sub>2C</sub> receptor isoform exhibit an anxiety-like phenotype*  
S. J. Stutz<sup>1,2</sup>, N. C. Anastasio<sup>1,2</sup>, M. V. Morabito<sup>4,5</sup>, C. M. Hernandez<sup>3</sup>, K. T. Dineley<sup>1,3</sup>, R. B. Emeson<sup>4,5</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Center for Addiction Research, <sup>2</sup>Pharmacology and Toxicology, and <sup>3</sup>Neurology, University of Texas Medical Branch, Galveston, TX, <sup>4</sup>Center for Molecular Neuroscience, and <sup>5</sup>Pharmacology, Vanderbilt University, Nashville, TN
- 136 *Selective activation of the 5-HT<sub>2C</sub> receptor reduces cocaine self-administration and cue-induced reinstatement*  
R. G. Fox, S. J. Stutz, K. A. Cunningham, Center for Addiction Research, Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX
- 137 *DAT blocker/SERT substrates: Compounds with hybrid transporter activity*  
B. Blough<sup>1</sup>, A. Landavazo<sup>1</sup>, J. S. Partilla<sup>2</sup>, F. I. Carroll<sup>1</sup>, R. B. Rothman<sup>2</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>Clinical Psychopharmacology, IRP, NIDA, Baltimore, MD

### OPIOIDS: ANIMAL STUDIES

- 138 *Relative expression of the five somatostatin receptors mRNA in the caudate putamen of C57BL/6J and 129P3/J mice: Strain and heroin effects*  
J. Cassin, S. D. Schlussman, Y. Zhang, O. Levrán, A. Ho, M. J. Kreek, The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY
- 139 *Role of ventral medial prefrontal cortex in context-induced reinstatement of heroin seeking*  
A. Stern, J. M. Bossert, Y. Shaham, Behavioral Neuroscience, National Institute on Drug Abuse, Baltimore, MD
- 140 *Effects of preweanling, preadolescent, and adolescent methylphenidate treatment on morphine-induced conditioned place preference*  
T. S. Der-Ghazarian, C. E. Britt, F. A. Varela, A. J. Roper, C. A. Crawford, Psychology, California State University, San Bernardino, San Bernardino, CA
- 141 *Is dopaminergic neuron projecting from the ventral tegmental area to the cingulate cortex critical for the morphine-induced rewarding effect?*  
K. Nakahara, M. Narita, Y. Matsushima, M. Narita, S. Takagi, K. Niikura, S. Imai, N. Kuzumaki, T. Suzuki, Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan
- 142 *Anabolic-androgenic steroid effects on acute and chronic nociception and morphine antinociception*  
K. Tsutsui, R. M. Craft, Psychology, Washington State University, Pullman, WA

- 143 *Effects of voluntary exercise on morphine antinociception and withdrawal*  
R. E. Balter<sup>1</sup>, K. T. Schmidt<sup>2</sup>, L. A. Dykstra<sup>1,2</sup>, <sup>1</sup>Neurobiology, and <sup>2</sup>Psychology, University of North Carolina, Chapel Hill, NC
- 144 *CXCR4 involvement in the gp120 antagonism of the antinociception induced by opioids in the cold water tail-flick test*  
X. Chen, J. Palma, E. B. Geller, T. K. Eisenstein, M. W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 145 *Functional interaction between SDF-1alpha in the brain and opioid medications*  
K. Benamar, A. Cowan, E. B. Geller, M. W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 146 *Evaluation of morphine and chlordiazepoxide withdrawal with telemetry*  
T. Wolinsky, P. Moser, O. Pouessel, S. Rompion, V. Castagne, C. Froger-Colleaux, Porsolt and Partners Pharmacology, Boulogne-Billancourt, France
- 147 *Socially-induced morphine pseudo-sensitization in adolescent mice*  
S. Eitan<sup>1</sup>, R. S. Hofford<sup>1</sup>, K. W. Roberts<sup>2</sup>, P. J. Wellman<sup>1</sup>, <sup>1</sup>Psychology, Texas A&M University, College Station, TX, <sup>2</sup>Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA

### Symposium XIV

**Salons HI**  
**2:00 - 4:00 PM**

#### NOVEL KAPPA OPIOIDS: FROM DESIGN TO FUNCTION

Chairs: Ellen Unterwald and Eduardo Butelman

- 2:00 *Peptide kappa opioid receptor ligands - potential for drug development*  
Jane Aldrich, University of Kansas, Kansas City, KS
- 2:25 *Kappa-opioid mediation of stress-induced behaviors*  
Jay McLaughlin, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL
- 2:50 *Regulation of trafficking of the kappa opioid receptor along the export pathway*  
Lee-Yuan Liu Chen, Pharmacology, Temple University School of Medicine, Philadelphia, PA
- 3:15 *Beyond morphine: Salvia divinorum and the quest for novel kappa opioids*  
Thomas E. Prisinzano, Medicinal Chemistry, University of Kansas, Kansas City, KS
- 3:40 *Salvinorin A and its analogs: Effects in translational animal models*  
Eduardo Butelman, The Rockefeller University, New York, NY

### Oral Communications 14

**Salon DE**  
**2:00 - 4:00 PM**

#### HATE TO WAIT: DRUGS AND IMPULSIVITY

Chairs: Justin J. Anker and Lawrence P. Carter

- 2:00 *Impulsivity + craving = drug use?*  
D. Tziortzis, J. J. Mahoney, A. D. Kalechstein, T. F. Newton, R. De La Garza, II, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX
- 2:15 *Substance use disorder risk and inhibitory control on an anti-saccade task*  
E. Long, D. L. Thatcher, B. Luna, C. F. Geier, D. B. Clark, Psychiatry, University of Pittsburgh, Pittsburgh, PA



- 2:30 *Validity of a behavioral task of negative reinforcement underlying risky alcohol use*  
N. T. Calvin, C. W. Lejuez, L. MacPherson, Psychology, University of Maryland, College Park, MD
- 2:45 *Interactions between delay discounting and DRD4 genotype on smoking following a treatment intervention*  
L. P. Carter<sup>1</sup>, R. D. Landes<sup>2</sup>, C. E. Sheffer<sup>3</sup>, L. C. Jackson<sup>1</sup>, D. Christensen<sup>1</sup>, M. L. Stitzer<sup>6,1</sup>, J. MacKillop<sup>4</sup>, J. E. McGeary<sup>5</sup>, B. A. Jones<sup>1</sup>, R. Yi<sup>1</sup>, W. K. Bickel<sup>1,3</sup>, <sup>1</sup>Psychiatry, <sup>2</sup>Biostatistics, and <sup>3</sup>Health Behavior and Health Education, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>4</sup>Psychology, University of Georgia Athens, Athens, GA, <sup>5</sup>Psychiatry, Brown University, Providence, RI, <sup>6</sup>Psychiatry, Johns Hopkins University, Baltimore, MD
- 3:00 *Drug abuse, posttraumatic stress, and impulsivity in women*  
A. E. Waldrop<sup>1,2</sup>, J. Coetzee<sup>1</sup>, S. L. Batki<sup>1,2</sup>, <sup>1</sup>University of California, San Francisco, San Francisco, CA, <sup>2</sup>San Francisco VAMC, San Francisco, CA
- 3:15 *Are adolescents gambling with cannabis use? A longitudinal study of observed and reported impulsivity measures in relation to adolescent substance use. The TRAILS Study*  
A. Prince van Leeuwen<sup>1,2</sup>, H. E. Creemers<sup>2</sup>, F. C. Verhulst<sup>2</sup>, J. Ormel<sup>3,4</sup>, A. C. Huizink<sup>1,2</sup>, <sup>1</sup>University of Amsterdam, Amsterdam, Netherlands, <sup>2</sup>Erasmus University Medical Center Sophia Children's Hospital, Rotterdam, Netherlands, <sup>3</sup>University Medical Center Groningen and University of Groningen, Groningen, Netherlands, <sup>4</sup>Graduate School for Experimental Psychopathology, Groningen, Netherlands
- 3:30 *An animal model of negative urgency and the effect of d-amphetamine on behavioral outcomes of unexpected nonreward*  
C. Gipson, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY
- 3:45 *Stimulant-seeking behavior in adolescent vs. adult rats*  
J. J. Anker, M. E. Carroll, University of Minnesota, Minneapolis, MN

## Oral Communications 15

Salon FG  
2:00 - 4:00 PM

### GENDER DIFFERENCES IN DRUG USE

Chairs: Leila Z. Islam and Karen Cropsey

- 2:00 *He said, she said: Gender differences in lifetime NMUPD dependence rates in two epidemiological samples*  
L. Islam, D. Svikis, L. Keyser-Marcus, R. Pickens, Virginia Commonwealth University, Richmond, VA
- 2:15 *Gender differences in presenting characteristics and severity of substance use among individuals with prescription opioid dependence*  
E. Hartwell, K. Lawson, L. Singleton, S. Back, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, NC
- 2:30 *Male-female differences in the estimated influence of caregiver, sibling, and peer smoking on the first chance to try tobacco during the pre-adolescent years*  
V. H. Accornero<sup>1</sup>, J. C. Anthony<sup>2</sup>, L. Xue<sup>1</sup>, C. B. McCoy<sup>3</sup>, E. S. Bandstra<sup>1</sup>, <sup>1</sup>Pediatrics, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Epidemiology, Michigan State University School of Human Medicine, East Lansing, MI, <sup>3</sup>Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, FL



- 2:45 *Male-female and age-of-onset variations in risk of clinical features associated with cocaine dependence*  
E. M. Meyer<sup>1</sup>, B. K. Ahmedani<sup>2,1</sup>, O. A. Adelaja<sup>1</sup>, J. C. Anthony<sup>1</sup>, <sup>1</sup>Epidemiology, and <sup>2</sup>School of Social Work, Michigan State University, East Lansing, MI
- 3:00 *A qualitative analysis of women's experiences in empirically supported single-gender vs. mixed-gender substance abuse group therapy*  
S. F. Greenfield<sup>1,2</sup>, A. M. Cummings<sup>1</sup>, L. A. Kuper<sup>1</sup>, M. Koro-Ljungberg<sup>3</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>University of Florida, Gainesville, FL
- 3:15 *Progesterone in cocaine abuse: Gender differences*  
S. Specker<sup>1</sup>, J. Whelan<sup>1</sup>, R. Crosby<sup>2</sup>, S. Collum<sup>1</sup>, <sup>1</sup>University of Minnesota, Minneapolis, MN, <sup>2</sup>Neuropsychological Research Institute, Grand Forks, ND
- 3:30 *Methadone maintenance treatment for probationers: Predictors and outcomes*  
J. Gryczynski, S. M. Kelly, T. W. Kinlock, M. Gordon, K. E. O'Grady, R. P. Schwartz, Social Research Center, Friends Research Institute, Baltimore, MD
- 3:45 *Results of a pilot RCT of buprenorphine for women in the criminal justice system: Preliminary analyses*  
K. Cropsey, G. Hale, D. Jackson, S. Jones-Whaley, A. Perkins, P. Lane, Psychiatry, University of Alabama at Birmingham, Birmingham, AL

## Oral Communications 16

Salons ABC  
2:00 - 4:00 PM

### TRANSMITTING INFORMATION ON SEROTONIN

Chairs: Gregory Miller and Ronald Cowan

- 2:00 *Altered serotonin 1A receptor system is related to the increased cocaine intake with extended access in rats*  
S. Wee, G. F. Koob, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA
- 2:15 *Elevated expression of 5-HT1B receptors in the mesolimbic pathway enhances the reinforcing effects of cocaine using the self-administration model in rats*  
N. S. Pentkowski<sup>1</sup>, T. H. Cheung<sup>1</sup>, W. A. Toy<sup>1</sup>, S. Liu<sup>1</sup>, J. F. Neumaier<sup>2</sup>, J. L. Neisewander<sup>1</sup>, <sup>1</sup>Psychology, Arizona State University, Tempe, AZ, <sup>2</sup>Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA
- 2:30 *Non-human primate genetic models of serotonergic dysfunction in addiction*  
E. J. Vallender, G. L. Chen, G. M. Miller, Harvard Medical School, New England Primate Research Center, Southborough, MA
- 2:45 *Effects of alcohol on serotonin receptors and histone deacetylase 2*  
M. Agudelo, Z. Saiyed, N. Gandhi, T. Samikkannu, P. Khatavkar, M. Nair, Florida International University, Miami, FL
- 3:00 *MDMA and related analogs increase plasma serotonin in rats*  
M. H. Baumann<sup>1</sup>, R. B. Rothman<sup>1</sup>, R. de la Torre<sup>2</sup>, S. Yubero<sup>2</sup>, <sup>1</sup>Clinical Psychopharmacology Section, NIH/NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>Pharmacology Research Program, Hospital del Mar, IMIM, Barcelona, Spain
- 3:15 *MDMA-induced feelings of sociability in humans may have a serotonergic mechanism*  
K. J. Garrison, M. J. Baggott, J. R. Coyle, E. K. Flower, G. P. Galloway, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA

---

## Wednesday, June 16, 2010

---

3:30 *Human MDMA use is associated with chronic alterations in cerebellar activation during a motor task: An fMRI study*

J. Karageorgiou, M. S. Dietrich, R. Cowan, Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN

3:45 *Antidepressant-like effects of ecstasy*

I. Majumder, R. J. Irvine, J. M. White, Pharmacology, The University of Adelaide, Adelaide, SA, Australia

**CPDD BUSINESS MEETING**  
**(Members Only)**

**Salons HI**  
**4:15 - 5:15 PM**

**DINNER AND DANCING**

**Ballroom Foyer**  
**7:30 - 9:30 PM**

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

## Poster Session IV (Breakfast)

Pavilion  
8:00 - 10:00 AM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Wednesday no earlier than 3:00 PM  
Must be removed by Thursday no later than 11:00 AM

### SEX/GENDER DIFFERENCES

- 1 *Characterization of users in a population of drug addicts*  
H. Geniaux<sup>1,2</sup>, F. Haramburu<sup>1</sup>, A. Umbricht<sup>2</sup>, A. Cadet-Taïrou<sup>3</sup>, <sup>1</sup>Département de Pharmacologie, Université Victor Segalen, CHU, Bordeaux, France, <sup>2</sup>The Johns Hopkins University School of Medicine, Behavioral Pharmacology Research Unit, Baltimore, MD, <sup>3</sup>Observatoire Français des Drogues et Toxicomanies (OFDT), Paris, France
- 2 *Distress tolerance and adolescent substance use problem severity*  
S. B. Daughters<sup>1</sup>, S. M. Gorka<sup>1,2</sup>, C. W. Lejuez<sup>2</sup>, R. M. Travers<sup>2</sup>, J. Leonard<sup>1</sup>, K. Smith<sup>2</sup>, <sup>1</sup>Public and Community Health, and <sup>2</sup>Psychology, University of Maryland, College Park, MD
- 3 *Sex differences in the relations between youth psychopathology and substance use*  
A. Goldweber, R. Evans, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 4 *Hispanic parenting women in women-only vs. mixed-gender drug treatment*  
Y. I. Hser, Y. J. Chang, E. Evans, N. Messina, Integrated Substance Abuse Programs, University of California, Los Angeles, CA
- 5 *Gender differences among urban American Indians in substance abuse treatment*  
S. E. Spear, D. Crevecœur-MacPhail, L. Ransom, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA
- 6 *Effectiveness of a mass mail-out distribution of nicotine replacement therapy to smokers in Ontario, Canada: Gender differences in cessation and relapse rates*  
P. Selby<sup>1,2,4</sup>, S. Voci<sup>1</sup>, S. Hussain<sup>1</sup>, L. Zawertailo<sup>1,3</sup>, <sup>1</sup>Addictions Program, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Family and Community Medicine, <sup>3</sup>Pharmacology and Toxicology, and <sup>4</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 7 *Comparative findings on sugar dependence between obese and substance dependence male and female subjects*  
M. C. Rosa<sup>1,2</sup>, C. Gomes<sup>3</sup>, S. Slavutzky<sup>4</sup>, F. Kessler<sup>2</sup>, E. Ferreira<sup>1</sup>, F. Pechansky<sup>2</sup>, <sup>1</sup>Social and Preventive Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil, <sup>2</sup>Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>3</sup>Psychology, Federal University of Minas Gerais, Belo Horizonte, Brazil, <sup>4</sup>Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 8 *Gender differences in treatment-seeking prescription opioid abusers*  
K. A. Saulsgiver, S. C. Sigmon, K. E. Dunn, M. Patrick, S. T. Higgins, Psychiatry, University of Vermont, Burlington, VT
- 9 *Gender differences in acceptability of a therapeutic telephone system in primary-care buprenorphine maintenance*  
T. L. Fazzino<sup>2</sup>, B. A. Moore<sup>1,2</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>APT Foundation, New Haven, CT

- 10 *Examining gender differences in substance use and age of first use among rural Appalachian drug users in Kentucky*  
L. M. Shannon, J. R. Havens, C. Oser, R. Crosby, C. Leukefeld, University of Kentucky, Lexington, KY
- 11 *The relationship between gender and psychotic symptoms in cocaine- and methamphetamine-dependent volunteers*  
R. Y. Hawkins, J. J. Mahoney, A. D. Kalechstein, R. De La Garza, II, T. F. Newton, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX
- 12 *Sex differences in the influence of neglect on total intracranial white matter in high-risk adolescents*  
R. Blanton, L. Mayes, M. Potenza, R. Sinha, Yale University, New Haven, CT
- 13 *Cocaine induces sex differences in PKA phosphorylation substrates, but not ERK phosphorylation*  
V. Quinones-Jenab, W. L. Sun, L. Zhou, A. Nazarian, S. Jenab, Psychology, Hunter College of CUNY, New York, NY
- 14 *Estradiol and progesterone differentially alter cocaine-induced responses in dopamine- PKA mediated intracellular pathway in the nucleus accumbens*  
J. Weiner, E. Ramirez, W. L. Sun, L. Zhou, S. Jenab, V. Quinones-Jenab, Psychology, Hunter College of CUNY, New York, NY
- 15 *Effect of cocaine dose and sex in selecting between food and cocaine*  
K. A. Kerstetter<sup>1</sup>, M. Ballis<sup>1</sup>, S. M. Duffin-Lutgen<sup>1</sup>, T. E. Kippin<sup>1,2</sup>, <sup>1</sup>Psychology, University of California Santa Barbara, Goleta, CA, <sup>2</sup>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA
- 16 *Effect of dopamine D1 receptor blockade in the nucleus accumbens on motivation for cocaine: Role of sex and stage of addiction*  
S. E. Doyle, C. King, C. Ramoa, W. J. Lynch, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA
- 17 *Sexually dimorphic pattern of striatal PKA signaling responses may mediate cocaine-induced sensitization and tolerance*  
L. Zhou, W. L. Sun, K. Weierstall, A. C. Minerly, J. Weiner, S. Jenab, V. Quinones-Jenab, Psychology, Hunter College of CUNY, New York, NY

**STRESS**

- 18 *Kappa opioid mediation of stress-induced behaviors*  
J. P. McLaughlin, Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL
- 19 *Sex influences on alterations in immune function and levels of the stress-protective hormone DHEAS in cocaine-dependent individuals*  
C. D'Sa<sup>1</sup>, H. C. Fox<sup>1</sup>, A. Kong<sup>1</sup>, R. Stowe<sup>2</sup>, R. Sinha<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Microgen Laboratories, Houston, TX
- 20 *Stress-induced changes in mood and cortisol release predict stimulant effects of amphetamine*  
A. Hamidovic<sup>1</sup>, E. Childs<sup>2</sup>, M. Conrad<sup>2</sup>, A. King<sup>2</sup>, H. de Wit<sup>2</sup>, <sup>1</sup>Preventive Medicine, Northwestern University, Chicago, IL, <sup>2</sup>Psychiatry, The University of Chicago, Chicago, IL
- 21 *A zero-inflated hidden Markov model of cocaine using behavior*  
S. DeSantis<sup>1</sup>, D. Bandyopadhyay<sup>1</sup>, S. E. Back<sup>2</sup>, K. T. Brady<sup>2</sup>, <sup>1</sup>Biostatistics, MUSC, Charleston, SC, <sup>2</sup>Psychiatry, Medical University of South Carolina, Charleston, SC
- 22 *Physiological stress profile by different types of stress exposures in young, low-income women*  
H. Wu<sup>1</sup>, L. Divine<sup>1</sup>, J. Grady<sup>1</sup>, R. Sinha<sup>2</sup>, <sup>1</sup>University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Yale University, New Haven, CT

- 23 *Gender disparity in the association between stress and addictive behaviors*  
G. P. Lee<sup>1</sup>, C. L. Storr<sup>2,1</sup>, S. S. Martins<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Family and Community Health, University of Maryland School of Nursing, Baltimore, MD
- 24 *Emotional and physiological response to stress and substance use in adolescents*  
T. Chaplin<sup>1</sup>, R. Sinha<sup>1</sup>, L. C. Mayes<sup>2</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Yale Child Study Center, Yale University School of Medicine, New Haven, CT
- 25 *Marijuana and cocaine users differ in responses to a social stressor*  
G. Bedi<sup>1,2</sup>, S. C. Reed<sup>1,2</sup>, S. M. Evans<sup>1,2</sup>, M. Haney<sup>1,2</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>Substance Abuse, New York State Psychiatric Institute, New York, NY

### POLYDRUGS II

- 26 *Mindfulness training and stress reactivity in substance abuse: Results from a randomized, controlled stage I pilot study*  
J. Brewer, R. Sinha, J. Chen, R. Michalsen, T. Babuscio, C. Nich, A. Greer, K. Bergquist, D. Reis, M. Potenza, K. Carroll, B. Rounsaville, Psychiatry, Yale University School of Medicine, West Haven, CT
- 27 *Is exposure therapy for posttraumatic stress disorder efficacious among people with substance use disorders? Results from a randomised controlled trial*  
K. L. Mills<sup>1</sup>, M. Teesson<sup>1</sup>, E. Barrett<sup>1</sup>, S. Merz<sup>1</sup>, J. Rosenfeld<sup>1</sup>, P. Farrugia<sup>1</sup>, C. Sannibale<sup>1</sup>, S. Hopwood<sup>2</sup>, A. Baker<sup>3</sup>, S. Back<sup>4</sup>, K. Brady<sup>4</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Centre for Traumatic Stress, Westmead Hospital, Sydney, NSW, Australia, <sup>3</sup>Centre for Brain and Mental Health Research, University of Newcastle, Newcastle, NSW, Australia, <sup>4</sup>Psychiatry, Medical University of South Carolina, Charleston, SC
- 28 *Predictors of family reunification and child maltreatment recurrence among substance abusing families*  
M. S. Shafer<sup>1,2</sup>, L. Williams<sup>2,1</sup>, B. Carlson<sup>2,1</sup>, R. Rivera<sup>1</sup>, <sup>1</sup>Center for Applied Behavioral Health Policy, and <sup>2</sup>School of Social Work, Arizona State University, Phoenix, AZ
- 29 *Maltreatment and early substance use*  
C. Larkby<sup>1</sup>, S. L. Leech<sup>2</sup>, M. D. Cornelius<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA
- 30 *Offspring early substance use and risks from parental drug problems and parental separation*  
M. Waldron<sup>1,2</sup>, A. C. Heath<sup>2</sup>, <sup>1</sup>Counseling and Educational Psychology, Indiana University, Bloomington, IN, <sup>2</sup>Psychiatry, Washington University School of Medicine, St Louis, MO
- 31 *Predicting and explaining multiple and simultaneous intimate relationships among African Americans in distressed households in New York City*  
V. Murugan<sup>1</sup>, L. C. Windsor<sup>1</sup>, E. Benoit<sup>2</sup>, E. Dunlap<sup>2</sup>, <sup>1</sup>School of Social Work, Rutgers: The State University of New Jersey, New Brunswick, NJ, <sup>2</sup>National Development and Research Institute, New York, NY
- 32 *Drug use and help-seeking behaviors among male and female victims of intimate partner violence*  
S. M. Resko<sup>1</sup>, K. Lacey<sup>2</sup>, <sup>1</sup>Social Work and Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, <sup>2</sup>Research Center for Group Dynamics, University of Michigan, Ann Arbor, MI



- 33 *Differences in risky behaviors and male partner characteristics as an explanation for race disparities in STIs*  
L. Floyd, T. Penniman, A. Lawson, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 34 *Is recent monogamy or being in a committed relationship a marker for low sexual risk in men in substance abuse treatment?*  
D. A. Calsyn<sup>1</sup>, S. Tross<sup>2,3</sup>, M. A. Hatch-Maillette<sup>1</sup>, A. N. Campbell<sup>2</sup>, <sup>1</sup>Alcohol and Drug Abuse Institute/Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, <sup>2</sup>Substance Abuse Division, New York State Psychiatric Institute, New York, NY, <sup>3</sup>Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY
- 35 *WITHDRAWN*
- 36 *Receipt of continuing care by parenting women*  
E. Evans, D. Huang, Y. Chang, Y. Hser, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 37 *Propensity to work among chronically unemployed adult drug users*  
S. O. Sigurdsson<sup>1,2</sup>, A. DeFulio<sup>2</sup>, K. Silverman<sup>2</sup>, <sup>1</sup>Psychology, University of Maryland, Baltimore County, Baltimore, MD, <sup>2</sup>School of Medicine, Johns Hopkins University, Baltimore, MD
- 38 *Patient and staff perspectives on managing addiction as a chronic disease*  
R. G. Carlson<sup>1</sup>, G. S. Brigham<sup>2</sup>, L. Hammar<sup>1</sup>, R. Falck<sup>1</sup>, <sup>1</sup>Wright State University Boonshoft School of Medicine, Dayton, OH, <sup>2</sup>Maryhaven, Columbus, OH
- 39 *Perceptions of impaired health professionals regarding participation in a state monitoring program*  
L. J. Merlo<sup>1,2</sup>, S. M. Cummings<sup>2</sup>, L. B. Cottler<sup>2</sup>, <sup>1</sup>Psychiatry, University of Florida, Gainesville, FL, <sup>2</sup>Psychiatry, Washington University, St. Louis, MO
- 40 *Psychosocial and substance use severity in unemployed patients enrolled in methadone maintenance and psychosocial abstinence-based programs*  
R. Pickens, L. A. Keyser-Marcus, A. Sepulveda, N. Snead, D. Svikis, Psychiatry, Virginia Commonwealth University, Richmond, VA
- 41 *French survey about students' health in 5 university Health and Prevention Centers*  
P. Courty<sup>1,2</sup>, G. Illes<sup>2</sup>, C. Auclair<sup>3</sup>, A. Perreve<sup>2</sup>, M. Argillet<sup>4</sup>, B. Poizat<sup>5</sup>, M. Zorman<sup>6</sup>, S. Blondel<sup>7</sup>, L. Gerbaud<sup>2,3</sup>, <sup>1</sup>CMP B, CSST SATIS, Clermont Ferrand cedex 1, France, <sup>2</sup>University Health and Prevention Center, CLERMONT FERRAND, France, <sup>3</sup>Epidemiology and Public Health, University Hospital Clermont Ferrand, CLERMONT FERRAND, France, <sup>4</sup>University Health and Prevention Center, SAVOIE, France, <sup>5</sup>University Health and Prevention Center, Saint Etienne, France, <sup>6</sup>University Health and Prevention Center, Grenoble, France, <sup>7</sup>University Health and Prevention Center, Lyon, France
- 42 *Computer-based identification of substance use in primary care patients*  
L. Hull<sup>1</sup>, P. Dillon<sup>1</sup>, L. Thacker<sup>1</sup>, D. Svikis<sup>1</sup>, S. Ondersma<sup>2</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Psychology and Behavior Neuroscience/OBYGN, Wayne State University School of Medicine, Detroit, MI
- 43 *Acceptability of a guided computerized health screening in primary care*  
T. B. Moore, D. Svikis, Virginia Commonwealth University, Richmond, VA



- 44 *A comparison of two methods of technology transfer for substance abuse clinicians*  
C. Barrick<sup>1</sup>, G. G. Homish<sup>2,1</sup>, <sup>1</sup>Research Institute on Addictions, University at Buffalo, Buffalo, NY, <sup>2</sup>Health Behavior, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY

### DRUG INTERACTIONS

- 45 *Effects of repeated disulfiram administration on the behavioral-stimulant effects of cocaine in squirrel monkeys*  
H. L. Kimmel<sup>1,2</sup>, D. F. Manvich<sup>2</sup>, M. Zhou<sup>2</sup>, J. H. Rose<sup>2</sup>, L. L. Howell<sup>1,2,3</sup>, <sup>1</sup>Pharmacology, Emory University School of Medicine, Atlanta, GA, <sup>2</sup>Division of Neuroscience, Yerkes National Primate Research Center, Emory University, Atlanta, GA, <sup>3</sup>Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA
- 46 *Reinforcing effects of nicotine and cocaine combinations in rhesus monkeys*  
J. Newman, N. K. Mello, Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA
- 47 *Concurrent nicotine and methamphetamine dependence – Why use both?*  
S. Raju, R. De La Garza, II, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX
- 48 *Discriminative-stimulus effects of methamphetamine in humans: Effects of acute d-amphetamine and bupropion pretreatment*  
A. R. Vansickel<sup>1,3,4</sup>, W. W. Stoops<sup>3</sup>, M. M. Poole<sup>3,4</sup>, C. R. Rush<sup>2,3,4</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Psychiatry, <sup>3</sup>Behavioral Science, and <sup>4</sup>Psychology, University of Kentucky, Lexington, KY
- 49 *Nicotine-dependent vs. non-dependent methadone-maintained smokers*  
G. Bart<sup>1,2</sup>, C. Nolan<sup>1</sup>, G. Carlson<sup>1</sup>, <sup>1</sup>Medicine, Hennepin County Medical Center, Minneapolis, MN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN
- 50 *Interaction between alcohol and opioids in opioid-dependent human subjects*  
R. Lees<sup>1</sup>, T. Williams<sup>1</sup>, S. Barford-Turner<sup>1</sup>, A. Pickering<sup>1</sup>, A. Kendrick<sup>2</sup>, C. Waygood<sup>2</sup>, G. Henderson<sup>1</sup>, M. Hickman<sup>1</sup>, A. Lingford-Hughes<sup>1</sup>, <sup>1</sup>Psychopharmacology Unit, University of Bristol, Bristol, UK, <sup>2</sup>Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK
- 51 *Efficacy of gabapentin in subjects with concurrent alcohol and cannabis dependence*  
A. E. Higley, V. Goodell, B. J. Mason, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, San Diego, CA
- 52 *Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence*  
P. K. Henry, B. A. Kleykamp, E. L. Winstanley, E. C. Strain, G. E. Bigelow, A. Umbricht, M. Z. Mintzer, Johns Hopkins University, Baltimore, MD
- 53 *The safety and efficacy of varenicline in cocaine-using smokers maintained on methadone: A pilot study*  
J. Poling<sup>1,2</sup>, B. Rounsaville<sup>1,2</sup>, K. Gonsai<sup>2,1</sup>, K. Severino<sup>2,1</sup>, M. Sofuoglu<sup>1,2</sup>, <sup>1</sup>Psychiatry, Yale University, West Haven, CT, <sup>2</sup>VA Connecticut Healthcare System, West Haven, CT
- 54 *Levetiracetam treatment for cocaine-dependent methadone-maintained patients*  
G. Gonzalez<sup>1</sup>, M. Romero-Gonzalez<sup>2</sup>, G. DiGirolamo<sup>3</sup>, R. Desai<sup>4</sup>, I. Petrakis<sup>4</sup>, D. Smelson<sup>1</sup>, M. Randall<sup>5</sup>, <sup>1</sup>Psychiatry, University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>MAYU of New England, New Haven, CT, <sup>3</sup>Psychology, College of Holy Cross, Worcester, MA, <sup>4</sup>Psychiatry, Yale University, New Haven, CT, <sup>5</sup>Brien Center, Pittsfield, MA

### OPIOIDS: HUMAN II

- 55 *Comparison of baseline and in-treatment measures of motivation and distress in predicting treatment retention*  
E. Gurling<sup>1</sup>, B. Brown<sup>2</sup>, R. Schwartz<sup>3</sup>, K. O'Grady<sup>4</sup>, E. C. Katz<sup>3,1</sup>, <sup>1</sup>Psychology, Towson University, Towson, MD, <sup>2</sup>University of North Carolina, Wilmington, NC, <sup>3</sup>Friends Research Institute, Baltimore, MD, <sup>4</sup>University of Maryland, College Park, MD
- 56 *Clinical efficacy of residential abstinence-based detoxification program in heroin dependence*  
H. Ekhtiari<sup>1</sup>, P. Hasani Abharian<sup>1,3</sup>, Z. Alam Mehrjerdi<sup>1</sup>, A. Deilamizadeh<sup>4</sup>, A. Mokri<sup>2</sup>, <sup>1</sup>Neurocognitive, Iranian National Center for Addiction Studies, <sup>2</sup>Clinical, Iranian National Center for Addiction Studies, <sup>3</sup>Institute for Cognitive Sciences Studies, and <sup>4</sup>Rebirth Addiction Treatment NGO, Tehran, Islamic Republic of Iran
- 57 *Racial/ethnic differences in recent drug detoxification enrollment and the association between discrimination and neighborhood factors in New York City drug-users*  
N. D. Crawford<sup>1,2</sup>, K. Jones<sup>1</sup>, C. Fuller<sup>1,2</sup>, <sup>1</sup>New York Academy of Medicine, New York, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY
- 58 *Delay discounting predicts voucher redemption among participants in a contingency management program*  
B. A. Jones<sup>1</sup>, R. D. Landes<sup>2</sup>, D. R. Christensen<sup>1</sup>, M. Mancino<sup>1</sup>, W. K. Bickel<sup>1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
- 59 *Promoting the use of depot naltrexone with an employment-based contingency management intervention*  
A. DeFulio, J. J. Everly, A. Umbricht, M. Fingerhood, G. E. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD
- 60 *Employment-based reinforcement of oral naltrexone compliance within unemployed injection drug users*  
K. E. Dunn, A. DeFulio, J. Everly, W. Donlin, A. Umbricht, M. Fingerhood, G. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD
- 61 *Opioids, chronic pain, and addiction in primary care*  
D. Barry<sup>1</sup>, K. S. Irwin<sup>2</sup>, W. C. Becker<sup>1</sup>, J. M. Tetrault<sup>1</sup>, L. E. Sullivan<sup>1</sup>, H. Hansen<sup>3</sup>, P. G. O'Connor<sup>1</sup>, R. S. Schottenfeld<sup>1</sup>, D. A. Fiellin<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Tufts University, Medford, MA, <sup>3</sup>NYU School of Medicine, New York, NY
- 62 *Probing acute opioid effects in bipolar disorder*  
B. Sproule<sup>1,2</sup>, J. Mascarenhas<sup>1</sup>, S. Manuel<sup>1</sup>, B. Brands<sup>3,1,2</sup>, U. Busto<sup>1,2</sup>, A. Ravindran<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Health Canada, Ottawa, ON, Canada
- 63 *Route of administration patterns across extended release prescription opioid products*  
S. F. Butler, T. A. Cassidy, S. H. Budman, Inflexxion, Inc., Newton, MA
- 64 *Associations between implicit and explicit drug-related cognitions and relapse: An ecological momentary assessment study*  
R. Marhe<sup>1</sup>, I. Franken<sup>1</sup>, A. J. Waters<sup>2</sup>, <sup>1</sup>Psychology, Erasmus University, Rotterdam, Netherlands, <sup>2</sup>Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD

### PRESCRIPTION DRUG ABUSE

- 65 *Chewing then swallowing in self-reported non-medical opioid use by college students as reported by the Researched Abuse, Diversion and Addiction-Related Surveillance System*  
C. Buchholtz<sup>1</sup>, L. Reifler<sup>1</sup>, J. E. Bailey<sup>1</sup>, R. Dart<sup>1,2</sup>, <sup>1</sup>Rocky Mountain Poison and Drug Center, Denver, CO, <sup>2</sup>University of Colorado Denver School of Medicine, Denver, CO

- 66 *Non-fatal overdose among people who abuse prescription opioids*  
T. C. Green<sup>1</sup>, T. A. Cassidy<sup>2</sup>, S. H. Budman<sup>2</sup>, S. F. Butler<sup>2</sup>, <sup>1</sup>Brown Medical School, Providence, RI, <sup>2</sup>Inflexxion, Inc., Newton, MA
- 67 *Internet-based post-marketing surveillance of newly marketed opioid analgesics*  
J. S. Brownstein, E. McNaughton, T. A. Cassidy, S. H. Budman, S. F. Butler, Inflexxion, Inc., Newton, MA
- 68 *Prescription drug misuse in an urban primary care clinic*  
M. F. Weaver, L. Thacker, P. Dillon, D. Svikis, Virginia Commonwealth University, Richmond, VA
- 69 *How accurate are estimates of community abuse made by local key informants?*  
S. H. Budman, T. A. Cassidy, K. Lioy, S. F. Butler, Inflexxion, Inc., Newton, MA
- 70 *Differences between treatment-seeking prescription opioid and heroin users in Australia*  
S. Nielsen<sup>1</sup>, R. Bruno<sup>2</sup>, M. Stooze<sup>3</sup>, N. Lintzeris<sup>4,5</sup>, <sup>1</sup>Turning Point Alcohol and Drug Centre, Fitzroy, VIC, Australia, <sup>2</sup>University of Tasmania, Hobart, TAS, Australia, <sup>3</sup>Burnett Institute, Melbourne, VIC, Australia, <sup>4</sup>Sydney South West Area Health Service, Sydney, NSW, Australia, <sup>5</sup>University of Sydney, Sydney, NSW, Australia
- 71 *Prescription opioid use and harms in Australia: A review of national data collections*  
A. Roxburgh<sup>1</sup>, B. Larance<sup>1</sup>, R. Bruno<sup>2</sup>, L. Burns<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>School of Psychology, University of Tasmania, Hobart, TAS, Australia
- 72 *Non-medical use of prescription ADHD stimulants is typically part of a pre-existing pattern of drug abuse*  
M. Ertischek<sup>1</sup>, C. T. Sweeney<sup>1</sup>, M. A. Sembower<sup>2</sup>, S. Shiffman<sup>2</sup>, S. H. Schnoll<sup>1</sup>, <sup>1</sup>Pinney Associates, Bethesda, MD, <sup>2</sup>Pinney Associates, Pittsburgh, PA
- 73 *Non-medical use of extended release prescription stimulants: An examination of amphetamine and methylphenidate*  
S. H. Schnoll<sup>1</sup>, M. A. Sembower<sup>2</sup>, S. Shiffman<sup>2</sup>, S. Varughese<sup>3</sup>, M. Ertischek<sup>1</sup>, E. St. Jean<sup>1</sup>, S. Rosen<sup>3</sup>, <sup>1</sup>Pinney Associates, Inc., Bethesda, MD, <sup>2</sup>Pinney Associates, Inc., Pittsburgh, PA, <sup>3</sup>Shire Development, Inc., Wayne, PA
- 74 *Predictors of non-medical prescription stimulant use among college students*  
S. J. Lookatch, E. C. Katz, Psychology, Towson University, Towson, MD
- 75 *Strategies that work in obtaining active consent for school-based adolescent drug studies*  
P. L. Ross-Durow<sup>1</sup>, S. E. McCabe<sup>1,2</sup>, A. M. Young<sup>1</sup>, T. Ackerson<sup>1</sup>, M. Epstein<sup>2</sup>, J. A. Cranford<sup>2</sup>, C. J. Boyd<sup>1,2</sup>, <sup>1</sup>Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI, <sup>2</sup>Substance Abuse Research Center, University of Michigan, Ann Arbor, MI
- 76 *Predictors of prescription opioid non-medical use, abuse and dependence: Findings from the National Survey on Drug Use and Health*  
S. E. Back, R. A. Payne, A. N. Simpson, K. T. Brady, Psychiatry, Medical University of South Carolina, Charleston, SC
- 77 *Data gaps regarding diversion and abuse of prescription opioid analgesics*  
W. Wakeland<sup>1</sup>, L. Lee<sup>5</sup>, D. McCarty<sup>6</sup>, J. D. Haddox<sup>2</sup>, J. Fitzgerald<sup>2</sup>, A. Gilson<sup>3</sup>, J. Homer<sup>4</sup>, L. Macovsky<sup>1</sup>, L. Webster<sup>7</sup>, <sup>1</sup>Systems Science, Portland State University, Portland, OR, <sup>2</sup>Purdue Pharma, L.P., Stamford, CT, <sup>3</sup>Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, <sup>4</sup>Homer Consulting, Voorhees, NJ, <sup>5</sup>University of California, Los Angeles, CA, <sup>6</sup>Public Health and Preventative Medicine, Oregon Health and Science University, Portland, OR, <sup>7</sup>Lifetree Clinical Research and Pain Clinic, Salt Lake City, UT

- 78 *Gender differences in motives to use and sources of prescription opioids*  
K. Lawson, L. M. Singleton, E. Hartwell, K. T. Brady, S. E. Back, Clinical Neuroscience Division, Medical University of South Carolina, Charleston, SC
- 79 *Pattern of OxyContin® use in opioid abusers experienced in tampering with the formulation: A retrospective assessment of drug administration methods from the first use to the current preferred method*  
M. Sokolowska<sup>1</sup>, S. D. Comer<sup>2</sup>, M. A. Sullivan<sup>2</sup>, J. B. Ashworth<sup>3</sup>, <sup>1</sup>Grünenthal USA, Bedminster, NJ, <sup>2</sup>New York State Psychiatric Institute, Columbia University, New York, NY, <sup>3</sup>Grünenthal GmbH, Aachen, Germany
- 80 *Comparing heroin users and prescription opioid users seeking Suboxone® treatment for opioid dependence*  
J. Fahey, M. Hillhouse, J. Jenkins, R. Rawson, W. Ling, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 81 *Prescription opioid abuse predicts first admission into methadone maintenance treatment*  
C. Cleland<sup>1</sup>, A. Rosenblum<sup>1</sup>, C. Fong<sup>1</sup>, M. Parrino<sup>2</sup>, S. Magura<sup>3</sup>, <sup>1</sup>National Development and Research Institute, New York, NY, <sup>2</sup>American Association for the Treatment of Opioid Dependence, New York, NY, <sup>3</sup>Western Michigan University, Kalamazoo, MI
- 82 *Parametric evaluation of buprenorphine taper duration for prescription opioid abuse*  
S. C. Sigmon<sup>1</sup>, K. Saulsgiver<sup>1</sup>, M. Patrick<sup>2</sup>, K. Dunn<sup>2</sup>, S. Heil<sup>1</sup>, S. Higgins<sup>1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Psychology, University of Vermont, Burlington, VT
- 83 *Abuse Deterrent Adjusted Measurement Model: Adjusting for local prescription opioid availability and local use of heroin*  
R. A. Black, S. H. Budman, T. A. Cassidy, S. F. Butler, Inflexxion, Inc., Newton, MA

### HIV/AIDS II

- 84 *Is sex trade for drugs different from sex trade for money? An examination of correlates among recent heroin- or cocaine-using women in Baltimore*  
T. V. Penniman, C. E. Cavanaugh, L. J. Floyd, W. W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 85 *The impact of homelessness on HIV risk behavior in drug-dependent pregnant women*  
Q. L. Brown, C. E. Cavanaugh, T. V. Penniman, W. W. Latimer, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD
- 86 *(Wo)man vs. machine: A comparison of a computer- vs. interviewer-directed assessment of perinatal drug use and HIV/STD risk behaviors*  
C. Smith<sup>1</sup>, D. L. Terrell<sup>1</sup>, S. J. Ondersma<sup>2</sup>, G. Villalobos<sup>1</sup>, N. Karjane<sup>1</sup>, D. S. Svikis<sup>1</sup>, <sup>1</sup>Psychology, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Psychiatry, Wayne State University, Detroit, MI
- 87 *Effect of audio computer-assisted self-interview on self-reported drug use and risky health behaviors*  
D. H. Caldwell, Friends Research Institute, Baltimore, MD
- 88 *The use of the ASSIST among HIV-positive patients on regular antiretroviral therapy in southern Brazil*  
C. Zubaran<sup>1</sup>, I. Tres<sup>2</sup>, K. Foresti<sup>2</sup>, ... UCS-UNESCO Group<sup>2</sup>, <sup>1</sup>University of Western Sydney, Sydney, NSW, Australia, <sup>2</sup>University of Caxias do Sul, Caxias do Sul, Brazil
- 89 *Technologically-enhanced intervention to reduce NIDU in HIV primary care patients*  
E. Aharonovich<sup>1</sup>, B. Johnston<sup>2</sup>, D. Hasin<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Saint Vincent's Catholic Medical Center, New York, NY



- 90 *Behavioral drug and HIV risk reduction counseling in MMT programs in Wuhan China*  
M. C. Chawarski<sup>1</sup>, W. Zhou<sup>2</sup>, P. Liu<sup>2</sup>, X. Wang<sup>2</sup>, L. Luo<sup>2</sup>, R. S. Schottenfeld<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Division of HIV/AIDS Prevention, Center for Disease Control and Prevention, Wuhan, China
- 91 *Training HIV+ drug-abstinent peers in a care linkage intervention (PEERLINK) for HIV+ substance users*  
H. Wolfe<sup>1</sup>, D. Haller<sup>1</sup>, E. Benoit<sup>1</sup>, K. Bolger<sup>1</sup>, V. Sharp<sup>1</sup>, K. Ingersoll<sup>2</sup>, <sup>1</sup>HIV Center for Comprehensive Care, St. Luke's-Roosevelt, New York, NY, <sup>2</sup>University of VA, Charlottesville, VA
- 92 *The association between individual social factors and neighborhood social context on frequent HIV testing among New York City drug users*  
C. Fuller<sup>1,2</sup>, N. D. Crawford<sup>1,2</sup>, D. Ompad<sup>1,2</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>New York Academy of Medicine, New York, NY
- 93 *Characteristics of treatment responders to a contingency management intervention for homeless, out-of-treatment, substance-abusing men who have sex with men*  
R. Dierst-Davies<sup>1</sup>, C. J. Reback<sup>1,2</sup>, J. A. Peck<sup>1,2</sup>, M. Nuno<sup>3</sup>, S. Shoptaw<sup>4</sup>, <sup>1</sup>Friends Research Institute Inc., Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse Programs, UCLA Psychiatry and Bio-Behavioral Sciences, Los Angeles, CA, <sup>3</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>4</sup>Family Medicine, UCLA School of Medicine, Los Angeles, CA
- 94 *Contingency management facilitates HIV post-exposure prophylaxis in methamphetamine-using MSM*  
R. J. Landovitz<sup>1</sup>, G. Inzhakova<sup>2</sup>, P. Ebrahimzadeh<sup>2</sup>, S. Shoptaw<sup>3</sup>, C. J. Reback<sup>2</sup>, <sup>1</sup>Center for Clinical AIDS Research and Education, UCLA, Los Angeles, CA, <sup>2</sup>Friends Research Institute, Los Angeles, CA, <sup>3</sup>Family Medicine, UCLA, Los Angeles, CA

## IMAGING II

- 95 *Altered default mode resting brain network in HIV-infected individuals*  
L. Chang<sup>1</sup>, R. Yakupov<sup>1</sup>, A. Stenger<sup>1</sup>, U. Feger<sup>1</sup>, H. Nakama<sup>2</sup>, T. Ernst<sup>1</sup>, <sup>1</sup>Medicine, and <sup>2</sup>Psychiatry, John A. Burns School of Medicine, Honolulu, HI
- 96 *Prolonged cocaine self-administration does not result in altered concentrations of dopamine D1 receptors in nonhuman primates: An autoradiographic analysis*  
H. R. Smith, T. J. Beveridge, K. E. Gill, B. H. Legg, M. A. Nader, L. J. Porrino, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC
- 97 *Cocaine rewards activate neural processing used for performance of cognitive tasks in nonhuman primates*  
S. Deadwyler, R. Hampson, J. Long, J. Noto, M. Todd, M. Miller, L. Porrino, Physiology/Pharmacology, Wake Forest University Health Sciences, Winston-Salem, NC
- 98 *Probabilistic fiber tracking of working memory pathways in cocaine-dependent subjects*  
L. Ma<sup>1</sup>, J. L. Steinberg<sup>1</sup>, K. M. Hasan<sup>2</sup>, P. A. Narayana<sup>2</sup>, L. A. Kramer<sup>2</sup>, F. G. Moeller<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, and <sup>2</sup>Diagnostic and Interventional Imaging, University of Texas Health Science Center, Houston, TX
- 99 *Addiction-associated spontaneous brain activation alterations in the resting state*  
Z. Wang, A. R. Childress, Y. Li, A. V. Hole, J. J. Suh, A. Fornash, D. Willard, R. N. Ehrman, T. Franklin, C. P. O'Brien, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 100 *The effects of ostracism on behavior and brain activity in chronic cocaine users*  
A. K. Lack, C. A. Hanlon, M. C. Torrence, M. D. Miller, L. J. Porrino, Wake Forest University School of Medicine, Winston-Salem, NC

- 101 *A whole-brain classifier approach for real-time fMRI feedback training in cocaine addiction*  
A. R. Childress<sup>1,2</sup>, J. Magland<sup>1</sup>, Z. Wang<sup>1</sup>, A. V. Hole<sup>1,2</sup>, J. J. Suh<sup>1,2</sup>, A. Fornash<sup>1,2</sup>, D. Willard<sup>1</sup>,  
R. Fabianski<sup>1</sup>, R. Carson<sup>1</sup>, R. Hazan<sup>1</sup>, R. N. Ehrman<sup>1,2</sup>, T. R. Franklin<sup>1</sup>, M. Goldman<sup>1</sup>,  
R. Szucs Reed<sup>1</sup>, C. P. O'Brien<sup>1,2</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania School of Medicine,  
Philadelphia, PA, <sup>2</sup>VA VISN 4 MIRECC, Philadelphia, PA
- 102 *FMRI of the selective adenosine A2A antagonist SYN115 in cocaine-dependent subjects*  
F. Moeller<sup>1</sup>, J. L. Steinberg<sup>1</sup>, K. L. Kjome<sup>1</sup>, S. I. Bandak<sup>2</sup>, L. Ma<sup>1</sup>, S. Liu<sup>1</sup>, N. Rathnayaka<sup>1</sup>,  
L. A. Kramer<sup>3</sup>, P. A. Narayana<sup>3</sup>, <sup>1</sup>Psychiatry, University of Texas Health Science Center at  
Houston, Houston, TX, <sup>2</sup>Synosia Therapeutics, San Francisco, CA, <sup>3</sup>Diagnostic and  
Interventional Imaging, University of Texas Health Science Center at Houston, Houston, TX
- 103 *Determining the effects of benzylpiperazine on reward pathways in comparison to  
dexamphetamine and placebo using a gambling task and functional magnetic resonance imaging*  
B. R. Russell<sup>1</sup>, N. A. McNair<sup>1</sup>, M. Kwok<sup>1</sup>, S. Gempton<sup>1</sup>, R. R. Kydd<sup>2</sup>, I. J. Kirk<sup>3</sup>, L. E. Curley<sup>1</sup>,  
<sup>1</sup>School of Pharmacy, <sup>2</sup>Psychological Medicine, and <sup>3</sup>Psychology, The University of Auckland,  
Auckland, New Zealand
- 104 *Determining the acute effects of benzylpiperazine combined with trifluoromethylphenylpiperazine  
on cognition and executive functioning using functional magnetic resonance imaging*  
R. R. Kydd<sup>1</sup>, N. A. McNair<sup>2</sup>, I. J. Kirk<sup>3</sup>, L. E. Curley<sup>2</sup>, B. R. Russell<sup>2</sup>, <sup>1</sup>Psychological Medicine,  
<sup>2</sup>School of Pharmacy, and <sup>3</sup>Psychology, The University of Auckland, Auckland, New Zealand
- 105 *Acute effects of benzylpiperazine on cognition and executive functioning using functional  
magnetic resonance imaging using the Stroop paradigm*  
L. E. Curley<sup>1</sup>, N. A. McNair<sup>1</sup>, R. R. Kydd<sup>2</sup>, I. J. Kirk<sup>3</sup>, B. R. Russell<sup>1</sup>, <sup>1</sup>School of Pharmacy,  
<sup>2</sup>Psychological Medicine, and <sup>3</sup>Psychology, The University of Auckland, Auckland, New  
Zealand
- 106 *Novelty detection and recognition memory among individuals varying in reward seeking and  
impulsivity*  
C. Kluemper, C. Black, C. Corbly, C. Benca, H. Collins, Y. Jiang, J. Joseph, T. Kelly,  
Behavioral Science, University of Kentucky, Lexington, KY
- 107 *Increased striatal activation in compulsive indoor tanners upon exposure to ultraviolet light  
compared to sham light*  
B. Adinoff<sup>1</sup>, C. R. Harrington<sup>2</sup>, T. C. Beswick<sup>2</sup>, M. Graves<sup>2</sup>, H. T. Jacobe<sup>2</sup>, M. D. Devous, Sr.<sup>3</sup>,  
T. S. Harris<sup>3</sup>, <sup>1</sup>Psychiatry, University of Texas Southwestern Medical Center and VA North  
Texas Health Care System, Dallas, TX, <sup>2</sup>Dermatology, UT Southwestern Med Ctr, Dallas, TX,  
<sup>3</sup>Radiology, University of Texas Southwestern Medical Center, Dallas, TX
- 108 *Comparison of psychosocial characteristics of subjects who volunteer for research involving  
PET scans vs. those who decline participation*  
V. Selby, R. Bausell, C. Storr, L. Oswald, University of Maryland School of Nursing,  
Baltimore, MD
- 109 *Intrasynaptic dopamine release measured by PET in alcohol-dependent subjects*  
D. Wong<sup>1</sup>, E. Weerts<sup>2</sup>, M. McCaul<sup>3</sup>, A. Kumar<sup>1</sup>, Y. Zhou<sup>1</sup>, M. Guevara<sup>1</sup>, V. Raymont<sup>1</sup>,  
H. Kuwabara<sup>1</sup>, J. Brasic<sup>1</sup>, W. Ye<sup>1</sup>, A. Nandi<sup>1</sup>, D. Jasinski<sup>4</sup>, G. Wand<sup>4</sup>, <sup>1</sup>Radiology, <sup>2</sup>Psychiatry  
and Behavioral Science, <sup>3</sup>Psychiatry, and <sup>4</sup>Medicine, Johns Hopkins University School of  
Medicine., Baltimore, MD
- 110 *Attentional control brain regions involved in attentional bias in smokers*  
M. Luijten<sup>1</sup>, D. J. Veltman<sup>2</sup>, I. H. Franken<sup>1</sup>, <sup>1</sup>Institute for Psychology, Erasmus University  
Rotterdam, Rotterdam, Netherlands, <sup>2</sup>Psychiatry, Academic Medical Centre, Amsterdam,  
Netherlands



- 111 *Varenicline's impact on BOLD fMRI activation during cue-induced craving and craving resistance in nicotine-dependent adults: Preliminary findings*  
K. Hartwell<sup>1</sup>, K. Johnson<sup>2</sup>, T. LeMatty<sup>1</sup>, H. Myrick<sup>1</sup>, M. S. George<sup>1</sup>, K. Brady<sup>1</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Stanford, Palo Alto, CA
- 112 *Brain reactivity to smoking cues is greater in smokers with an attentional bias for smoking words*  
A. C. Janes<sup>1</sup>, D. A. Pizzagalli<sup>2</sup>, S. Richardt<sup>1</sup>, B. Frederick<sup>1</sup>, A. J. Holmes<sup>2</sup>, M. Fava<sup>3</sup>, A. E. Evins<sup>3</sup>, M. J. Kaufman<sup>1</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard University, Cambridge, MA, <sup>3</sup>Massachusetts General Hospital, Boston, MA

### NICOTINE: ANIMAL

- 113 *Differential antagonism of the behavioral effects of nicotine, varenicline, and cytisine in mice*  
C. S. Cunningham, L. R. McMahon, Pharmacology, University of Texas Health Science Center, San Antonio, TX
- 114 *Cardiovascular effects of the nicotine receptor partial agonists cytisine and varenicline*  
E. M. Jutkiewicz, E. A. Brooks, J. H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI
- 115 *Varenicline demonstrates partial agonist characteristics by enhancing responding for non-pharmacological reinforcers and attenuating the reinforcement-enhancing effects of nicotine*  
M. Levin<sup>1</sup>, M. Weaver<sup>1</sup>, M. Palmatier<sup>3</sup>, A. Caggiula<sup>1</sup>, A. Sved<sup>2</sup>, E. Donny<sup>1</sup>, <sup>1</sup>Psychology, and <sup>2</sup>Neuroscience, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Psychology, Kansas State University, Manhattan, KS
- 116 *The roles of nicotinic and muscarinic cholinergic receptors in cost-benefit decision making*  
I. A. Mendez, J. L. Bizon, B. Setlow, Psychology, Texas A&M University, College Station, TX
- 117 *Cholinergic transmission in the nucleus accumbens is lower in adolescent vs adult rats experiencing nicotine withdrawal*  
J. E. Orfila, I. Torres, L. A. Natividad, E. Castaneda, L. E. O'Dell, Psychology, University of Texas at El Paso, El Paso, TX
- 118 *Effect of novel nicotinic receptor antagonist r-b3,5L/3PiDDB on nicotine- and food-maintained self-administration*  
A. C. Meyer<sup>1,2</sup>, T. E. Wooters<sup>2</sup>, Z. Zhang<sup>3</sup>, G. Zheng<sup>3</sup>, P. A. Crooks<sup>3</sup>, L. P. Dwoskin<sup>1,3</sup>, M. T. Bardo<sup>1,2</sup>, <sup>1</sup>Center for Drug Abuse Research Translation, <sup>2</sup>Psychology, and <sup>3</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY
- 119 *The novel mixed opioid RDC-5768 reduces the behavioral effects of nicotine and D-amphetamine in rats*  
M. S. Todtenkopf, R. L. Dean, B. M. Sullivan, K. S. O'Neill, D. Arnette, D. J. Eyerman, D. R. Deaver, Life Sciences, Alkermes, Inc., Cambridge, MA
- 120 *Insula inactivation as a novel therapeutic strategy for nicotine addiction*  
B. Le Foll<sup>1,2</sup>, A. Pushparaj<sup>1</sup>, B. Forget<sup>1</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 121 *Development of animal models of tobacco dependence using cigarette smoke exposure*  
A. C. Harris<sup>1,2</sup>, C. Mattson<sup>1</sup>, M. G. LeSage<sup>1,2</sup>, D. E. Keyler<sup>1,2,3</sup>, P. R. Pentel<sup>1,2,4</sup>, <sup>1</sup>Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>2</sup>Medicine, <sup>3</sup>Experimental and Clinical Pharmacology, College of Pharmacy, and <sup>4</sup>Pharmacology, University of Minnesota, Minneapolis, MN

- 122 *Reinforcement-enhancing effects of nicotine on responding for an unconditioned visual reinforcer in adolescent rats*  
M. T. Weaver<sup>1</sup>, K. Healey<sup>1</sup>, M. Levin<sup>1</sup>, A. Caggiula<sup>1</sup>, A. Sved<sup>2</sup>, E. Donny<sup>1</sup>, <sup>1</sup>Psychology, and <sup>2</sup>Neuroscience, University of Pittsburgh, Pittsburgh, PA
- 123 *Exposure to nicotine during periadolescence impacts the reinforcing effects of alcohol in adulthood*  
J. A. Rinker, A. L. Riley, Psychology, American University, Washington, DC
- 124 *Is nicotine susceptible to the blocking effect?*  
A. Jaffe<sup>1</sup>, A. Pham<sup>1</sup>, S. Gitsetan<sup>1</sup>, I. Tarash<sup>1</sup>, J. D. Jentsch<sup>1,2</sup>, <sup>1</sup>Psychology, UCLA, Los Angeles, CA, <sup>2</sup>Center for Addictive Behaviors, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA
- 125 *Comparison of acquisition of nicotine vs. cocaine self-administration without food restriction or prior training*  
N. A. Peartree, F. Sanabria, K. J. Thiel, D. Hills, M. R. Painter, S. M. Weber, L. E. Hood, N. M. Fruth, J. L. Neisewander, Psychology, Arizona State University, Tempe, AZ

**STIMULANTS: HUMAN II**

- 126 *Influence of methylphenidate on the reinforcing effects of cigarette smoking*  
M. M. Poole<sup>1</sup>, A. R. Vansickel<sup>4</sup>, W. W. Stoops<sup>2</sup>, C. R. Rush<sup>2,1,3</sup>, <sup>1</sup>Psychology, <sup>2</sup>Behavioral Science, and <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>4</sup>Psychology, Virginia Commonwealth University, Richmond, VA
- 127 *Pronounced attentional bias in methamphetamine-dependent subjects upon methamphetamine cue exposure: Relationship to craving*  
B. K. Tolliver, S. D. LaRowe, E. Chapman, M. Garrett, K. L. Price, M. Saladin, A. L. McRae-Clark, K. T. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 128 *Brain potential indices of reward vary with behavioral control*  
F. Gabbay, C. C. Duncan, S. Williams, Uniformed Services University of the Health Sciences, Bethesda, MD
- 129 *Effect of acute amphetamine on emotional memory*  
M. E. Ballard, G. Bedi, D. A. Gallo, H. de Wit, Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL
- 130 *The effects of oral d-amphetamine on impulsivity, mood and performance in smoked cocaine users*  
S. C. Reed, S. M. Evans, Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY
- 131 *Effects of naltrexone on amphetamine-induced changes in the brain dopamine system*  
N. Jayaram-Lindtröm<sup>1</sup>, J. Häggkvist<sup>1</sup>, T. Malmlöf<sup>2</sup>, T. Saijo<sup>1</sup>, C. Halldin<sup>1</sup>, S. Lindholm<sup>3</sup>, B. Schilström<sup>2</sup>, A. Nordström<sup>1</sup>, J. Franck<sup>1</sup>, <sup>1</sup>Clinical Neuroscience, and <sup>2</sup>Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, <sup>3</sup>Clinical Development Study Delivery, AstraZeneca R&D, Stockholm, Sweden
- 132 *Neurocognitive dysfunction is associated with treatment drop-out in methamphetamine dependence*  
K. G. Heinzerling<sup>1</sup>, A. N. Swanson<sup>1</sup>, W. Ling<sup>2</sup>, S. Shoptaw<sup>1,2</sup>, <sup>1</sup>Family Medicine, and <sup>2</sup>Psychiatry, UCLA, Los Angeles, CA

- 133 *Dissemination and implementation of cognitive behavioral therapy for stimulant dependence in South Africa*  
R. Sodano<sup>1</sup>, R. Rawson<sup>1</sup>, S. Rataemane<sup>2</sup>, L. Rataemane<sup>3</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>University of Limpopo, Sovenga, South Africa, <sup>3</sup>MEHADIC, Pretoria, South Africa
- 134 *Performance measures as predictors of client outcome among a methamphetamine-dependent sample at 24- and 36-month follow-up*  
R. Gonzales, L. Greenwell, R. Rawson, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 135 *Treatment outcomes for methamphetamine dependence: Findings from the Methamphetamine Treatment Evaluation Study*  
R. McKetin<sup>1</sup>, J. Ross<sup>1</sup>, J. M. Najman<sup>2</sup>, A. Baker<sup>3</sup>, D. Lubman<sup>4</sup>, S. Dawe<sup>5</sup>, R. Ali<sup>6</sup>, N. Lee<sup>7</sup>, R. Mattick<sup>1</sup>, A. A. Mamun<sup>2</sup>, <sup>1</sup>University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>University of Queensland, Brisbane, QLD, Australia, <sup>3</sup>University of Newcastle, Newcastle, NSW, Australia, <sup>4</sup>University of Melbourne, Melbourne, VIC, Australia, <sup>5</sup>Griffith University, Brisbane, QLD, Australia, <sup>6</sup>University of Adelaide, Adelaide, SA, Australia, <sup>7</sup>Turning Point Alcohol and Drug Centre, Melbourne, VIC, Australia
- 136 *Beliefs and treatment outcome*  
W. Ling, M. P. Hillhouse, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 137 *Physical, sexual, and emotional abuse in a methamphetamine-dependent treatment follow-up sample*  
S. M. Schroeder, M. Hillhouse, W. Ling, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 138 *Life trajectories of women methamphetamine users with child sexual abuse histories*  
A. Hamilton<sup>1</sup>, N. E. Goeders<sup>2</sup>, <sup>1</sup>Psychiatry, UCLA, Los Angeles, CA, <sup>2</sup>Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA
- 139 *False power: Qualitative research with women who use methamphetamine*  
D. J. Rinehart<sup>1</sup>, K. F. Corsi<sup>1</sup>, K. Mead<sup>1</sup>, W. Wechsberg<sup>2</sup>, R. E. Booth<sup>1</sup>, <sup>1</sup>Psychiatry, University of Colorado Denver, Denver, CO, <sup>2</sup>RTI International, Research Triangle Park, NC
- 140 *Racial/ethnic differences in morbidity and health status among adult methamphetamine users*  
D. Herbeck, M. Brecht, A. Pham, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 141 *Methamphetamine and other drug use in Native American communities*  
J. M. Houck<sup>1</sup>, R. Daw<sup>2</sup>, M. P. Davis<sup>1</sup>, A. A. Forcehimes<sup>1</sup>, M. P. Bogenschutz<sup>1</sup>, H. I. Perl<sup>3</sup>, <sup>1</sup>CASAA, University of New Mexico, Albuquerque, NM, <sup>2</sup>Totah Behavioral Health Authority, Farmington, NM, <sup>3</sup>NIDA, Rockville, MD
- 142 *Perceptions of methamphetamine/drug use among agency personnel in southwest Native American communities*  
M. P. Bogenschutz<sup>1</sup>, A. A. Forcehimes<sup>1</sup>, J. M. Houck<sup>1</sup>, A. Mondragon<sup>1</sup>, M. P. Davis<sup>1</sup>, A. Reid<sup>1</sup>, K. Foley<sup>2</sup>, <sup>1</sup>CASAA, University of New Mexico, Albuquerque, NM, <sup>2</sup>Na'nizhoozhi Center Incorporated, Gallup, NM

### Symposium XV

Salons HI  
10:00 AM - 12:00 PM

#### SCREENING AND BRIEF INTERVENTION FOR DRUG USE: DOES IT WORK? WILL IT WORK IN THE REAL WORLD?

Chairs: Richard Saitz and Richard Denisco

- 10:00 *Two approaches to screening and brief intervention for drug use in primary care: Do they work?*  
Richard Saitz, Boston Medical Center, Boston, MA
- 10:25 *SBIRT and substance use disorders: Can computers bridge the research to practice gap?*  
Dace Svikis, Virginia Commonwealth University, Richmond, VA
- 10:50 *Multidisciplinary approach to reduce injury and substance abuse in trauma settings*  
Mary M. Velasquez, School of Social Work, The University of Texas at Austin, Austin, TX
- 11:15 *Translating SBIRT for opioid dependence in the Emergency Department*  
Gail D'Onofrio, Emergency Medicine, Yale School of Medicine, New Haven, CT
- 11:40 *Discussant: The case for mainstreaming SBIRT into healthcare systems*  
Bertha K. Madras, Harvard Medical School, Southborough, MD

### Oral Communications 17

Salon DE  
10:00 AM - 12:00 PM

#### THE PAIN OF ADDICTION

Chairs: Ziva D. Cooper and Sandra Comer

- 10:00 *Pain during heroin self-administration enhances relapse of heroin-seeking in rats*  
M. W. Feltenstein<sup>1</sup>, T. S. Shippenberg<sup>2</sup>, A. Zapata<sup>2</sup>, R. E. See<sup>1</sup>, A. C. Riegel<sup>1</sup>, <sup>1</sup>Neurosciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>NIDA Intramural Research Program, NIH, Baltimore, MD
- 10:15 *Delta9-tetrahydrocannabinol attenuates i.v. heroin self-administration in rhesus monkeys*  
J. Li<sup>1</sup>, C. P. France<sup>1,2</sup>, <sup>1</sup>Pharmacology, and <sup>2</sup>Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 10:30 *Analgesic effects of smoked marijuana and oral THC in healthy marijuana smokers*  
Z. D. Cooper, S. D. Comer, M. Haney, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, NY
- 10:45 *Characterizing the subjective, reinforcing and analgesic effects of oxycodone in buprenorphine/naloxone-maintained chronic pain patients*  
J. D. Jones, M. A. Sullivan, J. Manubay, S. K. Vosburg, S. D. Comer, Division on Substance Abuse, New York State Psychiatric Institute and College of Physicians and Surgeons, New York, NY
- 11:00 *Early results of a protocol to use buprenorphine for chronic pain in patients with aberrant drug-related behavior*  
A. Rosenblum<sup>1</sup>, R. Cruciani<sup>2</sup>, E. Dvorkin<sup>2</sup>, A. Sundaram<sup>2</sup>, R. K. Portenoy<sup>2</sup>, <sup>1</sup>National Development and Research Institutes, Inc., New York, NY, <sup>2</sup>Beth Israel Medical Center, New York, NY

- 11:15 *The relationship between pain and treatment outcome during methadone maintenance: A prospective study*  
D. A. Tompkins<sup>1</sup>, A. Umbricht<sup>1</sup>, E. L. Winstanley<sup>2</sup>, G. E. Bigelow<sup>1</sup>, <sup>1</sup>Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH
- 11:30 *Hepatitis C virus infection and chronic pain in opioid-dependent injection drug users*  
J. I. Tsui<sup>1</sup>, D. M. Herman<sup>2</sup>, M. Kettavong<sup>2</sup>, B. J. Anderson<sup>2</sup>, M. D. Stein<sup>2</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Butler Hospital/Warren Alpert School of Medicine at Brown University, Providence, RI
- 11:45 *Opioid prescribing practices for adolescents with chronic pain*  
M. A. Sullivan<sup>1</sup>, W. Cheng<sup>1</sup>, J. M. Saroyan<sup>2</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Anesthesiology and Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian, New York, NY

## Oral Communications 18

Salon FG  
10:00 - 11:00 AM

### COCAINE/OPIATE INTERACTIONS: SOME THINGS GO BETTER WITH COKE

Chairs: Patrick M. Beardsley and Khampaseuth Rasakham

- 10:00 *Novel JDTic analogues block kappa opioid receptor agonist-induced diuresis and attenuate stress-induced cocaine reinstatement*  
P. M. Beardsley<sup>1</sup>, G. T. Pollard<sup>2</sup>, J. L. Howard<sup>2</sup>, F. I. Carroll<sup>3</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Howard Associates, LLC, and <sup>3</sup>Research Triangle Institute, Research Triangle Park, NC
- 10:15 *Serotonin depletion blocks the effects of a kappa-opioid agonist on cocaine self-administration*  
S. Izenwasser, E. Zakharova, M. Lenoir, B. Vignoli, C. Booth, University of Miami Miller School of Medicine, Miami, FL
- 10:30 *Sex difference in kappa opioid receptor modulation of acute cocaine-induced hyperactivity in the guinea pig*  
K. Rasakham<sup>1,2</sup>, Y. Wang<sup>1,2</sup>, J. Li<sup>1,2</sup>, E. M. Unterwald<sup>1,2</sup>, L. Y. Liu-Chen<sup>1,2</sup>, <sup>1</sup>Pharmacology, and <sup>2</sup>Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 10:45 *The choice between cocaine-remifentanyl mixtures and either drug alone: Increasing mixture dose*  
K. Freeman, W. L. Woolverton, Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*



## **Oral Communications 19**

**Salons ABC  
10:00 - 11:00 AM**

### **IMPACT OF AGE OF ONSET OF DRUG ABUSE**

Chairs: Cynthia Kuhn and Brittany E. Evans

- 10:00 *The relation between HPA axis reactivity and age of onset of alcohol use*  
B. E. Evans<sup>1</sup>, K. Greaves-Lord<sup>1</sup>, A. Euser<sup>1,2</sup>, I. H. Franken<sup>2</sup>, A. C. Huizink<sup>3</sup>, <sup>1</sup>Child and Adolescent Psychiatry, Erasmus Medical Center, Rotterdam, Netherlands, <sup>2</sup>Psychology, Erasmus University Rotterdam, Rotterdam, Netherlands, <sup>3</sup>Education, University of Amsterdam, Amsterdam, Netherlands
- 10:15 *Conditioned aversion to ethanol in adolescent vs. adult rats: Implications for future drinking*  
N. L. Schramm-Sapota<sup>1</sup>, A. DiFeliceantonio<sup>2</sup>, E. P. Foscue<sup>1</sup>, S. Glowacz<sup>1</sup>, N. Haseeb<sup>2</sup>, N. Wang<sup>2</sup>, C. Zhou<sup>2</sup>, C. M. Kuhn<sup>2,1</sup>, <sup>1</sup>Psychiatry, and <sup>2</sup>Pharmacology, Duke University Medical Center, Durham, NC
- 10:30 *Marijuana: Age of onset and frontal inhibitory tasks Using fMRI*  
S. A. Gruber<sup>1,2</sup>, M. K. Dahlgren<sup>1</sup>, S. E. Lukas<sup>1,2</sup>, <sup>1</sup>NeuroImaging Center, McLean Hospital, Belmont, MA, <sup>2</sup>Psychiatry, Harvard Medical School, Boston, MA
- 10:45 *Cortico-cerebellar abnormalities in adolescents with marijuana dependence*  
M. Lopez-Larson<sup>1,2</sup>, D. A. Yurgelun-Todd<sup>1,2</sup>, J. Rogowska<sup>3</sup>, <sup>1</sup>Brain Institute, University of Utah, Salt Lake City, UT, <sup>2</sup>VISN 19 MIRECC, Salt Lake City, UT, <sup>3</sup>Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA

## **Symposium XVI**

**Salon FG  
11:15 AM - 12:15 PM**

### **THE ROLE OF DOPAMINE D3 RECEPTORS IN COCAINE ABUSE**

Chair: Jane B. Acri

- 11:15 *The role of dopamine D3 receptors in drug abuse: Clinical implications*  
Jane B. Acri, DPMC, NIDA/NIH, Bethesda, MD
- 11:35 *Development of potential pharmacotherapies for cocaine abuse: In vitro assessment of dopamine D3 compounds*  
Robert R. Luedtke, Pharmacology, University of North Texas Health Science Center, Fort Worth, TX
- 11:55 *The behavioral pharmacology of novel dopamine D3 receptor compounds in rat and monkey models*  
James H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI

## **Oral Communications 20**

**Salons ABC**

**11:15 AM - 12:15 PM**

### **TRYING ON NEW GENES**

Chairs: Joseph Sakai and Caren L. Steinmiller

- 11:15 *Cannabinoid receptor gene polymorphism and marijuana's pharmacologic effects on negative and positive affect*  
J. McGeary<sup>1</sup>, J. Metrik<sup>2</sup>, V. Knopik<sup>3</sup>, C. Kahler<sup>2</sup>, P. Monti<sup>1</sup>, D. Rohsenow<sup>1</sup>, <sup>1</sup>Providence VAMC/Brown University, <sup>2</sup>Brown University Center for Alcohol and Addiction Studies, and <sup>3</sup>Rhode Island Hospital, Division of Behavior Genetics, Providence, RI
- 11:30 *Association study between the OPRM1 polymorphism 17C>T and heroin or cocaine addiction in African Americans*  
O. Awolesi<sup>1</sup>, S. Hamon<sup>1</sup>, E. Ducat<sup>1</sup>, M. Randesi<sup>1</sup>, J. Rotrosen<sup>2</sup>, P. Casadonte<sup>2</sup>, S. Linzy<sup>3</sup>, M. Adelson<sup>3,1</sup>, M. J. Kreek<sup>1</sup>, O. Levran<sup>1</sup>, <sup>1</sup>The Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, <sup>2</sup>VA New York Harbor Healthcare System and NYU School of Medicine, New York, NY, <sup>3</sup>Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse, Treatment, and Research, Las Vegas, NV
- 11:45 *Catechol-O-methyl transferase and corticotropin-releasing hormone receptor gene variants may impact opioid abstinence initiation and withdrawal symptoms in heroin-dependent volunteers*  
C. L. Steinmiller<sup>1</sup>, E. Sliwerska<sup>2</sup>, M. Burmeister<sup>2</sup>, M. K. Greenwald<sup>1</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>University of Michigan, Ann Arbor, MI
- 12:00 *Test of association between 10 SNPs in the Oxytocin receptor gene and conduct disorder utilizing a sample of clinic referred youth with serious substance and conduct problems, controls and available first degree relatives*  
J. Sakai<sup>1</sup>, T. J. Crowley<sup>1</sup>, M. C. Stallings<sup>2</sup>, M. McQueen<sup>2,3</sup>, M. A. Ehringer<sup>2,3</sup>, <sup>1</sup>School of Medicine, University of Colorado Denver, Aurora, CO, <sup>2</sup>Institute for Behavioral Genetics, and <sup>3</sup>Integrative Physiology, University of Colorado Boulder, Boulder, CO

## **BRUNCH WITH CHAMPIONS**

**(Pre-Registrants Only)**

**Sonoran**

**12:00 - 1:30 PM**

## **Symposium XVII**

**Salons HI**

**1:30 - 2:30 PM**

### **THE MULTI-SITE NIDA CLINICAL TRIALS NETWORK PRESCRIPTION OPIOID ADDICTION TREATMENT STUDY: OUTCOMES AND IMPLICATIONS**

Chairs: Roger Weiss and Petra Jacobs

- 1:30 *The prescription opioid addiction treatment study: Description of study and main outcome results*  
Roger D. Weiss, McLean Hospital, Belmont, MA
- 1:50 *Key secondary outcomes in the prescription opioid addiction treatment study: A focus on chronic pain*  
Jennifer S. Potter, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 2:10 *Clinical and scientific implications of results of the prescription opioid addiction treatment study*  
Walter Ling, University of California, Los Angeles, Los Angeles, CA

**Oral Communications 21**

**Salon DE  
1:30 - 2:30 PM**

**COCAINE SENSITIZATION—WHEN LESS IS MORE**

Chairs: Karen Szumlinski and Quentin D. Walker

- 1:30 *Changes in PFC glutamate/Homer-related signaling following long-access cocaine self-administration*  
K. K. Szumlinski<sup>1,2</sup>, O. Ben-Shahar<sup>1,2</sup>, B. W. Miller<sup>1</sup>, A. D. Sacramento<sup>1</sup>, N. M. Rudy<sup>1</sup>, M. G. Wroten<sup>1</sup>, N. Woodward<sup>1</sup>, <sup>1</sup>Psychology, and <sup>2</sup>Neuroscience Research Institute, University of California at Santa Barbara, Santa Barbara, CA
- 1:45 *Evidence for tolerance to the behavioral effects of cocaine after long-term self-administration by rhesus monkeys*  
N. M. Shinday, D. M. Platt, J. K. Rowlett, W. D. Yao, Neuroscience, New England Primate Center - Harvard Medical School/University of Massachusetts, Southborough, MA
- 2:00 *Effects of cocaine place conditioning, chronic escalating-dose “binge” pattern cocaine administration and chronic withdrawal on POMC gene expression in rat hypothalamus*  
Y. Zhou, A. Kruger, A. Ho, M. J. Kreek, The Rockefeller University, New York, NY
- 2:15 *Adolescent rats are more sensitive to behavioral activation by guarana and repeated administration during adolescence results in cocaine cross-sensitization*  
Q. D. Walker, J. C. Foster, C. M. Kuhn, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC

**Oral Communications 22**

**Salon FG  
1:30 - 2:30 PM**

**JAIL TIME: CRIMINAL JUSTICE AND DRUG ABUSE**

Chairs: Christine Grella and Michael Prendergast

- 1:30 *Characteristics of participants with co-occurring disorders in California's Prop 36 and their criminal justice and treatment outcomes*  
C. Grella<sup>1</sup>, B. T. Conner<sup>2</sup>, M. L. Brecht<sup>1</sup>, D. I. Urada<sup>1</sup>, J. Fan<sup>1</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Psychology, Temple University, Philadelphia, PA
- 1:45 *Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts*  
M. Finigan, T. Perkins, P. Zold-Kilbourn, Northwest Professional Consortium, Inc, Portland, OR
- 2:00 *Increasing access to services for rural re-entering offenders using telemedicine*  
M. Staton-Tindall<sup>1</sup>, C. Leukefeld<sup>2</sup>, J. M. Webster<sup>2</sup>, R. Freeman<sup>1</sup>, <sup>1</sup>College of Social Work, and <sup>2</sup>Behavioral Science, University of Kentucky, Lexington, KY
- 2:15 *Which parolees benefit from case management services? An application of classification and regression tree analysis*  
M. Prendergast<sup>1</sup>, L. Frisman<sup>2</sup>, H. Lin<sup>2</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>Mental Health and Addiction Services, Hartford, CT

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

### Oral Communications 23

Salons ABC  
1:30 - 2:30 PM

#### HIV/AIDS INFECTION AND DRUG ABUSE INTERSECTION

Chairs: Stacey B. Daughters and Steven A. Kritz

- 1:30 *Implementation of routine HIV rapid testing in a methadone program*  
R. M. Seewald, P. Friedmann, R. Tio, R. Elam, V. Bonilla, Jr., G. Sanders, D. C. Perlman,  
Beth Israel Medical Center, New York, NY
- 1:45 *Never HIV tested: Results of screening data from 12 drug treatment programs in the CTN 0032 HIV Rapid Testing and Counseling Study*  
L. R. Metsch, R. Mandler, D. Feaster, L. Gooden, S. Tross, L. Haynes, A. Douaihy,  
M. Das-Douglas, T. Kyle, T. Korthuis, R. Schwartz, S. Erickson, N. Snead, J. Sorensen,  
G. Colfax, Epidemiology, University of Miami Miller School of Medicine, Miami, FL
- 2:00 *HIV/AIDS-related health services in substance abuse treatment programs*  
L. S. Brown<sup>1</sup>, S. A. Kritz<sup>1</sup>, E. J. Bini<sup>2</sup>, J. Robinson<sup>3</sup>, J. Rotrosen<sup>4</sup>, <sup>1</sup>Medical Services, Research  
and Information Technology, ARTC, Brooklyn, NY, <sup>2</sup>Gastroenterology, VA NY Harbor  
Healthcare System, New York, NY, <sup>3</sup>Nathan Kline Institute, Orangeburg, NY, <sup>4</sup>Psychiatry, NY  
University College of Medicine, New York, NY
- 2:15 *ACT HEALTHY: Effectiveness of a behavioral activation and HIV medication adherence  
treatment for African-American HIV positive substance users*  
S. L. Howard<sup>1</sup>, A. Lavelle<sup>1</sup>, J. Magidson<sup>1</sup>, J. Hemberg<sup>1</sup>, F. Wang<sup>1</sup>, S. M. Gorka<sup>1</sup>, A. Ogunabi<sup>1</sup>,  
J. Leonard<sup>1</sup>, S. Safren<sup>2</sup>, S. B. Daughters<sup>1</sup>, <sup>1</sup>Public and Community Health, University of  
Maryland, College Park, MD, <sup>2</sup>Harvard Medical School, Boston, MA

### Symposium XVIII

Salons HI  
2:45 - 3:45 PM

#### COMMUNITY-BASED RESPONSES TO INCREASING OPIOID OVERDOSE DEATHS: STATE OF RESEARCH AND PRACTICE

Chairs: Alexander Y. Walley and Alex Kral

- 2:45 *Implementation of a statewide intranasal naloxone overdose prevention program*  
Alexander Y. Walley, Clinical Addiction Research and Education Unit, Boston University  
School of Medicine, Boston Medical Center, Boston, MA
- 3:05 *Evaluation of two overdose prevention programs in Los Angeles: Preliminary findings*  
Steven Lankenau, School of Public Health, Department of Community Health and Prevention,  
Drexel University, Philadelphia, PA
- 3:25 *Operation OpioidSAFE: A pilot naloxone program in an active duty military setting*  
Fred Brason, Project Lazarus, Wilkes County, NC

*BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS*

## **Oral Communications 24**

**Salon DE  
2:45 - 3:45 PM**

### **PUMP IT UP! IMPACT OF EXERCISE ON DRUG USE**

Chairs: Wendy J. Lynch and Mark A. Smith

- 2:45 *The relationship between increased exercise and smoking cessation*  
M. J. Dennis<sup>1</sup>, M. L. Dennis<sup>2</sup>, R. R. Funk<sup>2</sup>, <sup>1</sup>Heartland Community College, Normal, IL, <sup>2</sup>Chestnut Health Systems, Normal, IL
- 3:00 *Psychological benefits of exercise in the treatment of chemical dependency*  
P. M. Monchusie, L. K. Tennant, University of Kansas, Lawrence, KS
- 3:15 *Aerobic exercise blocks incubation of cocaine-craving and its associated neuroadaptations*  
W. J. Lynch<sup>1</sup>, K. Piehl<sup>1</sup>, G. Acosta<sup>2</sup>, A. Peterson<sup>1</sup>, S. E. Hemby<sup>2</sup>, <sup>1</sup>Psychiatry, University of Virginia, Charlottesville, VA, <sup>2</sup>Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC
- 3:30 *Effects of aerobic exercise on reinstatement of cocaine-seeking behavior*  
M. A. Smith, M. M. Pennock, K. L. Walker, Psychology, Davidson College, Davidson, NC

## **Oral Communications 25**

**Salon FG  
2:45 - 3:45 PM**

### **TECH SUPPORT: USE OF TECHNOLOGY IN RESEARCH AND TREATMENT**

Chairs: Gnatt Galloway and Michelle C. Acosta

- 2:45 *Using technology to assess substance use behaviors in a low income primary care clinic*  
P. H. Smith<sup>1</sup>, G. H. Homish<sup>1,2</sup>, C. Barrick<sup>2</sup>, N. Grier<sup>1</sup>, <sup>1</sup>Health Behavior, State University of New York at Buffalo, School of Public Health and Health Professions, Buffalo, NY, <sup>2</sup>Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY
- 3:00 *Development of a web-based psychosocial intervention for adolescents with substance use disorders*  
M. C. Acosta<sup>1</sup>, L. A. Marsch<sup>1</sup>, S. H. Godley<sup>2</sup>, Y. Kaminer<sup>3</sup>, Y. Hofstein<sup>1</sup>, <sup>1</sup>Center for Technology and Health, National Development and Research Institutes, Inc., New York, NY, <sup>2</sup>Lighthouse Institute, Chestnut Health Systems, Normal, IL, <sup>3</sup>Alcohol Research Center, University of Connecticut Health Center, Farmington, CT
- 3:15 *Using pill photos taken with a cell phone to assess adherence in a clinical trial*  
K. Flower, J. Guillén, J. Coyle, J. Mendelson, G. P. Galloway, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA
- 3:30 *Producing smoking craving by using immersive virtual environments*  
O. Garcia-Rodriguez<sup>1</sup>, I. Pericot-Valverde<sup>1</sup>, J. Gutierrez-Maldonado<sup>1</sup>, M. Ferrer-Garcia<sup>1</sup>, R. Secades-Villa<sup>2</sup>, F. Alonso-Perez<sup>3</sup>, <sup>1</sup>Clinical Psychology, University of Barcelona, Barcelona, Spain, <sup>2</sup>Psychology, University of Oviedo, Oviedo, Spain, <sup>3</sup>Public Health Service, Asturias, Spain



---

**Thursday, June 17, 2010**

---

## **Oral Communications 26**

**Salons ABC  
2:45 - 3:30 PM**

### **HEPATITIS**

Chairs: Jennifer Havens and William W. Latimer

- 2:45 *Characteristics of HIV and HBV mono and co-infections among black South African drug users*  
J. B. Zur, A. Hulbert, L. Ropelewski, W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 3:00 *Predictors of hepatitis C seroconversion among rural Appalachian prescription drug users*  
J. R. Havens<sup>1</sup>, C. B. Oser<sup>1</sup>, R. Crosby<sup>2</sup>, C. G. Leukefeld<sup>1</sup>, <sup>1</sup>Center on Drug and Alcohol Research, and <sup>2</sup>Health Behavior, University of Kentucky, Lexington, KY
- 3:15 *Does the way of drinking (binge drinking) affect the evolution of hepatitis C among alcohol abusers?*  
M. Guillaumot<sup>2</sup>, P. Melin<sup>1,2</sup>, M. Marc<sup>1,2</sup>, A. Hij<sup>1</sup>, S. Samouri<sup>1</sup>, M. Schoeny<sup>1</sup>, J. Fournier<sup>2</sup>, C. Bremard<sup>2</sup>, <sup>1</sup>CHG St Dizier, Saint Dizier, France, <sup>2</sup>CSAPA 52, Saint Dizier, France

## **SWEEPSTAKES DRAWING**

**Salon HI  
3:45 PM**

***YOU MUST BE SEATED IN ONE OF THE SESSIONS STARTING  
AT 2:45 PM IN ORDER TO HAVE YOUR BADGE COLLECTED***

HAVE A SAFE TRIP HOME!

SEE YOU IN HOLLYWOOD, FLORIDA, JUNE 18-23, 2011

***BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS***

# AUTHOR INDEX

- Abagiu, A.O. 14  
 Abdelrahman, D. 77  
 Ablondi, K. 71  
 Accornero, V.H. 25, 53, 85  
 Achara, I. 66  
 Achat-Mendes, C. 83  
 Ackerson, T.H. 72, 94  
 Acosta, G. 107  
 Acosta, M.C. 78, 107  
 Acri, J.B. 103  
 Adams, B. 82  
 Adams, E. 62  
 Adams, S. 10  
 Adelaja, O.A. 12, 86  
 Adelson, M. 59, 104  
 Adi, N. 17  
 Adinoff, B. 4, 97  
 Adler, M.W. 56, 84  
 Afful, S.E. 53  
 Agrawal, A. 69  
 Agster, K.L. 3  
 Agudelo, M. 74, 76, 86  
 Aguerretxe Colina, A. 57  
 Aharonovich, E. 51, 95  
 Ahmed, M.S. 77  
 Ahmedani, B.K. 86  
 Ait-Daoud, N. 74  
 Alam Mehrjerdi, Z. 4, 93  
 Alberati, D. 83  
 Alberg, A.J. 23  
 Albino, T. 65  
 Albright, L. 66  
 Aldrich, J. 84  
 Aleixandre-Benavent, R. 52, 73  
 Ali, R. 100  
 Alicata, D. 54  
 Allison, P.A. 50  
 Alonso-Perez, F. 107  
 Altice, F. 6, 75  
 Altman, J.K. 56  
 Alvarez, E. 73  
 Álvarez-García, J.A. 16  
 Álvarez-Rodríguez, H. 16  
 Amass, L. 58  
 Amato, T.D. 9  
 Amberg, A. 21  
 Ambrosio Flores, E. 2, 7  
 Ameringer, K.J. 51  
 Amico, J. 66  
 Amodio, K. 57  
 Anastasio, N.C. 15, 82, 83  
 Andersen, A.M. 52  
 Andersen, R.M. 57  
 Anderson, A. 74, 80  
 Anderson, B.J. 102  
 Anderson, K.G. 9, 73  
 Anderson, K.L. 69, 74  
 Ando, Y. 18  
 Andorn, A.C. 8  
 Ang, A. 71  
 Angarita, G.A. 77  
 Anghelescu, M. 14  
 Anglin, M.D. 50  
 Anguiano, F.J. 21  
 Anker, J.J. 84, 85  
 Annon, J.A. 14  
 Anthony, J.C. 2, 4, 9, 11, 12, 13, 53, 55, 73, 85, 86  
 Aoki, K. 19  
 Arangua, L.E. 57  
 Arenander, J. 15  
 Arends, L. 79  
 Arfken, C.L. 21, 50  
 Argillet, M. 91  
 Arheart, K.L. 25  
 Arnelle, D. 98  
 Arora, G. 53  
 Arria, A. 9, 25, 73  
 Ashworth, J.B. 95  
 Aston-Jones, G. 22  
 Ataya, A. 10  
 Ator, N.A. 6, 14  
 ATTC Network Technology Transfer Workgroup 14  
 Auber, A. 18  
 Auclair, C. 91  
 Augusto, L.P. 11  
 Auriacombe, M. 12, 13, 59, 78, 79  
 Authier, N. 18  
 Awgu, E. 48  
 Awolesi, O. 104  
 Babalonis, S. 10, 80  
 Babor, T.F. 15, 67  
 Babuscio, T. 90  
 Back, S.E. 85, 89, 90, 94, 95  
 Badger, G.J. 52  
 Bado, J. 19  
 BaDour, B. 62  
 Bagaric, A. 58  
 Baggott, M.J. 77, 81, 86  
 Baiget, M. 73  
 Bailey, J.E. 59, 93  
 Baker, A. 90, 100  
 Baker, A.K. 14  
 Baker, L.E. 19  
 Baker, N. 62  
 Baladi, M. 17  
 Baldwin, C.K. 17  
 Baliz, Y. 73  
 Ball, S. 58  
 Ballard, M.E. 99  
 Ballina, L. 54  
 Ballis, M. 89  
 Balster, R. 14  
 Balter, R.E. 84  
 Bamonte, A. 75  
 Bandak, S.I. 15, 97  
 Bandstra, E.S. 25, 53, 85  
 Banducci, A.N. 20  
 Bandyopadhyay, D. 70, 89  
 Banks, M.L. 18  
 Bao, Y. 24  
 Barajas, M. 17  
 Barcelona Group for Addiction Genetics 73  
 Bardo, M.T. 68, 81, 82, 85, 98  
 Barford-Turner, S. 92  
 Baron, D. 71  
 Barondess, D. 13  
 Barral, C. 57  
 Barrett, E. 90  
 Barrick, C. 92, 107  
 Barros, H.T. 70  
 Barry, D.T. 59, 68, 93  
 Barry, K.T. 9, 55  
 Bart, G. 92  
 Barthwell, A. 14  
 Bass, C.E. 17  
 Bastos, F.I. 11

# AUTHOR INDEX

- Batki, S.L. 21, 57, 85  
 Batra, V. 7  
 Baumann, M.H. 61, 62, 86  
 Bausell, R. 97  
 Bazerman, L. 75  
 Beardsley, P.M. 102  
 Beatty, J.R. 52  
 Beatty, L.A. 5  
 Beck, B. 23  
 Becker, W.C. 93  
 Beckmann, J. 68  
 Bedi, G. 90, 99  
 Beharie, R. 52, 69  
 Beltrand, V. 13, 57, 59, 79  
 Ben Abdallah, A. 23, 71, 72  
 Benamar, K. 84  
 Benbenishty, R. 60  
 Benca, C. 97  
 Benjamin, E.O. 12  
 Bennett, A.J. 82  
 Benoit, E. 90, 96  
 Ben-Shahar, O.M. 82, 105  
 Benzano, D. 11, 70  
 Berglund, M. 48  
 Bergquist, K. 90  
 Bergthold, T. 20, 21  
 Berlin, A.A. 17  
 Berman, M. 19  
 Bernstein, I.M. 52, 69  
 Berry, M.S. 11, 53  
 Berto, D. 49  
 Beswick, T.C. 97  
 Beveridge, T.J. 96  
 Bickel, W.K. 3, 16, 51, 55, 85, 93  
 Bidlack, J.M. 24  
 Bierut, L. 73  
 Bierut, L.J. 53  
 Bigelow, G.E. 3, 11, 16, 92, 93, 102  
 Billing, Jr., C.B. 79  
 Bini, E.J. 106  
 Bisaga, A. 15  
 Bizon, J.L. 98  
 Black, A.C. 16, 71  
 Black, C. 97  
 Black, R.A. 95  
 Blair, L. 51  
 Blankenship, A.L. 80  
 Blanton, R. 89  
 Bliznashki, S.E. 76  
 Blondel, S. 91  
 Blough, B.E. 18, 83  
 Blow, F.C. 8, 9, 55  
 Blume, L.C. 17  
 Bluthenthal, R. 76  
 Bobashev, G.V. 76  
 Bogenschutz, M.P. 78, 100  
 Bohnert, A.S. 8  
 Bohnert, K.M. 9  
 Bolden, M. 13  
 Bolger, K. 96  
 Bolo, N. 82  
 Bonilla, Jr., V. 106  
 Boone, Z. 52  
 Boos, T.L. 19  
 Booth, B.M. 9, 55  
 Booth, C. 102  
 Booth, R.E. 58, 100, 108  
 Booze, R.M. 18  
 Borgland, S.L. 22  
 Bortolato, M. 2  
 Bossert, J.M. 83  
 Botsko, M. 74, 75  
 Botzet, A. 22  
 Boubion, C. 20  
 Box, B. 57  
 Boyd, C.J. 72, 94  
 Boyd, S.J. 49  
 Bracken, B.K. 10  
 Brackenbury, L. 9  
 Bradford, S.E. 23, 72  
 Bradstreet, M.P. 51, 52  
 Brady, K.T. 15, 21, 62, 79, 89, 90, 94, 95, 98, 99  
 Brands, B. 13, 71, 93  
 Brasic, J. 97  
 Braud, J. 4  
 Brecht, M.L. 69, 100, 105  
 Brekke, M. 59  
 Breland, A. 78  
 Bremard, C. 11, 56, 108  
 Breslau, N. 9  
 Brewer, J. 90  
 Brewster, J.T. 58  
 Brigham, G.S. 51, 91  
 Brim, R.L. 77  
 Brimson, M. 82  
 Britt, C.E. 83  
 Brooks, A.C. 16  
 Brooks, D.J. 56  
 Brooks, E.A. 98  
 Brooner, R.K. 12, 59, 71  
 Brouwer, K.C. 56  
 Brown, B.S. 58, 60, 71, 76, 93  
 Brown, G. 80  
 Brown, L.S. 51, 57, 106  
 Brown, M. 53  
 Brown, Q.L. 95  
 Brown, R. 54  
 Brown, R.T. 50  
 Brown, S. 8, 72  
 Brown, S.A. 72  
 Browne, D.C. 69  
 Brownstein, J.S. 94  
 Bruno, R. 94  
 Bryan, B. 59  
 Buchholtz, C. 59, 93  
 Budman, S.H. 19, 20, 72, 93, 94, 95  
 Budney, A.J. 22, 55, 56  
 Budygin, E.A. 17  
 Bueler, E. 55  
 Bueno-Cañigral, F.J. 52, 73  
 Buffalari, D. 17  
 Bukstein, O. 72  
 Bumaguin, D. 70  
 Buras, M. 9  
 Burlew, K. 78  
 Burmeister, M. 104  
 Burns, L. 94  
 Busse, A. 21  
 Busto, U.E. 23, 70, 93  
 Butelman, E. 84  
 Butler, S.F. 19, 20, 72, 93, 94, 95  
 Cachay, C. 13  
 Caddell, L. 19, 24  
 Cadet, J. 67  
 Cadet-Taïrou, A. 88

# AUTHOR INDEX

- Caggiula, A. 98, 99  
 Cahoon, K.L. 21  
 Calafell, F. 73  
 Caldeira, K.M. 9, 73  
 Calderon, S.N. 65  
 Caldwell, D.H. 95  
 Calnan, J. 6  
 Calsyn, D.A. 91  
 Calvin, N.T. 16, 85  
 Cambraia Windsor, L. 5  
 Campbell, A.N. 91  
 Campbell, J. 74  
 Campbell, J.C. 54  
 Campello, G. 21  
 Campollo, O. 21  
 Canfield, K. 21, 57  
 Canlas, L. 50  
 Cao, A. 54  
 Carbonaro, T. 19  
 Carbone, C.L. 15  
 Cardus, M. 73  
 Carey, K.A. 17  
 Carey, P.D. 2, 55  
 Cargile, C. 3, 81  
 Carise, D. 16  
 Carlson, B. 90  
 Carlson, G. 92  
 Carlson, R.G. 91  
 Carlton, E. 78  
 Carney, T. 58  
 Caron, A. 50  
 Carpenter, M.J. 23, 51  
 Carr, C.M. 19  
 Carr, J. 52  
 Carr, S.M. 19  
 Carrieri, M.P. 57  
 Carroll, F.I. 18, 83, 102  
 Carroll, K. 90  
 Carroll, M.E. 6, 85  
 Carson, R. 4, 97  
 Carter, C.S. 7  
 Carter, L.P. 84, 85  
 Carter, R.E. 62  
 Casadonte, P.P. 20, 104  
 Casas, M. 57  
 Cassat, P. 13  
 Cassidy, T.A. 19, 20, 72, 93, 94, 95  
 Cassin, J. 83  
 Castagne, V. 84  
 Castaneda, E. 98  
 Castel, S. 71  
 Catacora, M.M. 13  
 Cavallo, D. 9  
 Cavanaugh, C.E. 17, 95  
 Cavazos, P. 73  
 Cayetano, K. 82  
 Cederblom, E. 23  
 Cepeda, E. 53  
 Cerda, M. 8  
 Chakraborty, B. 3  
 Chalk, M. 64  
 Chan, M. 51, 60  
 Chandler, R. 6  
 Chandra, S. 13  
 Chang, L. 54, 55, 96  
 Chang, Y.J. 88, 91  
 Chao, L. 13  
 Chaplin, T. 90  
 Chapman, E. 99  
 Charboneau, E.J. 54  
 Charnigo, R. 23  
 Chaudhry, A. 75  
 Chawarski, M.C. 96  
 Cheetham, S.C. 18  
 Chen, G.L. 86  
 Chen, H. 58  
 Chen, J. 90  
 Chen, N. 79  
 Chen, X. 84  
 Cheng, H. 12  
 Cheng, W.Y. 15, 102  
 Chermack, S.T. 9, 55  
 Cheung, T.H. 86  
 Chiamulera, C. 18  
 Chiang, N. 74, 80  
 Chien, C.S. 13  
 Chilcoat, H.D. 8, 10  
 Childress, A.R. 3, 4, 23, 55, 96, 97  
 Childs, E. 89  
 Chisolm, M.S. 24, 52  
 Choate, D. 49  
 Christensen, C. 19, 21, 53  
 Christensen, D.R. 16, 85, 93  
 Chu, M. 57  
 Chun, J. 60  
 Chun, L. 62  
 Churchwell, J.C. 55  
 Clark, B.D. 3  
 Clark, D.B. 72, 84  
 Clausen, T. 11, 49  
 Cleland, C. 95  
 Cleva, R.M. 61  
 Cloak, C. 54  
 Cobb-Burns, M. 16  
 Cobuzzi, J.L. 7  
 Coetzee, J. 85  
 Cohen, A.J. 20  
 Cohen, J. 80  
 Cohn, J. 21  
 Cojocar, E. 14  
 Coker, A.R. 10  
 Colfax, G. 106  
 Collado-Rodriguez, A. 51  
 Collins, G.T. 17  
 Collins, H. 97  
 Collins, L.M. 14  
 Collum, S. 86  
 Colussi-Mas, J. 81  
 Comer, S.D. 56, 65, 95, 101  
 Comerford, M. 15  
 Comment, L.A. 73  
 Compton, D. 67  
 Compton, W.M. 64  
 Condon, T.P. 6  
 Conn, N.A. 62, 64  
 Conner, B.T. 105  
 Connors, V. 52  
 Conrad, M. 89  
 Conti, K.E. 48  
 Cooley, M. 70  
 Coomes, C.M. 76  
 Cooper, Z.D. 56, 101  
 Copeland, J. 2  
 Copenhaver, M. 21  
 Corbley, C.R. 80  
 Corbly, C. 97  
 Cordes, J. 10  
 Cornelius, J.R. 72

# AUTHOR INDEX

- Cornelius, M.D. 90  
 Corrigall, W. 22  
 Corsi, K.F. 56, 100, 108  
 Corsi, M. 22  
 Costello, P. 55  
 Cottler, L.B. 13, 23, 50, 53, 71, 72, 73, 91  
 Cotton, S. 73  
 Courty, P. 18, 91  
 Coviello, D.M. 48  
 Cowan, A. 84  
 Cowan, R. 54, 86, 87  
 Cowhey, K.E. 82  
 Coyle, J.R. 81, 86, 107  
 Coyle, M. 24  
 Craft, R.M. 56, 83  
 Cranford, J.A. 72, 94  
 Crawford, C.A. 81, 83  
 Crawford, N.D. 12, 93, 96  
 Creemers, H.E. 24, 73, 85  
 Crevecoeur-MacPhail, D.A. 14, 88  
 Crits-Christoph, P. 78  
 Croft, D.E. 23  
 Croft, J.C. 16  
 Crooks, P.A. 98  
 Cropsey, K.L. 17, 48, 49, 85, 86  
 Crosby, R. 86, 89, 108  
 Crowley, T.J. 64, 104  
 Cruciani, R. 101  
 Cruz, G. 13  
 Cruz, J. 23  
 Cruz, S. 54  
 Cruz, V. 13  
 Culbertson, C. 23  
 Culmer, T. 62  
 Cummings, A.M. 86  
 Cummings, S.M. 50, 72, 91  
 Cunningham, C. 74, 75  
 Cunningham, C.S. 98  
 Cunningham, K.A. 15, 74, 82, 83  
 Curley, L.E. 97  
 Cutter, C.J. 59  
 Cuyas, E. 77  
 Czoty, P.W. 6  
 D'Addario, C. 64  
 D'Onofrio, G. 101  
 D'Sa, C. 89  
 Dackis, C. 16  
 Dahlgren, M.K. 103  
 Dailey, T. 72  
 Dakwar, E. 8  
 Daley, D. 72  
 Dallery, J. 51  
 Dart, R. 59, 93  
 Das-Douglas, M. 106  
 Daugherty, D.E. 7  
 Daughters, S.B. 71, 88, 106  
 Daulouède, J. 13, 57, 59, 79  
 Daunais, J.B. 82  
 Davey, J. 11  
 Davis, C.M. 7  
 Davis, K. 19, 24  
 Davis, M.P. 100  
 Daw, R. 100  
 Dawe, S. 100  
 De Boni, R. 11  
 De La Garza, II, R. 15, 23, 80, 84, 89, 92  
 de la Torre, R. 77, 81, 86  
 de Wit, H. 16, 89, 99  
 Deadwyler, S. 96  
 Dean, R.L. 98  
 Deaver, D.R. 98  
 DeBoni, R. 11, 70  
 Dechant, G. 82  
 DeFulio, A. 91, 93  
 Degenhardt, L. 4  
 Deilamizadeh, A. 93  
 Del Olmo, N. 7  
 Delaney, M. 78  
 Dellamonica, P. 57  
 Delucchi, K.L. 58, 69  
 Denis, C. 12, 13, 78, 79  
 Denisco, R. 101  
 Dennis, M. 25  
 Dennis, M.J. 107  
 Dennis, M.L. 25, 49, 72, 78, 107  
 Der-Ghazarian, T.S. 83  
 Des Jarlais, D.C. 57, 58  
 Desai, R. 9, 92  
 DeSantis, S.M. 15, 89  
 Desco, M. 7  
 Deslandes, C. 53  
 Desmond, R.C. 71  
 Detre, J.A. 23  
 Devous, Sr., M. 4, 97  
 Dewey, W.L. 67  
 Diaz-Gomez, C. 78  
 Dick, D. 73  
 Dickson, M.F. 48  
 Diemer, K. 11  
 Dierst-Davies, R. 96  
 Dietrich, M.S. 54, 87  
 DiFeliceantonio, A. 103  
 DiGirolamo, G. 92  
 Dillon, P. 91, 94  
 Dineley, K.T. 83  
 Dinh, A. 76  
 Diniz, B. 70  
 DiPietro, J.A. 53  
 Divine, L. 89  
 Dixon, L.B. 49  
 Dodrill, C. 60  
 Domingo-Salvany, A. 70  
 Donlin, W. 93  
 Donny, E. 98, 99  
 Donovan, R. 20  
 Dooley, C.T. 24  
 Douaihy, A. 72, 106  
 Dow-Edwards, D. 53, 61, 81  
 Doyle, S.E. 89  
 Draus, P.J. 21  
 Druid, H. 17  
 Du, J. 57  
 Duan, Y. 4  
 Ducat, E. 104  
 Duffin-Lutgen, S.M. 89  
 Dugosh, K.L. 16, 50  
 Duke, A.N. 50  
 Duncan, C. 20  
 Duncan, C.C. 99  
 Dunlap, E. 90  
 Dunn, K.E. 5, 57, 88, 93, 95  
 Dunne, E. 12  
 Duque, L. 17  
 Durbin, J. 17  
 Durif, F. 18



# AUTHOR INDEX

Durkin, S.J. 56  
 Duvall, J.L. 75  
 Dvorkin, E. 101  
 Dvoryak, S. 58  
 Dwoskin, L.P. 98  
 Dykes, S.G. 18  
 Dykstra, L.A. 5, 7, 56, 62, 84

Ebrahimzadeh, P. 96  
 Egan, J. 75  
 Egan, J.E. 20  
 Ehrich, E. 79  
 Ehringer, M.A. 104  
 Ehrman, R.N. 4, 55, 96, 97  
 Eiroa, F. 57  
 Eisenstein, T.K. 56, 84  
 Eitan, S. 84  
 Ekhtiari, H. 4, 93  
 Ekker, S. 63  
 El Marroun, H. 24  
 El Rawas, R. 82  
 Elam, R. 106  
 Elkashef, A. 74, 80  
 Elkins, K. 73  
 Elko, A. 53  
 Ellgren, M. 80  
 Elskén, C. 19  
 ElSohly, M. 19  
 Emeson, R.B. 83  
 Emurian, C.E. 80  
 Engelhardt, B. 68  
 Engels Dibble, A. 8  
 English, J.S. 51  
 Enman, N. 61  
 Entenman, S. 19  
 Epstein, D.H. 69, 79  
 Epstein, M. 72, 94  
 Erez, A. 48  
 Erickson, S. 106  
 Ernst, T. 54, 55, 96  
 Ertischek, M. 94  
 Ettenberg, A. 82  
 Euser, A.S. 79, 103  
 Evans, B.E. 103  
 Evans, E. 88, 91  
 Evans, R.J. 9, 88  
 Evans, S.M. 90, 99

Evatt, D.P. 80  
 Everhart, T. 77  
 Everly, J.J. 93  
 Evins, A.E. 98  
 Eyerman, D.J. 98  
 Ezeabogu, I. 21  
 Fabiano, J. 51  
 Fabianski, R. 4, 97  
 Fahey, J. 58, 95  
 Fahnhorst, T. 22  
 Fairman, B. 55  
 Faix, C. 51  
 Falck, R. 91  
 Faller, S. 70  
 Fan, J. 50, 105  
 Fang, L.J. 49  
 Fang, N. 73  
 Fanous, S. 3  
 Fant, R. 14, 15  
 Farley, C.M. 81  
 Farnum, S.O. 58  
 Farre, M. 77, 81  
 Farrell-Moore, D. 78  
 Farrugia, P. 90  
 Fatséas, M. 12, 13, 78, 79  
 Fava, M. 98  
 Fazzino, T.L. 59, 88  
 Fearer, S. 55  
 Feaster, D. 106  
 Feger, U. 96  
 Fein, G. 54  
 Feltenstein, M.W. 101  
 Feltner, D. 65, 79  
 Fenton, M. 8, 72  
 Ferigolo, M. 70  
 Fernandez-Artamendi, S. 16  
 Fernandez-Hermida, J. 16  
 Ferreira, E. 88  
 Ferrer-Garcia, M. 107  
 Ferris, J. 80  
 Festinger, D.S. 16, 25, 50  
 Fiellin, D.A. 20, 59, 64, 74, 75, 76, 93  
 Fiestas, F.A. 13  
 Fife, J. 17  
 Finch, A.J. 25

Fingerhood, M. 11, 93  
 Finigan, M. 105  
 Finkelstein, R. 75  
 Fintzy, R.T. 23  
 Fischer, G. 24, 26  
 Fishbein, D. 13  
 Fitterling, K.D. 23  
 Fitzgerald, A. 78  
 Fitzgerald, J. 72, 94  
 Flaherty, M.T. 5  
 Flower, E.K. 3, 81, 86, 107  
 Floyd, L.J. 17, 91, 95  
 Flynn, M.C. 52  
 Foley, K. 100  
 Foltin, R.W. 56, 63, 67, 80  
 Fong, C. 95  
 Fonseca, F. 70  
 Forcehimes, A.A. 78, 100  
 Ford, J.H. 11  
 Foresti, K. 95  
 Forget, B. 98  
 Forman, R. 78, 79  
 Fornash, A. 4, 96, 97  
 Forster, M.J. 19  
 Forsythe, S.R. 13  
 Foscue, E.P. 103  
 Foster, J.C. 105  
 Fournier, F. 11  
 Fournier, J. 11, 56, 108  
 Fox, H. 7  
 Fox, H.C. 89  
 Fox, R.G. 82, 83  
 France, C.P. 8, 17, 101  
 Francis, W. 20, 51  
 Franck, J. 99  
 Franken, I.H. 3, 51, 79, 93, 97, 103  
 Franklin, T.R. 4, 23, 96, 97  
 Frederick, B. 98  
 Freeman, J. 11  
 Freeman, K. 102  
 Freeman, R. 58, 105  
 Friedman, C. 53  
 Friedman, S. 48  
 Friedmann, P.D. 48, 49, 106  
 Frisman, L. 105  
 Fritz, M. 82

# AUTHOR INDEX

- Froger-Colleaux, C. 84  
 Froimowitz, M. 77  
 Fruth, N.M. 99  
 Fuchs, R.A. 68, 82  
 Fuller, C.M. 12, 93, 96  
 Fuller, M.A. 15  
 Fumagalli, G. 18  
 Funk, R.R. 49, 107  
 Furr- Holden, C.M. 13, 70  
 Fuste, G. 57  
  
 Gabbay, F. 99  
 Gabriele, A. 17  
 Gaebel, W. 10  
 Galea, S. 8  
 Galindo, J. 13  
 Gallo, D.A. 99  
 Gallop, R. 78  
 Galloway, G.P. 3, 77, 81, 86, 107  
 Gandhi, N.H. 24, 74, 76, 86  
 Ganjgahi, H. 4  
 Garcia, F. 4  
 Garcia-Fernandez, G. 16  
 García-Lecumberri, C. 7  
 García-Rodríguez, O. 16, 107  
 García-Vázquez, V. 7  
 Gardner, E. 69  
 Gardner, E.L. 62, 77  
 Garland, S. 52  
 Garnier-Dykstra, L.M. 9  
 Garrett, M. 99  
 Garrison, K.J. 86  
 Gastfriend, D.R. 6, 64  
 Gatch, M.B. 19  
 Gaydos, C. 17  
 Geier, C.F. 84  
 Geier, T. 8  
 Gelberg, L. 57  
 Geller, E.B. 84  
 Gempton, S. 97  
 Geniaux, H. 88  
 Gentry, W.B. 3  
 George, D. 20  
 George, M.S. 98  
 Georgescu, F. 14  
 Gerbaud, C. 58  
  
 Gerbaud, L. 91  
 Gerbautz, B. 21  
 Gerra, G. 21  
 Gheorghe, F. 14  
 Ghitza, U.E. 20  
 Ghozland, S.G. 19  
 Giarola, A.S. 18  
 Gilchrist, G. 70  
 Gill, K.E. 82, 96  
 Gillis, T. 82  
 Gilmour, B.P. 17  
 Gilson, A. 94  
 Giorgi, R. 57  
 Gipson, C. 85  
 Girling, E. 93  
 Gitisetan, S. 99  
 Glaser, P.E. 80, 81  
 Glasner-Edwards, S. 71  
 Glowacz, S. 103  
 Godley, S.H. 107  
 Goeders, N.E. 81, 100  
 Goldman, M. 4, 23, 55, 97  
 Goldweber, A.E. 9, 88  
 Golub, S.A. 69, 75, 81  
 Gomes, C. 88  
 Gomez, J. 78  
 Gonsai, K. 92  
 Gonzales, R. 54, 55, 100  
 Gonzalez, G. 51, 71, 92  
 Gonzalez, Y. 51  
 Goodell, V. 92  
 Gooden, L. 106  
 Goodwin, A.K. 81  
 Gorbach, P.M. 76  
 Gorden, G. 53  
 Gordon, E. 82  
 Gordon, M. 86  
 Gorelick, D.A. 49  
 Gorka, S.M. 88, 106  
 Gorodetzky, C. 63, 65, 81  
 Gottlieb, J. 51  
 Gourarier, L. 53  
 Gourevitch, M. 75  
 Grabinski, M. 55  
 Grabowski, J. 60, 77  
 Grady, J. 89  
 Graham, C. 76  
  
 Graham, J.A. 8  
 Grant, A. 73  
 Grant, K.A. 7  
 Grasing, K. 18  
 Graves, M. 97  
 Graves, S.M. 62  
 Gray, K.M. 51  
 Gray, K.M. 23  
 Greaves-Lord, K. 103  
 Green, C. 50, 60  
 Green, M.R. 66  
 Green, T.C. 49, 94  
 Greenfield, S.F. 86  
 Greenwald, M. 2, 19, 21, 65  
 Greenwald, M.K. 21, 63, 104  
 Greenwell, L. 100  
 Greer, A. 90  
 Grella, C. 105  
 Grier, N. 107  
 Griffin, B. 22  
 Griffiths, R.R. 10, 19, 50, 80  
 Grossman, L.E. 10  
 Gruber, S.A. 103  
 Gruber, V.A. 75  
 Grunwald, I. 73  
 Gryczynski, J. 86  
 Guenther, G. 23  
 Guentzel, H.L. 76  
 Gueorguieva, R. 77  
 Guerin, G.F. 81  
 Guevara, M. 97  
 Guillaumot, M. 11, 56, 108  
 Guillén, J. 107  
 Guise, J.B. 3  
 Gunderson, E.W. 59, 80  
 Gustafson, D. 11  
 Gutierrez-Maldonado, J. 107  
 Guydish, J. 51, 60  
 Guzman, L. 58  
  
 Haddox, J.D. 72, 94  
 Häggkvist, J. 99  
 Haile, C.N. 15, 23, 80  
 Hakansson, A. 48  
 Hakun, J. 55  
 Hale, G.J. 48, 49, 86  
 Hall, M.T. 10

# AUTHOR INDEX

- Halldin, C. 99  
 Haller, D.L. 76, 78, 96  
 Hallyburton, M. 51  
 Hamidovic, A. 89  
 Hamilton, A. 100  
 Hammar, L. 91  
 Hammell, J. 17  
 Hammer, Jr, R. 3  
 Hamon, S.C. 74, 104  
 Hampson, R. 96  
 Haney, M. 56, 63, 90, 101  
 Haning, W. 74  
 Hankins, G.D. 77  
 Hanlon, C.A. 6, 7, 96  
 Hansen, H. 93  
 Hanson, K.L. 72  
 Hao, X. 4  
 Hao, Y. 82  
 Harakeh, Z. 73  
 Haramburu, F. 88  
 Harocopos, A. 23  
 Harp, K.L. 49, 75  
 Harper, T.A. 15  
 Harrington, C.R. 97  
 Harrington, M. 49  
 Harris, A.C. 98  
 Harris, C.W. 3  
 Harris, E. 10  
 Harris, K. 22  
 Harris, K.S. 14  
 Harris, T.S. 4, 97  
 Harrod, S. 54  
 Hart, C.L. 4, 5, 56, 80  
 Hartje, J.A. 11, 21, 53  
 Hartwell, E. 85, 95  
 Hartwell, K. 98  
 Hartwell, K.J. 51  
 Hartzell, R. 56  
 Hasan, K.M. 96  
 Hasani Abharian, P. 4, 93  
 Haseeb, N. 103  
 Hasin, D. 8, 12, 51, 64, 95  
 Hasson, A.L. 20, 57, 58, 59  
 Hatch-Maillette, M.A. 91  
 Hatzenbuehler, M. 12  
 Hatzigeorgiou, M. 82  
 Havens, J.R. 75, 89, 108  
 Hawkins, R.Y. 23, 80, 89  
 Hayes, L. 16  
 Hayes, M.J. 53  
 Haynes, L. 21, 71, 106  
 Hays, L.R. 15, 81  
 Hazan, R. 4, 23, 97  
 Hazel, J. 52  
 Hazen, A. 9  
 Hazim, R. 18  
 He, S. 18  
 Heal, D.J. 15, 18  
 Healey, K. 99  
 Heath, A.C. 90  
 Heberlein, U. 63  
 Hedden, S.L. 22, 48  
 Heil, S.H. 24, 26, 52, 69, 95  
 Heimer, R. 76  
 Heinzerling, K.G. 23, 99  
 Heller, N. 53  
 Hemaue, S.J. 77  
 Hemberg, J. 106  
 Hemby, S.E. 107  
 Henderson, G. 92  
 Hendrickson, M. 10  
 Henningfield, J.E. 14, 15, 61  
 Henry, P.K. 92  
 Herbeck, D. 69, 100  
 Herbert, M.S. 81  
 Herin, D.V. 60, 77  
 Herman, D.M. 102  
 Hernandez, C.M. 83  
 Herran, E. 57, 59  
 Herrmann, E. 69  
 Hersh, D. 74  
 Herz, L. 51  
 Hester, R. 80  
 Hickie, T. 62  
 Hickman, M. 92  
 Higgins, S.T. 51, 52, 57, 69, 88, 95  
 Higley, A.E. 92  
 Higuera-Matas, A. 7  
 Hij, A. 11, 56, 108  
 Hilde, A. 50  
 Hillhouse, M.P. 20, 57, 58, 59, 71, 79, 95, 100  
 Hills, D. 99  
 Ho, A. 7, 73, 83, 105  
 Hoffer, R.S. 84  
 Hofman, A. 24  
 Hofstein, Y. 72, 107  
 Holbrook, A. 53  
 Hole, A.V. 4, 55, 96, 97  
 Holmes, A.J. 98  
 Holmes, B.W. 21, 71  
 Holstein, G.J. 15  
 Homer, J. 94  
 Homish, G.G. 51, 92  
 Homish, G.H. 107  
 Hong, H. 9  
 Hood, L.E. 68, 99  
 Hopwood, S. 90  
 Horn, L.A. 81  
 Horton, A.M. 14  
 Houck, J.M. 100  
 Houghten, R.A. 24  
 House, K. 23  
 Hovenga, B. 62  
 Howard, J.L. 102  
 Howard, M.O. 10  
 Howard, S.L. 106  
 Howell, L.L. 77, 83, 92  
 Howlett, A.C. 17  
 Hser, Y.I. 53, 59, 88, 91  
 Hsu, J. 13  
 Hu, L. 60  
 Huang, D. 53, 91  
 Huang, W. 74  
 Huerta Rivas, A. 54  
 Hughes, B. 54  
 Huizink, A.C. 24, 73, 79, 85, 103  
 Hulbert, A. 17, 48, 58, 108  
 Hull, L. 91  
 Hunt, N. 49  
 Hursh, S.R. 14  
 Husar, K. 52  
 Hussain, S. 88  
 Hyma, B.A. 17  
 Iacono, W.G. 8  
 Ialongo, N. 13  
 Ianos-Rancovici, R. 14  
 Ibanez de Benito, S. 21  
 Ignacio, R. 8

# AUTHOR INDEX

- Iguchi, M.Y. 5, 67, 76  
 Iijima, M. 53  
 Ilgen, M.A. 8, 68  
 Illeperuma, A. 79  
 Illes, G. 91  
 Imai, S. 74, 83  
 Ingersoll, K.S. 11, 79, 96  
 Inzhakova, G. 96  
 Irvine, R.J. 87  
 Irwin, K.S. 93  
 Islam, L.Z. 85  
 Iturriaga, E. 74, 80  
 Itzhak, Y. 69, 74  
 Ives, M.L. 72  
 Izenwasser, S. 22, 53, 60, 102  
  
 Jack, B.W. 13  
 Jackson Bloom, J. 23  
 Jackson, A. 53  
 Jackson, D.O. 48, 49, 86  
 Jackson, L.C. 16, 85  
 Jacobbe, H.T. 97  
 Jacobs, P. 104  
 Jacome, M. 66  
 Jaddoe, V. 24  
 Jaffe, A. 50, 99  
 Jaffe, J.H. 60  
 Jan, R.K. 54  
 Janes, A.C. 98  
 Jang, M. 3  
 Jansson, L.M. 53  
 Jasinski, D. 97  
 Jatlow, P. 15  
 Jayaram-Lindtröm, N. 99  
 Jayroe, J.B. 15  
 Jenab, S. 18, 89  
 Jenkins, J. 95  
 Jenner, L.L. 20  
 Jens, W. 55  
 Jensen, E. 82  
 Jentsch, J.D. 6, 99  
 Jiang, H. 59  
 Jiang, Y. 97  
 Jobes, M.L. 79  
 Johanson, C.E. 14, 63, 80  
 Johansson, B. 64  
 Johnson, B.A. 74, 80  
 Johnson, C. 52  
 Johnson, D. 21  
 Johnson, E.O. 4, 13, 69  
 Johnson, J.E. 48  
 Johnson, K. 98  
 Johnson, M.W. 19, 75  
 Johnston, B. 95  
 Jones, B.A. 16, 85, 93  
 Jones, H.E. 24, 26, 53  
 Jones, J.D. 101  
 Jones, K. 93  
 Jones, S.C. 70  
 Jones-Whaley, S. 48, 86  
 Jordan, A.E. 57, 58  
 Joseph, J.E. 80, 97  
 Juliano, L.M. 80  
 Jun, M. 8  
 Jungman, J. 53  
 Justice, A. 64  
 Jutkiewicz, E.M. 98  
  
 Kahler, C.W. 62, 104  
 Kahn, R. 74, 80  
 Kalayasiri, R. 77  
 Kalechstein, A.D. 15, 84, 89  
 Kallman, M. 67  
 Kalman, D. 51, 71  
 Kaltenbach, K. 24, 26, 53  
 Kaminer, Y. 107  
 Kaminski, B.J. 14, 81  
 Kampman, K.M. 10, 16, 55  
 Kang, J.M. 56  
 Kangarlu, A. 4  
 Kantak, K.M. 68, 83  
 Kaplan, G. 23  
 Karageorgiou, J. 87  
 Karch, S.B. 17  
 Karjane, N. 95  
 Kaskutas, L. 69  
 Kaszycki, S.J. 68  
 Katz, C. 49  
 Katz, E.C. 58, 93, 94  
 Kaufman, M.J. 82, 98  
 Keilp, J.G. 63  
 Kellar, K. 2  
 Kelley, C.J. 77  
 Kelley, J.B. 74  
 Kelly, B.C. 81  
 Kelly, S.M. 60, 71, 76, 86  
 Kelly, T.H. 10, 23, 56, 80, 97  
 Kendrick, A. 92  
 Kennedy, M. 52  
 Kenny, P. 2  
 Kerloc'h, C. 57  
 Kersch, V. 49  
 Kerstetter, K.A. 89  
 Kertesz, S. 12, 16, 71  
 Kerwin, M.E. 26  
 Kessler, E. 77  
 Kessler, F.H. 70, 88  
 Kettavong, M. 102  
 Keyes, K. 8, 12  
 Keyes, K.M. 72  
 Keyler, D.E. 98  
 Keyser-Marcus, L.A. 8, 52, 70, 85, 91  
 Khan, M. 48  
 Khatavkar, P. 76, 86  
 Khodneva, Y. 12, 71  
 Kidorf, M. 71  
 Kidorf, M.S. 12, 59  
 Kierksick, R. 20  
 Kim, H. 8  
 Kim, S. 49  
 Kimbro, J. 20  
 Kimmel, H.L. 92  
 King, A. 89  
 King, C. 89  
 King, G.R. 54, 55  
 King, J. 55  
 King, V.L. 12, 59, 71  
 Kinlock, T.W. 86  
 Kippin, T.E. 54, 89  
 Kirby, K.C. 16, 25  
 Kirisci, L. 9, 55  
 Kirk, I.J. 54, 97  
 Kirkpatrick, M.G. 80  
 Kjome, K.L. 54, 97  
 Klement, S. 82  
 Kleykamp, B.A. 2, 3, 10, 92  
 Kline, A. 71  
 Kluemper, C. 97  
 Knapp, B.I. 24  
 Knopf, S. 9

# AUTHOR INDEX

- Knopik, V. 104  
 Knudsen, H.K. 58  
 Ko, M.C. 17  
 Kober, H. 3, 4  
 Koch, J.R. 78  
 Koek, W. 8  
 Koenig, B. 65  
 Koerper, L. 7  
 Koffarnus, M.N. 11  
 Kofner, A. 22  
 Kollins, S.H. 51  
 Kong, A. 89  
 Kong, G. 9  
 Konijnenberg, C. 25  
 Koob, G.F. 86  
 Kopetz, C. 16  
 Koro-Ljungberg, M. 86  
 Korte, J.E. 79  
 Korthuis, T. 106  
 Kosinski, A.S. 78  
 Kosten, T. 54, 61  
 Koutroulakis, A. 10  
 Kowalczyk, W.J. 69, 75  
 Kozal, M. 76  
 Kraenau, E. 13  
 Kral, A.H. 13, 58, 76, 106  
 Kramer, L.A. 54, 96, 97  
 Kranzler, H.R. 64  
 Krauss, M. 73  
 Kreek, M.J. 7, 73, 74, 83, 104, 105  
 Krishnan, R. 53  
 Krishnan-Sarin, S. 9, 63  
 Kritz, S.A. 57, 106  
 Kross, E.F. 4  
 Kruyer, A. 105  
 Kubiak, S.P. 50  
 Kuhn, C.M. 103, 105  
 Kulaga, A. 51, 78  
 Kumar, A. 97  
 Kuper, L.A. 86  
 Kushnir, T. 12  
 Kuwabara, H. 97  
 Kuzumaki, N. 19, 74, 83  
 Kwok, M. 97  
 Kydd, R.R. 54, 97  
 Kyle, T. 106  
 Labounty, K.R. 23  
 Lacagnina, M. 3  
 Lacey, K. 90  
 Lack, A.K. 96  
 Lacy, R.T. 54  
 LaFlair, L.N. 72  
 Lam, P.K. 52  
 Landavazo, A. 83  
 Landes, R.D. 16, 51, 85, 93  
 Landovitz, R.J. 96  
 Lane, P.S. 48, 86  
 Lane, S.D. 15, 54  
 Langlois, C. 20  
 Langlois, E. 78  
 Langston, T. 17  
 Lanier, R.K. 13, 50  
 Lankenau, S. 23, 106  
 Larance, B. 94  
 Larkby, C. 90  
 LaRowe, S.D. 99  
 Lasseter, H.C. 68, 82  
 Latimer, W.W. 9, 12, 17, 22, 48, 58, 76, 88, 91, 95, 108  
 Latkin, C. 12  
 Lattal, M. 63  
 Laudet, A.B. 8, 79  
 Laura, B. 1  
 Lavelle, A. 71, 106  
 Lavignasse, P. 57  
 Lawson, A. 91  
 Lawson, K. 85, 95  
 Le Foll, B. 98  
 Leaf, P.J. 13, 70  
 Leahy, P. 19  
 Lecea, L. 22  
 Ledgerwood, D.M. 52  
 Lee, A. 16  
 Lee, D.C. 56  
 Lee, D.Y. 10  
 Lee, E.C. 13  
 Lee, G.P. 90  
 Lee, L.K. 72, 94  
 Lee, N.K. 20, 80, 100  
 Leech, S.L. 90  
 Lees, R. 92  
 Leff, M. 60  
 Legg, B.H. 96  
 Leimberger, J. 22, 71  
 Lejeune, C. 53  
 Lejuez, C.W. 16, 20, 51, 71, 85, 88  
 Lelutiu-Weinberger, C. 75  
 LeMatty, T. 98  
 Lenoir, M. 102  
 Leonard, J.R. 20, 88, 106  
 Leri, F. 7  
 Lerman, C. 1  
 LeSage, M.G. 18, 98  
 Leukefeld, C.G. 11, 49, 75, 78, 89, 105, 108  
 Leung, K.S. 13, 71  
 Leventhal, A.M. 51  
 Levin, F.R. 8, 15, 56, 59, 63, 80  
 Levin, M. 98, 99  
 Levine, R. 57  
 Levit, S. 60  
 Levran, O. 83, 104  
 Levy, M. 51  
 Levy-Cooperman, N. 79  
 Lewis, D. 78  
 Li, J. 59, 69, 77, 101, 102  
 Li, L. 77  
 Li, M.D. 74, 80  
 Li, S. 24  
 Li, S.H. 74, 80  
 Li, X. 69, 77  
 Li, Y. 4, 23, 55, 96  
 Licata, S.C. 10  
 Lile, J.A. 10, 15, 23, 56, 80, 81  
 Lin, C.H. 13  
 Lin, H. 105  
 Lin, J.C. 54  
 Lindbæk, M. 59  
 Lindholm, S. 99  
 Lindsay, J.A. 60  
 Lindsey, K. 64  
 Ling, W. 20, 57, 58, 59, 79, 95, 99, 100, 104  
 Lingford-Hughes, A. 92  
 Lintzeris, N. 94  
 Linzy, S. 104  
 Lioy, K. 94  
 Lipshultz, S.E. 25  
 Littel, M. 51



# AUTHOR INDEX

- Liu Chen, L. 84  
 Liu, D. 20  
 Liu, H. 74  
 Liu, P. 96  
 Liu, S. 15, 74, 82, 86, 97  
 Liu, X. 82  
 Liu, Y. 24  
 Liu-Chen, L.Y. 102  
 Llaudó, J. 57  
 Llorca, P. 18  
 Llosa, T. 14  
 Locatelli, A.E. 55  
 Locatelli, D.P. 9, 52  
 Lofwall, M.R. 2, 59  
 Lokireddy, M. 80  
 Lominac, K.D. 82  
 London, E.D. 23  
 Londono, D. 74  
 Long, E. 67, 84  
 Long, J. 96  
 Lookatch, S.J. 94  
 Lopez, A.A. 51  
 Lopez, J. 77  
 Lopez-Larson, M. 103  
 López-Rubalcava, C. 54  
 Lorvick, J. 58  
 Losonczy, M. 71  
 Lou, X. 74  
 Lowen, S. 64  
 Lozada, R. 56  
 Lozier, E. 51  
 Lu, L. 24  
 Lubman, D. 73, 100  
 Ludwig, D. 25  
 Luedtke, R.R. 17, 103  
 Luijten, M. 97  
 Lukacs, N.W. 17  
 Lukas, S.E. 10, 62, 64, 103  
 Lum, P.J. 74, 75  
 Luna, B. 84  
 Lundahl, L.H. 62, 63  
 Luo, L. 96  
 Lutnick, A. 58  
 Lutz, G. 20  
 Lynch, F. 50  
 Lynch, K. 16  
 Lynch, M.E. 52  
 Lynch, W.J. 89, 107  
 Lynch, W.L. 77  
 Lynskey, M.T. 69  
 Ma, J.Z. 74, 80  
 Ma, L. 54, 96, 97  
 Maan, R. 10  
 Mach, R.H. 17  
 Mackesy-Amiti, M.E. 75  
 MacKillop, J. 85  
 MacLean, K. 19  
 Maclean, R.R. 10  
 Macovsky, L. 94  
 MacPherson, L. 20, 51, 85  
 Mactutus, C.F. 18  
 Madden, L. 58  
 Madras, B.K. 61, 101  
 Magidson, J. 71, 106  
 Magland, J. 97  
 Magruder, K. 79  
 Magura, S. 48, 95  
 Mahoney, J.J. 15, 23, 80, 84, 89  
 Maili, L. 74  
 Maitre, C. 59  
 Majumder, I. 87  
 Malison, R.T. 77  
 Mallya, G. 64  
 MalmLöf, T. 99  
 Malson, J. 50  
 Malte, C.A. 60  
 Mamun, A.A. 100  
 Mancha, B.E. 22, 48  
 Mancino, M.J. 3, 81, 93  
 Mandell, T. 5  
 Mandler, R. 106  
 Mann, R. 13  
 Manser, K. 57  
 Manser, S. 60  
 Mansoor, E. 53  
 Manubay, J. 101  
 Manuel, S. 93  
 Manvich, D.F. 92  
 Marc, M. 11, 56, 108  
 Marhe, R. 3, 93  
 Marinelli-Casey, P. 71  
 Mark, T. 64  
 Markgraf, C.G. 67  
 Marlowe, D.B. 16, 50  
 Marmorstein, N.R. 8  
 Marroun, H.E. 24  
 Marsch, L.A. 72, 107  
 Marsh, R. 4  
 Martin, C.A. 10, 23, 56, 80  
 Martin, J. 20  
 Martin, P.R. 24, 26  
 Martin, R. 50  
 Martin, S. 77  
 Martinez, D. 4  
 Martinez, P. 11  
 Martinez-Luna, N. 57  
 Martin-Fardon, R. 68, 82  
 Martino, S. 20  
 Martins, S.S. 4, 22, 72, 90  
 Martin-Santos, R. 70  
 Martin-Thormeyer, E.M. 76  
 Marusich, J.A. 81  
 Mascarenhas, J. 93  
 Mash, D.C. 17  
 Mashhoon, Y. 10  
 Masho, S. 52  
 Mason, B.J. 92  
 Mason, M.J. 22  
 Masson, C.L. 57, 58  
 Matano-Logan, B. 53  
 Mateu-Gelabert, P. 57, 58  
 Matsushima, Y. 83  
 Mattick, R. 100  
 Mattson, C. 98  
 Mawhinney, J. 74  
 Maxwell, J.C. 11  
 May, J. 78  
 Mayer, C. 53  
 Mayes, L.C. 89, 90  
 Maysonnave, C. 12  
 Mazzarulli, A. 4  
 Mc Clernon, J. 4  
 McBride, O. 11  
 McCabe, S.E. 10, 72, 94  
 McCance-Katz, E.F. 15, 20, 75  
 McCann, D. 63  
 McCann, M. 74  
 McCann, U.D. 10, 56  
 McCarty, C. 8  
 McCarty, D. 11, 50, 72, 94

# AUTHOR INDEX

- McCaul, M. 97  
 McCleary, M. 19  
 McClernon, F.J. 51  
 McClung, J.C. 83  
 McClure, B. 78  
 McClure, E.A. 50  
 McCoy, C.B. 15, 85  
 McCullumsmith, C. 17  
 McGaugh, J. 81  
 McGear, J.E. 62, 85, 104  
 McGinnis, K. 64  
 McGlade, E.C. 55  
 McGlinchy, A. 10  
 McKendrick, K. 20, 49  
 McKetin, R. 100  
 McKnight, C. 57, 58  
 McLaughlin, G. 26  
 McLaughlin, J.P. 24, 84, 89  
 McLaughlin, K. 12  
 McLellan, A. 1  
 McMahan, L.R. 62, 98  
 McMorn, S.O. 3  
 McNair, N.A. 54, 97  
 McNaughton, E. 19, 94  
 McQueen, M. 104  
 McRae-Clark, A.L. 15, 62, 99  
 McSherry, F. 80  
 McSweeney, T. 49  
 McWhite, C.B. 15  
 Mead, K. 100  
 Medoff, D.R. 49  
 Mehtani, S. 80  
 Meier, A. 21  
 Meissler, J.J. 56  
 Melin, P. 11, 56, 108  
 Melinder, A. 25  
 Mello, N.K. 92  
 Melnick, G. 49  
 Melnikov, A. 12  
 Meloy, L. 52, 70  
 Mendelson, J. 3, 67, 68, 77, 81, 86, 107  
 Mende-Siedlecki, P. 4  
 Mendez, I.A. 82, 98  
 Mennemeyer, S. 16  
 Mennis, J. 71  
 Menoyo, E. 77  
 Merlo, L.J. 50, 91  
 Mertens, J. 50  
 Merz, S. 90  
 Messiah, S.E. 25  
 Messina, N. 88  
 Messing, R.O. 10  
 Metrik, J. 62, 104  
 Metsch, L.R. 21, 106  
 Mewton, L.R. 55  
 Meyer, A.C. 98  
 Meyer, E.M. 86  
 Meyers, J. 73  
 Mezzich, A. 55  
 Michalsen, R. 90  
 Michel, L. 57  
 Middleton, L.S. 2  
 Miguéns, M. 7  
 Mikulich-Gilbertson, S.K. 22  
 Milam, A.J. 13, 70  
 Milby, J. 16  
 Miles, D. 78  
 Miller, B.W. 105  
 Miller, G.M. 61, 86  
 Miller, L.L. 56  
 Miller, M.D. 96  
 Miller, N.S. 12  
 Miller, T.L. 25  
 Mills, K.L. 90  
 Min, M. 53  
 Min, S. 108  
 Minerly, A.C. 89  
 Ming, Y. 64  
 Minhajuddin, A. 4  
 Minnes, S. 53  
 Mintzer, M.Z. 3, 10, 16, 92  
 Mischel, W. 4  
 Mitchell, J. 10  
 Mitchell, M.R. 80, 82  
 Mitchell, S.G. 60, 71, 76  
 Mitty, J.A. 74  
 Mitzelfelt, J.D. 7  
 Moberg, D. 25  
 Moeller, F.G. 15, 54, 74, 82, 96, 97  
 Mohd-Yusof, A. 81  
 Mokri, A. 93  
 Monchusie, P.M. 107  
 Mondragon, A. 100  
 Montejano, L. 64  
 Montgomery, L. 78  
 Monti, P.M. 51, 62, 104  
 Montoya, G.L. 7  
 Montoya, I.D. 26  
 Moody, D.E. 2, 15  
 Mooney, J. 75  
 Mooney, L.J. 71  
 Mooney, M.E. 77  
 Moore, B.A. 59, 88  
 Moore, S.K. 72  
 Moore, T.B. 91  
 Morabito, M.V. 83  
 Morales-Manrique, C.C. 52, 73  
 Moran, L. 18  
 Morasco, B.J. 68  
 Moreira, T. 70  
 Moreno, A. 20  
 Morgan, D. 7  
 Morgan, P.T. 77  
 Morgello, S. 73  
 Mori, T. 19  
 Morisano, D. 15  
 Morral, A. 22  
 Morris, R. 74  
 Morrow, C.E. 53  
 Moser, P. 84  
 Mosovsky, S. 9  
 Moulounguet-Cordier, S. 12  
 Moura, H. 70  
 Moura, Y.G. 52  
 Mouri, A. 18  
 Mueller, E.T. 51  
 Mulvey, P. 49  
 Munafò, M.R. 10  
 Murty, R. 24  
 Murugan, V. 90  
 Mustata, C. 77, 81  
 Myers, A.C. 14  
 Myrick, H. 98  
 Nabeshima, T. 18  
 Nabhan, A.N. 82  
 Nacache, L. 58  
 Nader, M.A. 82, 96  
 Nahas, E. 7

# AUTHOR INDEX

- Nair, M.N. 24, 76, 86  
 Nair, M.P. 74  
 Najman, J.M. 100  
 Nakahara, K. 83  
 Nakama, H. 54, 96  
 Nakazawa, M. 78  
 Nanda, J.P. 16  
 Nandi, A. 97  
 Nandi, V. 12  
 Nandola, N. 14  
 Nanovskaya, T. 77  
 Nanovskaya, T.N. 77  
 Napier, T.C. 62  
 Nappo, S.A. 17  
 Napuri, J. 76  
 Narasimhan, D. 17  
 Narayana, P.A. 54, 96, 97  
 Narita, M. 19, 74, 83  
 Natividad, L.A. 98  
 Navarro, H.A. 17  
 Nazarian, A. 89  
 Ndichu, E.W. 72  
 Neale, A. 15  
 Negus, S.S. 18, 61  
 Neisewander, J.L. 3, 17, 63, 68, 86, 99  
 Neumaier, J.F. 86  
 Neumeyer, J.L. 24  
 Newman, J. 92  
 Newton, T.F. 15, 23, 80, 84, 89  
 Newville, H. 76, 78  
 Niaz, K. 21  
 Nic Dhonnchadha, B.Á. 83  
 Nich, C. 90  
 Nickerson, L.D. 62  
 Nielsen, D.A. 74  
 Nielsen, D.N. 74  
 Nielsen, S. 80, 94  
 Nieto, F.J. 50  
 Niikura, K. 74, 83  
 Nikulina, E. 3  
 Niu, T. 74  
 Nixon, C. 25  
 Noble, R. 20  
 Noda, Y. 18  
 Nolan, B.C. 17  
 Nolan, C. 92  
 Nordström, A. 99  
 Norton, G. 22  
 Noto, A.R. 9, 11, 52  
 Noto, J. 96  
 Novak, S.P. 13, 69  
 Nunes, E.V. 8, 15  
 Nuno, M. 96  
 Nurnberger, J.I. 69  
 Nuzzo, P.A. 2  
 O'Brien, C.P. 4, 6, 23, 55, 64, 96, 97  
 O'Connor, P.G. 59, 74, 75, 93  
 O'Dell, L.E. 63, 98  
 O'Grady, K.E. 9, 58, 60, 71, 73, 76, 86, 93  
 O'Mahony, B. 77, 81  
 O'Neill, K.S. 98  
 Ober, A.J. 76  
 Ochsner, K.N. 4  
 Ofir, A.Y. 53  
 Oghabian, M. 4  
 Ogunabi, A. 106  
 Oh Min, M. 8  
 Ojeda, V.D. 56  
 Oleson, E.B. 17  
 Olive, M.F. 61  
 Oliveto, A. 3, 81  
 Omar, Y. 80  
 Ompad, D. 96  
 Ompad, D.C. 5, 12  
 Ondersma, S.J. 52, 91, 95  
 Opaleye, E.S. 9, 52  
 Orfila, J.E. 98  
 Ormel, J. 73, 85  
 Oser, C.B. 49, 75, 89, 108  
 Ostos, M. 3  
 Oswald, L. 97  
 Ott, J. 74  
 Ouellet, L.J. 75, 76  
 Paasche-Orlow, M.K. 13  
 Pablo, J.P. 17  
 Pacchioni, A.M. 17  
 Packard, M. 4  
 Padkopacz, M.R. 50  
 Pagano, K. 82  
 Painter, M.R. 68, 99  
 Palacios, I. 21  
 Palma, J. 84  
 Palman, N.R. 48  
 Palmatier, M. 98  
 Palmer, A.J. 81  
 Palmer, C. 64  
 Pande, A. 49  
 Pande, P.G. 19, 24  
 Pang, J.M. 17  
 Panos, J.J. 19  
 Pardo, R. 77, 81  
 Parrino, M. 95  
 Parry, C.D. 58  
 Parsons, J. 75  
 Parsons, J.T. 69, 75, 81  
 Parsons, L.H. 62  
 Parthasarathy, S. 50  
 Partilla, J.S. 83  
 Pascau, J. 7  
 Passalacqua, E. 51, 60  
 Patel, H.R. 23  
 Patrick, M.E. 57, 88, 95  
 Patrikeeva, S.L. 77  
 Paul, J. 53  
 Pawson, M.P. 75  
 Payne, R.A. 94  
 Peartree, N.A. 17, 68, 99  
 Pechansky, F. 2, 11, 70, 88  
 Peck, J.A. 96  
 Peet, M.M. 19  
 Peipert, J.F. 73  
 Peirce, J. 12, 59, 71  
 Peles, E. 59  
 Penetar, D.M. 10, 62, 64  
 Peng, C. 59  
 Peng, X. 77  
 Pennay, A. 80  
 Penniman, T.V. 17, 91, 95  
 Pennock, M.M. 107  
 Pentel, P.R. 98  
 Pentkowski, N.S. 3, 68, 86  
 Pepper, N. 57, 58  
 Pérez de los Cobos, J.C. 73  
 Perez, C. 77, 81  
 Perez, M. 77  
 Pericot-Valverde, I. 107

# AUTHOR INDEX

- Perkins, A.C. 48, 49, 86  
 Perkins, T. 105  
 Perl, H.I. 100  
 Perlman, D.C. 57, 58, 106  
 Perlman, D.J. 57  
 Perreve, A. 91  
 Perrey, D.A. 17  
 Perrin, N. 50  
 Perrine, S. 6  
 Perry, B. 75  
 Peters, C. 14  
 Petersen, P.M. 58  
 Peterson, A. 107  
 Peterson, B. 4  
 Petrakis, I. 92  
 Petry, N.M. 64  
 Pettegrew, J. 72  
 Pettinati, H. 16  
 Peuker, A. 70  
 Pham, A. 99, 100  
 Phillips, K.A. 69  
 Phillips, K.T. 56  
 Pich, E.M. 22  
 Pickens, R. 8, 70, 85, 91  
 Picker, M.J. 7, 56  
 Pickering, A. 92  
 Pickford, L. 15  
 Pickworth, W. 50  
 Piehl, K. 107  
 Pierre, P.J. 82  
 Pinard, E. 83  
 Pittman, B. 77  
 Pizzagalli, D.A. 98  
 Plaehn, G. 58  
 Plasters, E. 61  
 Platt, D.M. 83, 105  
 Plebani, J.G. 10  
 Pletcher, M. 12, 71  
 Ploense, K.L. 82  
 Ploutz-Snyder, R. 57  
 Pluddemann, A. 58  
 Pockros, L.A. 3  
 Poizat, B. 91  
 Poizot-Martin, I. 57  
 Polen, M. 50  
 Poling, J. 92  
 Polis, I. 62  
 Pollard, G.T. 102  
 Pollini, R.A. 56  
 Ponds, K.L. 68  
 Poole, M.M. 56, 80, 92, 99  
 Porrino, L.J. 1, 82, 96  
 Portenoy, R.K. 101  
 Potenza, M. 9, 89, 90  
 Potrepka, J. 21  
 Potter, J.S. 70, 104  
 Pouessel, O. 84  
 Prendergast, M. 105  
 Prescott, A. 82  
 Prescott, A.P. 55  
 Preston, K.E. 79  
 Preston, K.L. 69, 79  
 Price, K.L. 15, 62, 99  
 Price, R.K. 12  
 Prince van Leeuwen, A. 85  
 Prioleau, C. 19  
 Prisinzano, T.E. 84  
 Protopopescu, C. 57  
 Proudnikov, D. 74  
 Prow, M.R. 18  
 PsyCoBarcelona, G. 70  
 Pulaski, A.R. 79  
 Pulvermacher, A. 11  
 Pushparaj, A. 98  
 Quanbeck, A.R. 11, 58  
 Quinones-Jenab, V. 18, 89  
 Raboisson, P. 19  
 Radovanovic, M. 12  
 Ragot, E. 56  
 Rahmadi, M. 83  
 Raiff, B.R. 51  
 Rainey, P.M. 15  
 Raju, S. 92  
 Ramchand, R. 22  
 Ramin, C. 58  
 Ramirez, D.R. 68, 82  
 Ramirez, E. 89  
 Ramoa, C. 89  
 Ramos, A. 21  
 Randall, M. 92  
 Randall, S. 10  
 Randesi, M. 104  
 Ransom, L.L. 14, 88  
 Rasakham, K. 102  
 Rataemane, L. 100  
 Rataemane, S. 100  
 Rathnayaka, N. 97  
 Ravindran, A. 93  
 Rawson, R. 80, 95, 100  
 Rawson, R.A. 14, 71  
 Raymont, V. 97  
 Raynov, I.T. 76  
 Reback, C.J. 96  
 Rebec, G.V. 82  
 Reddy, P.V. 74  
 Reed, B. 7  
 Reed, S.C. 63, 90, 99  
 Reese, J. 16  
 Reggio, P.H. 62  
 Reid, A. 100  
 Reid, M.S. 50  
 Reifler, L. 93  
 Reiman, K. 15  
 Reis, D. 90  
 Renaudin, J. 59  
 Renner, J. 20  
 Renshaw, P.F. 55, 82  
 Resko, S.M. 9, 55, 90  
 Reuter, P. 67  
 Reynolds, C.R. 14  
 Reynolds, M.D. 9, 55  
 Rhodes, A.G. 49  
 Rhodes, G.L. 19  
 Ribeiro, L.A. 17  
 Richardt, S. 98  
 Richman, J. 12  
 Ridenour, T. 55, 73  
 Riegel, A.C. 101  
 Riggs, P. 11, 22, 71  
 Rigler, R. 64  
 Riley, A.L. 7, 99  
 Riley, B.B. 49  
 Rinehart, D.J. 100  
 Ring-Kurtz, S. 78  
 Rinker, J.A. 99  
 Ritter, A. 2  
 Rivera, D.E. 14  
 Rivera, R. 49, 90  
 Robbins, G. 56

# AUTHOR INDEX

- Roberts, D.C. 17, 61  
 Roberts, K.W. 84  
 Robertson, L.M. 3, 17  
 Robertson, M. 57  
 Robinson, J. 11, 106  
 Roddy, J.K. 21  
 Rodolico, J. 64  
 Roebke, P. 56  
 Roehrs, T. 10  
 Roget, N.A. 11, 21, 53  
 Rogowska, J. 103  
 Rohsenow, D.J. 23, 62, 104  
 Røislien, J. 11  
 Roma, P. 14  
 Roman, P.M. 58  
 Romano, A. 80  
 Romero-Gonzalez, M. 92  
 Rompion, S. 84  
 Roncero, C. 57  
 Ronzani, T.M. 9  
 Room, R. 67  
 Ropelewski, L. 48, 58, 108  
 Roper, A.J. 83  
 Rosa, M.C. 88  
 Rose, J. 65  
 Rose, J.H. 92  
 Rosen, M.I. 16, 71  
 Rosen, S. 94  
 Rosenblum, A. 48, 95, 101  
 Rosenfeld, J. 90  
 Rosenheck, R.A. 71  
 Rosenthal, R. 70  
 Ross, E. 59  
 Ross, J. 100  
 Ross-Durow, P.L. 72, 94  
 Roth, K.B. 12  
 Roth, T. 10  
 Rothman, R.B. 62, 83, 86  
 Rotrosen, J. 78, 104, 106  
 Rounsaville, B.J. 20, 71, 90, 92  
 Rowlett, J.K. 105  
 Roxburgh, A. 94  
 Royer, M.S. 58, 108  
 Rudolph, A. 12  
 Rudy, N.M. 82, 105  
 Ruiz, J. 26  
 Rush, B.R. 71  
 Rush, C.R. 15, 56, 61, 80, 81, 92, 99  
 Russell, B.R. 54, 97  
 Rusu, B. 14  
 Rutter, J.L. 1  
 Ryder, D. 16  
 Saadvandi, J. 74, 80  
 Saavedra, J. 13  
 Sabag-Cohen, S. 78  
 Sabharwal, S. 19, 24  
 Sabugo, J. 55  
 Sacerio, L. 16  
 Sacks, J.Y. 20, 49  
 Sacks, S. 20, 49  
 Sacramento, A.D. 82, 105  
 Sadee, W. 3  
 Saeki, M. 74  
 Saenz, E. 21  
 Safford, M. 12, 71  
 Safren, S. 106  
 Saijo, T. 99  
 Saitz, R. 101  
 Saiyed, Z. 76, 86  
 Saiyed, Z.M. 24, 74  
 Sakai, J. 104  
 Sakoman, S. 58  
 Saladin, M.E. 15, 23, 51, 62, 99  
 Salazar, J. 73  
 Saleh, M. 53  
 Salti, A. 82  
 Sambamoorthi, U. 51  
 Samikkannu, T. 76, 86  
 Samouri, S. 11, 56, 108  
 Sampson, R. 79  
 Sanabria, F. 99  
 Sanchez, B.N. 8  
 Sanchez, H. 68  
 Sanchez, J. 58  
 Sanchez, Z.V. 9, 17, 52  
 Sánchez-Hervás, E. 16  
 Sanders, G. 106  
 Sannerud, C.A. 19, 67  
 Sannibale, C. 90  
 Santa Ana, E.J. 20  
 Sarfi, M. 25  
 Saria, A. 82  
 Saroyan, J.M. 102  
 Sason, A. 59  
 Satterlee, J. 63  
 Saulsgiver, K.A. 5, 57, 88, 95  
 Savvas, S. 3  
 Saxon, A.J. 20, 60  
 Schaub, M.P. 49  
 Schenk, S. 81  
 Schiano, T. 78  
 Schiff, M. 60  
 Schilström, B. 99  
 Schlussman, S.D. 83  
 Schlyter, F. 48  
 Schmidt, K.T. 56, 84  
 Schmitz, J.M. 15, 60, 77  
 Schnoll, S.H. 14, 94  
 Schoedel, K.A. 3, 65, 79  
 Schoeny, M. 11, 56, 108  
 Schootman, M. 73  
 Schottenfeld, R.S. 59, 74, 75, 93, 96  
 Schramm-Sapota, N.L. 103  
 Schreiber, S. 59  
 Schroeder, S.M. 100  
 Schrott, L.M. 7  
 Schuetz, C.G. 10  
 Schumacher, J. 16, 71  
 Schuster, C.R. 14  
 Schwartz, R.P. 6, 58, 60, 71, 76, 86, 93, 106  
 Scott, C.K. 49, 78  
 Secades-Villa, R. 16, 107  
 See, R.E. 17, 101  
 Seewald, R.M. 57, 58, 106  
 Seip, K.M. 7  
 Selby, P. 23, 70, 88  
 Selby, V. 97  
 Sellers, E.M. 3, 65, 79  
 Seltzman, H.H. 62  
 Sembower, M.A. 14, 94  
 Sepulveda, A. 52, 91  
 Serre, F. 12  
 Setlow, B. 80, 82, 98  
 Sevak, R. 80  
 Severino, K. 92  
 Shafer, M.S. 49, 90  
 Shaham, Y. 83



# AUTHOR INDEX

- Shannon, L.M. 89  
 Shapiro, P. 78  
 Sharifian, S.W. 51  
 Sharp, V. 96  
 Sheffer, C.E. 85  
 Sheikhattari, P. 13, 52  
 Shiffman, S. 94  
 Shin, S.H. 9  
 Shinday, N.M. 105  
 Shippenberg, T.S. 101  
 Shmulewitz, D. 51  
 Shoptaw, S. 23, 76, 96, 99  
 Short, E. 53  
 Shram, M. 79  
 Shumsky, J.S. 3  
 Shurtleff, D. 22  
 Siegal, N. 61, 81  
 Siegrist, J. 81  
 Sigmon, S.C. 52, 57, 88, 95  
 Sigurdsson, S.O. 91  
 Silva, O. 78  
 Silverman, B.L. 64, 79  
 Silverman, K. 11, 91, 93  
 Simon, N.W. 80  
 Simpson, A.N. 94  
 Singer, L. 8, 53  
 Singleton, L. 85  
 Singleton, L.M. 95  
 Sinha, R. 89, 90  
 Siñol, N. 73  
 Skeie, I. 59  
 Skelly, J. 52  
 Skinstad, A.H. 14, 20, 21, 66  
 Skurtveit, S. 49  
 Slade, T. 55  
 Slavutzky, S. 88  
 Sliwerska, E. 104  
 Smelson, D.A. 71, 92  
 Smith, C. 95  
 Smith, H.R. 96  
 Smith, K. 88  
 Smith, K.D. 82  
 Smith, K.E. 15  
 Smith, M. 56  
 Smith, M.A. 107  
 Smith, M.T. 10  
 Smith, P.H. 107  
 Smith, S. 20, 61  
 Smith, V.M. 50  
 Smith, W. 52  
 Smock, S.A. 14  
 Smyth, E. 57  
 Snape, W. 3  
 Snead, N. 91, 106  
 Soberanes-Chávez, P. 54  
 Sodano, R. 100  
 Sofuoglu, M. 92  
 Sokolowska, M. 95  
 Solhkhah, R. 72  
 Solomon, L.J. 52, 69  
 Somogyi, A.A. 3  
 Somoza, E. 66  
 Sonne, S.C. 70, 79  
 Sorensen, J. 106  
 Sorensen, J.L. 57, 58  
 Soto-Montenegro, M.L. 7  
 Sparenborg, S. 20, 60  
 Spealman, R.D. 83  
 Spear, S.E. 88  
 Specker, S. 86  
 Spiga, R. 14  
 Spire, B. 57  
 Spitznagel, E. 73  
 Sproule, B. 93  
 St. Jean, E. 94  
 Ståhlberg, M. 19  
 Stahler, G. 71  
 Staio, G. 23, 70  
 Stairs, D.J. 62  
 Stallings, D.L. 20  
 Stallings, M.C. 104  
 Stanciut, L. 14  
 Stanger, C. 22, 55  
 Stanick, V. 79  
 Stanley, M.D. 80  
 Staples, V. 49  
 Starks, T.J. 69, 81  
 Staton-Tindall, M. 48, 75, 78, 105  
 Steegers, E. 24  
 Stein, J. 57  
 Stein, M.D. 56, 102  
 Steinberg, J.L. 54, 96, 97  
 Steinmiller, C.L. 2, 63, 104  
 Stemmler, M.S. 53  
 Stenger, A. 54, 55, 96  
 Stephenson, S. 53  
 Stern, A. 83  
 Stevens, A. 49  
 Stevenson, L. 8  
 Stewart, J.L. 62  
 Stewart, K. 9  
 Stine, S.M. 24, 26, 53  
 Stitzer, M.L. 50, 72, 85  
 Stock, C. 74  
 Stoduto, G. 13  
 Stoica, I.G. 14  
 Stolf, A.R. 70  
 Stoops, W.W. 15, 80, 81, 92, 99  
 Stooove, M. 94  
 Storr, C.L. 12, 69, 72, 90, 97  
 Stotts, A.L. 60  
 Stowe, R. 89  
 Strain, E.C. 3, 16, 92  
 Strang, J. 67  
 Strathdee, S.A. 56  
 Strickland, J.R. 53  
 Striley, C.L. 71, 72  
 Striley, C.W. 72  
 Stutz, S.J. 83  
 Su, Z. 82  
 subramaniam, G. 72  
 Sughondhabirom, A. 77  
 Suh, J.J. 4, 23, 55, 96, 97  
 Sullivan, B.M. 98  
 Sullivan, J. 61  
 Sullivan, L.E. 59, 64, 74, 75, 76, 93  
 Sullivan, M.A. 95, 101, 102  
 Summers, K. 14, 20, 21  
 Sun, H. 24  
 Sun, W.L. 18, 89  
 Sunahara, R.K. 17, 77  
 Sundaram, A. 101  
 Sung, Y.H. 55  
 Sussner, B. 71  
 Sutton, R. 75  
 Suzuki, T. 19, 74, 83  
 Sved, A. 98, 99  
 Svikis, D.S. 8, 52, 70, 78, 85, 91, 94, 95, 101

# AUTHOR INDEX

- Swanson, A.N. 23, 99  
 Swedberg, M.D. 19, 80  
 Sweeney, C.T. 94  
 Swieter, M. 66  
 Swift, R. 23  
 Swinford, S.E. 3  
 Szalay, J.J. 68  
 Szobot, C. 70  
 Szucs Reed, R.P. 4, 55, 97  
 Szumlinski, K.K. 54, 82, 105
- Tabatabaei, H. 4  
 Taffe, M.A. 61, 62  
 Tai, B. 20, 60  
 Tajima, B. 51, 60  
 Takagi, M. 73  
 Takagi, S. 83  
 Talal, A. 57  
 Tansil, D. 53  
 Tapert, S.F. 72  
 Tarash, I. 99  
 Tartarini, W.L. 62, 64  
 Tarter, R. 9, 55  
 Tau, G. 4  
 Taxman, F.S. 48, 49, 78  
 Taylor, C. 19  
 Taylor, J.R. 68  
 Tedesco, V. 18  
 Teesson, M. 55, 90  
 Tella, S.R. 19  
 Temes, C. 78  
 Tennant, L.K. 107  
 Teplinsky, J. 82  
 Terenius, L. 64  
 Terplan, M. 53  
 Terra, M. 70  
 Terrell, D.L. 95  
 Terry, J. 55  
 Teruya, C. 59  
 Teter, C.E. 72  
 Teti, M. 23  
 Tetrault, J.M. 64, 76, 93  
 Thacker, L. 91, 94  
 Thakkar, V. 50  
 Thakur, P. 53  
 Thangavel, S. 74  
 Thanos, P. 67
- Thatcher, D.L. 84  
 Thiel, K.J. 68, 99  
 Thomas, B.F. 17, 19, 24  
 Thomas, C.M. 20, 57, 59  
 Thomas, R. 13  
 Tidey, J. 23  
 Tiemeier, H. 24  
 Tillander, E. 50  
 Tio, R. 106  
 Tisher, P. 53  
 Toaz, E. 54  
 Todd, M. 96  
 Todtenkopf, M.S. 98  
 Tolleson Knee, R. 53  
 Tolliver, B.K. 99  
 Tomas-Rossello, J. 21  
 Tomassilli, J. 75  
 Tompkins, D.A. 16, 102  
 Torregrossa, M.M. 68  
 Torrence, M.C. 96  
 Torrens, M. 70, 77, 81  
 Torres, I. 98  
 Torres, L. 5  
 Torrington, M. 79  
 Touzeau, D. 58  
 Toy, W.A. 86  
 Tozzi, F. 8  
 Tracy, E.M. 8  
 Tracy, M.S. 8  
 Travers, R.M. 88  
 Treese, M. 23  
 Tres, I. 95  
 Trinkl, B. 49  
 Trksak, G.H. 62  
 Tross, S. 91, 106  
 Trujols, J. 73  
 Tsay, W.I. 13  
 Tsui, J.I. 102  
 Tsutsui, K. 83  
 Tucker, A. 73  
 Tucker, J. 71  
 Turncliff, R. 79  
 Turturici, M. 51  
 Tzall, D. 71  
 Tziortzis, D. 84
- Uchtenhagen, A. 49
- UCS-UNESCO Group 95  
 Uhl, G. 65  
 Umberger, M.D. 56  
 Umbricht, A. 16, 88, 92, 93, 102  
 Unterwald, E.M. 61, 84, 102  
 Urada, D.I. 50, 105
- Vadhan, N.P. 56, 63  
 Valderrama-Zurián, J.C. 52, 73  
 Vallender, E.J. 86, 61  
 van den Brink, W. 24  
 Van der Linden, M. 20  
 Vandrey, R.G. 3, 50, 56  
 Vansickel, A.R. 92, 99  
 Vanyukov, M. 55  
 Vaquero, J.J. 7  
 Varela, F.A. 83  
 Varillo, K. 16  
 Varner, S.B. 52  
 Varughese, S. 94  
 Vasconcellos, M.T. 11  
 Vasilev, G.N. 76  
 Vassileva, J. 76  
 Velasquez, C. 19  
 Velasquez, M.M. 101  
 Velez, M.L. 53  
 Velica, L. 14  
 Veltman, D.J. 97  
 Vera, A. 56  
 Véré tout, A. 78  
 Verhulst, F.C. 24, 73, 85  
 Vickers, S.P. 18  
 Vignoli, B. 53, 102  
 Villalobos, G. 95  
 Villeger, P. 58  
 Villes, V. 57  
 Vimieiro, C. 20  
 Vincent, K.B. 9, 73  
 Vincent, R. 25  
 Vitezic, D. 58  
 Vittet, S. 13  
 Vlahov, D. 12  
 Voci, S. 88  
 Vokes, C.M. 80, 82  
 Volkmann, T.A. 56  
 Volkow, N.D. 1, 2

# AUTHOR INDEX

- Vollebergh, W. 73  
 von Diemen, L. 70  
 Vosburg, S.K. 56, 101  
 Vuchinich, R. 16  
 Vukojevic, V. 64  
  
 W.M.H.S. Initiative 12  
 Waal, H. 59  
 Wagner, C.C. 11, 79  
 Wagner, F.A. 13, 52, 69  
 Wagner, F.P. 56  
 Wagner, K.D. 56  
 Wakeland, W. 72, 94  
 Waki, Y. 18  
 Wakley, A.A. 56  
 Waldron, M. 9, 90  
 Waldrop, A.E. 85  
 Walker, K.L. 107  
 Walker, Q.D. 105  
 Walker, S.L. 19  
 Wall, D. 13  
 Wallace, D. 16  
 Walley, A.Y. 13, 106  
 Walsh, S.L. 2, 59  
 Walton, M.A. 9, 55  
 Wand, G. 97  
 Wang, D. 18  
 Wang, F. 106  
 Wang, J. 3, 74  
 Wang, N. 103  
 Wang, S. 23, 70  
 Wang, X. 77, 96  
 Wang, X.Q. 59  
 Wang, Y. 102  
 Wang, Z. 4, 23, 55, 57, 96, 97  
 Ware, D.L. 15  
 Warnecke, M. 10  
 Warner, K. 17  
 Wasarhaley, N.E. 48  
 Washio, Y.T. 52  
 Waterhouse, B. 3  
 Waters, A.J. 3, 15, 54, 93  
 Waygood, C. 92  
 Weaver, M. 98  
 Weaver, M.F. 94  
 Weaver, M.T. 99  
 Webb, D.J. 8  
  
 Weber, J. 4  
 Weber, S.M. 17, 99  
 Webster, J.M. 105  
 Webster, L. 72, 94  
 Webster, M. 48  
 Wechsberg, W.M. 58, 76, 100  
 Wee, S. 86  
 Weerts, E.M. 81, 97  
 Wei, Y. 58  
 Weierstall, K. 89  
 Weiner, J. 89  
 Weis, D. 74  
 Weiss, D. 80  
 Weiss, F. 68, 82  
 Weiss, L. 20, 75  
 Weiss, M. 19  
 Weiss, R.D. 104  
 Weiss, R.E. 76  
 Wellman, P.J. 82, 84  
 Wells, A.M. 82  
 Wells, B. 75  
 Wenger, L.D. 58  
 Werdenich, W. 49  
 Wermeling, D.P. 80  
 Wesnoski, S.A. 48  
 West, P.A. 82  
 Wetherington, C. 6  
 Wetli, C.V. 17  
 Wettstein, J.G. 83  
 Whalley, E. 19  
 Wheelock, A. 11  
 Whelan, J. 86  
 Whitaker, D.E. 70, 76, 79  
 White, J.M. 3, 87  
 White, K. 12  
 White, N.M. 7  
 White, T.L. 16, 56  
 Widner, G. 12  
 Wilcox, C. 78  
 Willard, D. 4, 96, 97  
 Williams, L. 90  
 Williams, S. 53, 99  
 Williams, T. 92  
 Williams, Z. 62  
 Windsor, L.C. 5, 90  
 Winhusen, T. 22  
 Winship, D. 81  
  
 Winstanley, E.L. 16, 92, 102  
 Winters, K.C. 22, 26  
 Winward, J. 72  
 Wise, R.J. 81  
 Wohl, D. 6  
 Wolfe, H. 96  
 Wolinsky, T. 84  
 Wolven, T. 16  
 Wong, C.J. 11  
 Wong, D. 97  
 Wong, L.L. 19  
 Wooditch, A. 48  
 Woods, J.H. 17, 77, 98, 103  
 Woods, W.L. 11, 21  
 Woodward, N. 105  
 Woody, G. 78  
 Woolverton, W.L. 102  
 Wooters, T.E. 98  
 Worley, M. 72  
 Wright, C. 13, 50  
 Wright, L.J. 72  
 Wright, M.J. 62  
 Wroten, M.G. 105  
 Wu, F. 59  
 Wu, H. 89  
 Wunsch, M.J. 2, 59  
  
 Xi, Z. 77  
 Xi, Z.X. 62, 69  
 Xie, X. 17, 68, 82  
 Xu, D. 4  
 Xu, S. 4  
 Xue, L. 25, 53, 85  
  
 Yakupov, R. 96  
 Yamada, S. 18  
 Yang, Y. 18  
 Yao, W.D. 105  
 Ye, W. 97  
 Yi, R. 51, 85  
 Yomjinda, D. 20  
 Yoon, J.H. 23  
 Yoshizawa, K. 19  
 Young, A.M. 72, 94  
 Young, C. 57, 58  
 Young, K. 51  
 Youssef, R. 56

## AUTHOR INDEX

- |                             |                             |                           |
|-----------------------------|-----------------------------|---------------------------|
| Yu, E. 74, 80               | Zawertailo, L.A. 23, 70, 88 | Zhou, M. 92               |
| Yubero, S. 77, 81, 86       | Zeman, L.L. 21              | Zhou, W. 96               |
| Yücel, M. 73                | Zengin, Y. 18               | Zhou, Y. 97, 105          |
| Yuferov, V. 73              | Zernig, G. 82               | Ziedonis, D. 51, 71       |
| Yunus, F. 52                | Zhang, R. 59                | Zimmerman, M.A. 9, 55     |
| Yurgelun-Todd, D.A. 55, 103 | Zhang, T. 24                | Zold-Kilbourn, P. 105     |
|                             | Zhang, Y. 7, 17, 83         | Zorman, M. 91             |
| Zakharova, E. 102           | Zhang, Z. 98                | Zosel, A. 59              |
| Zalcman, R. 13              | Zhao, M. 57, 59             | Zubaran, C. 95            |
| Zamarelli, L. 51            | Zhao, N. 81                 | Zucker, R.A. 9, 55        |
| Zanis, D.A. 48              | Zharikova, O. 77            | Zule, W.A. 76             |
| Zapata, A. 101              | Zheng, G. 98                | Zuo, C.S. 82              |
| Zavala, A.R. 81             | Zhou, C. 103                | Zur, J.B. 12, 48, 58, 108 |
| Zavala, R. 51, 57           | Zhou, L. 18, 89             | Zwick, J. 20              |

## SYMPOSIA

Sunday, June 13

### *I. Translating the genetics and neurochemistry of nicotine dependence to drug development*

Chairs: Linda Porrino and Joni L. Rutter

Tobacco addiction is a complex disorder involving genetic, environmental and developmental factors. There has been a recent explosion of research findings, using genome-wide association studies that link genetic variations to complex diseases, including addiction. Finding a single polymorphism within a gene that contributes to disease, however, is only the first step towards improved treatment and prevention interventions. The next goal is to understand how to take highly reproducible genetic findings and pursue their biological implications for developing diagnostic tests and targets for potential therapeutics. This symposium describes recent research into the genetics of tobacco addiction. Our speakers will present their findings about the genes encoding nicotinic acetylcholine subunit receptors, some of which have been associated with nicotine dependence, others of which have been associated with smoking cessation. These genetic findings represent examples of the power of genetics to set the stage for further translational research, such as understanding gene variant x environment interactions, or understanding the effects of genetic variation on gene function and gene pathways. The session will conclude with a discussion of drug development and future ligand development for the nicotinic acetylcholine subunit receptors, which are relatively rare, but which are expressed in areas of the brain involved in addiction and reward. These receptor subunits provide potential targets for drug development that may provide specificity and efficacy for drug dependence treatment.

### *II. CPDD International Committee Symposium*

*A comprehensive approach to examine the use and impact of cannabis:  
From brain effects to epidemiological impact across the world*

Chairs: Flavio Pechansky and Alison Ritter

Despite the tremendous effort to curtail the experimentation, use and abuse of cannabis, the WHO reports that more than 147 million people are cannabis consumers, with a trend towards lower ages of initiation. Some of cannabis' mechanisms of action have already been understood, and novel approaches are being tested – ranging from agents that affect the endocannabinoid system in animal models, the understanding and functional imaging of the effects of drug combinations in adolescents models of animals and humans, up to the epidemiological impact of its regular or chronic use and potential novel interventions to inhibit the development of a full cannabis use disorder. The international panel of speakers from the U.S., Spain, Italy, South Africa and Australia will provide a comprehensive approach. The speakers will make a deliberate attempt to forge bridgework between the fields and will be aided in this task by the discussant, who is an experienced cannabis researcher and who brings a broad global health perspective to the task.



## SYMPOSIA

Monday, June 14

### III. *Addressing the intersection of addiction and HIV in criminal justice-involved populations*

Chairs: Timothy P. Condon and Redonna Chandler

Researchers and public health officials have recognized that the criminal justice system provides a unique opportunity for addiction treatment and HIV intervention. For a variety of reasons, access to testing and HIV treatment varies across the criminal justice system. The same is true for the treatment of substance use disorders. Despite the presumption that drug-addicted prisoners undergo a period of forced abstinence during incarceration, without effective treatment, they remain at very high risk for relapse and overdose when released back into the community. Compounding this problem is the well established link between opioid drug use and the spread of HIV. This symposium will discuss emerging research findings showing that medications such as buprenorphine, methadone and long-acting naltrexone, can reduce the risk for relapse and overdose upon community re-entry as well as discuss new approaches for developing a continuum of care for HIV-infected individuals involved in the criminal justice system.

### IV. *Gender differences in response to social stress:*

*Parallels from cocaine and alcohol research in human and non-human primates*

Chairs: Colleen A. Hanlon and Cora Lee Wetherington

Although men are nearly twice as likely to be classified as substance-dependent, women experience a more rapid progression to dependence when introduced to drugs. Women appear to be particularly vulnerable to social stress, which may contribute to drug abuse, dependence and relapse. The primary aim of this symposium is to highlight recent translational data from clinical and nonhuman primate laboratories that suggest that this association between gender, stress, and drug use is present for several drugs of abuse. Specifically, compared to male cocaine users or non-drug using females, female cocaine users have a significantly larger neural response to social exclusion in brain regions involved in drug seeking. These data are supported by nonhuman primate investigations which demonstrate an association between social rank and cocaine self-administration in female monkeys opposite to that observed in males. In addition to substance abusers, there are gender differences among social drinkers, with females having greater hormonal responses to stress and drug craving than males, particularly with more chronic patterns of substance use. Furthermore, in nonhuman primates, as alcohol consumption progresses from acute to chronic consumption, circulating levels of ACTH/cortisol rise faster in females than males. The common themes emerging from both clinical and preclinical laboratories studying gender differences in cocaine and alcohol abuse suggest that understanding how women react to social information and environmental influences will aid the development of effective, gender-specific strategies for prevention and treatment of drug abuse.

## SYMPOSIA

### V. *The role of the hypocretin/orexin system in addiction: Current status and rationale as a drug discovery target* Chairs: David Shurtleff and Sari Izenwasser

Drug addiction is a chronic relapsing disorder consisting of a persistent desire or compulsion to use a drug, loss of control of drug intake, reduction in other important activities because of drug use, continued use despite knowledge of harm, marked tolerance, characteristic withdrawal symptoms, or intense craving and compulsive, uncontrollable drug taking and relapse following periods of abstinence. A challenge for drug abuse research is to identify targets associated with drug addiction in order to develop mechanism-based medications for treating it. One intriguing newly discovered potential target is the hypothalamic hypocretin (Hcrt)/orexin neuropeptide system. Initially implicated in feeding and energy balance, Hcrts have more recently been linked to arousal mechanisms such as sleep and narcolepsy, stress, and reward processing. Much of the emphasis with respect to the latter has focused on the mesocorticolimbic pathway, potentially involving many of these brain regions implicated in drug addiction including the ventral tegmental area and nucleus accumbens, and beyond. The wide projection field of the Hcrt-containing neurons, and the ability of drugs of abuse to influence them, suggests that Hcrt mechanisms may evoke numerous additional neurobiological and behavioral mechanisms in response to these drugs. Speakers for this symposium will discuss in detail recent research that suggest the Hcrts do play a role in pathological reward processing for addictive drugs, and in neurobiological mechanism of relapse. In addition, advances in the development of putative medications specifically targeting and involving the Hcrt system for drug addiction will be addressed and discussed.

Tuesday, June 15

### VI. *Hair of the dog: Agonists for stimulant dependence* Chairs: John Grabowski and David Herin

Stimulant abuse and dependence have contributed to prominent public health problems worldwide for many decades. In the treatment domain, behavioral interventions have shown promise; however, no pharmacotherapy has been approved despite evaluation of a wide spectrum of agents. Early work examining an ‘agonist approach,’ akin to methadone for the treatment of opioid dependence or nicotine for tobacco/nicotine dependence, provided titillating results. Now, a maturing literature is available that includes clinical trials and human laboratory research as well as preclinical nonhuman primate and rodent studies conducted with diverse methods from behavioral pharmacology and neuroscience. The combined data and literature point to potential efficacy of agonist pharmacotherapies, distinct refinements of the agonist strategy conceptualization, a broader array of potential medications, as well as possible limitations. In addition, these data support the view that stimulant abuse and dependence exist on a continuum of severity, and that different pharmacotherapies might be appropriate for treatment at different points along this continuum. The cumulative and latest results of clinical trials and community interventions will be described and elucidated by consideration of human

## SYMPOSIA

laboratory studies, preclinical studies and the neuroscience perspective of the available data, Bedside to Bench. An integrative discussion will include consideration of science, medication development, policy as well as regulatory and marketing realities.

### VII. *The role of GABA in drug abuse*

Chair: Diana Dow-Edwards and Nora Siegal

Evidence for overlapping reward circuits for multiple drugs of abuse including alcohol supports a role for many neurotransmitters in the induction, maintenance and relapse of drug dependence including, of course, dopamine but also glutamate and GABA. Recently, several lines of evidence have suggested that GABA modulation can alter the reinforcing effects of stimulants (particularly GABA B agonists) and may be useful to eliminate craving. This symposium will present the emerging preclinical evidence related to the usefulness of GABA modulation in the responses to psychostimulants. In addition, clinical evidence that drugs like flumazenil are effective will be presented. Since the role of GABA modulation in substance abuse has received relatively little attention and new clinical and preclinical data are available, this is an important topic. The major aims of the symposium will be to present the preclinical data showing that both GABA A and GABA B receptor subtypes are involved in the responses to psychostimulants and to present new data from clinical trials using GABA modulating drugs as treatments for substance abuse.

### VIII. *Medications development for the treatment of substance dependence:*

*Status of advanced projects*

Chairs: David McCann

Medications can play an important role in the treatment of substance dependence disorders; however, there are many areas of unmet clinical need. Most notably, FDA-approved medications for the treatment of cocaine, methamphetamine, or cannabis dependence are lacking. These clinical needs have driven extensive medications discovery and development efforts in both the private and public sector. The purpose of this symposium is to provide an update on the status of some of the most promising medications in clinical testing. Presenters will describe evaluations of dronabinol for the treatment of cannabis dependence, evaluations of bupropion for the treatment of methamphetamine dependence, and evaluations of vigabatrin for the treatment of cocaine and methamphetamine dependence.

### IX. *New pathways to future addiction therapy*

Chair: John Satterlee

Genetic studies in both humans and model organisms are leading to the identification of new and previously unsuspected genes and pathways involved in addictive processes. This symposium will highlight the use of three different model organisms (fruit flies,

## SYMPOSIA

zebra fish, and mice) to identify novel pathways involved in these processes. Potential translation of these discoveries to new diagnostic or therapeutic strategies will be explored.

### *X. NICO-TEEN: Adolescence is a period of enhanced vulnerability to tobacco abuse*

Chairs: Laura O'Dell and Janet Neisewander

Adolescence is a period of development characterized by insidious susceptibility to tobacco abuse. The underlying mechanisms that enhance adolescent tobacco abuse are largely unknown. The aim of this symposium is to highlight the multiple social and biological factors that contribute to increased tobacco abuse during adolescence. Recent work suggests that adolescents are more sensitive to the rewarding effects of nicotine but, in contrast, are less sensitive to aversive effects during nicotine withdrawal. These data provide a framework for this symposium to explore the various factors that influence enhanced vulnerability to tobacco abuse during adolescence. Recent pre-clinical studies demonstrate that nicotine preferentially facilitates the social- and cognitive-enhancing effects of this drug during adolescence. Across various animal models, the rewarding effects of nicotine are also enhanced whereas the negative affective properties of withdrawal (such as stress) are reduced during adolescence. Dopamine and opiate systems play an important role in modulating these developmental differences in nicotine reward and withdrawal. Clinical data that show adolescent smokers also display reduced nicotine withdrawal and, furthermore, they show concurrent enhanced risk-taking, impulsivity, and poor decision-making—all of which contribute to increased tobacco use during adolescence. This symposium will provide important information regarding psychosocial and biological factors that make adolescence a unique period of vulnerability to tobacco abuse.

Wednesday, June 16

### *XI. Preclinical to clinical abuse liability assessment:*

#### *Current challenges in industry practices*

Chairs: Mary Jeanne Kallman and David Compton

New governmental regulations, such as the recent ICH M3(R2) guidance, have focused attention on the assessment of drugs with central nervous system activity for abuse liability potential. Both nonclinical and clinical studies contribute to the classification scheduling of a drug by regulatory agencies and to information in the product label. It is, thus, critical to understand the current issues facing pharmaceutical development in the evaluation of new drugs for abuse and dependence potential. Animal models for the study of *known* drugs of abuse are well characterized, and clinical trial protocols in drug-experienced users have been widely used. However, unique challenges are encountered in both nonclinical and clinical settings when evaluating drugs with novel mechanisms. In this symposium, speakers from industry, academia and regulatory communities will discuss the critical issues. Topics will include an overview and update on recent and emerging events, a review of some recent scheduling decisions and how the nonclinical and clinical data supported the decision; how the conditioned place preference (CPP)

## SYMPOSIA

animal model can be used in nonclinical abuse liability evaluation; special challenges posed in evaluating novel drug combinations for abuse potential as well as drugs that *per se* have no reinforcing effects but which could potentiate the self-administration of known drugs of abuse, and the status and future of trial design for the clinical abuse liability study. The symposium will focus on bridging nonclinical, clinical and regulatory areas of interest.

### XII. *Methamphetamine addiction: From molecular mechanisms to treatment*

Chairs: John Mendelson and Jean Lud Cadet

There are an estimated 11.7 million methamphetamine (MA) abusers in the United States and epidemics of MA addiction are occurring worldwide. In this symposium we will proceed from molecular mechanisms of methamphetamine action to developing treatments for methamphetamine addiction. Neurobiological and translational principles that drive methamphetamine addiction, imaging studies, and the state of the art in developing pharmacotherapies for methamphetamine addiction will be discussed. Finding an effective treatment for methamphetamine addiction has been difficult. This series of presentations will help define a path forward for understanding this addictive disorder.

### XIII. *Current issues surrounding chronic pain among individuals with a substance use disorder*

Chair: Benjamin J. Morasco

There is a high rate of comorbid chronic pain conditions among patients with substance use disorders (SUDs), and the presence of this comorbidity complicates treatment. While empirical information describing this patient population has improved in recent years, there continues to be a need to expand our evidence base to guide assessment and treatment approaches for chronic pain in patients with a SUD. The aims of this symposium are to highlight contemporary clinical issues of chronic pain management among patients with comorbid SUD and to provide direction for future empirical investigations. Results of a systematic review summarizing the prevalence, demographic and clinical correlates, and treatment outcomes of chronic pain interventions in patients with comorbid SUD will be reviewed. Issues related to measuring chronic pain among SUD patients will be discussed and recommendations presented, with a focus on pain assessment in individuals misusing prescription opioids. An overview of co-occurring opioid dependence and pain in methadone maintenance treatment (MMT) will be provided, with emphasis on treatment needs, clinicians' experiences, and initial treatment findings. A cognitive-behavioral treatment approach to addressing pain management for patients enrolled in a substance abuse treatment program will be described, and outcome data from a pilot trial will be reported. The symposium will close with a broader discussion of overarching issues for the treatment of pain in patients with SUDs, including treatment issues in primary care and key research priorities.



## SYMPOSIA

### XIV. *Novel kappa opioids: From design to function*

Ellen Unterwald and Eduardo Butelman

This symposium will cover new innovations in kappa opioid receptor pharmacology. Topics will include synthesis of novel peptide and non-peptide agonists and antagonists that are selective for kappa opioid receptors, the molecular basis of kappa opioid receptor regulation in response to agonist drugs, kappa opioids in a non-human primate model, and the in vivo pharmacology of traditional and novel kappa opioid receptor ligands. The presentations will also cover the novel kappa drug of abuse, salvinorin A and its pharmacology.

Thursday, June 17

### XV. *Screening and brief intervention for drug use: Does it work?*

*Will it work in the real world?*

Chairs: Richard Saitz and Richard Denisco

Alcohol screening and brief intervention (SBI) is effective, but there is insufficient evidence to recommend drug SBI widely. This symposium will describe the design and implementation (including preliminary data) of a diverse mix of real-world drug SBI randomized controlled trials (RCTs) supported by NIDA/SAMHSA to fill the evidence gap. Trial 1 compares effectiveness and efficacy of approaches in urban primary care patients with drug use screening and (1) standard BI by health advocates and (2) motivational intervention (MI) by psychologists, versus control (written resources). Trial 2 compares effectiveness of 3 levels of intervention: (1) brief advice, (2) brief MI with feedback, and (3) brief MI with feedback and booster in injured patients with drug problems at a trauma center. Trial 3, a pragmatic effectiveness and cost study, evaluates BI and referral to treatment (when indicated) for problem drug use at a safety net hospital primary care setting. Trial 4 in medical outpatients tests novel solutions, comparing: (1) screening only, (2) assessment only, (3) assessment plus computer-delivered BI, or (4) assessment plus therapist-delivered BI. Trial 5 takes an innovative step to deliver treatment to opioid-dependent emergency department (ED) patients: (1) SBI with a facilitated referral to treatment and (2) SBI with ED-initiated buprenorphine, versus standard care (written information). These studies, each unique, are all based in general medical settings, incorporate pragmatic design features, have faced implementation challenges, propose innovative ways to translate brief interventions into more universal practice, and will thus have significant implications for policy and clinical care.

## SYMPOSIA

### XVI. *The role of dopamine D3 receptors in cocaine abuse*

Chair: Jane B. Acri

The dopamine D3 receptor is a subtype of the D2-like superfamily of receptors and because the relative expression of D3 receptors in the striatum is significantly less than that for D2 receptors, it has been hypothesized that preferential blockade of D3 receptors may lead to selective antagonism of the reinforcing and discriminative stimulus effects of cocaine without producing motor side-effects. This symposium will describe the latest research involving this novel target and a general overview of the dopamine receptor system, the preclinical strategies to be employed and some exciting clinical work. Next, describes the latest compounds in development, with an emphasis on early identification of potential treatment agents based on in vitro screens. The last two talks will describe the use of these novel compounds in several well-established animal models including the use of unconditioned behaviors, cocaine reinstatement models, drug discrimination and drug self-administration. This symposium is of importance to attendees of CPDD because it describes translational studies involving very novel treatment agents, as well as preclinical strategies for future clinical work.

### XVII. *The multi-site NIDA Clinical Trials Network prescription opioid addiction treatment study: Outcomes and implications*

Chairs: Roger D. Weiss and Petra Jacobs

Prescription opioid dependence has become a national public health priority; prescription opioids are now the most common form of drug initiation. Most treatment studies of opioid-dependent populations have focused exclusively or predominantly on heroin users, and thus do not adequately address those with prescription opioid dependence. This symposium will provide an opportunity to review findings from the Prescription Opioid Addiction Treatment Study – the first multi-site randomized controlled trial to specifically examine treatments for individuals with prescription opioid dependence including those with chronic pain. This study, part of the NIDA Clinical Trials Network, compared the efficacy of different lengths of buprenorphine/naloxone in combination with different intensities of medical and psychosocial counseling. The study contained two treatment phases: 1) 4 weeks of buprenorphine/naloxone, including a 2-week dose taper; and, for those who relapsed during this phase, 2) a 3-month buprenorphine/naloxone treatment, followed by a one-month taper. In both phases, participants were randomized to standard medical management (SMM) alone or SMM plus individual drug counseling. A total of 653 participants at 10 sites were randomized to Phase 1; 360 entered Phase 2. This mini-symposium will review 1) the primary study outcomes involving treatment response in Phase 1 and Phase 2; 2) key secondary outcomes, including treatment response among the 42% of study participants with chronic pain; and 3) the clinical and scientific implications of study results for the treatment of prescription opioids-dependence.

## SYMPOSIA

### XVIII. *Community-based responses to increasing opioid overdose deaths:*

#### *State of research and practice*

Chairs: Alexander Y. Walley and Alex Kral

From 1999 to 2006, the number of unintentional poisoning deaths involving opioids in the United States has increased 3.4 fold, from 4,041 to 13,755. This increase has been driven by growth in opioid analgesic prescriptions, increasing nonmedical use of prescription opioids, and the availability of low cost, high purity heroin. By 2006, overdose led motor vehicle accidents as the leading cause of accidental death in 16 states. Public health and community organizations in North America, Europe, and Australia have responded to increased overdoses by creating programs that educate opioid users and other laypeople how to prevent fatal overdoses. Often these programs include the distribution of naloxone, an opioid antagonist. By the end of 2007, over 20,000 lay people have been trained, reporting over 2500 overdose reversals with bystander-administered naloxone. Until 2009, there has been no federally funded research of community overdose prevention programs. This symposium will present findings from the first CDC and NIDA-funded research studies of community overdose prevention programs, the former implemented throughout Massachusetts in HIV prevention programs and the latter among two homeless outreach programs in Los Angeles and will contextualize the presentations within the epidemiology of overdose and the history of community responses to overdose with attention to future directions for this emerging field of research.

## WORKSHOPS

Sunday, June 13

### *I. Epidemiology and public health research methods workshop*

*Chairs: James C. Anthony and Silvia Martins*

This year, the workshop presentations are on methodological topics that are prominent in NIDA global health research projects, including issues raised during recent journal review processes on within-country and between-country research. Presenters will cover methodological issues faced in global and international research on problems of drug dependence, measurement challenges in race-ethnic and cross-national research on nicotine dependence, methods issues faced in epidemiological research on problems of dependence upon opioid analgesics, and zero inflated statistical models that can help us understand how it happens that some people try a drug once or twice but never progress beyond first occasions of drug self-administration. We will start with introductions, an overview, and a 30 minute panel discussion of these issues. Then, we will repeat a ‘mini-lecture and demonstration carousel’ approach we used in the 2008 CPDD quantitative methodology workshop, which was well-received. In this format, after the panel discussion, we allow the attendees to organize themselves into three separate subgroups for the first short mini-lecture and demonstration of software. Then, after the first 30” mini-lecture, attendees select and move to a different spot for a different mini-lecture/demonstration. Then, attendees move to the third and final mini-lecture/demonstration. In this way, there is a small group mini-lecture/demonstration coverage of three different topics during the workshop session, in addition to the overview and panel discussion at the start.

### *II. Effectively mentoring trainees from diverse backgrounds:*

*Funding opportunities and practical advice*

*Chairs: Danielle C. Ompad and Liliane Cambraia Windsor*

The purpose of this workshop is to encourage CPDD members to mentor minority researchers, and provide support to investigators that mentor students from diverse backgrounds. Specifically we will focus on mentoring students who identify as being from one or more racial/ethnic minority groups and those who come from economically disadvantaged backgrounds, consistent with CPDD’s commitment to increase minority participation and representation in CPDD activities. Topics to be addressed in this workshop will include funding opportunities within NIDA for increasing diversity, cultural competency for senior investigators, effective strategies for mentorship and challenges faced by students.

## WORKSHOPS

### *III. Minimize liability, manage risk, ensure patient safety: Effective strategies in outpatient methadone treatment*

*Chair: Michael T. Flaherty*

Learn how to employ best practices and reduce the risks associated with delivering methadone to treat opioid addiction. Conducted by experts in insurance, law, policy, and daily clinical practices, the training will provide the framework for applying best practices and developing comprehensive risk management strategies that improve patient safety and enable opiate treatment programs and methadone maintenance programs to eliminate, transfer, reduce, and manage the risks. The 2009 Government Accountability Office Report examined factors contributing to the significant increase in methadone-associated overdose deaths more often found in pain management situations. These concerns and adverse incidents have led to an increased number of lawsuits and legislation that seeks to legislate clinical practice, patient safety, and community values. Physicians, psychiatrists, clinical staff, nurses, and opiate treatment program directors need to understand how to minimize incidents, such as patients driving under the influence, unsafe diversion of take-home meds, and dosing practices without consideration of clinically assessed severity of dependence and metabolism rates.

### *IV. 16<sup>th</sup> Annual Contingency Management Working Group*

*Chairs: Kelly Dunn and Kathryn Saulsgiver*

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the dissemination and discussion of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 16th Annual Meeting of the CM Working Group, researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

Monday, June 14

### *V. School-based systems of care for substance abuse:*

*Student assistance programs and recovery schools / SASATE business meeting*

*Chairs: Andrew J. Finch and Michael Dennis*

One of the key barriers for treating substance abuse and co-occurring disorders is access to services. While many schools in the U.S. collaborate with community agencies and even locate health centers on school grounds, few have fully integrated systems of care for substance abuse and mental health within their schools. This presentation will examine recent research supporting the institutionalization of school-based systems of care. Student assistance and recovery school programs will be discussed as providing a

## WORKSHOPS

continuum of services for prevention, screening, assessment, intervention, and recovery support. Student assistance helps students achieve academic and social success and avoid substance abuse by promoting healthy development, while recovery high schools provide drug-free holding environments to support recovery from substance use disorders. Over 35 recovery high schools operate nationally, and most are public alternative or charter schools. The presentation will describe components of successful programs, including prevention activities, screening and assessment instruments, brief intervention, and recovery school programs. Following the panel discussion will be a brief business meeting for the Society for Adolescent Substance Abuse Treatment Effectiveness (SASATE).

### *VI. Teach your parents well: Teaching and training parents concerned about their child's drug use Chair: Kimberly C. Kirby*

Parents are often concerned about their children's involvement with drugs, and with good reason. Close to half of 12th graders have used illicit drugs at some point and almost a quarter have used in the past month. While multiple influences shape substance use parents could play a critical role at every stage of drug use involvement if they were provided with evidence-based knowledge, instruction, skills and practical tools. The specific aims of this workshop are 1) to introduce treatment providers to methods for assisting parents to manage drug use risks for their children at all levels of drug involvement, and 2) to inform researchers of new developments in translational research. The workshop will describe and discuss 1) development and research regarding a tool to help parents protect children from drugs on the internet, 2) examining how parent-child communication and relationship quality is associated with risk for drug use among college students, and how this information can be helpful to parents, 3) developing and implementing a training program to assist parents in dealing with adolescents in early stages of drug involvement, and 4) methods for training parents to act as change agents for children at risk for drug use and for adolescents who are more heavily engaged in drug use.

### *VII. Comparison of methadone and buprenorphine: Results of the Maternal Opioid Treatment: Human Experimental Research (MOTHER) trial Chairs: Ivan D. Montoya and Sarah H. Heil*

The specific aim of this workshop is to provide the much-anticipated neonatal and maternal outcomes of the Maternal Opioid Treatment: Human Experimental Research (MOTHER) project. MOTHER is an international, eight-site, double-blind, double-dummy, flexible-dosing, parallel-group randomized clinical trial. The MOTHER study examined the comparative safety and efficacy of methadone and buprenorphine for the treatment of opioid-dependence among pregnant women and their neonates. Topics will include the primary neonatal outcomes [e.g., incidence and severity of neonatal abstinence syndrome (NAS) and physical birth parameters] and key maternal outcomes (e.g., maternal treatment retention, average doses received, obstetrical and delivery outcomes), predictors of maternal treatment outcome, how the MOTHER sample is



## WORKSHOPS

representative of the larger pool of opioid-dependent pregnant women, comparisons and contrasts between the treatment and patient characteristics of U.S. and European women screened for the study, prevalence and management of co-occurring psychiatric disorders and medication interactions, and the implications of these data for affirming and changing clinical practice.

### *VIII. Career development: A perspective from junior and senior researchers*

*Chairs: Gerald McLaughlin and Jose Ruiz*

Developing a career involves a series of decisions, often made with limited information or assistance. The purpose of this workshop is to provide a forum for thinking more creatively and systematically about one's career decisions by inviting both junior and more senior scientists to reflect on their own career choices and experiences, as well as those of their colleagues, and encouraging substantial audience participation. Topics such as how to choose a mentor and what mentors look for; how to network effectively at a professional meeting; how to move to academia, industry or government positions; what not to do at job interviews, as well as what to be sure to do, will be some of the topics considered. Approximately half the time will be allotted for presentations and half the time for audience interactions and questions.

Tuesday, June 15

### *IX. New approaches to diagnosis in the DSM-V*

*Chairs: Wilson M. Compton and Charles P. O'Brien*

The multidisciplinary working group for Substance Related Disorders in DSM-V was charged with making improvements that were data-based, that moved the classification towards clinical neuroscience and, above all, improved the utility of the system for clinicians. The changes being considered are in keeping with these goals and are on schedule for a 2012 publication. Each speaker in this workshop will address in detail major concepts that are under consideration. In addition to an accumulating body of research suggesting that the categories of disorder, "abuse" and "dependence", are not distinct enough to warrant separation, research is accumulating on other topics and many other questions are being considered, including: Can we clarify the nomenclature between two states of neuro-plasticity induced by drugs of abuse: "physical dependence", which is a normal adaptation to repeated dose of several categories of CNS active medications, and "dependence", meaning addiction or compulsive drug-seeking as used in DSM-IV? Do we have the data to incorporate non-substance compulsive behaviors such as gambling which have clinical and neuro-imaging similarities to drug use disorders into our classification? Can we create a severity dimension that can inform clinicians about progress in treatment? Should we continue to use the same symptoms created in DSM-III-R and continued in DSM-IV or should some be added or deleted?

## WORKSHOPS

What is the threshold for a diagnosis? How can we best incorporate co-morbidity, a significant issue for a severity rating of substance use disorder as well as for the co-existing disorder such as depression or anxiety? The speakers will address these issues and provide an overview of DSM workgroup ongoing activities for CPDD participants to discuss.

*X. Established and emerging approaches to human abuse liability testing:  
Is there room for improvement?  
Chair: Edward Sellers*

Premarket abuse liability evaluation of prescription drugs is critical to identifying and controlling public health risks of drug abuse. The ‘gold standard’ subjective effects study is scientifically robust and subjective measures have strong face validity; however, questions remain. Are some designs/measures better than others? What distinguishes a drug with significant abuse liability? With older opioids and stimulants, unequivocally strong effects make evaluation of data relatively easy. However, for novel drugs, interpretation may require considerable expertise since despite a large historical record, an accepted standard for ‘clinically relevant’ effects has not yet been established. In addition, while there is generally good agreement between subjective effects and actual abuse patterns, these studies alone cannot necessarily predict whether experimental/recreational use will translate into repeated/escalating use, dependence or ‘addiction’, or whether there may be adverse consequences to the user and public health as a result. Although emerging methods such as self-administration or behavioral economics approaches are not yet widely used, they may have the potential to answer some of these additional questions. Thus, this workshop will review current human abuse liability testing within the drug development process and the potential role for novel testing methods. The aim of the workshop is to promote a dialogue between academic, regulatory, and industry representatives on improving clinical abuse liability evaluation. Refining existing approaches and exploring new methods may increase the predictive and convergent validity of premarket abuse liability assessments, in order to help address the public health need for safer drugs.

*XI. Academics and regulated industries: Perspectives on 21st century interactions with  
pharmaceutical and tobacco companies  
Chairs: Jed Rose and George Uhl*

Regulatory frameworks now increase the need to focus our best scientific expertise to optimize the efforts of progressive elements in pharmaceutical and tobacco companies to minimize harm, including the results from products whose use can lead to dependence in many individuals. However, academic researchers who interact with even enlightened members of the for-profit pharmaceutical and tobacco industries can be stigmatized by other members of the scientific community, even those whose research is funded indirectly through taxes, settlement funds etc from these industries. This workshop seeks to explore ethical issues and to provide examples of the ways in which interactions between academic and such for-profit industries can be managed appropriately, and

## WORKSHOPS

potential pitfalls avoided. We present several models that appear to work in specific cases. We seek to engender thought and discussion about tough yet flexible frameworks in which the best elements of academic/for profit interactions can be maintained while the risks inherent in such interactions can be reduced.

### *XII. Empirically supported treatments and diverse populations:*

#### *Some examples of challenges to adaptation*

*Chairs: Anne Helene Skinstad and Lonnetta Albright*

The goals for this workshop include sharing experiences in translating efficacious methods to make them more culturally sensitive and discussing barriers to implementation of empirically supported treatments with diverse populations. Many treatment approaches for clients with substance use disorders have been developed over the last 50 years, prominently including motivational interviewing, cognitive behavioral treatment, and motivational incentives to mention a few. These interventions have been shown to be efficacious in randomized clinical trials. While these treatments have been shown to be efficacious in clinical trials, the translation and subsequent adoption of these methods for use with diverse populations may not meet the evidence-base standard and also not be effective with diverse populations unless reworked.

### *XIII. What's new at NIDA and NIH: Enhancing peer review implementation and more*

*Chairs: Mark R. Green and Mark Swieter*

This workshop is intended to provide an opportunity for participants to learn about new policies and procedures at NIH and NIDA that are relevant to them. Topics will include changes in the peer review process at NIDA and the Center for Scientific Review (CSR) following implementation of Enhancing Peer Review modifications such as the new 1-9 scoring system, individual criterion scoring, the new format of summary statements; as well as new grant application forms and page limits, tips on how to write a good grant application, and ways to get help on application preparation. Other topics and questions of interest to the audience will be addressed. This is very much an interactive, audience-directed activity.

The following organizations have generously supported the work of the  
College on Problems of Drug Dependence during the past year:

**Catalyst Pharmaceutical Partners, Inc**

**Grunenthal USA, Inc**

**NIDA (National Institute on Drug Abuse)**

**Sanofi Aventis**

Funding for this conference was made possible (in part) by  
Grant Agreement # R13 DA 0019790 from NIDA.

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government